answer
stringlengths 1
16.1k
| id
stringlengths 7
56
| instruction
stringlengths 106
72.6k
| ner_tags
list | text
stringlengths 5
72.4k
| tokens
list | types
list |
---|---|---|---|---|---|---|
autopsy is an umlsterm, mouth is an umlsterm, chest is an umlsterm, letters is an umlsterm, suicide is an umlsterm, objective is an umlsterm, historical aspects is an umlsterm, suicide is an umlsterm
|
Rechtsmedizin.90090112.eng.abstr_task1
|
Sentence: On 21.11.1811 the poet Heinrich von Kleist and his companion Henriette Vogel were found dead in a small hollow by the Wannsee . The autopsy revealed that Kleist was shot in the mouth and Vogel died from a close-contact shot to the chest . The tragedy , which was reflected in letters and documents ended in a suicide pact . The conclusions of the pathologists were influenced by current medical opinions which were based on interpretations of the ancient humoral doctrine of Hypocrates . Subjective and objective opinions were mixed together . Some forensic and historical aspects of this suicide pact are highlighted .
Instructions: please typing these entity words according to sentence: autopsy, mouth, chest, letters, suicide, objective, historical aspects, suicide
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O"
] |
On 21.11.1811 the poet Heinrich von Kleist and his companion Henriette Vogel were found dead in a small hollow by the Wannsee . The autopsy revealed that Kleist was shot in the mouth and Vogel died from a close-contact shot to the chest . The tragedy , which was reflected in letters and documents ended in a suicide pact . The conclusions of the pathologists were influenced by current medical opinions which were based on interpretations of the ancient humoral doctrine of Hypocrates . Subjective and objective opinions were mixed together . Some forensic and historical aspects of this suicide pact are highlighted .
|
[
"On",
"21.11.1811",
"the",
"poet",
"Heinrich",
"von",
"Kleist",
"and",
"his",
"companion",
"Henriette",
"Vogel",
"were",
"found",
"dead",
"in",
"a",
"small",
"hollow",
"by",
"the",
"Wannsee",
".",
"The",
"autopsy",
"revealed",
"that",
"Kleist",
"was",
"shot",
"in",
"the",
"mouth",
"and",
"Vogel",
"died",
"from",
"a",
"close",
"-",
"contact",
"shot",
"to",
"the",
"chest",
".",
"The",
"tragedy",
",",
"which",
"was",
"reflected",
"in",
"letters",
"and",
"documents",
"ended",
"in",
"a",
"suicide",
"pact",
".",
"The",
"conclusions",
"of",
"the",
"pathologists",
"were",
"influenced",
"by",
"current",
"medical",
"opinions",
"which",
"were",
"based",
"on",
"interpretations",
"of",
"the",
"ancient",
"humoral",
"doctrine",
"of",
"Hypocrates",
".",
"Subjective",
"and",
"objective",
"opinions",
"were",
"mixed",
"together",
".",
"Some",
"forensic",
"and",
"historical",
"aspects",
"of",
"this",
"suicide",
"pact",
"are",
"highlighted",
"."
] |
[
"umlsterm"
] |
autopsy, mouth, chest, letters, suicide, objective, historical aspects, suicide
|
Rechtsmedizin.90090112.eng.abstr_task2
|
Sentence: On 21.11.1811 the poet Heinrich von Kleist and his companion Henriette Vogel were found dead in a small hollow by the Wannsee . The autopsy revealed that Kleist was shot in the mouth and Vogel died from a close-contact shot to the chest . The tragedy , which was reflected in letters and documents ended in a suicide pact . The conclusions of the pathologists were influenced by current medical opinions which were based on interpretations of the ancient humoral doctrine of Hypocrates . Subjective and objective opinions were mixed together . Some forensic and historical aspects of this suicide pact are highlighted .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O"
] |
On 21.11.1811 the poet Heinrich von Kleist and his companion Henriette Vogel were found dead in a small hollow by the Wannsee . The autopsy revealed that Kleist was shot in the mouth and Vogel died from a close-contact shot to the chest . The tragedy , which was reflected in letters and documents ended in a suicide pact . The conclusions of the pathologists were influenced by current medical opinions which were based on interpretations of the ancient humoral doctrine of Hypocrates . Subjective and objective opinions were mixed together . Some forensic and historical aspects of this suicide pact are highlighted .
|
[
"On",
"21.11.1811",
"the",
"poet",
"Heinrich",
"von",
"Kleist",
"and",
"his",
"companion",
"Henriette",
"Vogel",
"were",
"found",
"dead",
"in",
"a",
"small",
"hollow",
"by",
"the",
"Wannsee",
".",
"The",
"autopsy",
"revealed",
"that",
"Kleist",
"was",
"shot",
"in",
"the",
"mouth",
"and",
"Vogel",
"died",
"from",
"a",
"close",
"-",
"contact",
"shot",
"to",
"the",
"chest",
".",
"The",
"tragedy",
",",
"which",
"was",
"reflected",
"in",
"letters",
"and",
"documents",
"ended",
"in",
"a",
"suicide",
"pact",
".",
"The",
"conclusions",
"of",
"the",
"pathologists",
"were",
"influenced",
"by",
"current",
"medical",
"opinions",
"which",
"were",
"based",
"on",
"interpretations",
"of",
"the",
"ancient",
"humoral",
"doctrine",
"of",
"Hypocrates",
".",
"Subjective",
"and",
"objective",
"opinions",
"were",
"mixed",
"together",
".",
"Some",
"forensic",
"and",
"historical",
"aspects",
"of",
"this",
"suicide",
"pact",
"are",
"highlighted",
"."
] |
[
"umlsterm"
] |
neoplásico con afectación metastásica is a MORFOLOGIA_NEOPLASIA, neoplasia tímica is a MORFOLOGIA_NEOPLASIA, neoplásico is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, neoplásica metastásica is a MORFOLOGIA_NEOPLASIA
|
727_task0
|
Sentence: Anamnesis
Escenario clínico
Varón de 75 años que acude por segunda vez durante la última semana al Servicio de Urgencias por deterioro del estado general y clínica respiratoria. Desde el Servicio de Urgencias se solicita valoración por parte del equipo de guardia de Medicina Interna bajo sospecha de infección respiratoria que no ha respondido a antibioterapia.
Antecedentes personales
Paciente exfumador desde hace un año (IPA 70) e hipertenso. Actualmente jubilado, vida activa, independiente para todas las actividades básicas de la vida diaria.
Anamnesis
La anamnesis se presenta complicada. Paciente poco colaborador, malhumorado, irritable e inapetente.
El paciente acude al Servicio de Urgencias el día 12 de febrero de 2018 por deterioro del estado general y clínica respiratoria. Refiere dificultad respiratoria, tos y expectoración blanquecina, e incluso, hemoptisis. Recibe el alta sin ingreso con diagnóstico de infección respiratoria, e inicia antibioterapia con levofloxacino en domicilio.
Dos días más tarde, el día 15 de febrero, vuelve a acudir a dicho servicio por persistencia del deterioro de su estado basal. No ha percibido mejoría clínica, sino, al contrario, se encuentra tan debilitado que "no tiene fuerzas para caminar". El paciente insiste en que su deterioro tiene un desencadenante claro: una fractura de clavícula derecha que sufre mientras trabajaba en su huerta hace un mes y medio.
Refiere que, desde ese momento, la posición que debe adoptar por dicha fractura de clavícula le impide conciliar el sueño y que, además, comienza a ocasionarle dolor lumbar postural. Este dolor se intensifica con el paso de los días, sobre todo por la noche, al tener que dormir sobre un lateral.
Consulta en varias ocasiones en su centro de salud, recibiendo tratamiento analgésico que le alivia sólo parcialmente.
El paciente refiere que la imposibilidad de descansar adecuadamente ha deteriorado su estado general. Se encuentra muy cansado, debilitado, apenas come, por lo que refiere haber perdido algo de peso, no sale de casa. La debilidad es tal que hace días que "no tiene fuerzas para caminar". Además, desde hace varios días se le ha añadido el cuadro respiratorio descrito anteriormente para el cual está recibiendo tratamiento antibiótico.
Exploración física
La exploración física es poco llamativa. Paciente estable, eupneico, tolerando decúbito. En la auscultación pulmonar únicamente se detectan crepitantes finos bibasales. Destaca edema con fóvea leve a la presión hasta raíz de muslo.
Dada la clínica de "debilidad" que refiere el paciente, se realiza exploración neurológica en la que destaca: miembros inferiores (MMII) con paraparesia proximal de predominio derecho, con miembro inferior derecho (MID) a II/V proximal y miembro inferior izquierdo (MII) a III/IV proximal. Fuerza distal conservada a V/V de forma simétrica. Se objetivan fasciculaciones aisladas de localización proximal en MID. Sensibilidad tacto-algésica disminuida en muslo izquierdo.
Pruebas complementarias
En el análisis destaca una plaquetopenia de 63.000/mm3 , tiempo de protrombina 66 %, aumento fibrinógeno (551 mg/dl), leve aumento de bilirrubina total (1,5 mg/dl), elevación transaminasas (GOT/GPT 179/240 U/l), LDH 6.460 mg/dl y PCR 60,9 mg/l.
En la radiografía de tórax, se objetiva un ensanchamiento mediastínico.
Diagnóstico
Dada la clínica y alteraciones analíticas debemos plantearnos un diagnóstico diferencial más allá de una infección respiratoria que no ha respondido a antibioterapia.
El paciente presenta clínica de deterioro del estado general progresivo, que relaciona directamente con descanso insuficiente, secundario al dolor lumbar que le provoca la postura antiálgica que debe adoptar tras la fractura de clavícula.
Sin embargo, puede que el aparente factor desencadenante, la fractura de clavícula, nos esté enmascarando el diagnóstico. Eliminando dicho componente, destaca como síntoma clave un dolor lumbar de difícil control con analgesia convencional que empeora por la noche, seguido de "dificultad para caminar" de menor tiempo de evolución, que en la exploración neurológica se traduce en alteración motora de la musculatura proximal de MMII y alteración sensitiva. En un paciente con una radiografía de tórax con ensanchamiento mediastínico y alteración de la función hepática, nuestra primera sospecha diagnóstica es un proceso neoplásico con afectación metastásica que debuta con un síndrome de compresión medular.
En este caso, el diagnóstico diferencial incluimos:
» Aneurisma aórtico: ensanchamiento mediastínico y disnea. No obstante, el nivel de la masa mediastínica no se relaciona con el nivel del dolor dorso/lumbar ni con la clínica motora y sensitiva, se palpan pulsos femorales y pedios normales y, aunque puede justificar el deterioro del estado general y la pérdida de peso, no justifica las alteraciones objetivadas en el análisis.
» Miastenia gravis: ensanchamiento mediastínico que podría corresponder a neoplasia tímica y debilidad proximal en MMII. Sin embargo, esta debilidad no presenta fluctuaciones ni mejoría con el descanso. Tampoco presenta afectación de oculomotores ni clínica bulbar. No justifica el dolor lumbar invalidante.
» Síndrome de Eaton Lambert: ensanchamiento mediastínico que podría corresponderse con proceso neoplásico y debilidad proximal. Sin embargo, ésta se mantiene constante durante el día sin mejorar con la actividad. Los reflejos osteotendinosos (ROT) resultaron normales. No justifica el dolor lumbar invalidante.
» Esclerosis lateral amiotrófica: debilidad muscular con fasciculaciones aisladas. El resto de la exploración (ROT conservados, alteración sensitiva en MII, etc.) no orienta a dicha enfermedad.
Tratamiento
Ante la alta sospecha de síndrome de compresión medular iniciamos tratamiento corticoide con 10 mg endovenoso de dexametasona y, dado que nuestro centro carece de resonancia magnética (RM) en Urgencias, solicitamos RM a primera hora de la mañana.
En el informe de la RM se describe infiltración metastásica difusa de la médula ósea de todo el esqueleto axial visualizado, así como una masa de partes blandas en el agujero de conjunción izquierdo y receso lateral izquierdo del espacio D11-D12. Además, se ve afectada la raíz D12 izquierda. La masa de partes blandas contacta con el saco tecal y con la médula, aunque sin datos de mielopatía en el momento actual.
Evolución
Ante estos resultados, el paciente ingresa a cargo de Oncología Médica para completar estudio de extensión y diagnóstico histológico. El caso es comentado con el servicio de Oncología radioterápica que, dada la afectación radicular sin datos de mielopatía y la ausencia de diagnóstico histológico, desestima radioterapia urgente.
El paciente presenta una evolución tórpida muy precipitada, con empeoramiento progresivo de la función hepática, tendente al sueño, en situación de apatoabulia. El día 21 de febrero, el paciente presenta un cuadro de marcada dificultad respiratoria, con desconexión del medio. Se presenta sin respuesta estímulos, taquipneico, con importante trabajo respiratorio, cianótico, con edema en esclavina. Todo ello compatible con un episodio de síndrome de vena cava superior (SVS).
Dada la inestabilidad hemodinámica y datos de sufrimiento, en un paciente con signos de neoplásica metastásica avanzada se acuerda con la familia iniciar sedación paliativa. El paciente fallece sin haber podido iniciar estudio de extensión ni obtener diagnóstico histológico.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: MORFOLOGIA_NEOPLASIA
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Anamnesis
Escenario clínico
Varón de 75 años que acude por segunda vez durante la última semana al Servicio de Urgencias por deterioro del estado general y clínica respiratoria. Desde el Servicio de Urgencias se solicita valoración por parte del equipo de guardia de Medicina Interna bajo sospecha de infección respiratoria que no ha respondido a antibioterapia.
Antecedentes personales
Paciente exfumador desde hace un año (IPA 70) e hipertenso. Actualmente jubilado, vida activa, independiente para todas las actividades básicas de la vida diaria.
Anamnesis
La anamnesis se presenta complicada. Paciente poco colaborador, malhumorado, irritable e inapetente.
El paciente acude al Servicio de Urgencias el día 12 de febrero de 2018 por deterioro del estado general y clínica respiratoria. Refiere dificultad respiratoria, tos y expectoración blanquecina, e incluso, hemoptisis. Recibe el alta sin ingreso con diagnóstico de infección respiratoria, e inicia antibioterapia con levofloxacino en domicilio.
Dos días más tarde, el día 15 de febrero, vuelve a acudir a dicho servicio por persistencia del deterioro de su estado basal. No ha percibido mejoría clínica, sino, al contrario, se encuentra tan debilitado que "no tiene fuerzas para caminar". El paciente insiste en que su deterioro tiene un desencadenante claro: una fractura de clavícula derecha que sufre mientras trabajaba en su huerta hace un mes y medio.
Refiere que, desde ese momento, la posición que debe adoptar por dicha fractura de clavícula le impide conciliar el sueño y que, además, comienza a ocasionarle dolor lumbar postural. Este dolor se intensifica con el paso de los días, sobre todo por la noche, al tener que dormir sobre un lateral.
Consulta en varias ocasiones en su centro de salud, recibiendo tratamiento analgésico que le alivia sólo parcialmente.
El paciente refiere que la imposibilidad de descansar adecuadamente ha deteriorado su estado general. Se encuentra muy cansado, debilitado, apenas come, por lo que refiere haber perdido algo de peso, no sale de casa. La debilidad es tal que hace días que "no tiene fuerzas para caminar". Además, desde hace varios días se le ha añadido el cuadro respiratorio descrito anteriormente para el cual está recibiendo tratamiento antibiótico.
Exploración física
La exploración física es poco llamativa. Paciente estable, eupneico, tolerando decúbito. En la auscultación pulmonar únicamente se detectan crepitantes finos bibasales. Destaca edema con fóvea leve a la presión hasta raíz de muslo.
Dada la clínica de "debilidad" que refiere el paciente, se realiza exploración neurológica en la que destaca: miembros inferiores (MMII) con paraparesia proximal de predominio derecho, con miembro inferior derecho (MID) a II/V proximal y miembro inferior izquierdo (MII) a III/IV proximal. Fuerza distal conservada a V/V de forma simétrica. Se objetivan fasciculaciones aisladas de localización proximal en MID. Sensibilidad tacto-algésica disminuida en muslo izquierdo.
Pruebas complementarias
En el análisis destaca una plaquetopenia de 63.000/mm3 , tiempo de protrombina 66 %, aumento fibrinógeno (551 mg/dl), leve aumento de bilirrubina total (1,5 mg/dl), elevación transaminasas (GOT/GPT 179/240 U/l), LDH 6.460 mg/dl y PCR 60,9 mg/l.
En la radiografía de tórax, se objetiva un ensanchamiento mediastínico.
Diagnóstico
Dada la clínica y alteraciones analíticas debemos plantearnos un diagnóstico diferencial más allá de una infección respiratoria que no ha respondido a antibioterapia.
El paciente presenta clínica de deterioro del estado general progresivo, que relaciona directamente con descanso insuficiente, secundario al dolor lumbar que le provoca la postura antiálgica que debe adoptar tras la fractura de clavícula.
Sin embargo, puede que el aparente factor desencadenante, la fractura de clavícula, nos esté enmascarando el diagnóstico. Eliminando dicho componente, destaca como síntoma clave un dolor lumbar de difícil control con analgesia convencional que empeora por la noche, seguido de "dificultad para caminar" de menor tiempo de evolución, que en la exploración neurológica se traduce en alteración motora de la musculatura proximal de MMII y alteración sensitiva. En un paciente con una radiografía de tórax con ensanchamiento mediastínico y alteración de la función hepática, nuestra primera sospecha diagnóstica es un proceso neoplásico con afectación metastásica que debuta con un síndrome de compresión medular.
En este caso, el diagnóstico diferencial incluimos:
» Aneurisma aórtico: ensanchamiento mediastínico y disnea. No obstante, el nivel de la masa mediastínica no se relaciona con el nivel del dolor dorso/lumbar ni con la clínica motora y sensitiva, se palpan pulsos femorales y pedios normales y, aunque puede justificar el deterioro del estado general y la pérdida de peso, no justifica las alteraciones objetivadas en el análisis.
» Miastenia gravis: ensanchamiento mediastínico que podría corresponder a neoplasia tímica y debilidad proximal en MMII. Sin embargo, esta debilidad no presenta fluctuaciones ni mejoría con el descanso. Tampoco presenta afectación de oculomotores ni clínica bulbar. No justifica el dolor lumbar invalidante.
» Síndrome de Eaton Lambert: ensanchamiento mediastínico que podría corresponderse con proceso neoplásico y debilidad proximal. Sin embargo, ésta se mantiene constante durante el día sin mejorar con la actividad. Los reflejos osteotendinosos (ROT) resultaron normales. No justifica el dolor lumbar invalidante.
» Esclerosis lateral amiotrófica: debilidad muscular con fasciculaciones aisladas. El resto de la exploración (ROT conservados, alteración sensitiva en MII, etc.) no orienta a dicha enfermedad.
Tratamiento
Ante la alta sospecha de síndrome de compresión medular iniciamos tratamiento corticoide con 10 mg endovenoso de dexametasona y, dado que nuestro centro carece de resonancia magnética (RM) en Urgencias, solicitamos RM a primera hora de la mañana.
En el informe de la RM se describe infiltración metastásica difusa de la médula ósea de todo el esqueleto axial visualizado, así como una masa de partes blandas en el agujero de conjunción izquierdo y receso lateral izquierdo del espacio D11-D12. Además, se ve afectada la raíz D12 izquierda. La masa de partes blandas contacta con el saco tecal y con la médula, aunque sin datos de mielopatía en el momento actual.
Evolución
Ante estos resultados, el paciente ingresa a cargo de Oncología Médica para completar estudio de extensión y diagnóstico histológico. El caso es comentado con el servicio de Oncología radioterápica que, dada la afectación radicular sin datos de mielopatía y la ausencia de diagnóstico histológico, desestima radioterapia urgente.
El paciente presenta una evolución tórpida muy precipitada, con empeoramiento progresivo de la función hepática, tendente al sueño, en situación de apatoabulia. El día 21 de febrero, el paciente presenta un cuadro de marcada dificultad respiratoria, con desconexión del medio. Se presenta sin respuesta estímulos, taquipneico, con importante trabajo respiratorio, cianótico, con edema en esclavina. Todo ello compatible con un episodio de síndrome de vena cava superior (SVS).
Dada la inestabilidad hemodinámica y datos de sufrimiento, en un paciente con signos de neoplásica metastásica avanzada se acuerda con la familia iniciar sedación paliativa. El paciente fallece sin haber podido iniciar estudio de extensión ni obtener diagnóstico histológico.
|
[
"Anamnesis",
"\n",
"Escenario",
"clínico",
"\n",
"Varón",
"de",
"75",
"años",
"que",
"acude",
"por",
"segunda",
"vez",
"durante",
"la",
"última",
"semana",
"al",
"Servicio",
"de",
"Urgencias",
"por",
"deterioro",
"del",
"estado",
"general",
"y",
"clínica",
"respiratoria",
".",
"Desde",
"el",
"Servicio",
"de",
"Urgencias",
"se",
"solicita",
"valoración",
"por",
"parte",
"del",
"equipo",
"de",
"guardia",
"de",
"Medicina",
"Interna",
"bajo",
"sospecha",
"de",
"infección",
"respiratoria",
"que",
"no",
"ha",
"respondido",
"a",
"antibioterapia",
".",
"\n\n",
"Antecedentes",
"personales",
"\n",
"Paciente",
"exfumador",
"desde",
"hace",
"un",
"año",
"(",
"IPA",
"70",
")",
"e",
"hipertenso",
".",
"Actualmente",
"jubilado",
",",
"vida",
"activa",
",",
"independiente",
"para",
"todas",
"las",
"actividades",
"básicas",
"de",
"la",
"vida",
"diaria",
".",
"\n",
"Anamnesis",
"\n",
"La",
"anamnesis",
"se",
"presenta",
"complicada",
".",
"Paciente",
"poco",
"colaborador",
",",
"malhumorado",
",",
"irritable",
"e",
"inapetente",
".",
"\n",
"El",
"paciente",
"acude",
"al",
"Servicio",
"de",
"Urgencias",
"el",
"día",
"12",
"de",
"febrero",
"de",
"2018",
"por",
"deterioro",
"del",
"estado",
"general",
"y",
"clínica",
"respiratoria",
".",
"Refiere",
"dificultad",
"respiratoria",
",",
"tos",
"y",
"expectoración",
"blanquecina",
",",
"e",
"incluso",
",",
"hemoptisis",
".",
"Recibe",
"el",
"alta",
"sin",
"ingreso",
"con",
"diagnóstico",
"de",
"infección",
"respiratoria",
",",
"e",
"inicia",
"antibioterapia",
"con",
"levofloxacino",
"en",
"domicilio",
".",
"\n",
"Dos",
"días",
"más",
"tarde",
",",
"el",
"día",
"15",
"de",
"febrero",
",",
"vuelve",
"a",
"acudir",
"a",
"dicho",
"servicio",
"por",
"persistencia",
"del",
"deterioro",
"de",
"su",
"estado",
"basal",
".",
"No",
"ha",
"percibido",
"mejoría",
"clínica",
",",
"sino",
",",
"al",
"contrario",
",",
"se",
"encuentra",
"tan",
"debilitado",
"que",
"\"",
"no",
"tiene",
"fuerzas",
"para",
"caminar",
"\"",
".",
"El",
"paciente",
"insiste",
"en",
"que",
"su",
"deterioro",
"tiene",
"un",
"desencadenante",
"claro",
":",
"una",
"fractura",
"de",
"clavícula",
"derecha",
"que",
"sufre",
"mientras",
"trabajaba",
"en",
"su",
"huerta",
"hace",
"un",
"mes",
"y",
"medio",
".",
"\n",
"Refiere",
"que",
",",
"desde",
"ese",
"momento",
",",
"la",
"posición",
"que",
"debe",
"adoptar",
"por",
"dicha",
"fractura",
"de",
"clavícula",
"le",
"impide",
"conciliar",
"el",
"sueño",
"y",
"que",
",",
"además",
",",
"comienza",
"a",
"ocasionarle",
"dolor",
"lumbar",
"postural",
".",
"Este",
"dolor",
"se",
"intensifica",
"con",
"el",
"paso",
"de",
"los",
"días",
",",
"sobre",
"todo",
"por",
"la",
"noche",
",",
"al",
"tener",
"que",
"dormir",
"sobre",
"un",
"lateral",
".",
"\n",
"Consulta",
"en",
"varias",
"ocasiones",
"en",
"su",
"centro",
"de",
"salud",
",",
"recibiendo",
"tratamiento",
"analgésico",
"que",
"le",
"alivia",
"sólo",
"parcialmente",
".",
"\n",
"El",
"paciente",
"refiere",
"que",
"la",
"imposibilidad",
"de",
"descansar",
"adecuadamente",
"ha",
"deteriorado",
"su",
"estado",
"general",
".",
"Se",
"encuentra",
"muy",
"cansado",
",",
"debilitado",
",",
"apenas",
"come",
",",
"por",
"lo",
"que",
"refiere",
"haber",
"perdido",
"algo",
"de",
"peso",
",",
"no",
"sale",
"de",
"casa",
".",
"La",
"debilidad",
"es",
"tal",
"que",
"hace",
"días",
"que",
"\"",
"no",
"tiene",
"fuerzas",
"para",
"caminar",
"\"",
".",
"Además",
",",
"desde",
"hace",
"varios",
"días",
"se",
"le",
"ha",
"añadido",
"el",
"cuadro",
"respiratorio",
"descrito",
"anteriormente",
"para",
"el",
"cual",
"está",
"recibiendo",
"tratamiento",
"antibiótico",
".",
"\n\n",
"Exploración",
"física",
"\n",
"La",
"exploración",
"física",
"es",
"poco",
"llamativa",
".",
"Paciente",
"estable",
",",
"eupneico",
",",
"tolerando",
"decúbito",
".",
"En",
"la",
"auscultación",
"pulmonar",
"únicamente",
"se",
"detectan",
"crepitantes",
"finos",
"bibasales",
".",
"Destaca",
"edema",
"con",
"fóvea",
"leve",
"a",
"la",
"presión",
"hasta",
"raíz",
"de",
"muslo",
".",
"\n",
"Dada",
"la",
"clínica",
"de",
"\"",
"debilidad",
"\"",
"que",
"refiere",
"el",
"paciente",
",",
"se",
"realiza",
"exploración",
"neurológica",
"en",
"la",
"que",
"destaca",
":",
"miembros",
"inferiores",
"(",
"MMII",
")",
"con",
"paraparesia",
"proximal",
"de",
"predominio",
"derecho",
",",
"con",
"miembro",
"inferior",
"derecho",
"(",
"MID",
")",
"a",
"II",
"/",
"V",
"proximal",
"y",
"miembro",
"inferior",
"izquierdo",
"(",
"MII",
")",
"a",
"III",
"/",
"IV",
"proximal",
".",
"Fuerza",
"distal",
"conservada",
"a",
"V",
"/",
"V",
"de",
"forma",
"simétrica",
".",
"Se",
"objetivan",
"fasciculaciones",
"aisladas",
"de",
"localización",
"proximal",
"en",
"MID",
".",
"Sensibilidad",
"tacto",
"-",
"algésica",
"disminuida",
"en",
"muslo",
"izquierdo",
".",
"\n\n",
"Pruebas",
"complementarias",
"\n",
"En",
"el",
"análisis",
"destaca",
"una",
"plaquetopenia",
"de",
"63.000",
"/",
"mm3",
",",
"tiempo",
"de",
"protrombina",
"66",
"%",
",",
"aumento",
"fibrinógeno",
"(",
"551",
"mg",
"/",
"dl",
")",
",",
"leve",
"aumento",
"de",
"bilirrubina",
"total",
"(",
"1,5",
"mg",
"/",
"dl",
")",
",",
"elevación",
"transaminasas",
"(",
"GOT",
"/",
"GPT",
"179/240",
"U",
"/",
"l",
")",
",",
"LDH",
"6.460",
"mg",
"/",
"dl",
"y",
"PCR",
"60,9",
"mg",
"/",
"l.",
"\n",
"En",
"la",
"radiografía",
"de",
"tórax",
",",
"se",
"objetiva",
"un",
"ensanchamiento",
"mediastínico",
".",
"\n\n",
"Diagnóstico",
"\n",
"Dada",
"la",
"clínica",
"y",
"alteraciones",
"analíticas",
"debemos",
"plantearnos",
"un",
"diagnóstico",
"diferencial",
"más",
"allá",
"de",
"una",
"infección",
"respiratoria",
"que",
"no",
"ha",
"respondido",
"a",
"antibioterapia",
".",
"\n",
"El",
"paciente",
"presenta",
"clínica",
"de",
"deterioro",
"del",
"estado",
"general",
"progresivo",
",",
"que",
"relaciona",
"directamente",
"con",
"descanso",
"insuficiente",
",",
"secundario",
"al",
"dolor",
"lumbar",
"que",
"le",
"provoca",
"la",
"postura",
"antiálgica",
"que",
"debe",
"adoptar",
"tras",
"la",
"fractura",
"de",
"clavícula",
".",
"\n",
"Sin",
"embargo",
",",
"puede",
"que",
"el",
"aparente",
"factor",
"desencadenante",
",",
"la",
"fractura",
"de",
"clavícula",
",",
"nos",
"esté",
"enmascarando",
"el",
"diagnóstico",
".",
"Eliminando",
"dicho",
"componente",
",",
"destaca",
"como",
"síntoma",
"clave",
"un",
"dolor",
"lumbar",
"de",
"difícil",
"control",
"con",
"analgesia",
"convencional",
"que",
"empeora",
"por",
"la",
"noche",
",",
"seguido",
"de",
"\"",
"dificultad",
"para",
"caminar",
"\"",
"de",
"menor",
"tiempo",
"de",
"evolución",
",",
"que",
"en",
"la",
"exploración",
"neurológica",
"se",
"traduce",
"en",
"alteración",
"motora",
"de",
"la",
"musculatura",
"proximal",
"de",
"MMII",
"y",
"alteración",
"sensitiva",
".",
"En",
"un",
"paciente",
"con",
"una",
"radiografía",
"de",
"tórax",
"con",
"ensanchamiento",
"mediastínico",
"y",
"alteración",
"de",
"la",
"función",
"hepática",
",",
"nuestra",
"primera",
"sospecha",
"diagnóstica",
"es",
"un",
"proceso",
"neoplásico",
"con",
"afectación",
"metastásica",
"que",
"debuta",
"con",
"un",
"síndrome",
"de",
"compresión",
"medular",
".",
"\n",
"En",
"este",
"caso",
",",
"el",
"diagnóstico",
"diferencial",
"incluimos",
":",
"\n",
"»",
"Aneurisma",
"aórtico",
":",
"ensanchamiento",
"mediastínico",
"y",
"disnea",
".",
"No",
"obstante",
",",
"el",
"nivel",
"de",
"la",
"masa",
"mediastínica",
"no",
"se",
"relaciona",
"con",
"el",
"nivel",
"del",
"dolor",
"dorso",
"/",
"lumbar",
"ni",
"con",
"la",
"clínica",
"motora",
"y",
"sensitiva",
",",
"se",
"palpan",
"pulsos",
"femorales",
"y",
"pedios",
"normales",
"y",
",",
"aunque",
"puede",
"justificar",
"el",
"deterioro",
"del",
"estado",
"general",
"y",
"la",
"pérdida",
"de",
"peso",
",",
"no",
"justifica",
"las",
"alteraciones",
"objetivadas",
"en",
"el",
"análisis",
".",
"\n",
"»",
"Miastenia",
"gravis",
":",
"ensanchamiento",
"mediastínico",
"que",
"podría",
"corresponder",
"a",
"neoplasia",
"tímica",
"y",
"debilidad",
"proximal",
"en",
"MMII",
".",
"Sin",
"embargo",
",",
"esta",
"debilidad",
"no",
"presenta",
"fluctuaciones",
"ni",
"mejoría",
"con",
"el",
"descanso",
".",
"Tampoco",
"presenta",
"afectación",
"de",
"oculomotores",
"ni",
"clínica",
"bulbar",
".",
"No",
"justifica",
"el",
"dolor",
"lumbar",
"invalidante",
".",
"\n",
"»",
"Síndrome",
"de",
"Eaton",
"Lambert",
":",
"ensanchamiento",
"mediastínico",
"que",
"podría",
"corresponderse",
"con",
"proceso",
"neoplásico",
"y",
"debilidad",
"proximal",
".",
"Sin",
"embargo",
",",
"ésta",
"se",
"mantiene",
"constante",
"durante",
"el",
"día",
"sin",
"mejorar",
"con",
"la",
"actividad",
".",
"Los",
"reflejos",
"osteotendinosos",
"(",
"ROT",
")",
"resultaron",
"normales",
".",
"No",
"justifica",
"el",
"dolor",
"lumbar",
"invalidante",
".",
"\n",
"»",
"Esclerosis",
"lateral",
"amiotrófica",
":",
"debilidad",
"muscular",
"con",
"fasciculaciones",
"aisladas",
".",
"El",
"resto",
"de",
"la",
"exploración",
"(",
"ROT",
"conservados",
",",
"alteración",
"sensitiva",
"en",
"MII",
",",
"etc",
".",
")",
"no",
"orienta",
"a",
"dicha",
"enfermedad",
".",
"\n\n",
"Tratamiento",
"\n",
"Ante",
"la",
"alta",
"sospecha",
"de",
"síndrome",
"de",
"compresión",
"medular",
"iniciamos",
"tratamiento",
"corticoide",
"con",
"10",
"mg",
"endovenoso",
"de",
"dexametasona",
"y",
",",
"dado",
"que",
"nuestro",
"centro",
"carece",
"de",
"resonancia",
"magnética",
"(",
"RM",
")",
"en",
"Urgencias",
",",
"solicitamos",
"RM",
"a",
"primera",
"hora",
"de",
"la",
"mañana",
".",
"\n",
"En",
"el",
"informe",
"de",
"la",
"RM",
"se",
"describe",
"infiltración",
"metastásica",
"difusa",
"de",
"la",
"médula",
"ósea",
"de",
"todo",
"el",
"esqueleto",
"axial",
"visualizado",
",",
"así",
"como",
"una",
"masa",
"de",
"partes",
"blandas",
"en",
"el",
"agujero",
"de",
"conjunción",
"izquierdo",
"y",
"receso",
"lateral",
"izquierdo",
"del",
"espacio",
"D11-D12",
".",
"Además",
",",
"se",
"ve",
"afectada",
"la",
"raíz",
"D12",
"izquierda",
".",
"La",
"masa",
"de",
"partes",
"blandas",
"contacta",
"con",
"el",
"saco",
"tecal",
"y",
"con",
"la",
"médula",
",",
"aunque",
"sin",
"datos",
"de",
"mielopatía",
"en",
"el",
"momento",
"actual",
".",
"\n\n",
"Evolución",
"\n",
"Ante",
"estos",
"resultados",
",",
"el",
"paciente",
"ingresa",
"a",
"cargo",
"de",
"Oncología",
"Médica",
"para",
"completar",
"estudio",
"de",
"extensión",
"y",
"diagnóstico",
"histológico",
".",
"El",
"caso",
"es",
"comentado",
"con",
"el",
"servicio",
"de",
"Oncología",
"radioterápica",
"que",
",",
"dada",
"la",
"afectación",
"radicular",
"sin",
"datos",
"de",
"mielopatía",
"y",
"la",
"ausencia",
"de",
"diagnóstico",
"histológico",
",",
"desestima",
"radioterapia",
"urgente",
".",
"\n",
"El",
"paciente",
"presenta",
"una",
"evolución",
"tórpida",
"muy",
"precipitada",
",",
"con",
"empeoramiento",
"progresivo",
"de",
"la",
"función",
"hepática",
",",
"tendente",
"al",
"sueño",
",",
"en",
"situación",
"de",
"apatoabulia",
".",
"El",
"día",
"21",
"de",
"febrero",
",",
"el",
"paciente",
"presenta",
"un",
"cuadro",
"de",
"marcada",
"dificultad",
"respiratoria",
",",
"con",
"desconexión",
"del",
"medio",
".",
"Se",
"presenta",
"sin",
"respuesta",
"estímulos",
",",
"taquipneico",
",",
"con",
"importante",
"trabajo",
"respiratorio",
",",
"cianótico",
",",
"con",
"edema",
"en",
"esclavina",
".",
"Todo",
"ello",
"compatible",
"con",
"un",
"episodio",
"de",
"síndrome",
"de",
"vena",
"cava",
"superior",
"(",
"SVS",
")",
".",
"\n",
"Dada",
"la",
"inestabilidad",
"hemodinámica",
"y",
"datos",
"de",
"sufrimiento",
",",
"en",
"un",
"paciente",
"con",
"signos",
"de",
"neoplásica",
"metastásica",
"avanzada",
"se",
"acuerda",
"con",
"la",
"familia",
"iniciar",
"sedación",
"paliativa",
".",
"El",
"paciente",
"fallece",
"sin",
"haber",
"podido",
"iniciar",
"estudio",
"de",
"extensión",
"ni",
"obtener",
"diagnóstico",
"histológico",
"."
] |
[
"MORFOLOGIA_NEOPLASIA"
] |
neoplásico con afectación metastásica is a MORFOLOGIA_NEOPLASIA, neoplasia tímica is a MORFOLOGIA_NEOPLASIA, neoplásico is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, neoplásica metastásica is a MORFOLOGIA_NEOPLASIA
|
727_task1
|
Sentence: Anamnesis
Escenario clínico
Varón de 75 años que acude por segunda vez durante la última semana al Servicio de Urgencias por deterioro del estado general y clínica respiratoria. Desde el Servicio de Urgencias se solicita valoración por parte del equipo de guardia de Medicina Interna bajo sospecha de infección respiratoria que no ha respondido a antibioterapia.
Antecedentes personales
Paciente exfumador desde hace un año (IPA 70) e hipertenso. Actualmente jubilado, vida activa, independiente para todas las actividades básicas de la vida diaria.
Anamnesis
La anamnesis se presenta complicada. Paciente poco colaborador, malhumorado, irritable e inapetente.
El paciente acude al Servicio de Urgencias el día 12 de febrero de 2018 por deterioro del estado general y clínica respiratoria. Refiere dificultad respiratoria, tos y expectoración blanquecina, e incluso, hemoptisis. Recibe el alta sin ingreso con diagnóstico de infección respiratoria, e inicia antibioterapia con levofloxacino en domicilio.
Dos días más tarde, el día 15 de febrero, vuelve a acudir a dicho servicio por persistencia del deterioro de su estado basal. No ha percibido mejoría clínica, sino, al contrario, se encuentra tan debilitado que "no tiene fuerzas para caminar". El paciente insiste en que su deterioro tiene un desencadenante claro: una fractura de clavícula derecha que sufre mientras trabajaba en su huerta hace un mes y medio.
Refiere que, desde ese momento, la posición que debe adoptar por dicha fractura de clavícula le impide conciliar el sueño y que, además, comienza a ocasionarle dolor lumbar postural. Este dolor se intensifica con el paso de los días, sobre todo por la noche, al tener que dormir sobre un lateral.
Consulta en varias ocasiones en su centro de salud, recibiendo tratamiento analgésico que le alivia sólo parcialmente.
El paciente refiere que la imposibilidad de descansar adecuadamente ha deteriorado su estado general. Se encuentra muy cansado, debilitado, apenas come, por lo que refiere haber perdido algo de peso, no sale de casa. La debilidad es tal que hace días que "no tiene fuerzas para caminar". Además, desde hace varios días se le ha añadido el cuadro respiratorio descrito anteriormente para el cual está recibiendo tratamiento antibiótico.
Exploración física
La exploración física es poco llamativa. Paciente estable, eupneico, tolerando decúbito. En la auscultación pulmonar únicamente se detectan crepitantes finos bibasales. Destaca edema con fóvea leve a la presión hasta raíz de muslo.
Dada la clínica de "debilidad" que refiere el paciente, se realiza exploración neurológica en la que destaca: miembros inferiores (MMII) con paraparesia proximal de predominio derecho, con miembro inferior derecho (MID) a II/V proximal y miembro inferior izquierdo (MII) a III/IV proximal. Fuerza distal conservada a V/V de forma simétrica. Se objetivan fasciculaciones aisladas de localización proximal en MID. Sensibilidad tacto-algésica disminuida en muslo izquierdo.
Pruebas complementarias
En el análisis destaca una plaquetopenia de 63.000/mm3 , tiempo de protrombina 66 %, aumento fibrinógeno (551 mg/dl), leve aumento de bilirrubina total (1,5 mg/dl), elevación transaminasas (GOT/GPT 179/240 U/l), LDH 6.460 mg/dl y PCR 60,9 mg/l.
En la radiografía de tórax, se objetiva un ensanchamiento mediastínico.
Diagnóstico
Dada la clínica y alteraciones analíticas debemos plantearnos un diagnóstico diferencial más allá de una infección respiratoria que no ha respondido a antibioterapia.
El paciente presenta clínica de deterioro del estado general progresivo, que relaciona directamente con descanso insuficiente, secundario al dolor lumbar que le provoca la postura antiálgica que debe adoptar tras la fractura de clavícula.
Sin embargo, puede que el aparente factor desencadenante, la fractura de clavícula, nos esté enmascarando el diagnóstico. Eliminando dicho componente, destaca como síntoma clave un dolor lumbar de difícil control con analgesia convencional que empeora por la noche, seguido de "dificultad para caminar" de menor tiempo de evolución, que en la exploración neurológica se traduce en alteración motora de la musculatura proximal de MMII y alteración sensitiva. En un paciente con una radiografía de tórax con ensanchamiento mediastínico y alteración de la función hepática, nuestra primera sospecha diagnóstica es un proceso neoplásico con afectación metastásica que debuta con un síndrome de compresión medular.
En este caso, el diagnóstico diferencial incluimos:
» Aneurisma aórtico: ensanchamiento mediastínico y disnea. No obstante, el nivel de la masa mediastínica no se relaciona con el nivel del dolor dorso/lumbar ni con la clínica motora y sensitiva, se palpan pulsos femorales y pedios normales y, aunque puede justificar el deterioro del estado general y la pérdida de peso, no justifica las alteraciones objetivadas en el análisis.
» Miastenia gravis: ensanchamiento mediastínico que podría corresponder a neoplasia tímica y debilidad proximal en MMII. Sin embargo, esta debilidad no presenta fluctuaciones ni mejoría con el descanso. Tampoco presenta afectación de oculomotores ni clínica bulbar. No justifica el dolor lumbar invalidante.
» Síndrome de Eaton Lambert: ensanchamiento mediastínico que podría corresponderse con proceso neoplásico y debilidad proximal. Sin embargo, ésta se mantiene constante durante el día sin mejorar con la actividad. Los reflejos osteotendinosos (ROT) resultaron normales. No justifica el dolor lumbar invalidante.
» Esclerosis lateral amiotrófica: debilidad muscular con fasciculaciones aisladas. El resto de la exploración (ROT conservados, alteración sensitiva en MII, etc.) no orienta a dicha enfermedad.
Tratamiento
Ante la alta sospecha de síndrome de compresión medular iniciamos tratamiento corticoide con 10 mg endovenoso de dexametasona y, dado que nuestro centro carece de resonancia magnética (RM) en Urgencias, solicitamos RM a primera hora de la mañana.
En el informe de la RM se describe infiltración metastásica difusa de la médula ósea de todo el esqueleto axial visualizado, así como una masa de partes blandas en el agujero de conjunción izquierdo y receso lateral izquierdo del espacio D11-D12. Además, se ve afectada la raíz D12 izquierda. La masa de partes blandas contacta con el saco tecal y con la médula, aunque sin datos de mielopatía en el momento actual.
Evolución
Ante estos resultados, el paciente ingresa a cargo de Oncología Médica para completar estudio de extensión y diagnóstico histológico. El caso es comentado con el servicio de Oncología radioterápica que, dada la afectación radicular sin datos de mielopatía y la ausencia de diagnóstico histológico, desestima radioterapia urgente.
El paciente presenta una evolución tórpida muy precipitada, con empeoramiento progresivo de la función hepática, tendente al sueño, en situación de apatoabulia. El día 21 de febrero, el paciente presenta un cuadro de marcada dificultad respiratoria, con desconexión del medio. Se presenta sin respuesta estímulos, taquipneico, con importante trabajo respiratorio, cianótico, con edema en esclavina. Todo ello compatible con un episodio de síndrome de vena cava superior (SVS).
Dada la inestabilidad hemodinámica y datos de sufrimiento, en un paciente con signos de neoplásica metastásica avanzada se acuerda con la familia iniciar sedación paliativa. El paciente fallece sin haber podido iniciar estudio de extensión ni obtener diagnóstico histológico.
Instructions: please typing these entity words according to sentence: neoplásico con afectación metastásica, neoplasia tímica, neoplásico, metastásica, neoplásica metastásica
Options: MORFOLOGIA_NEOPLASIA
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Anamnesis
Escenario clínico
Varón de 75 años que acude por segunda vez durante la última semana al Servicio de Urgencias por deterioro del estado general y clínica respiratoria. Desde el Servicio de Urgencias se solicita valoración por parte del equipo de guardia de Medicina Interna bajo sospecha de infección respiratoria que no ha respondido a antibioterapia.
Antecedentes personales
Paciente exfumador desde hace un año (IPA 70) e hipertenso. Actualmente jubilado, vida activa, independiente para todas las actividades básicas de la vida diaria.
Anamnesis
La anamnesis se presenta complicada. Paciente poco colaborador, malhumorado, irritable e inapetente.
El paciente acude al Servicio de Urgencias el día 12 de febrero de 2018 por deterioro del estado general y clínica respiratoria. Refiere dificultad respiratoria, tos y expectoración blanquecina, e incluso, hemoptisis. Recibe el alta sin ingreso con diagnóstico de infección respiratoria, e inicia antibioterapia con levofloxacino en domicilio.
Dos días más tarde, el día 15 de febrero, vuelve a acudir a dicho servicio por persistencia del deterioro de su estado basal. No ha percibido mejoría clínica, sino, al contrario, se encuentra tan debilitado que "no tiene fuerzas para caminar". El paciente insiste en que su deterioro tiene un desencadenante claro: una fractura de clavícula derecha que sufre mientras trabajaba en su huerta hace un mes y medio.
Refiere que, desde ese momento, la posición que debe adoptar por dicha fractura de clavícula le impide conciliar el sueño y que, además, comienza a ocasionarle dolor lumbar postural. Este dolor se intensifica con el paso de los días, sobre todo por la noche, al tener que dormir sobre un lateral.
Consulta en varias ocasiones en su centro de salud, recibiendo tratamiento analgésico que le alivia sólo parcialmente.
El paciente refiere que la imposibilidad de descansar adecuadamente ha deteriorado su estado general. Se encuentra muy cansado, debilitado, apenas come, por lo que refiere haber perdido algo de peso, no sale de casa. La debilidad es tal que hace días que "no tiene fuerzas para caminar". Además, desde hace varios días se le ha añadido el cuadro respiratorio descrito anteriormente para el cual está recibiendo tratamiento antibiótico.
Exploración física
La exploración física es poco llamativa. Paciente estable, eupneico, tolerando decúbito. En la auscultación pulmonar únicamente se detectan crepitantes finos bibasales. Destaca edema con fóvea leve a la presión hasta raíz de muslo.
Dada la clínica de "debilidad" que refiere el paciente, se realiza exploración neurológica en la que destaca: miembros inferiores (MMII) con paraparesia proximal de predominio derecho, con miembro inferior derecho (MID) a II/V proximal y miembro inferior izquierdo (MII) a III/IV proximal. Fuerza distal conservada a V/V de forma simétrica. Se objetivan fasciculaciones aisladas de localización proximal en MID. Sensibilidad tacto-algésica disminuida en muslo izquierdo.
Pruebas complementarias
En el análisis destaca una plaquetopenia de 63.000/mm3 , tiempo de protrombina 66 %, aumento fibrinógeno (551 mg/dl), leve aumento de bilirrubina total (1,5 mg/dl), elevación transaminasas (GOT/GPT 179/240 U/l), LDH 6.460 mg/dl y PCR 60,9 mg/l.
En la radiografía de tórax, se objetiva un ensanchamiento mediastínico.
Diagnóstico
Dada la clínica y alteraciones analíticas debemos plantearnos un diagnóstico diferencial más allá de una infección respiratoria que no ha respondido a antibioterapia.
El paciente presenta clínica de deterioro del estado general progresivo, que relaciona directamente con descanso insuficiente, secundario al dolor lumbar que le provoca la postura antiálgica que debe adoptar tras la fractura de clavícula.
Sin embargo, puede que el aparente factor desencadenante, la fractura de clavícula, nos esté enmascarando el diagnóstico. Eliminando dicho componente, destaca como síntoma clave un dolor lumbar de difícil control con analgesia convencional que empeora por la noche, seguido de "dificultad para caminar" de menor tiempo de evolución, que en la exploración neurológica se traduce en alteración motora de la musculatura proximal de MMII y alteración sensitiva. En un paciente con una radiografía de tórax con ensanchamiento mediastínico y alteración de la función hepática, nuestra primera sospecha diagnóstica es un proceso neoplásico con afectación metastásica que debuta con un síndrome de compresión medular.
En este caso, el diagnóstico diferencial incluimos:
» Aneurisma aórtico: ensanchamiento mediastínico y disnea. No obstante, el nivel de la masa mediastínica no se relaciona con el nivel del dolor dorso/lumbar ni con la clínica motora y sensitiva, se palpan pulsos femorales y pedios normales y, aunque puede justificar el deterioro del estado general y la pérdida de peso, no justifica las alteraciones objetivadas en el análisis.
» Miastenia gravis: ensanchamiento mediastínico que podría corresponder a neoplasia tímica y debilidad proximal en MMII. Sin embargo, esta debilidad no presenta fluctuaciones ni mejoría con el descanso. Tampoco presenta afectación de oculomotores ni clínica bulbar. No justifica el dolor lumbar invalidante.
» Síndrome de Eaton Lambert: ensanchamiento mediastínico que podría corresponderse con proceso neoplásico y debilidad proximal. Sin embargo, ésta se mantiene constante durante el día sin mejorar con la actividad. Los reflejos osteotendinosos (ROT) resultaron normales. No justifica el dolor lumbar invalidante.
» Esclerosis lateral amiotrófica: debilidad muscular con fasciculaciones aisladas. El resto de la exploración (ROT conservados, alteración sensitiva en MII, etc.) no orienta a dicha enfermedad.
Tratamiento
Ante la alta sospecha de síndrome de compresión medular iniciamos tratamiento corticoide con 10 mg endovenoso de dexametasona y, dado que nuestro centro carece de resonancia magnética (RM) en Urgencias, solicitamos RM a primera hora de la mañana.
En el informe de la RM se describe infiltración metastásica difusa de la médula ósea de todo el esqueleto axial visualizado, así como una masa de partes blandas en el agujero de conjunción izquierdo y receso lateral izquierdo del espacio D11-D12. Además, se ve afectada la raíz D12 izquierda. La masa de partes blandas contacta con el saco tecal y con la médula, aunque sin datos de mielopatía en el momento actual.
Evolución
Ante estos resultados, el paciente ingresa a cargo de Oncología Médica para completar estudio de extensión y diagnóstico histológico. El caso es comentado con el servicio de Oncología radioterápica que, dada la afectación radicular sin datos de mielopatía y la ausencia de diagnóstico histológico, desestima radioterapia urgente.
El paciente presenta una evolución tórpida muy precipitada, con empeoramiento progresivo de la función hepática, tendente al sueño, en situación de apatoabulia. El día 21 de febrero, el paciente presenta un cuadro de marcada dificultad respiratoria, con desconexión del medio. Se presenta sin respuesta estímulos, taquipneico, con importante trabajo respiratorio, cianótico, con edema en esclavina. Todo ello compatible con un episodio de síndrome de vena cava superior (SVS).
Dada la inestabilidad hemodinámica y datos de sufrimiento, en un paciente con signos de neoplásica metastásica avanzada se acuerda con la familia iniciar sedación paliativa. El paciente fallece sin haber podido iniciar estudio de extensión ni obtener diagnóstico histológico.
|
[
"Anamnesis",
"\n",
"Escenario",
"clínico",
"\n",
"Varón",
"de",
"75",
"años",
"que",
"acude",
"por",
"segunda",
"vez",
"durante",
"la",
"última",
"semana",
"al",
"Servicio",
"de",
"Urgencias",
"por",
"deterioro",
"del",
"estado",
"general",
"y",
"clínica",
"respiratoria",
".",
"Desde",
"el",
"Servicio",
"de",
"Urgencias",
"se",
"solicita",
"valoración",
"por",
"parte",
"del",
"equipo",
"de",
"guardia",
"de",
"Medicina",
"Interna",
"bajo",
"sospecha",
"de",
"infección",
"respiratoria",
"que",
"no",
"ha",
"respondido",
"a",
"antibioterapia",
".",
"\n\n",
"Antecedentes",
"personales",
"\n",
"Paciente",
"exfumador",
"desde",
"hace",
"un",
"año",
"(",
"IPA",
"70",
")",
"e",
"hipertenso",
".",
"Actualmente",
"jubilado",
",",
"vida",
"activa",
",",
"independiente",
"para",
"todas",
"las",
"actividades",
"básicas",
"de",
"la",
"vida",
"diaria",
".",
"\n",
"Anamnesis",
"\n",
"La",
"anamnesis",
"se",
"presenta",
"complicada",
".",
"Paciente",
"poco",
"colaborador",
",",
"malhumorado",
",",
"irritable",
"e",
"inapetente",
".",
"\n",
"El",
"paciente",
"acude",
"al",
"Servicio",
"de",
"Urgencias",
"el",
"día",
"12",
"de",
"febrero",
"de",
"2018",
"por",
"deterioro",
"del",
"estado",
"general",
"y",
"clínica",
"respiratoria",
".",
"Refiere",
"dificultad",
"respiratoria",
",",
"tos",
"y",
"expectoración",
"blanquecina",
",",
"e",
"incluso",
",",
"hemoptisis",
".",
"Recibe",
"el",
"alta",
"sin",
"ingreso",
"con",
"diagnóstico",
"de",
"infección",
"respiratoria",
",",
"e",
"inicia",
"antibioterapia",
"con",
"levofloxacino",
"en",
"domicilio",
".",
"\n",
"Dos",
"días",
"más",
"tarde",
",",
"el",
"día",
"15",
"de",
"febrero",
",",
"vuelve",
"a",
"acudir",
"a",
"dicho",
"servicio",
"por",
"persistencia",
"del",
"deterioro",
"de",
"su",
"estado",
"basal",
".",
"No",
"ha",
"percibido",
"mejoría",
"clínica",
",",
"sino",
",",
"al",
"contrario",
",",
"se",
"encuentra",
"tan",
"debilitado",
"que",
"\"",
"no",
"tiene",
"fuerzas",
"para",
"caminar",
"\"",
".",
"El",
"paciente",
"insiste",
"en",
"que",
"su",
"deterioro",
"tiene",
"un",
"desencadenante",
"claro",
":",
"una",
"fractura",
"de",
"clavícula",
"derecha",
"que",
"sufre",
"mientras",
"trabajaba",
"en",
"su",
"huerta",
"hace",
"un",
"mes",
"y",
"medio",
".",
"\n",
"Refiere",
"que",
",",
"desde",
"ese",
"momento",
",",
"la",
"posición",
"que",
"debe",
"adoptar",
"por",
"dicha",
"fractura",
"de",
"clavícula",
"le",
"impide",
"conciliar",
"el",
"sueño",
"y",
"que",
",",
"además",
",",
"comienza",
"a",
"ocasionarle",
"dolor",
"lumbar",
"postural",
".",
"Este",
"dolor",
"se",
"intensifica",
"con",
"el",
"paso",
"de",
"los",
"días",
",",
"sobre",
"todo",
"por",
"la",
"noche",
",",
"al",
"tener",
"que",
"dormir",
"sobre",
"un",
"lateral",
".",
"\n",
"Consulta",
"en",
"varias",
"ocasiones",
"en",
"su",
"centro",
"de",
"salud",
",",
"recibiendo",
"tratamiento",
"analgésico",
"que",
"le",
"alivia",
"sólo",
"parcialmente",
".",
"\n",
"El",
"paciente",
"refiere",
"que",
"la",
"imposibilidad",
"de",
"descansar",
"adecuadamente",
"ha",
"deteriorado",
"su",
"estado",
"general",
".",
"Se",
"encuentra",
"muy",
"cansado",
",",
"debilitado",
",",
"apenas",
"come",
",",
"por",
"lo",
"que",
"refiere",
"haber",
"perdido",
"algo",
"de",
"peso",
",",
"no",
"sale",
"de",
"casa",
".",
"La",
"debilidad",
"es",
"tal",
"que",
"hace",
"días",
"que",
"\"",
"no",
"tiene",
"fuerzas",
"para",
"caminar",
"\"",
".",
"Además",
",",
"desde",
"hace",
"varios",
"días",
"se",
"le",
"ha",
"añadido",
"el",
"cuadro",
"respiratorio",
"descrito",
"anteriormente",
"para",
"el",
"cual",
"está",
"recibiendo",
"tratamiento",
"antibiótico",
".",
"\n\n",
"Exploración",
"física",
"\n",
"La",
"exploración",
"física",
"es",
"poco",
"llamativa",
".",
"Paciente",
"estable",
",",
"eupneico",
",",
"tolerando",
"decúbito",
".",
"En",
"la",
"auscultación",
"pulmonar",
"únicamente",
"se",
"detectan",
"crepitantes",
"finos",
"bibasales",
".",
"Destaca",
"edema",
"con",
"fóvea",
"leve",
"a",
"la",
"presión",
"hasta",
"raíz",
"de",
"muslo",
".",
"\n",
"Dada",
"la",
"clínica",
"de",
"\"",
"debilidad",
"\"",
"que",
"refiere",
"el",
"paciente",
",",
"se",
"realiza",
"exploración",
"neurológica",
"en",
"la",
"que",
"destaca",
":",
"miembros",
"inferiores",
"(",
"MMII",
")",
"con",
"paraparesia",
"proximal",
"de",
"predominio",
"derecho",
",",
"con",
"miembro",
"inferior",
"derecho",
"(",
"MID",
")",
"a",
"II",
"/",
"V",
"proximal",
"y",
"miembro",
"inferior",
"izquierdo",
"(",
"MII",
")",
"a",
"III",
"/",
"IV",
"proximal",
".",
"Fuerza",
"distal",
"conservada",
"a",
"V",
"/",
"V",
"de",
"forma",
"simétrica",
".",
"Se",
"objetivan",
"fasciculaciones",
"aisladas",
"de",
"localización",
"proximal",
"en",
"MID",
".",
"Sensibilidad",
"tacto",
"-",
"algésica",
"disminuida",
"en",
"muslo",
"izquierdo",
".",
"\n\n",
"Pruebas",
"complementarias",
"\n",
"En",
"el",
"análisis",
"destaca",
"una",
"plaquetopenia",
"de",
"63.000",
"/",
"mm3",
",",
"tiempo",
"de",
"protrombina",
"66",
"%",
",",
"aumento",
"fibrinógeno",
"(",
"551",
"mg",
"/",
"dl",
")",
",",
"leve",
"aumento",
"de",
"bilirrubina",
"total",
"(",
"1,5",
"mg",
"/",
"dl",
")",
",",
"elevación",
"transaminasas",
"(",
"GOT",
"/",
"GPT",
"179/240",
"U",
"/",
"l",
")",
",",
"LDH",
"6.460",
"mg",
"/",
"dl",
"y",
"PCR",
"60,9",
"mg",
"/",
"l.",
"\n",
"En",
"la",
"radiografía",
"de",
"tórax",
",",
"se",
"objetiva",
"un",
"ensanchamiento",
"mediastínico",
".",
"\n\n",
"Diagnóstico",
"\n",
"Dada",
"la",
"clínica",
"y",
"alteraciones",
"analíticas",
"debemos",
"plantearnos",
"un",
"diagnóstico",
"diferencial",
"más",
"allá",
"de",
"una",
"infección",
"respiratoria",
"que",
"no",
"ha",
"respondido",
"a",
"antibioterapia",
".",
"\n",
"El",
"paciente",
"presenta",
"clínica",
"de",
"deterioro",
"del",
"estado",
"general",
"progresivo",
",",
"que",
"relaciona",
"directamente",
"con",
"descanso",
"insuficiente",
",",
"secundario",
"al",
"dolor",
"lumbar",
"que",
"le",
"provoca",
"la",
"postura",
"antiálgica",
"que",
"debe",
"adoptar",
"tras",
"la",
"fractura",
"de",
"clavícula",
".",
"\n",
"Sin",
"embargo",
",",
"puede",
"que",
"el",
"aparente",
"factor",
"desencadenante",
",",
"la",
"fractura",
"de",
"clavícula",
",",
"nos",
"esté",
"enmascarando",
"el",
"diagnóstico",
".",
"Eliminando",
"dicho",
"componente",
",",
"destaca",
"como",
"síntoma",
"clave",
"un",
"dolor",
"lumbar",
"de",
"difícil",
"control",
"con",
"analgesia",
"convencional",
"que",
"empeora",
"por",
"la",
"noche",
",",
"seguido",
"de",
"\"",
"dificultad",
"para",
"caminar",
"\"",
"de",
"menor",
"tiempo",
"de",
"evolución",
",",
"que",
"en",
"la",
"exploración",
"neurológica",
"se",
"traduce",
"en",
"alteración",
"motora",
"de",
"la",
"musculatura",
"proximal",
"de",
"MMII",
"y",
"alteración",
"sensitiva",
".",
"En",
"un",
"paciente",
"con",
"una",
"radiografía",
"de",
"tórax",
"con",
"ensanchamiento",
"mediastínico",
"y",
"alteración",
"de",
"la",
"función",
"hepática",
",",
"nuestra",
"primera",
"sospecha",
"diagnóstica",
"es",
"un",
"proceso",
"neoplásico",
"con",
"afectación",
"metastásica",
"que",
"debuta",
"con",
"un",
"síndrome",
"de",
"compresión",
"medular",
".",
"\n",
"En",
"este",
"caso",
",",
"el",
"diagnóstico",
"diferencial",
"incluimos",
":",
"\n",
"»",
"Aneurisma",
"aórtico",
":",
"ensanchamiento",
"mediastínico",
"y",
"disnea",
".",
"No",
"obstante",
",",
"el",
"nivel",
"de",
"la",
"masa",
"mediastínica",
"no",
"se",
"relaciona",
"con",
"el",
"nivel",
"del",
"dolor",
"dorso",
"/",
"lumbar",
"ni",
"con",
"la",
"clínica",
"motora",
"y",
"sensitiva",
",",
"se",
"palpan",
"pulsos",
"femorales",
"y",
"pedios",
"normales",
"y",
",",
"aunque",
"puede",
"justificar",
"el",
"deterioro",
"del",
"estado",
"general",
"y",
"la",
"pérdida",
"de",
"peso",
",",
"no",
"justifica",
"las",
"alteraciones",
"objetivadas",
"en",
"el",
"análisis",
".",
"\n",
"»",
"Miastenia",
"gravis",
":",
"ensanchamiento",
"mediastínico",
"que",
"podría",
"corresponder",
"a",
"neoplasia",
"tímica",
"y",
"debilidad",
"proximal",
"en",
"MMII",
".",
"Sin",
"embargo",
",",
"esta",
"debilidad",
"no",
"presenta",
"fluctuaciones",
"ni",
"mejoría",
"con",
"el",
"descanso",
".",
"Tampoco",
"presenta",
"afectación",
"de",
"oculomotores",
"ni",
"clínica",
"bulbar",
".",
"No",
"justifica",
"el",
"dolor",
"lumbar",
"invalidante",
".",
"\n",
"»",
"Síndrome",
"de",
"Eaton",
"Lambert",
":",
"ensanchamiento",
"mediastínico",
"que",
"podría",
"corresponderse",
"con",
"proceso",
"neoplásico",
"y",
"debilidad",
"proximal",
".",
"Sin",
"embargo",
",",
"ésta",
"se",
"mantiene",
"constante",
"durante",
"el",
"día",
"sin",
"mejorar",
"con",
"la",
"actividad",
".",
"Los",
"reflejos",
"osteotendinosos",
"(",
"ROT",
")",
"resultaron",
"normales",
".",
"No",
"justifica",
"el",
"dolor",
"lumbar",
"invalidante",
".",
"\n",
"»",
"Esclerosis",
"lateral",
"amiotrófica",
":",
"debilidad",
"muscular",
"con",
"fasciculaciones",
"aisladas",
".",
"El",
"resto",
"de",
"la",
"exploración",
"(",
"ROT",
"conservados",
",",
"alteración",
"sensitiva",
"en",
"MII",
",",
"etc",
".",
")",
"no",
"orienta",
"a",
"dicha",
"enfermedad",
".",
"\n\n",
"Tratamiento",
"\n",
"Ante",
"la",
"alta",
"sospecha",
"de",
"síndrome",
"de",
"compresión",
"medular",
"iniciamos",
"tratamiento",
"corticoide",
"con",
"10",
"mg",
"endovenoso",
"de",
"dexametasona",
"y",
",",
"dado",
"que",
"nuestro",
"centro",
"carece",
"de",
"resonancia",
"magnética",
"(",
"RM",
")",
"en",
"Urgencias",
",",
"solicitamos",
"RM",
"a",
"primera",
"hora",
"de",
"la",
"mañana",
".",
"\n",
"En",
"el",
"informe",
"de",
"la",
"RM",
"se",
"describe",
"infiltración",
"metastásica",
"difusa",
"de",
"la",
"médula",
"ósea",
"de",
"todo",
"el",
"esqueleto",
"axial",
"visualizado",
",",
"así",
"como",
"una",
"masa",
"de",
"partes",
"blandas",
"en",
"el",
"agujero",
"de",
"conjunción",
"izquierdo",
"y",
"receso",
"lateral",
"izquierdo",
"del",
"espacio",
"D11-D12",
".",
"Además",
",",
"se",
"ve",
"afectada",
"la",
"raíz",
"D12",
"izquierda",
".",
"La",
"masa",
"de",
"partes",
"blandas",
"contacta",
"con",
"el",
"saco",
"tecal",
"y",
"con",
"la",
"médula",
",",
"aunque",
"sin",
"datos",
"de",
"mielopatía",
"en",
"el",
"momento",
"actual",
".",
"\n\n",
"Evolución",
"\n",
"Ante",
"estos",
"resultados",
",",
"el",
"paciente",
"ingresa",
"a",
"cargo",
"de",
"Oncología",
"Médica",
"para",
"completar",
"estudio",
"de",
"extensión",
"y",
"diagnóstico",
"histológico",
".",
"El",
"caso",
"es",
"comentado",
"con",
"el",
"servicio",
"de",
"Oncología",
"radioterápica",
"que",
",",
"dada",
"la",
"afectación",
"radicular",
"sin",
"datos",
"de",
"mielopatía",
"y",
"la",
"ausencia",
"de",
"diagnóstico",
"histológico",
",",
"desestima",
"radioterapia",
"urgente",
".",
"\n",
"El",
"paciente",
"presenta",
"una",
"evolución",
"tórpida",
"muy",
"precipitada",
",",
"con",
"empeoramiento",
"progresivo",
"de",
"la",
"función",
"hepática",
",",
"tendente",
"al",
"sueño",
",",
"en",
"situación",
"de",
"apatoabulia",
".",
"El",
"día",
"21",
"de",
"febrero",
",",
"el",
"paciente",
"presenta",
"un",
"cuadro",
"de",
"marcada",
"dificultad",
"respiratoria",
",",
"con",
"desconexión",
"del",
"medio",
".",
"Se",
"presenta",
"sin",
"respuesta",
"estímulos",
",",
"taquipneico",
",",
"con",
"importante",
"trabajo",
"respiratorio",
",",
"cianótico",
",",
"con",
"edema",
"en",
"esclavina",
".",
"Todo",
"ello",
"compatible",
"con",
"un",
"episodio",
"de",
"síndrome",
"de",
"vena",
"cava",
"superior",
"(",
"SVS",
")",
".",
"\n",
"Dada",
"la",
"inestabilidad",
"hemodinámica",
"y",
"datos",
"de",
"sufrimiento",
",",
"en",
"un",
"paciente",
"con",
"signos",
"de",
"neoplásica",
"metastásica",
"avanzada",
"se",
"acuerda",
"con",
"la",
"familia",
"iniciar",
"sedación",
"paliativa",
".",
"El",
"paciente",
"fallece",
"sin",
"haber",
"podido",
"iniciar",
"estudio",
"de",
"extensión",
"ni",
"obtener",
"diagnóstico",
"histológico",
"."
] |
[
"MORFOLOGIA_NEOPLASIA"
] |
neoplásico con afectación metastásica, neoplasia tímica, neoplásico, metastásica, neoplásica metastásica
|
727_task2
|
Sentence: Anamnesis
Escenario clínico
Varón de 75 años que acude por segunda vez durante la última semana al Servicio de Urgencias por deterioro del estado general y clínica respiratoria. Desde el Servicio de Urgencias se solicita valoración por parte del equipo de guardia de Medicina Interna bajo sospecha de infección respiratoria que no ha respondido a antibioterapia.
Antecedentes personales
Paciente exfumador desde hace un año (IPA 70) e hipertenso. Actualmente jubilado, vida activa, independiente para todas las actividades básicas de la vida diaria.
Anamnesis
La anamnesis se presenta complicada. Paciente poco colaborador, malhumorado, irritable e inapetente.
El paciente acude al Servicio de Urgencias el día 12 de febrero de 2018 por deterioro del estado general y clínica respiratoria. Refiere dificultad respiratoria, tos y expectoración blanquecina, e incluso, hemoptisis. Recibe el alta sin ingreso con diagnóstico de infección respiratoria, e inicia antibioterapia con levofloxacino en domicilio.
Dos días más tarde, el día 15 de febrero, vuelve a acudir a dicho servicio por persistencia del deterioro de su estado basal. No ha percibido mejoría clínica, sino, al contrario, se encuentra tan debilitado que "no tiene fuerzas para caminar". El paciente insiste en que su deterioro tiene un desencadenante claro: una fractura de clavícula derecha que sufre mientras trabajaba en su huerta hace un mes y medio.
Refiere que, desde ese momento, la posición que debe adoptar por dicha fractura de clavícula le impide conciliar el sueño y que, además, comienza a ocasionarle dolor lumbar postural. Este dolor se intensifica con el paso de los días, sobre todo por la noche, al tener que dormir sobre un lateral.
Consulta en varias ocasiones en su centro de salud, recibiendo tratamiento analgésico que le alivia sólo parcialmente.
El paciente refiere que la imposibilidad de descansar adecuadamente ha deteriorado su estado general. Se encuentra muy cansado, debilitado, apenas come, por lo que refiere haber perdido algo de peso, no sale de casa. La debilidad es tal que hace días que "no tiene fuerzas para caminar". Además, desde hace varios días se le ha añadido el cuadro respiratorio descrito anteriormente para el cual está recibiendo tratamiento antibiótico.
Exploración física
La exploración física es poco llamativa. Paciente estable, eupneico, tolerando decúbito. En la auscultación pulmonar únicamente se detectan crepitantes finos bibasales. Destaca edema con fóvea leve a la presión hasta raíz de muslo.
Dada la clínica de "debilidad" que refiere el paciente, se realiza exploración neurológica en la que destaca: miembros inferiores (MMII) con paraparesia proximal de predominio derecho, con miembro inferior derecho (MID) a II/V proximal y miembro inferior izquierdo (MII) a III/IV proximal. Fuerza distal conservada a V/V de forma simétrica. Se objetivan fasciculaciones aisladas de localización proximal en MID. Sensibilidad tacto-algésica disminuida en muslo izquierdo.
Pruebas complementarias
En el análisis destaca una plaquetopenia de 63.000/mm3 , tiempo de protrombina 66 %, aumento fibrinógeno (551 mg/dl), leve aumento de bilirrubina total (1,5 mg/dl), elevación transaminasas (GOT/GPT 179/240 U/l), LDH 6.460 mg/dl y PCR 60,9 mg/l.
En la radiografía de tórax, se objetiva un ensanchamiento mediastínico.
Diagnóstico
Dada la clínica y alteraciones analíticas debemos plantearnos un diagnóstico diferencial más allá de una infección respiratoria que no ha respondido a antibioterapia.
El paciente presenta clínica de deterioro del estado general progresivo, que relaciona directamente con descanso insuficiente, secundario al dolor lumbar que le provoca la postura antiálgica que debe adoptar tras la fractura de clavícula.
Sin embargo, puede que el aparente factor desencadenante, la fractura de clavícula, nos esté enmascarando el diagnóstico. Eliminando dicho componente, destaca como síntoma clave un dolor lumbar de difícil control con analgesia convencional que empeora por la noche, seguido de "dificultad para caminar" de menor tiempo de evolución, que en la exploración neurológica se traduce en alteración motora de la musculatura proximal de MMII y alteración sensitiva. En un paciente con una radiografía de tórax con ensanchamiento mediastínico y alteración de la función hepática, nuestra primera sospecha diagnóstica es un proceso neoplásico con afectación metastásica que debuta con un síndrome de compresión medular.
En este caso, el diagnóstico diferencial incluimos:
» Aneurisma aórtico: ensanchamiento mediastínico y disnea. No obstante, el nivel de la masa mediastínica no se relaciona con el nivel del dolor dorso/lumbar ni con la clínica motora y sensitiva, se palpan pulsos femorales y pedios normales y, aunque puede justificar el deterioro del estado general y la pérdida de peso, no justifica las alteraciones objetivadas en el análisis.
» Miastenia gravis: ensanchamiento mediastínico que podría corresponder a neoplasia tímica y debilidad proximal en MMII. Sin embargo, esta debilidad no presenta fluctuaciones ni mejoría con el descanso. Tampoco presenta afectación de oculomotores ni clínica bulbar. No justifica el dolor lumbar invalidante.
» Síndrome de Eaton Lambert: ensanchamiento mediastínico que podría corresponderse con proceso neoplásico y debilidad proximal. Sin embargo, ésta se mantiene constante durante el día sin mejorar con la actividad. Los reflejos osteotendinosos (ROT) resultaron normales. No justifica el dolor lumbar invalidante.
» Esclerosis lateral amiotrófica: debilidad muscular con fasciculaciones aisladas. El resto de la exploración (ROT conservados, alteración sensitiva en MII, etc.) no orienta a dicha enfermedad.
Tratamiento
Ante la alta sospecha de síndrome de compresión medular iniciamos tratamiento corticoide con 10 mg endovenoso de dexametasona y, dado que nuestro centro carece de resonancia magnética (RM) en Urgencias, solicitamos RM a primera hora de la mañana.
En el informe de la RM se describe infiltración metastásica difusa de la médula ósea de todo el esqueleto axial visualizado, así como una masa de partes blandas en el agujero de conjunción izquierdo y receso lateral izquierdo del espacio D11-D12. Además, se ve afectada la raíz D12 izquierda. La masa de partes blandas contacta con el saco tecal y con la médula, aunque sin datos de mielopatía en el momento actual.
Evolución
Ante estos resultados, el paciente ingresa a cargo de Oncología Médica para completar estudio de extensión y diagnóstico histológico. El caso es comentado con el servicio de Oncología radioterápica que, dada la afectación radicular sin datos de mielopatía y la ausencia de diagnóstico histológico, desestima radioterapia urgente.
El paciente presenta una evolución tórpida muy precipitada, con empeoramiento progresivo de la función hepática, tendente al sueño, en situación de apatoabulia. El día 21 de febrero, el paciente presenta un cuadro de marcada dificultad respiratoria, con desconexión del medio. Se presenta sin respuesta estímulos, taquipneico, con importante trabajo respiratorio, cianótico, con edema en esclavina. Todo ello compatible con un episodio de síndrome de vena cava superior (SVS).
Dada la inestabilidad hemodinámica y datos de sufrimiento, en un paciente con signos de neoplásica metastásica avanzada se acuerda con la familia iniciar sedación paliativa. El paciente fallece sin haber podido iniciar estudio de extensión ni obtener diagnóstico histológico.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Anamnesis
Escenario clínico
Varón de 75 años que acude por segunda vez durante la última semana al Servicio de Urgencias por deterioro del estado general y clínica respiratoria. Desde el Servicio de Urgencias se solicita valoración por parte del equipo de guardia de Medicina Interna bajo sospecha de infección respiratoria que no ha respondido a antibioterapia.
Antecedentes personales
Paciente exfumador desde hace un año (IPA 70) e hipertenso. Actualmente jubilado, vida activa, independiente para todas las actividades básicas de la vida diaria.
Anamnesis
La anamnesis se presenta complicada. Paciente poco colaborador, malhumorado, irritable e inapetente.
El paciente acude al Servicio de Urgencias el día 12 de febrero de 2018 por deterioro del estado general y clínica respiratoria. Refiere dificultad respiratoria, tos y expectoración blanquecina, e incluso, hemoptisis. Recibe el alta sin ingreso con diagnóstico de infección respiratoria, e inicia antibioterapia con levofloxacino en domicilio.
Dos días más tarde, el día 15 de febrero, vuelve a acudir a dicho servicio por persistencia del deterioro de su estado basal. No ha percibido mejoría clínica, sino, al contrario, se encuentra tan debilitado que "no tiene fuerzas para caminar". El paciente insiste en que su deterioro tiene un desencadenante claro: una fractura de clavícula derecha que sufre mientras trabajaba en su huerta hace un mes y medio.
Refiere que, desde ese momento, la posición que debe adoptar por dicha fractura de clavícula le impide conciliar el sueño y que, además, comienza a ocasionarle dolor lumbar postural. Este dolor se intensifica con el paso de los días, sobre todo por la noche, al tener que dormir sobre un lateral.
Consulta en varias ocasiones en su centro de salud, recibiendo tratamiento analgésico que le alivia sólo parcialmente.
El paciente refiere que la imposibilidad de descansar adecuadamente ha deteriorado su estado general. Se encuentra muy cansado, debilitado, apenas come, por lo que refiere haber perdido algo de peso, no sale de casa. La debilidad es tal que hace días que "no tiene fuerzas para caminar". Además, desde hace varios días se le ha añadido el cuadro respiratorio descrito anteriormente para el cual está recibiendo tratamiento antibiótico.
Exploración física
La exploración física es poco llamativa. Paciente estable, eupneico, tolerando decúbito. En la auscultación pulmonar únicamente se detectan crepitantes finos bibasales. Destaca edema con fóvea leve a la presión hasta raíz de muslo.
Dada la clínica de "debilidad" que refiere el paciente, se realiza exploración neurológica en la que destaca: miembros inferiores (MMII) con paraparesia proximal de predominio derecho, con miembro inferior derecho (MID) a II/V proximal y miembro inferior izquierdo (MII) a III/IV proximal. Fuerza distal conservada a V/V de forma simétrica. Se objetivan fasciculaciones aisladas de localización proximal en MID. Sensibilidad tacto-algésica disminuida en muslo izquierdo.
Pruebas complementarias
En el análisis destaca una plaquetopenia de 63.000/mm3 , tiempo de protrombina 66 %, aumento fibrinógeno (551 mg/dl), leve aumento de bilirrubina total (1,5 mg/dl), elevación transaminasas (GOT/GPT 179/240 U/l), LDH 6.460 mg/dl y PCR 60,9 mg/l.
En la radiografía de tórax, se objetiva un ensanchamiento mediastínico.
Diagnóstico
Dada la clínica y alteraciones analíticas debemos plantearnos un diagnóstico diferencial más allá de una infección respiratoria que no ha respondido a antibioterapia.
El paciente presenta clínica de deterioro del estado general progresivo, que relaciona directamente con descanso insuficiente, secundario al dolor lumbar que le provoca la postura antiálgica que debe adoptar tras la fractura de clavícula.
Sin embargo, puede que el aparente factor desencadenante, la fractura de clavícula, nos esté enmascarando el diagnóstico. Eliminando dicho componente, destaca como síntoma clave un dolor lumbar de difícil control con analgesia convencional que empeora por la noche, seguido de "dificultad para caminar" de menor tiempo de evolución, que en la exploración neurológica se traduce en alteración motora de la musculatura proximal de MMII y alteración sensitiva. En un paciente con una radiografía de tórax con ensanchamiento mediastínico y alteración de la función hepática, nuestra primera sospecha diagnóstica es un proceso neoplásico con afectación metastásica que debuta con un síndrome de compresión medular.
En este caso, el diagnóstico diferencial incluimos:
» Aneurisma aórtico: ensanchamiento mediastínico y disnea. No obstante, el nivel de la masa mediastínica no se relaciona con el nivel del dolor dorso/lumbar ni con la clínica motora y sensitiva, se palpan pulsos femorales y pedios normales y, aunque puede justificar el deterioro del estado general y la pérdida de peso, no justifica las alteraciones objetivadas en el análisis.
» Miastenia gravis: ensanchamiento mediastínico que podría corresponder a neoplasia tímica y debilidad proximal en MMII. Sin embargo, esta debilidad no presenta fluctuaciones ni mejoría con el descanso. Tampoco presenta afectación de oculomotores ni clínica bulbar. No justifica el dolor lumbar invalidante.
» Síndrome de Eaton Lambert: ensanchamiento mediastínico que podría corresponderse con proceso neoplásico y debilidad proximal. Sin embargo, ésta se mantiene constante durante el día sin mejorar con la actividad. Los reflejos osteotendinosos (ROT) resultaron normales. No justifica el dolor lumbar invalidante.
» Esclerosis lateral amiotrófica: debilidad muscular con fasciculaciones aisladas. El resto de la exploración (ROT conservados, alteración sensitiva en MII, etc.) no orienta a dicha enfermedad.
Tratamiento
Ante la alta sospecha de síndrome de compresión medular iniciamos tratamiento corticoide con 10 mg endovenoso de dexametasona y, dado que nuestro centro carece de resonancia magnética (RM) en Urgencias, solicitamos RM a primera hora de la mañana.
En el informe de la RM se describe infiltración metastásica difusa de la médula ósea de todo el esqueleto axial visualizado, así como una masa de partes blandas en el agujero de conjunción izquierdo y receso lateral izquierdo del espacio D11-D12. Además, se ve afectada la raíz D12 izquierda. La masa de partes blandas contacta con el saco tecal y con la médula, aunque sin datos de mielopatía en el momento actual.
Evolución
Ante estos resultados, el paciente ingresa a cargo de Oncología Médica para completar estudio de extensión y diagnóstico histológico. El caso es comentado con el servicio de Oncología radioterápica que, dada la afectación radicular sin datos de mielopatía y la ausencia de diagnóstico histológico, desestima radioterapia urgente.
El paciente presenta una evolución tórpida muy precipitada, con empeoramiento progresivo de la función hepática, tendente al sueño, en situación de apatoabulia. El día 21 de febrero, el paciente presenta un cuadro de marcada dificultad respiratoria, con desconexión del medio. Se presenta sin respuesta estímulos, taquipneico, con importante trabajo respiratorio, cianótico, con edema en esclavina. Todo ello compatible con un episodio de síndrome de vena cava superior (SVS).
Dada la inestabilidad hemodinámica y datos de sufrimiento, en un paciente con signos de neoplásica metastásica avanzada se acuerda con la familia iniciar sedación paliativa. El paciente fallece sin haber podido iniciar estudio de extensión ni obtener diagnóstico histológico.
|
[
"Anamnesis",
"\n",
"Escenario",
"clínico",
"\n",
"Varón",
"de",
"75",
"años",
"que",
"acude",
"por",
"segunda",
"vez",
"durante",
"la",
"última",
"semana",
"al",
"Servicio",
"de",
"Urgencias",
"por",
"deterioro",
"del",
"estado",
"general",
"y",
"clínica",
"respiratoria",
".",
"Desde",
"el",
"Servicio",
"de",
"Urgencias",
"se",
"solicita",
"valoración",
"por",
"parte",
"del",
"equipo",
"de",
"guardia",
"de",
"Medicina",
"Interna",
"bajo",
"sospecha",
"de",
"infección",
"respiratoria",
"que",
"no",
"ha",
"respondido",
"a",
"antibioterapia",
".",
"\n\n",
"Antecedentes",
"personales",
"\n",
"Paciente",
"exfumador",
"desde",
"hace",
"un",
"año",
"(",
"IPA",
"70",
")",
"e",
"hipertenso",
".",
"Actualmente",
"jubilado",
",",
"vida",
"activa",
",",
"independiente",
"para",
"todas",
"las",
"actividades",
"básicas",
"de",
"la",
"vida",
"diaria",
".",
"\n",
"Anamnesis",
"\n",
"La",
"anamnesis",
"se",
"presenta",
"complicada",
".",
"Paciente",
"poco",
"colaborador",
",",
"malhumorado",
",",
"irritable",
"e",
"inapetente",
".",
"\n",
"El",
"paciente",
"acude",
"al",
"Servicio",
"de",
"Urgencias",
"el",
"día",
"12",
"de",
"febrero",
"de",
"2018",
"por",
"deterioro",
"del",
"estado",
"general",
"y",
"clínica",
"respiratoria",
".",
"Refiere",
"dificultad",
"respiratoria",
",",
"tos",
"y",
"expectoración",
"blanquecina",
",",
"e",
"incluso",
",",
"hemoptisis",
".",
"Recibe",
"el",
"alta",
"sin",
"ingreso",
"con",
"diagnóstico",
"de",
"infección",
"respiratoria",
",",
"e",
"inicia",
"antibioterapia",
"con",
"levofloxacino",
"en",
"domicilio",
".",
"\n",
"Dos",
"días",
"más",
"tarde",
",",
"el",
"día",
"15",
"de",
"febrero",
",",
"vuelve",
"a",
"acudir",
"a",
"dicho",
"servicio",
"por",
"persistencia",
"del",
"deterioro",
"de",
"su",
"estado",
"basal",
".",
"No",
"ha",
"percibido",
"mejoría",
"clínica",
",",
"sino",
",",
"al",
"contrario",
",",
"se",
"encuentra",
"tan",
"debilitado",
"que",
"\"",
"no",
"tiene",
"fuerzas",
"para",
"caminar",
"\"",
".",
"El",
"paciente",
"insiste",
"en",
"que",
"su",
"deterioro",
"tiene",
"un",
"desencadenante",
"claro",
":",
"una",
"fractura",
"de",
"clavícula",
"derecha",
"que",
"sufre",
"mientras",
"trabajaba",
"en",
"su",
"huerta",
"hace",
"un",
"mes",
"y",
"medio",
".",
"\n",
"Refiere",
"que",
",",
"desde",
"ese",
"momento",
",",
"la",
"posición",
"que",
"debe",
"adoptar",
"por",
"dicha",
"fractura",
"de",
"clavícula",
"le",
"impide",
"conciliar",
"el",
"sueño",
"y",
"que",
",",
"además",
",",
"comienza",
"a",
"ocasionarle",
"dolor",
"lumbar",
"postural",
".",
"Este",
"dolor",
"se",
"intensifica",
"con",
"el",
"paso",
"de",
"los",
"días",
",",
"sobre",
"todo",
"por",
"la",
"noche",
",",
"al",
"tener",
"que",
"dormir",
"sobre",
"un",
"lateral",
".",
"\n",
"Consulta",
"en",
"varias",
"ocasiones",
"en",
"su",
"centro",
"de",
"salud",
",",
"recibiendo",
"tratamiento",
"analgésico",
"que",
"le",
"alivia",
"sólo",
"parcialmente",
".",
"\n",
"El",
"paciente",
"refiere",
"que",
"la",
"imposibilidad",
"de",
"descansar",
"adecuadamente",
"ha",
"deteriorado",
"su",
"estado",
"general",
".",
"Se",
"encuentra",
"muy",
"cansado",
",",
"debilitado",
",",
"apenas",
"come",
",",
"por",
"lo",
"que",
"refiere",
"haber",
"perdido",
"algo",
"de",
"peso",
",",
"no",
"sale",
"de",
"casa",
".",
"La",
"debilidad",
"es",
"tal",
"que",
"hace",
"días",
"que",
"\"",
"no",
"tiene",
"fuerzas",
"para",
"caminar",
"\"",
".",
"Además",
",",
"desde",
"hace",
"varios",
"días",
"se",
"le",
"ha",
"añadido",
"el",
"cuadro",
"respiratorio",
"descrito",
"anteriormente",
"para",
"el",
"cual",
"está",
"recibiendo",
"tratamiento",
"antibiótico",
".",
"\n\n",
"Exploración",
"física",
"\n",
"La",
"exploración",
"física",
"es",
"poco",
"llamativa",
".",
"Paciente",
"estable",
",",
"eupneico",
",",
"tolerando",
"decúbito",
".",
"En",
"la",
"auscultación",
"pulmonar",
"únicamente",
"se",
"detectan",
"crepitantes",
"finos",
"bibasales",
".",
"Destaca",
"edema",
"con",
"fóvea",
"leve",
"a",
"la",
"presión",
"hasta",
"raíz",
"de",
"muslo",
".",
"\n",
"Dada",
"la",
"clínica",
"de",
"\"",
"debilidad",
"\"",
"que",
"refiere",
"el",
"paciente",
",",
"se",
"realiza",
"exploración",
"neurológica",
"en",
"la",
"que",
"destaca",
":",
"miembros",
"inferiores",
"(",
"MMII",
")",
"con",
"paraparesia",
"proximal",
"de",
"predominio",
"derecho",
",",
"con",
"miembro",
"inferior",
"derecho",
"(",
"MID",
")",
"a",
"II",
"/",
"V",
"proximal",
"y",
"miembro",
"inferior",
"izquierdo",
"(",
"MII",
")",
"a",
"III",
"/",
"IV",
"proximal",
".",
"Fuerza",
"distal",
"conservada",
"a",
"V",
"/",
"V",
"de",
"forma",
"simétrica",
".",
"Se",
"objetivan",
"fasciculaciones",
"aisladas",
"de",
"localización",
"proximal",
"en",
"MID",
".",
"Sensibilidad",
"tacto",
"-",
"algésica",
"disminuida",
"en",
"muslo",
"izquierdo",
".",
"\n\n",
"Pruebas",
"complementarias",
"\n",
"En",
"el",
"análisis",
"destaca",
"una",
"plaquetopenia",
"de",
"63.000",
"/",
"mm3",
",",
"tiempo",
"de",
"protrombina",
"66",
"%",
",",
"aumento",
"fibrinógeno",
"(",
"551",
"mg",
"/",
"dl",
")",
",",
"leve",
"aumento",
"de",
"bilirrubina",
"total",
"(",
"1,5",
"mg",
"/",
"dl",
")",
",",
"elevación",
"transaminasas",
"(",
"GOT",
"/",
"GPT",
"179/240",
"U",
"/",
"l",
")",
",",
"LDH",
"6.460",
"mg",
"/",
"dl",
"y",
"PCR",
"60,9",
"mg",
"/",
"l.",
"\n",
"En",
"la",
"radiografía",
"de",
"tórax",
",",
"se",
"objetiva",
"un",
"ensanchamiento",
"mediastínico",
".",
"\n\n",
"Diagnóstico",
"\n",
"Dada",
"la",
"clínica",
"y",
"alteraciones",
"analíticas",
"debemos",
"plantearnos",
"un",
"diagnóstico",
"diferencial",
"más",
"allá",
"de",
"una",
"infección",
"respiratoria",
"que",
"no",
"ha",
"respondido",
"a",
"antibioterapia",
".",
"\n",
"El",
"paciente",
"presenta",
"clínica",
"de",
"deterioro",
"del",
"estado",
"general",
"progresivo",
",",
"que",
"relaciona",
"directamente",
"con",
"descanso",
"insuficiente",
",",
"secundario",
"al",
"dolor",
"lumbar",
"que",
"le",
"provoca",
"la",
"postura",
"antiálgica",
"que",
"debe",
"adoptar",
"tras",
"la",
"fractura",
"de",
"clavícula",
".",
"\n",
"Sin",
"embargo",
",",
"puede",
"que",
"el",
"aparente",
"factor",
"desencadenante",
",",
"la",
"fractura",
"de",
"clavícula",
",",
"nos",
"esté",
"enmascarando",
"el",
"diagnóstico",
".",
"Eliminando",
"dicho",
"componente",
",",
"destaca",
"como",
"síntoma",
"clave",
"un",
"dolor",
"lumbar",
"de",
"difícil",
"control",
"con",
"analgesia",
"convencional",
"que",
"empeora",
"por",
"la",
"noche",
",",
"seguido",
"de",
"\"",
"dificultad",
"para",
"caminar",
"\"",
"de",
"menor",
"tiempo",
"de",
"evolución",
",",
"que",
"en",
"la",
"exploración",
"neurológica",
"se",
"traduce",
"en",
"alteración",
"motora",
"de",
"la",
"musculatura",
"proximal",
"de",
"MMII",
"y",
"alteración",
"sensitiva",
".",
"En",
"un",
"paciente",
"con",
"una",
"radiografía",
"de",
"tórax",
"con",
"ensanchamiento",
"mediastínico",
"y",
"alteración",
"de",
"la",
"función",
"hepática",
",",
"nuestra",
"primera",
"sospecha",
"diagnóstica",
"es",
"un",
"proceso",
"neoplásico",
"con",
"afectación",
"metastásica",
"que",
"debuta",
"con",
"un",
"síndrome",
"de",
"compresión",
"medular",
".",
"\n",
"En",
"este",
"caso",
",",
"el",
"diagnóstico",
"diferencial",
"incluimos",
":",
"\n",
"»",
"Aneurisma",
"aórtico",
":",
"ensanchamiento",
"mediastínico",
"y",
"disnea",
".",
"No",
"obstante",
",",
"el",
"nivel",
"de",
"la",
"masa",
"mediastínica",
"no",
"se",
"relaciona",
"con",
"el",
"nivel",
"del",
"dolor",
"dorso",
"/",
"lumbar",
"ni",
"con",
"la",
"clínica",
"motora",
"y",
"sensitiva",
",",
"se",
"palpan",
"pulsos",
"femorales",
"y",
"pedios",
"normales",
"y",
",",
"aunque",
"puede",
"justificar",
"el",
"deterioro",
"del",
"estado",
"general",
"y",
"la",
"pérdida",
"de",
"peso",
",",
"no",
"justifica",
"las",
"alteraciones",
"objetivadas",
"en",
"el",
"análisis",
".",
"\n",
"»",
"Miastenia",
"gravis",
":",
"ensanchamiento",
"mediastínico",
"que",
"podría",
"corresponder",
"a",
"neoplasia",
"tímica",
"y",
"debilidad",
"proximal",
"en",
"MMII",
".",
"Sin",
"embargo",
",",
"esta",
"debilidad",
"no",
"presenta",
"fluctuaciones",
"ni",
"mejoría",
"con",
"el",
"descanso",
".",
"Tampoco",
"presenta",
"afectación",
"de",
"oculomotores",
"ni",
"clínica",
"bulbar",
".",
"No",
"justifica",
"el",
"dolor",
"lumbar",
"invalidante",
".",
"\n",
"»",
"Síndrome",
"de",
"Eaton",
"Lambert",
":",
"ensanchamiento",
"mediastínico",
"que",
"podría",
"corresponderse",
"con",
"proceso",
"neoplásico",
"y",
"debilidad",
"proximal",
".",
"Sin",
"embargo",
",",
"ésta",
"se",
"mantiene",
"constante",
"durante",
"el",
"día",
"sin",
"mejorar",
"con",
"la",
"actividad",
".",
"Los",
"reflejos",
"osteotendinosos",
"(",
"ROT",
")",
"resultaron",
"normales",
".",
"No",
"justifica",
"el",
"dolor",
"lumbar",
"invalidante",
".",
"\n",
"»",
"Esclerosis",
"lateral",
"amiotrófica",
":",
"debilidad",
"muscular",
"con",
"fasciculaciones",
"aisladas",
".",
"El",
"resto",
"de",
"la",
"exploración",
"(",
"ROT",
"conservados",
",",
"alteración",
"sensitiva",
"en",
"MII",
",",
"etc",
".",
")",
"no",
"orienta",
"a",
"dicha",
"enfermedad",
".",
"\n\n",
"Tratamiento",
"\n",
"Ante",
"la",
"alta",
"sospecha",
"de",
"síndrome",
"de",
"compresión",
"medular",
"iniciamos",
"tratamiento",
"corticoide",
"con",
"10",
"mg",
"endovenoso",
"de",
"dexametasona",
"y",
",",
"dado",
"que",
"nuestro",
"centro",
"carece",
"de",
"resonancia",
"magnética",
"(",
"RM",
")",
"en",
"Urgencias",
",",
"solicitamos",
"RM",
"a",
"primera",
"hora",
"de",
"la",
"mañana",
".",
"\n",
"En",
"el",
"informe",
"de",
"la",
"RM",
"se",
"describe",
"infiltración",
"metastásica",
"difusa",
"de",
"la",
"médula",
"ósea",
"de",
"todo",
"el",
"esqueleto",
"axial",
"visualizado",
",",
"así",
"como",
"una",
"masa",
"de",
"partes",
"blandas",
"en",
"el",
"agujero",
"de",
"conjunción",
"izquierdo",
"y",
"receso",
"lateral",
"izquierdo",
"del",
"espacio",
"D11-D12",
".",
"Además",
",",
"se",
"ve",
"afectada",
"la",
"raíz",
"D12",
"izquierda",
".",
"La",
"masa",
"de",
"partes",
"blandas",
"contacta",
"con",
"el",
"saco",
"tecal",
"y",
"con",
"la",
"médula",
",",
"aunque",
"sin",
"datos",
"de",
"mielopatía",
"en",
"el",
"momento",
"actual",
".",
"\n\n",
"Evolución",
"\n",
"Ante",
"estos",
"resultados",
",",
"el",
"paciente",
"ingresa",
"a",
"cargo",
"de",
"Oncología",
"Médica",
"para",
"completar",
"estudio",
"de",
"extensión",
"y",
"diagnóstico",
"histológico",
".",
"El",
"caso",
"es",
"comentado",
"con",
"el",
"servicio",
"de",
"Oncología",
"radioterápica",
"que",
",",
"dada",
"la",
"afectación",
"radicular",
"sin",
"datos",
"de",
"mielopatía",
"y",
"la",
"ausencia",
"de",
"diagnóstico",
"histológico",
",",
"desestima",
"radioterapia",
"urgente",
".",
"\n",
"El",
"paciente",
"presenta",
"una",
"evolución",
"tórpida",
"muy",
"precipitada",
",",
"con",
"empeoramiento",
"progresivo",
"de",
"la",
"función",
"hepática",
",",
"tendente",
"al",
"sueño",
",",
"en",
"situación",
"de",
"apatoabulia",
".",
"El",
"día",
"21",
"de",
"febrero",
",",
"el",
"paciente",
"presenta",
"un",
"cuadro",
"de",
"marcada",
"dificultad",
"respiratoria",
",",
"con",
"desconexión",
"del",
"medio",
".",
"Se",
"presenta",
"sin",
"respuesta",
"estímulos",
",",
"taquipneico",
",",
"con",
"importante",
"trabajo",
"respiratorio",
",",
"cianótico",
",",
"con",
"edema",
"en",
"esclavina",
".",
"Todo",
"ello",
"compatible",
"con",
"un",
"episodio",
"de",
"síndrome",
"de",
"vena",
"cava",
"superior",
"(",
"SVS",
")",
".",
"\n",
"Dada",
"la",
"inestabilidad",
"hemodinámica",
"y",
"datos",
"de",
"sufrimiento",
",",
"en",
"un",
"paciente",
"con",
"signos",
"de",
"neoplásica",
"metastásica",
"avanzada",
"se",
"acuerda",
"con",
"la",
"familia",
"iniciar",
"sedación",
"paliativa",
".",
"El",
"paciente",
"fallece",
"sin",
"haber",
"podido",
"iniciar",
"estudio",
"de",
"extensión",
"ni",
"obtener",
"diagnóstico",
"histológico",
"."
] |
[
"MORFOLOGIA_NEOPLASIA"
] |
c - Fos is a Protein, c - Jun is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Fos is a Protein, c - Jun is a Protein, Con A is a Protein, c - Fos is a Protein, c - Jun is a Protein, PKC is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Fos is a Protein, c - Jun is a Protein, PKC is a Protein, PKC is a Protein, Con A is a Protein, c - Fos is a Protein, c - Jun is a Protein, PKC is a Protein
|
254_task0
|
Sentence: Mitogen stimulation of T-cells increases c-Fos and c-Jun protein levels, AP-1 binding and AP-1 transcriptional activity.
We have analysed the effect of mitogenic lectins on c-Fos and c-Jun protein levels as well as on activator protein-1 (AP-1) binding and enhancer activity in Jurkat T-cells. Both c-Fos and c-Jun protein levels were increased after Con A and PHA stimulation. Since T-cell stimulation increases both intracellular Ca2+ and cAMP levels and activates protein kinase C (PKC), the possible involvement of these intracellular messengers in c-Fos and c-Jun induction was tested. PMA, which directly activates PKC, mimicked the effect of the lectins on c-Fos and c-Jun, but elevation of either intracellular Ca2+ or cAMP levels had little or no effect. The mitogen-induced increase of c-Fos and c-Jun immunoreactivity was inhibited by H-7, a kinase inhibitor with relatively high specificity for PKC, and less efficiently by H-8, a structurally related kinase inhibitor less active on PKC, but more active on cyclic nucleotide-dependent kinases. Con A stimulation was found to increase both binding of AP-1 to the AP-1 consensus sequence, TRE, and AP-1 enhancer activity, in Jurkat cells. PMA was also found to increase the AP-1 enhancer activity, whereas elevation of Ca2+ or cAMP had only minor effects. We conclude that stimulation with mitogenic lectins is sufficient to increase both c-Fos and c-Jun protein levels, AP-1 binding and AP-1 enhancer activity in Jurkat cells and that they act via mechanisms that could involve the activation of PKC.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Protein
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O"
] |
Mitogen stimulation of T-cells increases c-Fos and c-Jun protein levels, AP-1 binding and AP-1 transcriptional activity.
We have analysed the effect of mitogenic lectins on c-Fos and c-Jun protein levels as well as on activator protein-1 (AP-1) binding and enhancer activity in Jurkat T-cells. Both c-Fos and c-Jun protein levels were increased after Con A and PHA stimulation. Since T-cell stimulation increases both intracellular Ca2+ and cAMP levels and activates protein kinase C (PKC), the possible involvement of these intracellular messengers in c-Fos and c-Jun induction was tested. PMA, which directly activates PKC, mimicked the effect of the lectins on c-Fos and c-Jun, but elevation of either intracellular Ca2+ or cAMP levels had little or no effect. The mitogen-induced increase of c-Fos and c-Jun immunoreactivity was inhibited by H-7, a kinase inhibitor with relatively high specificity for PKC, and less efficiently by H-8, a structurally related kinase inhibitor less active on PKC, but more active on cyclic nucleotide-dependent kinases. Con A stimulation was found to increase both binding of AP-1 to the AP-1 consensus sequence, TRE, and AP-1 enhancer activity, in Jurkat cells. PMA was also found to increase the AP-1 enhancer activity, whereas elevation of Ca2+ or cAMP had only minor effects. We conclude that stimulation with mitogenic lectins is sufficient to increase both c-Fos and c-Jun protein levels, AP-1 binding and AP-1 enhancer activity in Jurkat cells and that they act via mechanisms that could involve the activation of PKC.
|
[
"Mitogen",
"stimulation",
"of",
"T",
"-",
"cells",
"increases",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
",",
"AP-1",
"binding",
"and",
"AP-1",
"transcriptional",
"activity",
".",
"\n",
"We",
"have",
"analysed",
"the",
"effect",
"of",
"mitogenic",
"lectins",
"on",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
"as",
"well",
"as",
"on",
"activator",
"protein-1",
"(",
"AP-1",
")",
"binding",
"and",
"enhancer",
"activity",
"in",
"Jurkat",
"T",
"-",
"cells",
".",
"Both",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
"were",
"increased",
"after",
"Con",
"A",
"and",
"PHA",
"stimulation",
".",
"Since",
"T",
"-",
"cell",
"stimulation",
"increases",
"both",
"intracellular",
"Ca2",
"+",
"and",
"cAMP",
"levels",
"and",
"activates",
"protein",
"kinase",
"C",
"(",
"PKC",
")",
",",
"the",
"possible",
"involvement",
"of",
"these",
"intracellular",
"messengers",
"in",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"induction",
"was",
"tested",
".",
"PMA",
",",
"which",
"directly",
"activates",
"PKC",
",",
"mimicked",
"the",
"effect",
"of",
"the",
"lectins",
"on",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
",",
"but",
"elevation",
"of",
"either",
"intracellular",
"Ca2",
"+",
"or",
"cAMP",
"levels",
"had",
"little",
"or",
"no",
"effect",
".",
"The",
"mitogen",
"-",
"induced",
"increase",
"of",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"immunoreactivity",
"was",
"inhibited",
"by",
"H-7",
",",
"a",
"kinase",
"inhibitor",
"with",
"relatively",
"high",
"specificity",
"for",
"PKC",
",",
"and",
"less",
"efficiently",
"by",
"H-8",
",",
"a",
"structurally",
"related",
"kinase",
"inhibitor",
"less",
"active",
"on",
"PKC",
",",
"but",
"more",
"active",
"on",
"cyclic",
"nucleotide",
"-",
"dependent",
"kinases",
".",
"Con",
"A",
"stimulation",
"was",
"found",
"to",
"increase",
"both",
"binding",
"of",
"AP-1",
"to",
"the",
"AP-1",
"consensus",
"sequence",
",",
"TRE",
",",
"and",
"AP-1",
"enhancer",
"activity",
",",
"in",
"Jurkat",
"cells",
".",
"PMA",
"was",
"also",
"found",
"to",
"increase",
"the",
"AP-1",
"enhancer",
"activity",
",",
"whereas",
"elevation",
"of",
"Ca2",
"+",
"or",
"cAMP",
"had",
"only",
"minor",
"effects",
".",
"We",
"conclude",
"that",
"stimulation",
"with",
"mitogenic",
"lectins",
"is",
"sufficient",
"to",
"increase",
"both",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
",",
"AP-1",
"binding",
"and",
"AP-1",
"enhancer",
"activity",
"in",
"Jurkat",
"cells",
"and",
"that",
"they",
"act",
"via",
"mechanisms",
"that",
"could",
"involve",
"the",
"activation",
"of",
"PKC",
"."
] |
[
"Protein"
] |
c - Fos is a Protein, c - Jun is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Fos is a Protein, c - Jun is a Protein, Con A is a Protein, c - Fos is a Protein, c - Jun is a Protein, PKC is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Fos is a Protein, c - Jun is a Protein, PKC is a Protein, PKC is a Protein, Con A is a Protein, c - Fos is a Protein, c - Jun is a Protein, PKC is a Protein
|
254_task1
|
Sentence: Mitogen stimulation of T-cells increases c-Fos and c-Jun protein levels, AP-1 binding and AP-1 transcriptional activity.
We have analysed the effect of mitogenic lectins on c-Fos and c-Jun protein levels as well as on activator protein-1 (AP-1) binding and enhancer activity in Jurkat T-cells. Both c-Fos and c-Jun protein levels were increased after Con A and PHA stimulation. Since T-cell stimulation increases both intracellular Ca2+ and cAMP levels and activates protein kinase C (PKC), the possible involvement of these intracellular messengers in c-Fos and c-Jun induction was tested. PMA, which directly activates PKC, mimicked the effect of the lectins on c-Fos and c-Jun, but elevation of either intracellular Ca2+ or cAMP levels had little or no effect. The mitogen-induced increase of c-Fos and c-Jun immunoreactivity was inhibited by H-7, a kinase inhibitor with relatively high specificity for PKC, and less efficiently by H-8, a structurally related kinase inhibitor less active on PKC, but more active on cyclic nucleotide-dependent kinases. Con A stimulation was found to increase both binding of AP-1 to the AP-1 consensus sequence, TRE, and AP-1 enhancer activity, in Jurkat cells. PMA was also found to increase the AP-1 enhancer activity, whereas elevation of Ca2+ or cAMP had only minor effects. We conclude that stimulation with mitogenic lectins is sufficient to increase both c-Fos and c-Jun protein levels, AP-1 binding and AP-1 enhancer activity in Jurkat cells and that they act via mechanisms that could involve the activation of PKC.
Instructions: please typing these entity words according to sentence: c - Fos, c - Jun, c - Fos, c - Jun, c - Fos, c - Jun, Con A, c - Fos, c - Jun, PKC, c - Fos, c - Jun, c - Fos, c - Jun, PKC, PKC, Con A, c - Fos, c - Jun, PKC
Options: Protein
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O"
] |
Mitogen stimulation of T-cells increases c-Fos and c-Jun protein levels, AP-1 binding and AP-1 transcriptional activity.
We have analysed the effect of mitogenic lectins on c-Fos and c-Jun protein levels as well as on activator protein-1 (AP-1) binding and enhancer activity in Jurkat T-cells. Both c-Fos and c-Jun protein levels were increased after Con A and PHA stimulation. Since T-cell stimulation increases both intracellular Ca2+ and cAMP levels and activates protein kinase C (PKC), the possible involvement of these intracellular messengers in c-Fos and c-Jun induction was tested. PMA, which directly activates PKC, mimicked the effect of the lectins on c-Fos and c-Jun, but elevation of either intracellular Ca2+ or cAMP levels had little or no effect. The mitogen-induced increase of c-Fos and c-Jun immunoreactivity was inhibited by H-7, a kinase inhibitor with relatively high specificity for PKC, and less efficiently by H-8, a structurally related kinase inhibitor less active on PKC, but more active on cyclic nucleotide-dependent kinases. Con A stimulation was found to increase both binding of AP-1 to the AP-1 consensus sequence, TRE, and AP-1 enhancer activity, in Jurkat cells. PMA was also found to increase the AP-1 enhancer activity, whereas elevation of Ca2+ or cAMP had only minor effects. We conclude that stimulation with mitogenic lectins is sufficient to increase both c-Fos and c-Jun protein levels, AP-1 binding and AP-1 enhancer activity in Jurkat cells and that they act via mechanisms that could involve the activation of PKC.
|
[
"Mitogen",
"stimulation",
"of",
"T",
"-",
"cells",
"increases",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
",",
"AP-1",
"binding",
"and",
"AP-1",
"transcriptional",
"activity",
".",
"\n",
"We",
"have",
"analysed",
"the",
"effect",
"of",
"mitogenic",
"lectins",
"on",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
"as",
"well",
"as",
"on",
"activator",
"protein-1",
"(",
"AP-1",
")",
"binding",
"and",
"enhancer",
"activity",
"in",
"Jurkat",
"T",
"-",
"cells",
".",
"Both",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
"were",
"increased",
"after",
"Con",
"A",
"and",
"PHA",
"stimulation",
".",
"Since",
"T",
"-",
"cell",
"stimulation",
"increases",
"both",
"intracellular",
"Ca2",
"+",
"and",
"cAMP",
"levels",
"and",
"activates",
"protein",
"kinase",
"C",
"(",
"PKC",
")",
",",
"the",
"possible",
"involvement",
"of",
"these",
"intracellular",
"messengers",
"in",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"induction",
"was",
"tested",
".",
"PMA",
",",
"which",
"directly",
"activates",
"PKC",
",",
"mimicked",
"the",
"effect",
"of",
"the",
"lectins",
"on",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
",",
"but",
"elevation",
"of",
"either",
"intracellular",
"Ca2",
"+",
"or",
"cAMP",
"levels",
"had",
"little",
"or",
"no",
"effect",
".",
"The",
"mitogen",
"-",
"induced",
"increase",
"of",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"immunoreactivity",
"was",
"inhibited",
"by",
"H-7",
",",
"a",
"kinase",
"inhibitor",
"with",
"relatively",
"high",
"specificity",
"for",
"PKC",
",",
"and",
"less",
"efficiently",
"by",
"H-8",
",",
"a",
"structurally",
"related",
"kinase",
"inhibitor",
"less",
"active",
"on",
"PKC",
",",
"but",
"more",
"active",
"on",
"cyclic",
"nucleotide",
"-",
"dependent",
"kinases",
".",
"Con",
"A",
"stimulation",
"was",
"found",
"to",
"increase",
"both",
"binding",
"of",
"AP-1",
"to",
"the",
"AP-1",
"consensus",
"sequence",
",",
"TRE",
",",
"and",
"AP-1",
"enhancer",
"activity",
",",
"in",
"Jurkat",
"cells",
".",
"PMA",
"was",
"also",
"found",
"to",
"increase",
"the",
"AP-1",
"enhancer",
"activity",
",",
"whereas",
"elevation",
"of",
"Ca2",
"+",
"or",
"cAMP",
"had",
"only",
"minor",
"effects",
".",
"We",
"conclude",
"that",
"stimulation",
"with",
"mitogenic",
"lectins",
"is",
"sufficient",
"to",
"increase",
"both",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
",",
"AP-1",
"binding",
"and",
"AP-1",
"enhancer",
"activity",
"in",
"Jurkat",
"cells",
"and",
"that",
"they",
"act",
"via",
"mechanisms",
"that",
"could",
"involve",
"the",
"activation",
"of",
"PKC",
"."
] |
[
"Protein"
] |
c - Fos, c - Jun, c - Fos, c - Jun, c - Fos, c - Jun, Con A, c - Fos, c - Jun, PKC, c - Fos, c - Jun, c - Fos, c - Jun, PKC, PKC, Con A, c - Fos, c - Jun, PKC
|
254_task2
|
Sentence: Mitogen stimulation of T-cells increases c-Fos and c-Jun protein levels, AP-1 binding and AP-1 transcriptional activity.
We have analysed the effect of mitogenic lectins on c-Fos and c-Jun protein levels as well as on activator protein-1 (AP-1) binding and enhancer activity in Jurkat T-cells. Both c-Fos and c-Jun protein levels were increased after Con A and PHA stimulation. Since T-cell stimulation increases both intracellular Ca2+ and cAMP levels and activates protein kinase C (PKC), the possible involvement of these intracellular messengers in c-Fos and c-Jun induction was tested. PMA, which directly activates PKC, mimicked the effect of the lectins on c-Fos and c-Jun, but elevation of either intracellular Ca2+ or cAMP levels had little or no effect. The mitogen-induced increase of c-Fos and c-Jun immunoreactivity was inhibited by H-7, a kinase inhibitor with relatively high specificity for PKC, and less efficiently by H-8, a structurally related kinase inhibitor less active on PKC, but more active on cyclic nucleotide-dependent kinases. Con A stimulation was found to increase both binding of AP-1 to the AP-1 consensus sequence, TRE, and AP-1 enhancer activity, in Jurkat cells. PMA was also found to increase the AP-1 enhancer activity, whereas elevation of Ca2+ or cAMP had only minor effects. We conclude that stimulation with mitogenic lectins is sufficient to increase both c-Fos and c-Jun protein levels, AP-1 binding and AP-1 enhancer activity in Jurkat cells and that they act via mechanisms that could involve the activation of PKC.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O"
] |
Mitogen stimulation of T-cells increases c-Fos and c-Jun protein levels, AP-1 binding and AP-1 transcriptional activity.
We have analysed the effect of mitogenic lectins on c-Fos and c-Jun protein levels as well as on activator protein-1 (AP-1) binding and enhancer activity in Jurkat T-cells. Both c-Fos and c-Jun protein levels were increased after Con A and PHA stimulation. Since T-cell stimulation increases both intracellular Ca2+ and cAMP levels and activates protein kinase C (PKC), the possible involvement of these intracellular messengers in c-Fos and c-Jun induction was tested. PMA, which directly activates PKC, mimicked the effect of the lectins on c-Fos and c-Jun, but elevation of either intracellular Ca2+ or cAMP levels had little or no effect. The mitogen-induced increase of c-Fos and c-Jun immunoreactivity was inhibited by H-7, a kinase inhibitor with relatively high specificity for PKC, and less efficiently by H-8, a structurally related kinase inhibitor less active on PKC, but more active on cyclic nucleotide-dependent kinases. Con A stimulation was found to increase both binding of AP-1 to the AP-1 consensus sequence, TRE, and AP-1 enhancer activity, in Jurkat cells. PMA was also found to increase the AP-1 enhancer activity, whereas elevation of Ca2+ or cAMP had only minor effects. We conclude that stimulation with mitogenic lectins is sufficient to increase both c-Fos and c-Jun protein levels, AP-1 binding and AP-1 enhancer activity in Jurkat cells and that they act via mechanisms that could involve the activation of PKC.
|
[
"Mitogen",
"stimulation",
"of",
"T",
"-",
"cells",
"increases",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
",",
"AP-1",
"binding",
"and",
"AP-1",
"transcriptional",
"activity",
".",
"\n",
"We",
"have",
"analysed",
"the",
"effect",
"of",
"mitogenic",
"lectins",
"on",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
"as",
"well",
"as",
"on",
"activator",
"protein-1",
"(",
"AP-1",
")",
"binding",
"and",
"enhancer",
"activity",
"in",
"Jurkat",
"T",
"-",
"cells",
".",
"Both",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
"were",
"increased",
"after",
"Con",
"A",
"and",
"PHA",
"stimulation",
".",
"Since",
"T",
"-",
"cell",
"stimulation",
"increases",
"both",
"intracellular",
"Ca2",
"+",
"and",
"cAMP",
"levels",
"and",
"activates",
"protein",
"kinase",
"C",
"(",
"PKC",
")",
",",
"the",
"possible",
"involvement",
"of",
"these",
"intracellular",
"messengers",
"in",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"induction",
"was",
"tested",
".",
"PMA",
",",
"which",
"directly",
"activates",
"PKC",
",",
"mimicked",
"the",
"effect",
"of",
"the",
"lectins",
"on",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
",",
"but",
"elevation",
"of",
"either",
"intracellular",
"Ca2",
"+",
"or",
"cAMP",
"levels",
"had",
"little",
"or",
"no",
"effect",
".",
"The",
"mitogen",
"-",
"induced",
"increase",
"of",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"immunoreactivity",
"was",
"inhibited",
"by",
"H-7",
",",
"a",
"kinase",
"inhibitor",
"with",
"relatively",
"high",
"specificity",
"for",
"PKC",
",",
"and",
"less",
"efficiently",
"by",
"H-8",
",",
"a",
"structurally",
"related",
"kinase",
"inhibitor",
"less",
"active",
"on",
"PKC",
",",
"but",
"more",
"active",
"on",
"cyclic",
"nucleotide",
"-",
"dependent",
"kinases",
".",
"Con",
"A",
"stimulation",
"was",
"found",
"to",
"increase",
"both",
"binding",
"of",
"AP-1",
"to",
"the",
"AP-1",
"consensus",
"sequence",
",",
"TRE",
",",
"and",
"AP-1",
"enhancer",
"activity",
",",
"in",
"Jurkat",
"cells",
".",
"PMA",
"was",
"also",
"found",
"to",
"increase",
"the",
"AP-1",
"enhancer",
"activity",
",",
"whereas",
"elevation",
"of",
"Ca2",
"+",
"or",
"cAMP",
"had",
"only",
"minor",
"effects",
".",
"We",
"conclude",
"that",
"stimulation",
"with",
"mitogenic",
"lectins",
"is",
"sufficient",
"to",
"increase",
"both",
"c",
"-",
"Fos",
"and",
"c",
"-",
"Jun",
"protein",
"levels",
",",
"AP-1",
"binding",
"and",
"AP-1",
"enhancer",
"activity",
"in",
"Jurkat",
"cells",
"and",
"that",
"they",
"act",
"via",
"mechanisms",
"that",
"could",
"involve",
"the",
"activation",
"of",
"PKC",
"."
] |
[
"Protein"
] |
amoxapine is a CHEMICAL, loxapine is a CHEMICAL
|
1966571_task0
|
Sentence: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: CHEMICAL
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
[Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
|
[
"[",
"Comparison",
"of",
"the",
"affinities",
"of",
"amoxapine",
"and",
"loxapine",
"for",
"various",
"receptors",
"in",
"rat",
"brain",
"and",
"the",
"receptor",
"down",
"-",
"regulation",
"after",
"chronic",
"administration",
"]",
"."
] |
[
"GENE-N",
"GENE-Y",
"CHEMICAL"
] |
amoxapine is a CHEMICAL, loxapine is a CHEMICAL
|
1966571_task1
|
Sentence: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
Instructions: please typing these entity words according to sentence: amoxapine, loxapine
Options: CHEMICAL
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
[Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
|
[
"[",
"Comparison",
"of",
"the",
"affinities",
"of",
"amoxapine",
"and",
"loxapine",
"for",
"various",
"receptors",
"in",
"rat",
"brain",
"and",
"the",
"receptor",
"down",
"-",
"regulation",
"after",
"chronic",
"administration",
"]",
"."
] |
[
"GENE-N",
"GENE-Y",
"CHEMICAL"
] |
amoxapine, loxapine
|
1966571_task2
|
Sentence: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
[Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
|
[
"[",
"Comparison",
"of",
"the",
"affinities",
"of",
"amoxapine",
"and",
"loxapine",
"for",
"various",
"receptors",
"in",
"rat",
"brain",
"and",
"the",
"receptor",
"down",
"-",
"regulation",
"after",
"chronic",
"administration",
"]",
"."
] |
[
"GENE-N",
"GENE-Y",
"CHEMICAL"
] |
Urea is a CHEMICAL, Rho Kinase is a GENE-N
|
23570561_task0
|
Sentence: Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: GENE-N, CHEMICAL
|
[
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"B-GENE-N",
"I-GENE-N",
"O",
"O"
] |
Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.
|
[
"Synthesis",
"and",
"Biological",
"Evaluation",
"of",
"Urea",
"Derivatives",
"as",
"Highly",
"Potent",
"and",
"Selective",
"Rho",
"Kinase",
"Inhibitors",
"."
] |
[
"GENE-N",
"CHEMICAL",
"GENE-Y"
] |
Urea is a CHEMICAL, Rho Kinase is a GENE-N
|
23570561_task1
|
Sentence: Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.
Instructions: please typing these entity words according to sentence: Urea, Rho Kinase
Options: GENE-N, CHEMICAL
|
[
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"B-GENE-N",
"I-GENE-N",
"O",
"O"
] |
Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.
|
[
"Synthesis",
"and",
"Biological",
"Evaluation",
"of",
"Urea",
"Derivatives",
"as",
"Highly",
"Potent",
"and",
"Selective",
"Rho",
"Kinase",
"Inhibitors",
"."
] |
[
"GENE-N",
"CHEMICAL",
"GENE-Y"
] |
Urea, Rho Kinase
|
23570561_task2
|
Sentence: Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"B-GENE-N",
"I-GENE-N",
"O",
"O"
] |
Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.
|
[
"Synthesis",
"and",
"Biological",
"Evaluation",
"of",
"Urea",
"Derivatives",
"as",
"Highly",
"Potent",
"and",
"Selective",
"Rho",
"Kinase",
"Inhibitors",
"."
] |
[
"GENE-N",
"CHEMICAL",
"GENE-Y"
] |
Reanimation is an umlsterm, Kammerflimmern is an umlsterm, AV - Block is an umlsterm, Extrasystolie is an umlsterm, Zeiten is an umlsterm, Ventrikelerregung is an umlsterm, Herzzyklus is an umlsterm, Extrasystolie is an umlsterm, Arrhythmien is an umlsterm, Inzidenz is an umlsterm
|
ZfuerKardiologie.80870640.ger.abstr_task0
|
Sentence: Wir berichten ueber den Fall einer 56jaehrigen Patientin mit einem ICD-System Typ Ventak AV ( CPI ) , implantiert nach mehrfacher Reanimation bei Kammerflimmern und vorbestehendem , intermittierendem AV-Block III Grad . Bei ventrikulaerer Extrasystolie kam es wiederholt zur asynchronen Stimulation , wobei der ventrikulaere Stimulus zu unterschiedlichen Zeiten der Ventrikelerregung einfiel . Ursache des Undersensings der ventrikulaeren Extrasystolen war eine Blankingzeit von 66 ms nach atrialer Stimulation , wodurch die ventrikulaere Extrasystole vom ICD nicht wahrgenommen werden konnte . Folge war eine ventrikulaere Stimulation in die vulnerable Phase des Herzzyklus bei ventrikulaerer Extrasystolie . Die Induktion hoehergradiger ventrikulaerer Arrhythmien wurde nicht dokumentiert . Bei fehlender Programmierbarkeit der ventrikulaeren Blankingzeit sowie einer Sicherheitsstimulation und bereits maximaler Empfindlichkeit des ICD konnte die Inzidenz dieser Ereignisse durch eine Anhebung der Grundfrequenz und durch eine medikamentoese Suppression der VES weitgehend reduziert werden .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Wir berichten ueber den Fall einer 56jaehrigen Patientin mit einem ICD-System Typ Ventak AV ( CPI ) , implantiert nach mehrfacher Reanimation bei Kammerflimmern und vorbestehendem , intermittierendem AV-Block III Grad . Bei ventrikulaerer Extrasystolie kam es wiederholt zur asynchronen Stimulation , wobei der ventrikulaere Stimulus zu unterschiedlichen Zeiten der Ventrikelerregung einfiel . Ursache des Undersensings der ventrikulaeren Extrasystolen war eine Blankingzeit von 66 ms nach atrialer Stimulation , wodurch die ventrikulaere Extrasystole vom ICD nicht wahrgenommen werden konnte . Folge war eine ventrikulaere Stimulation in die vulnerable Phase des Herzzyklus bei ventrikulaerer Extrasystolie . Die Induktion hoehergradiger ventrikulaerer Arrhythmien wurde nicht dokumentiert . Bei fehlender Programmierbarkeit der ventrikulaeren Blankingzeit sowie einer Sicherheitsstimulation und bereits maximaler Empfindlichkeit des ICD konnte die Inzidenz dieser Ereignisse durch eine Anhebung der Grundfrequenz und durch eine medikamentoese Suppression der VES weitgehend reduziert werden .
|
[
"Wir",
"berichten",
"ueber",
"den",
"Fall",
"einer",
"56jaehrigen",
"Patientin",
"mit",
"einem",
"ICD",
"-",
"System",
"Typ",
"Ventak",
"AV",
"(",
"CPI",
")",
",",
"implantiert",
"nach",
"mehrfacher",
"Reanimation",
"bei",
"Kammerflimmern",
"und",
"vorbestehendem",
",",
"intermittierendem",
"AV",
"-",
"Block",
"III",
"Grad",
".",
"Bei",
"ventrikulaerer",
"Extrasystolie",
"kam",
"es",
"wiederholt",
"zur",
"asynchronen",
"Stimulation",
",",
"wobei",
"der",
"ventrikulaere",
"Stimulus",
"zu",
"unterschiedlichen",
"Zeiten",
"der",
"Ventrikelerregung",
"einfiel",
".",
"Ursache",
"des",
"Undersensings",
"der",
"ventrikulaeren",
"Extrasystolen",
"war",
"eine",
"Blankingzeit",
"von",
"66",
"ms",
"nach",
"atrialer",
"Stimulation",
",",
"wodurch",
"die",
"ventrikulaere",
"Extrasystole",
"vom",
"ICD",
"nicht",
"wahrgenommen",
"werden",
"konnte",
".",
"Folge",
"war",
"eine",
"ventrikulaere",
"Stimulation",
"in",
"die",
"vulnerable",
"Phase",
"des",
"Herzzyklus",
"bei",
"ventrikulaerer",
"Extrasystolie",
".",
"Die",
"Induktion",
"hoehergradiger",
"ventrikulaerer",
"Arrhythmien",
"wurde",
"nicht",
"dokumentiert",
".",
"Bei",
"fehlender",
"Programmierbarkeit",
"der",
"ventrikulaeren",
"Blankingzeit",
"sowie",
"einer",
"Sicherheitsstimulation",
"und",
"bereits",
"maximaler",
"Empfindlichkeit",
"des",
"ICD",
"konnte",
"die",
"Inzidenz",
"dieser",
"Ereignisse",
"durch",
"eine",
"Anhebung",
"der",
"Grundfrequenz",
"und",
"durch",
"eine",
"medikamentoese",
"Suppression",
"der",
"VES",
"weitgehend",
"reduziert",
"werden",
"."
] |
[
"umlsterm"
] |
Reanimation is an umlsterm, Kammerflimmern is an umlsterm, AV - Block is an umlsterm, Extrasystolie is an umlsterm, Zeiten is an umlsterm, Ventrikelerregung is an umlsterm, Herzzyklus is an umlsterm, Extrasystolie is an umlsterm, Arrhythmien is an umlsterm, Inzidenz is an umlsterm
|
ZfuerKardiologie.80870640.ger.abstr_task1
|
Sentence: Wir berichten ueber den Fall einer 56jaehrigen Patientin mit einem ICD-System Typ Ventak AV ( CPI ) , implantiert nach mehrfacher Reanimation bei Kammerflimmern und vorbestehendem , intermittierendem AV-Block III Grad . Bei ventrikulaerer Extrasystolie kam es wiederholt zur asynchronen Stimulation , wobei der ventrikulaere Stimulus zu unterschiedlichen Zeiten der Ventrikelerregung einfiel . Ursache des Undersensings der ventrikulaeren Extrasystolen war eine Blankingzeit von 66 ms nach atrialer Stimulation , wodurch die ventrikulaere Extrasystole vom ICD nicht wahrgenommen werden konnte . Folge war eine ventrikulaere Stimulation in die vulnerable Phase des Herzzyklus bei ventrikulaerer Extrasystolie . Die Induktion hoehergradiger ventrikulaerer Arrhythmien wurde nicht dokumentiert . Bei fehlender Programmierbarkeit der ventrikulaeren Blankingzeit sowie einer Sicherheitsstimulation und bereits maximaler Empfindlichkeit des ICD konnte die Inzidenz dieser Ereignisse durch eine Anhebung der Grundfrequenz und durch eine medikamentoese Suppression der VES weitgehend reduziert werden .
Instructions: please typing these entity words according to sentence: Reanimation, Kammerflimmern, AV - Block, Extrasystolie, Zeiten, Ventrikelerregung, Herzzyklus, Extrasystolie, Arrhythmien, Inzidenz
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Wir berichten ueber den Fall einer 56jaehrigen Patientin mit einem ICD-System Typ Ventak AV ( CPI ) , implantiert nach mehrfacher Reanimation bei Kammerflimmern und vorbestehendem , intermittierendem AV-Block III Grad . Bei ventrikulaerer Extrasystolie kam es wiederholt zur asynchronen Stimulation , wobei der ventrikulaere Stimulus zu unterschiedlichen Zeiten der Ventrikelerregung einfiel . Ursache des Undersensings der ventrikulaeren Extrasystolen war eine Blankingzeit von 66 ms nach atrialer Stimulation , wodurch die ventrikulaere Extrasystole vom ICD nicht wahrgenommen werden konnte . Folge war eine ventrikulaere Stimulation in die vulnerable Phase des Herzzyklus bei ventrikulaerer Extrasystolie . Die Induktion hoehergradiger ventrikulaerer Arrhythmien wurde nicht dokumentiert . Bei fehlender Programmierbarkeit der ventrikulaeren Blankingzeit sowie einer Sicherheitsstimulation und bereits maximaler Empfindlichkeit des ICD konnte die Inzidenz dieser Ereignisse durch eine Anhebung der Grundfrequenz und durch eine medikamentoese Suppression der VES weitgehend reduziert werden .
|
[
"Wir",
"berichten",
"ueber",
"den",
"Fall",
"einer",
"56jaehrigen",
"Patientin",
"mit",
"einem",
"ICD",
"-",
"System",
"Typ",
"Ventak",
"AV",
"(",
"CPI",
")",
",",
"implantiert",
"nach",
"mehrfacher",
"Reanimation",
"bei",
"Kammerflimmern",
"und",
"vorbestehendem",
",",
"intermittierendem",
"AV",
"-",
"Block",
"III",
"Grad",
".",
"Bei",
"ventrikulaerer",
"Extrasystolie",
"kam",
"es",
"wiederholt",
"zur",
"asynchronen",
"Stimulation",
",",
"wobei",
"der",
"ventrikulaere",
"Stimulus",
"zu",
"unterschiedlichen",
"Zeiten",
"der",
"Ventrikelerregung",
"einfiel",
".",
"Ursache",
"des",
"Undersensings",
"der",
"ventrikulaeren",
"Extrasystolen",
"war",
"eine",
"Blankingzeit",
"von",
"66",
"ms",
"nach",
"atrialer",
"Stimulation",
",",
"wodurch",
"die",
"ventrikulaere",
"Extrasystole",
"vom",
"ICD",
"nicht",
"wahrgenommen",
"werden",
"konnte",
".",
"Folge",
"war",
"eine",
"ventrikulaere",
"Stimulation",
"in",
"die",
"vulnerable",
"Phase",
"des",
"Herzzyklus",
"bei",
"ventrikulaerer",
"Extrasystolie",
".",
"Die",
"Induktion",
"hoehergradiger",
"ventrikulaerer",
"Arrhythmien",
"wurde",
"nicht",
"dokumentiert",
".",
"Bei",
"fehlender",
"Programmierbarkeit",
"der",
"ventrikulaeren",
"Blankingzeit",
"sowie",
"einer",
"Sicherheitsstimulation",
"und",
"bereits",
"maximaler",
"Empfindlichkeit",
"des",
"ICD",
"konnte",
"die",
"Inzidenz",
"dieser",
"Ereignisse",
"durch",
"eine",
"Anhebung",
"der",
"Grundfrequenz",
"und",
"durch",
"eine",
"medikamentoese",
"Suppression",
"der",
"VES",
"weitgehend",
"reduziert",
"werden",
"."
] |
[
"umlsterm"
] |
Reanimation, Kammerflimmern, AV - Block, Extrasystolie, Zeiten, Ventrikelerregung, Herzzyklus, Extrasystolie, Arrhythmien, Inzidenz
|
ZfuerKardiologie.80870640.ger.abstr_task2
|
Sentence: Wir berichten ueber den Fall einer 56jaehrigen Patientin mit einem ICD-System Typ Ventak AV ( CPI ) , implantiert nach mehrfacher Reanimation bei Kammerflimmern und vorbestehendem , intermittierendem AV-Block III Grad . Bei ventrikulaerer Extrasystolie kam es wiederholt zur asynchronen Stimulation , wobei der ventrikulaere Stimulus zu unterschiedlichen Zeiten der Ventrikelerregung einfiel . Ursache des Undersensings der ventrikulaeren Extrasystolen war eine Blankingzeit von 66 ms nach atrialer Stimulation , wodurch die ventrikulaere Extrasystole vom ICD nicht wahrgenommen werden konnte . Folge war eine ventrikulaere Stimulation in die vulnerable Phase des Herzzyklus bei ventrikulaerer Extrasystolie . Die Induktion hoehergradiger ventrikulaerer Arrhythmien wurde nicht dokumentiert . Bei fehlender Programmierbarkeit der ventrikulaeren Blankingzeit sowie einer Sicherheitsstimulation und bereits maximaler Empfindlichkeit des ICD konnte die Inzidenz dieser Ereignisse durch eine Anhebung der Grundfrequenz und durch eine medikamentoese Suppression der VES weitgehend reduziert werden .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Wir berichten ueber den Fall einer 56jaehrigen Patientin mit einem ICD-System Typ Ventak AV ( CPI ) , implantiert nach mehrfacher Reanimation bei Kammerflimmern und vorbestehendem , intermittierendem AV-Block III Grad . Bei ventrikulaerer Extrasystolie kam es wiederholt zur asynchronen Stimulation , wobei der ventrikulaere Stimulus zu unterschiedlichen Zeiten der Ventrikelerregung einfiel . Ursache des Undersensings der ventrikulaeren Extrasystolen war eine Blankingzeit von 66 ms nach atrialer Stimulation , wodurch die ventrikulaere Extrasystole vom ICD nicht wahrgenommen werden konnte . Folge war eine ventrikulaere Stimulation in die vulnerable Phase des Herzzyklus bei ventrikulaerer Extrasystolie . Die Induktion hoehergradiger ventrikulaerer Arrhythmien wurde nicht dokumentiert . Bei fehlender Programmierbarkeit der ventrikulaeren Blankingzeit sowie einer Sicherheitsstimulation und bereits maximaler Empfindlichkeit des ICD konnte die Inzidenz dieser Ereignisse durch eine Anhebung der Grundfrequenz und durch eine medikamentoese Suppression der VES weitgehend reduziert werden .
|
[
"Wir",
"berichten",
"ueber",
"den",
"Fall",
"einer",
"56jaehrigen",
"Patientin",
"mit",
"einem",
"ICD",
"-",
"System",
"Typ",
"Ventak",
"AV",
"(",
"CPI",
")",
",",
"implantiert",
"nach",
"mehrfacher",
"Reanimation",
"bei",
"Kammerflimmern",
"und",
"vorbestehendem",
",",
"intermittierendem",
"AV",
"-",
"Block",
"III",
"Grad",
".",
"Bei",
"ventrikulaerer",
"Extrasystolie",
"kam",
"es",
"wiederholt",
"zur",
"asynchronen",
"Stimulation",
",",
"wobei",
"der",
"ventrikulaere",
"Stimulus",
"zu",
"unterschiedlichen",
"Zeiten",
"der",
"Ventrikelerregung",
"einfiel",
".",
"Ursache",
"des",
"Undersensings",
"der",
"ventrikulaeren",
"Extrasystolen",
"war",
"eine",
"Blankingzeit",
"von",
"66",
"ms",
"nach",
"atrialer",
"Stimulation",
",",
"wodurch",
"die",
"ventrikulaere",
"Extrasystole",
"vom",
"ICD",
"nicht",
"wahrgenommen",
"werden",
"konnte",
".",
"Folge",
"war",
"eine",
"ventrikulaere",
"Stimulation",
"in",
"die",
"vulnerable",
"Phase",
"des",
"Herzzyklus",
"bei",
"ventrikulaerer",
"Extrasystolie",
".",
"Die",
"Induktion",
"hoehergradiger",
"ventrikulaerer",
"Arrhythmien",
"wurde",
"nicht",
"dokumentiert",
".",
"Bei",
"fehlender",
"Programmierbarkeit",
"der",
"ventrikulaeren",
"Blankingzeit",
"sowie",
"einer",
"Sicherheitsstimulation",
"und",
"bereits",
"maximaler",
"Empfindlichkeit",
"des",
"ICD",
"konnte",
"die",
"Inzidenz",
"dieser",
"Ereignisse",
"durch",
"eine",
"Anhebung",
"der",
"Grundfrequenz",
"und",
"durch",
"eine",
"medikamentoese",
"Suppression",
"der",
"VES",
"weitgehend",
"reduziert",
"werden",
"."
] |
[
"umlsterm"
] |
DRF 2655 is a CHEMICAL
|
12582227_task0
|
Sentence: DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: CHEMICAL
|
[
"B-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
|
[
"DRF",
"2655",
":",
"a",
"unique",
"molecule",
"that",
"reduces",
"body",
"weight",
"and",
"ameliorates",
"metabolic",
"abnormalities",
"."
] |
[
"GENE-Y",
"GENE-N",
"CHEMICAL"
] |
DRF 2655 is a CHEMICAL
|
12582227_task1
|
Sentence: DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Instructions: please typing these entity words according to sentence: DRF 2655
Options: CHEMICAL
|
[
"B-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
|
[
"DRF",
"2655",
":",
"a",
"unique",
"molecule",
"that",
"reduces",
"body",
"weight",
"and",
"ameliorates",
"metabolic",
"abnormalities",
"."
] |
[
"GENE-Y",
"GENE-N",
"CHEMICAL"
] |
DRF 2655
|
12582227_task2
|
Sentence: DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Instructions: please extract entity words from the input sentence
|
[
"B-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
|
[
"DRF",
"2655",
":",
"a",
"unique",
"molecule",
"that",
"reduces",
"body",
"weight",
"and",
"ameliorates",
"metabolic",
"abnormalities",
"."
] |
[
"GENE-Y",
"GENE-N",
"CHEMICAL"
] |
Myelographie is an umlsterm, Diagnostik is an umlsterm, Patienten is an umlsterm, PMS is an umlsterm, Punktionsleck is an umlsterm, Nadeltypen is an umlsterm, Nadel is an umlsterm, Nadel is an umlsterm, Inzidenz is an umlsterm
|
DerRadiologe.60360921.ger.abstr_task0
|
Sentence: Die Myelographie zusammen mit der Postmyelographie-CT ist eine wichtige Untersuchungsmethode in der praeoperativen Diagnostik . Bei nahezu der Haelfte der Patienten koennen postpunktionelle Beschwerden bis zu einem Postmyelographie-Syndrom ( PMS ) auftreten . Pathophysiologisch kann dies durch ein Punktionsleck mit anschliessendem Liquorverlust erklaert werden . Ziel der Studie ist es , den Einfluss zweier Nadeltypen ( 21 G Nadel nach Sprotte vs 22 G Nadel nach Quincke ) auf die Inzidenz postpunktioneller Beschwerden zu ueberpruefen .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O"
] |
Die Myelographie zusammen mit der Postmyelographie-CT ist eine wichtige Untersuchungsmethode in der praeoperativen Diagnostik . Bei nahezu der Haelfte der Patienten koennen postpunktionelle Beschwerden bis zu einem Postmyelographie-Syndrom ( PMS ) auftreten . Pathophysiologisch kann dies durch ein Punktionsleck mit anschliessendem Liquorverlust erklaert werden . Ziel der Studie ist es , den Einfluss zweier Nadeltypen ( 21 G Nadel nach Sprotte vs 22 G Nadel nach Quincke ) auf die Inzidenz postpunktioneller Beschwerden zu ueberpruefen .
|
[
"Die",
"Myelographie",
"zusammen",
"mit",
"der",
"Postmyelographie",
"-",
"CT",
"ist",
"eine",
"wichtige",
"Untersuchungsmethode",
"in",
"der",
"praeoperativen",
"Diagnostik",
".",
"Bei",
"nahezu",
"der",
"Haelfte",
"der",
"Patienten",
"koennen",
"postpunktionelle",
"Beschwerden",
"bis",
"zu",
"einem",
"Postmyelographie",
"-",
"Syndrom",
"(",
"PMS",
")",
"auftreten",
".",
"Pathophysiologisch",
"kann",
"dies",
"durch",
"ein",
"Punktionsleck",
"mit",
"anschliessendem",
"Liquorverlust",
"erklaert",
"werden",
".",
"Ziel",
"der",
"Studie",
"ist",
"es",
",",
"den",
"Einfluss",
"zweier",
"Nadeltypen",
"(",
"21",
"G",
"Nadel",
"nach",
"Sprotte",
"vs",
"22",
"G",
"Nadel",
"nach",
"Quincke",
")",
"auf",
"die",
"Inzidenz",
"postpunktioneller",
"Beschwerden",
"zu",
"ueberpruefen",
"."
] |
[
"umlsterm"
] |
Myelographie is an umlsterm, Diagnostik is an umlsterm, Patienten is an umlsterm, PMS is an umlsterm, Punktionsleck is an umlsterm, Nadeltypen is an umlsterm, Nadel is an umlsterm, Nadel is an umlsterm, Inzidenz is an umlsterm
|
DerRadiologe.60360921.ger.abstr_task1
|
Sentence: Die Myelographie zusammen mit der Postmyelographie-CT ist eine wichtige Untersuchungsmethode in der praeoperativen Diagnostik . Bei nahezu der Haelfte der Patienten koennen postpunktionelle Beschwerden bis zu einem Postmyelographie-Syndrom ( PMS ) auftreten . Pathophysiologisch kann dies durch ein Punktionsleck mit anschliessendem Liquorverlust erklaert werden . Ziel der Studie ist es , den Einfluss zweier Nadeltypen ( 21 G Nadel nach Sprotte vs 22 G Nadel nach Quincke ) auf die Inzidenz postpunktioneller Beschwerden zu ueberpruefen .
Instructions: please typing these entity words according to sentence: Myelographie, Diagnostik, Patienten, PMS, Punktionsleck, Nadeltypen, Nadel, Nadel, Inzidenz
Options: umlsterm
|
[
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O"
] |
Die Myelographie zusammen mit der Postmyelographie-CT ist eine wichtige Untersuchungsmethode in der praeoperativen Diagnostik . Bei nahezu der Haelfte der Patienten koennen postpunktionelle Beschwerden bis zu einem Postmyelographie-Syndrom ( PMS ) auftreten . Pathophysiologisch kann dies durch ein Punktionsleck mit anschliessendem Liquorverlust erklaert werden . Ziel der Studie ist es , den Einfluss zweier Nadeltypen ( 21 G Nadel nach Sprotte vs 22 G Nadel nach Quincke ) auf die Inzidenz postpunktioneller Beschwerden zu ueberpruefen .
|
[
"Die",
"Myelographie",
"zusammen",
"mit",
"der",
"Postmyelographie",
"-",
"CT",
"ist",
"eine",
"wichtige",
"Untersuchungsmethode",
"in",
"der",
"praeoperativen",
"Diagnostik",
".",
"Bei",
"nahezu",
"der",
"Haelfte",
"der",
"Patienten",
"koennen",
"postpunktionelle",
"Beschwerden",
"bis",
"zu",
"einem",
"Postmyelographie",
"-",
"Syndrom",
"(",
"PMS",
")",
"auftreten",
".",
"Pathophysiologisch",
"kann",
"dies",
"durch",
"ein",
"Punktionsleck",
"mit",
"anschliessendem",
"Liquorverlust",
"erklaert",
"werden",
".",
"Ziel",
"der",
"Studie",
"ist",
"es",
",",
"den",
"Einfluss",
"zweier",
"Nadeltypen",
"(",
"21",
"G",
"Nadel",
"nach",
"Sprotte",
"vs",
"22",
"G",
"Nadel",
"nach",
"Quincke",
")",
"auf",
"die",
"Inzidenz",
"postpunktioneller",
"Beschwerden",
"zu",
"ueberpruefen",
"."
] |
[
"umlsterm"
] |
Myelographie, Diagnostik, Patienten, PMS, Punktionsleck, Nadeltypen, Nadel, Nadel, Inzidenz
|
DerRadiologe.60360921.ger.abstr_task2
|
Sentence: Die Myelographie zusammen mit der Postmyelographie-CT ist eine wichtige Untersuchungsmethode in der praeoperativen Diagnostik . Bei nahezu der Haelfte der Patienten koennen postpunktionelle Beschwerden bis zu einem Postmyelographie-Syndrom ( PMS ) auftreten . Pathophysiologisch kann dies durch ein Punktionsleck mit anschliessendem Liquorverlust erklaert werden . Ziel der Studie ist es , den Einfluss zweier Nadeltypen ( 21 G Nadel nach Sprotte vs 22 G Nadel nach Quincke ) auf die Inzidenz postpunktioneller Beschwerden zu ueberpruefen .
Instructions: please extract entity words from the input sentence
|
[
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O"
] |
Die Myelographie zusammen mit der Postmyelographie-CT ist eine wichtige Untersuchungsmethode in der praeoperativen Diagnostik . Bei nahezu der Haelfte der Patienten koennen postpunktionelle Beschwerden bis zu einem Postmyelographie-Syndrom ( PMS ) auftreten . Pathophysiologisch kann dies durch ein Punktionsleck mit anschliessendem Liquorverlust erklaert werden . Ziel der Studie ist es , den Einfluss zweier Nadeltypen ( 21 G Nadel nach Sprotte vs 22 G Nadel nach Quincke ) auf die Inzidenz postpunktioneller Beschwerden zu ueberpruefen .
|
[
"Die",
"Myelographie",
"zusammen",
"mit",
"der",
"Postmyelographie",
"-",
"CT",
"ist",
"eine",
"wichtige",
"Untersuchungsmethode",
"in",
"der",
"praeoperativen",
"Diagnostik",
".",
"Bei",
"nahezu",
"der",
"Haelfte",
"der",
"Patienten",
"koennen",
"postpunktionelle",
"Beschwerden",
"bis",
"zu",
"einem",
"Postmyelographie",
"-",
"Syndrom",
"(",
"PMS",
")",
"auftreten",
".",
"Pathophysiologisch",
"kann",
"dies",
"durch",
"ein",
"Punktionsleck",
"mit",
"anschliessendem",
"Liquorverlust",
"erklaert",
"werden",
".",
"Ziel",
"der",
"Studie",
"ist",
"es",
",",
"den",
"Einfluss",
"zweier",
"Nadeltypen",
"(",
"21",
"G",
"Nadel",
"nach",
"Sprotte",
"vs",
"22",
"G",
"Nadel",
"nach",
"Quincke",
")",
"auf",
"die",
"Inzidenz",
"postpunktioneller",
"Beschwerden",
"zu",
"ueberpruefen",
"."
] |
[
"umlsterm"
] |
Men is a Person, non - pregnant is a Qualifier, women is a Person, age is a Person, 18 and 45 years old is a Value, non - smokers is a Person, BMI is a Measurement, between > 17 and = 28 kg / m2 is a Value, no is a Negation, acute or intermittent pain , postoperative pain , respiratory compromise , acute or severe asthma , or constipation is a Scope, Negative is a Value, urine drug screening test is a Measurement, normal is a Value, white blood cells ( WBC ) , hemoglobin ( Hgb ) , platelets , sodium , potassium , chloride , bicarbonate , blood urea nitrogen ( BUN ) , creatinine , ALT ( liver function ) , AST ( liver function ) and bilirubin is a Scope, normal is a Value, urine protein and urine glucose is a Scope, normal is a Value, ECG is a Measurement, not is a Negation, pathologic Q wave abnormalities , significant ST - T wave changes , left ventricular hypertrophy , right bundle branch block , left bundle branch block . is a Scope, Temperature is a Measurement, 35 - 37.9 ° C is a Value, 95 - 100.3 ° F is a Value, Systolic blood pressure is a Measurement, 90 - 140 mmHg is a Value, Diastolic blood pressure is a Measurement, 60 - 90 mmHg is a Value, Heart rate is a Measurement, 55 - 100 beats per minute is a Value, Respiration rate is a Measurement, 12 - 18 breaths per minute is a Value
|
NCT02531971_inc_task0
|
Sentence: Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old
Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
Provide written informed consent before initiation of any study procedures
Available for follow-up for the planned duration of the study
Able to communicate well with the investigators
Able to adhere to the study protocol schedule, study restrictions and examination schedule
Subjects who are within their ideal body weight (BMI between >17 and =28 kg/m2)
Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)
Negative urine drug screening test at the time of screening
Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin
Have normal screening laboratories for urine protein and urine glucose
Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter
Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session
Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day
Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
Temperature 35-37.9°C (95-100.3°F)
Systolic blood pressure 90-140 mmHg
Diastolic blood pressure 60-90 mmHg
Heart rate 55-100 beats per minute
Respiration rate 12-18 breaths per minute
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Qualifier, Value, Person, Negation, Scope, Measurement
|
[
"B-Person",
"O",
"B-Qualifier",
"I-Qualifier",
"I-Qualifier",
"B-Person",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Person",
"O",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"O",
"O",
"B-Person",
"I-Person",
"I-Person",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Negation",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"I-Measurement",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"B-Value",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"B-Measurement",
"O",
"O",
"B-Negation",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O"
] |
Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old
Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
Provide written informed consent before initiation of any study procedures
Available for follow-up for the planned duration of the study
Able to communicate well with the investigators
Able to adhere to the study protocol schedule, study restrictions and examination schedule
Subjects who are within their ideal body weight (BMI between >17 and =28 kg/m2)
Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)
Negative urine drug screening test at the time of screening
Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin
Have normal screening laboratories for urine protein and urine glucose
Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter
Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session
Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day
Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
Temperature 35-37.9°C (95-100.3°F)
Systolic blood pressure 90-140 mmHg
Diastolic blood pressure 60-90 mmHg
Heart rate 55-100 beats per minute
Respiration rate 12-18 breaths per minute
|
[
"Men",
"or",
"non",
"-",
"pregnant",
"women",
"of",
"any",
"ethnic",
"background",
"between",
"the",
"age",
"of",
"18",
"and",
"45",
"years",
"old",
"\n",
"Subjects",
"must",
"be",
"non",
"-",
"smokers",
"(",
"must",
"have",
"refrained",
"from",
"the",
"use",
"of",
"nicotine",
"-",
"containing",
"substances",
",",
"including",
"tobacco",
"products",
"(",
"e.g",
".",
"cigarettes",
",",
"cigars",
",",
"chewing",
"tobacco",
",",
"gum",
",",
"patch",
"or",
"electronic",
"cigarettes",
")",
"over",
"the",
"previous",
"2",
"months",
"and",
"are",
"not",
"currently",
"using",
"tobacco",
"products",
"\n",
"Provide",
"written",
"informed",
"consent",
"before",
"initiation",
"of",
"any",
"study",
"procedures",
"\n",
"Available",
"for",
"follow",
"-",
"up",
"for",
"the",
"planned",
"duration",
"of",
"the",
"study",
"\n",
"Able",
"to",
"communicate",
"well",
"with",
"the",
"investigators",
"\n",
"Able",
"to",
"adhere",
"to",
"the",
"study",
"protocol",
"schedule",
",",
"study",
"restrictions",
"and",
"examination",
"schedule",
"\n",
"Subjects",
"who",
"are",
"within",
"their",
"ideal",
"body",
"weight",
"(",
"BMI",
"between",
">",
"17",
"and",
"=",
"28",
"kg",
"/",
"m2",
")",
"\n",
"Subjects",
"deemed",
"to",
"be",
"healthy",
"as",
"judged",
"by",
"the",
"Medically",
"Accountable",
"Investigator",
"(",
"MAI",
")",
"and",
"determined",
"by",
"medical",
"history",
",",
"physical",
"examination",
"and",
"medication",
"history",
"\n",
"Subjects",
"have",
"no",
"history",
"of",
"the",
"following",
":",
"ongoing",
"acute",
"or",
"intermittent",
"pain",
",",
"postoperative",
"pain",
",",
"respiratory",
"compromise",
",",
"acute",
"or",
"severe",
"asthma",
",",
"or",
"constipation",
"(",
"less",
"than",
"1",
"bowel",
"movement",
"every",
"2",
"days",
")",
"\n",
"Negative",
"urine",
"drug",
"screening",
"test",
"at",
"the",
"time",
"of",
"screening",
"\n",
"Have",
"normal",
"screening",
"laboratories",
"for",
"white",
"blood",
"cells",
"(",
"WBC",
")",
",",
"hemoglobin",
"(",
"Hgb",
")",
",",
"platelets",
",",
"sodium",
",",
"potassium",
",",
"chloride",
",",
"bicarbonate",
",",
"blood",
"urea",
"nitrogen",
"(",
"BUN",
")",
",",
"creatinine",
",",
"ALT",
"(",
"liver",
"function",
")",
",",
"AST",
"(",
"liver",
"function",
")",
"and",
"bilirubin",
"\n",
"Have",
"normal",
"screening",
"laboratories",
"for",
"urine",
"protein",
"and",
"urine",
"glucose",
"\n",
"Female",
"subjects",
"must",
"be",
"of",
"non",
"-",
"childbearing",
"potential",
"(",
"as",
"defined",
"as",
"surgically",
"sterile",
"[",
"i.e",
".",
"history",
"of",
"hysterectomy",
"or",
"tubal",
"ligation",
"]",
"or",
"postmenopausal",
"for",
"more",
"than",
"1",
"year",
"[",
"no",
"bleeding",
"for",
"12",
"consecutive",
"months",
"]",
",",
"or",
"if",
"of",
"childbearing",
"potential",
"must",
"be",
"non",
"-",
"pregnant",
"at",
"the",
"time",
"of",
"enrollment",
"and",
"on",
"the",
"morning",
"of",
"the",
"first",
"day",
"of",
"each",
"study",
"session",
",",
"and",
"must",
"agree",
"to",
"use",
"hormonal",
"or",
"barrier",
"birth",
"control",
"such",
"as",
"implants",
",",
"injectables",
",",
"combined",
"oral",
"contraceptives",
",",
"some",
"intrauterine",
"devices",
"(",
"IUDs",
")",
",",
"sexual",
"abstinence",
"or",
"a",
"vasectomized",
"parter",
"\n",
"Agrees",
"not",
"to",
"participate",
"in",
"another",
"clinical",
"study",
"/",
"trial",
"during",
"the",
"study",
"period",
"or",
"to",
"participate",
"in",
"an",
"investigational",
"drug",
"study",
"for",
"at",
"least",
"one",
"month",
"after",
"last",
"study",
"session",
"\n",
"Agrees",
"not",
"to",
"donate",
"blood",
"to",
"a",
"blood",
"bank",
"throughout",
"participation",
"in",
"the",
"study",
"and",
"for",
"at",
"least",
"3",
"months",
"after",
"last",
"study",
"day",
"\n",
"Have",
"a",
"normal",
"ECG",
";",
"must",
"not",
"have",
"the",
"following",
"to",
"be",
"acceptable",
":",
"pathologic",
"Q",
"wave",
"abnormalities",
",",
"significant",
"ST",
"-",
"T",
"wave",
"changes",
",",
"left",
"ventricular",
"hypertrophy",
",",
"right",
"bundle",
"branch",
"block",
",",
"left",
"bundle",
"branch",
"block",
".",
"(",
"sinus",
"rhythm",
"is",
"between",
"55",
"-",
"100",
"beats",
"per",
"minute",
")",
"\n",
"Temperature",
"35",
"-",
"37.9",
"°",
"C",
"(",
"95",
"-",
"100.3",
"°",
"F",
")",
"\n",
"Systolic",
"blood",
"pressure",
"90",
"-",
"140",
"mmHg",
"\n",
"Diastolic",
"blood",
"pressure",
"60",
"-",
"90",
"mmHg",
"\n",
"Heart",
"rate",
"55",
"-",
"100",
"beats",
"per",
"minute",
"\n",
"Respiration",
"rate",
"12",
"-",
"18",
"breaths",
"per",
"minute",
"\n"
] |
[
"Scope",
"Observation",
"Condition",
"Value",
"Measurement",
"Qualifier",
"Person",
"Negation"
] |
Men is a Person, non - pregnant is a Qualifier, women is a Person, age is a Person, 18 and 45 years old is a Value, non - smokers is a Person, BMI is a Measurement, between > 17 and = 28 kg / m2 is a Value, no is a Negation, acute or intermittent pain , postoperative pain , respiratory compromise , acute or severe asthma , or constipation is a Scope, Negative is a Value, urine drug screening test is a Measurement, normal is a Value, white blood cells ( WBC ) , hemoglobin ( Hgb ) , platelets , sodium , potassium , chloride , bicarbonate , blood urea nitrogen ( BUN ) , creatinine , ALT ( liver function ) , AST ( liver function ) and bilirubin is a Scope, normal is a Value, urine protein and urine glucose is a Scope, normal is a Value, ECG is a Measurement, not is a Negation, pathologic Q wave abnormalities , significant ST - T wave changes , left ventricular hypertrophy , right bundle branch block , left bundle branch block . is a Scope, Temperature is a Measurement, 35 - 37.9 ° C is a Value, 95 - 100.3 ° F is a Value, Systolic blood pressure is a Measurement, 90 - 140 mmHg is a Value, Diastolic blood pressure is a Measurement, 60 - 90 mmHg is a Value, Heart rate is a Measurement, 55 - 100 beats per minute is a Value, Respiration rate is a Measurement, 12 - 18 breaths per minute is a Value
|
NCT02531971_inc_task1
|
Sentence: Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old
Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
Provide written informed consent before initiation of any study procedures
Available for follow-up for the planned duration of the study
Able to communicate well with the investigators
Able to adhere to the study protocol schedule, study restrictions and examination schedule
Subjects who are within their ideal body weight (BMI between >17 and =28 kg/m2)
Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)
Negative urine drug screening test at the time of screening
Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin
Have normal screening laboratories for urine protein and urine glucose
Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter
Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session
Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day
Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
Temperature 35-37.9°C (95-100.3°F)
Systolic blood pressure 90-140 mmHg
Diastolic blood pressure 60-90 mmHg
Heart rate 55-100 beats per minute
Respiration rate 12-18 breaths per minute
Instructions: please typing these entity words according to sentence: Men, non - pregnant, women, age, 18 and 45 years old, non - smokers, BMI, between > 17 and = 28 kg / m2, no, acute or intermittent pain , postoperative pain , respiratory compromise , acute or severe asthma , or constipation, Negative, urine drug screening test, normal, white blood cells ( WBC ) , hemoglobin ( Hgb ) , platelets , sodium , potassium , chloride , bicarbonate , blood urea nitrogen ( BUN ) , creatinine , ALT ( liver function ) , AST ( liver function ) and bilirubin, normal, urine protein and urine glucose, normal, ECG, not, pathologic Q wave abnormalities , significant ST - T wave changes , left ventricular hypertrophy , right bundle branch block , left bundle branch block ., Temperature, 35 - 37.9 ° C, 95 - 100.3 ° F, Systolic blood pressure, 90 - 140 mmHg, Diastolic blood pressure, 60 - 90 mmHg, Heart rate, 55 - 100 beats per minute, Respiration rate, 12 - 18 breaths per minute
Options: Qualifier, Value, Person, Negation, Scope, Measurement
|
[
"B-Person",
"O",
"B-Qualifier",
"I-Qualifier",
"I-Qualifier",
"B-Person",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Person",
"O",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"O",
"O",
"B-Person",
"I-Person",
"I-Person",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Negation",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"I-Measurement",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"B-Value",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"B-Measurement",
"O",
"O",
"B-Negation",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O"
] |
Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old
Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
Provide written informed consent before initiation of any study procedures
Available for follow-up for the planned duration of the study
Able to communicate well with the investigators
Able to adhere to the study protocol schedule, study restrictions and examination schedule
Subjects who are within their ideal body weight (BMI between >17 and =28 kg/m2)
Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)
Negative urine drug screening test at the time of screening
Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin
Have normal screening laboratories for urine protein and urine glucose
Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter
Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session
Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day
Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
Temperature 35-37.9°C (95-100.3°F)
Systolic blood pressure 90-140 mmHg
Diastolic blood pressure 60-90 mmHg
Heart rate 55-100 beats per minute
Respiration rate 12-18 breaths per minute
|
[
"Men",
"or",
"non",
"-",
"pregnant",
"women",
"of",
"any",
"ethnic",
"background",
"between",
"the",
"age",
"of",
"18",
"and",
"45",
"years",
"old",
"\n",
"Subjects",
"must",
"be",
"non",
"-",
"smokers",
"(",
"must",
"have",
"refrained",
"from",
"the",
"use",
"of",
"nicotine",
"-",
"containing",
"substances",
",",
"including",
"tobacco",
"products",
"(",
"e.g",
".",
"cigarettes",
",",
"cigars",
",",
"chewing",
"tobacco",
",",
"gum",
",",
"patch",
"or",
"electronic",
"cigarettes",
")",
"over",
"the",
"previous",
"2",
"months",
"and",
"are",
"not",
"currently",
"using",
"tobacco",
"products",
"\n",
"Provide",
"written",
"informed",
"consent",
"before",
"initiation",
"of",
"any",
"study",
"procedures",
"\n",
"Available",
"for",
"follow",
"-",
"up",
"for",
"the",
"planned",
"duration",
"of",
"the",
"study",
"\n",
"Able",
"to",
"communicate",
"well",
"with",
"the",
"investigators",
"\n",
"Able",
"to",
"adhere",
"to",
"the",
"study",
"protocol",
"schedule",
",",
"study",
"restrictions",
"and",
"examination",
"schedule",
"\n",
"Subjects",
"who",
"are",
"within",
"their",
"ideal",
"body",
"weight",
"(",
"BMI",
"between",
">",
"17",
"and",
"=",
"28",
"kg",
"/",
"m2",
")",
"\n",
"Subjects",
"deemed",
"to",
"be",
"healthy",
"as",
"judged",
"by",
"the",
"Medically",
"Accountable",
"Investigator",
"(",
"MAI",
")",
"and",
"determined",
"by",
"medical",
"history",
",",
"physical",
"examination",
"and",
"medication",
"history",
"\n",
"Subjects",
"have",
"no",
"history",
"of",
"the",
"following",
":",
"ongoing",
"acute",
"or",
"intermittent",
"pain",
",",
"postoperative",
"pain",
",",
"respiratory",
"compromise",
",",
"acute",
"or",
"severe",
"asthma",
",",
"or",
"constipation",
"(",
"less",
"than",
"1",
"bowel",
"movement",
"every",
"2",
"days",
")",
"\n",
"Negative",
"urine",
"drug",
"screening",
"test",
"at",
"the",
"time",
"of",
"screening",
"\n",
"Have",
"normal",
"screening",
"laboratories",
"for",
"white",
"blood",
"cells",
"(",
"WBC",
")",
",",
"hemoglobin",
"(",
"Hgb",
")",
",",
"platelets",
",",
"sodium",
",",
"potassium",
",",
"chloride",
",",
"bicarbonate",
",",
"blood",
"urea",
"nitrogen",
"(",
"BUN",
")",
",",
"creatinine",
",",
"ALT",
"(",
"liver",
"function",
")",
",",
"AST",
"(",
"liver",
"function",
")",
"and",
"bilirubin",
"\n",
"Have",
"normal",
"screening",
"laboratories",
"for",
"urine",
"protein",
"and",
"urine",
"glucose",
"\n",
"Female",
"subjects",
"must",
"be",
"of",
"non",
"-",
"childbearing",
"potential",
"(",
"as",
"defined",
"as",
"surgically",
"sterile",
"[",
"i.e",
".",
"history",
"of",
"hysterectomy",
"or",
"tubal",
"ligation",
"]",
"or",
"postmenopausal",
"for",
"more",
"than",
"1",
"year",
"[",
"no",
"bleeding",
"for",
"12",
"consecutive",
"months",
"]",
",",
"or",
"if",
"of",
"childbearing",
"potential",
"must",
"be",
"non",
"-",
"pregnant",
"at",
"the",
"time",
"of",
"enrollment",
"and",
"on",
"the",
"morning",
"of",
"the",
"first",
"day",
"of",
"each",
"study",
"session",
",",
"and",
"must",
"agree",
"to",
"use",
"hormonal",
"or",
"barrier",
"birth",
"control",
"such",
"as",
"implants",
",",
"injectables",
",",
"combined",
"oral",
"contraceptives",
",",
"some",
"intrauterine",
"devices",
"(",
"IUDs",
")",
",",
"sexual",
"abstinence",
"or",
"a",
"vasectomized",
"parter",
"\n",
"Agrees",
"not",
"to",
"participate",
"in",
"another",
"clinical",
"study",
"/",
"trial",
"during",
"the",
"study",
"period",
"or",
"to",
"participate",
"in",
"an",
"investigational",
"drug",
"study",
"for",
"at",
"least",
"one",
"month",
"after",
"last",
"study",
"session",
"\n",
"Agrees",
"not",
"to",
"donate",
"blood",
"to",
"a",
"blood",
"bank",
"throughout",
"participation",
"in",
"the",
"study",
"and",
"for",
"at",
"least",
"3",
"months",
"after",
"last",
"study",
"day",
"\n",
"Have",
"a",
"normal",
"ECG",
";",
"must",
"not",
"have",
"the",
"following",
"to",
"be",
"acceptable",
":",
"pathologic",
"Q",
"wave",
"abnormalities",
",",
"significant",
"ST",
"-",
"T",
"wave",
"changes",
",",
"left",
"ventricular",
"hypertrophy",
",",
"right",
"bundle",
"branch",
"block",
",",
"left",
"bundle",
"branch",
"block",
".",
"(",
"sinus",
"rhythm",
"is",
"between",
"55",
"-",
"100",
"beats",
"per",
"minute",
")",
"\n",
"Temperature",
"35",
"-",
"37.9",
"°",
"C",
"(",
"95",
"-",
"100.3",
"°",
"F",
")",
"\n",
"Systolic",
"blood",
"pressure",
"90",
"-",
"140",
"mmHg",
"\n",
"Diastolic",
"blood",
"pressure",
"60",
"-",
"90",
"mmHg",
"\n",
"Heart",
"rate",
"55",
"-",
"100",
"beats",
"per",
"minute",
"\n",
"Respiration",
"rate",
"12",
"-",
"18",
"breaths",
"per",
"minute",
"\n"
] |
[
"Scope",
"Observation",
"Condition",
"Value",
"Measurement",
"Qualifier",
"Person",
"Negation"
] |
Men, non - pregnant, women, age, 18 and 45 years old, non - smokers, BMI, between > 17 and = 28 kg / m2, no, acute or intermittent pain , postoperative pain , respiratory compromise , acute or severe asthma , or constipation, Negative, urine drug screening test, normal, white blood cells ( WBC ) , hemoglobin ( Hgb ) , platelets , sodium , potassium , chloride , bicarbonate , blood urea nitrogen ( BUN ) , creatinine , ALT ( liver function ) , AST ( liver function ) and bilirubin, normal, urine protein and urine glucose, normal, ECG, not, pathologic Q wave abnormalities , significant ST - T wave changes , left ventricular hypertrophy , right bundle branch block , left bundle branch block ., Temperature, 35 - 37.9 ° C, 95 - 100.3 ° F, Systolic blood pressure, 90 - 140 mmHg, Diastolic blood pressure, 60 - 90 mmHg, Heart rate, 55 - 100 beats per minute, Respiration rate, 12 - 18 breaths per minute
|
NCT02531971_inc_task2
|
Sentence: Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old
Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
Provide written informed consent before initiation of any study procedures
Available for follow-up for the planned duration of the study
Able to communicate well with the investigators
Able to adhere to the study protocol schedule, study restrictions and examination schedule
Subjects who are within their ideal body weight (BMI between >17 and =28 kg/m2)
Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)
Negative urine drug screening test at the time of screening
Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin
Have normal screening laboratories for urine protein and urine glucose
Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter
Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session
Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day
Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
Temperature 35-37.9°C (95-100.3°F)
Systolic blood pressure 90-140 mmHg
Diastolic blood pressure 60-90 mmHg
Heart rate 55-100 beats per minute
Respiration rate 12-18 breaths per minute
Instructions: please extract entity words from the input sentence
|
[
"B-Person",
"O",
"B-Qualifier",
"I-Qualifier",
"I-Qualifier",
"B-Person",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Person",
"O",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"O",
"O",
"B-Person",
"I-Person",
"I-Person",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Negation",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"I-Measurement",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"B-Value",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Value",
"B-Measurement",
"O",
"O",
"B-Negation",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"I-Scope",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"O",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O",
"B-Measurement",
"I-Measurement",
"B-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"I-Value",
"O"
] |
Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old
Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g. cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products
Provide written informed consent before initiation of any study procedures
Available for follow-up for the planned duration of the study
Able to communicate well with the investigators
Able to adhere to the study protocol schedule, study restrictions and examination schedule
Subjects who are within their ideal body weight (BMI between >17 and =28 kg/m2)
Subjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history
Subjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)
Negative urine drug screening test at the time of screening
Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin
Have normal screening laboratories for urine protein and urine glucose
Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter
Agrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session
Agrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day
Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
Temperature 35-37.9°C (95-100.3°F)
Systolic blood pressure 90-140 mmHg
Diastolic blood pressure 60-90 mmHg
Heart rate 55-100 beats per minute
Respiration rate 12-18 breaths per minute
|
[
"Men",
"or",
"non",
"-",
"pregnant",
"women",
"of",
"any",
"ethnic",
"background",
"between",
"the",
"age",
"of",
"18",
"and",
"45",
"years",
"old",
"\n",
"Subjects",
"must",
"be",
"non",
"-",
"smokers",
"(",
"must",
"have",
"refrained",
"from",
"the",
"use",
"of",
"nicotine",
"-",
"containing",
"substances",
",",
"including",
"tobacco",
"products",
"(",
"e.g",
".",
"cigarettes",
",",
"cigars",
",",
"chewing",
"tobacco",
",",
"gum",
",",
"patch",
"or",
"electronic",
"cigarettes",
")",
"over",
"the",
"previous",
"2",
"months",
"and",
"are",
"not",
"currently",
"using",
"tobacco",
"products",
"\n",
"Provide",
"written",
"informed",
"consent",
"before",
"initiation",
"of",
"any",
"study",
"procedures",
"\n",
"Available",
"for",
"follow",
"-",
"up",
"for",
"the",
"planned",
"duration",
"of",
"the",
"study",
"\n",
"Able",
"to",
"communicate",
"well",
"with",
"the",
"investigators",
"\n",
"Able",
"to",
"adhere",
"to",
"the",
"study",
"protocol",
"schedule",
",",
"study",
"restrictions",
"and",
"examination",
"schedule",
"\n",
"Subjects",
"who",
"are",
"within",
"their",
"ideal",
"body",
"weight",
"(",
"BMI",
"between",
">",
"17",
"and",
"=",
"28",
"kg",
"/",
"m2",
")",
"\n",
"Subjects",
"deemed",
"to",
"be",
"healthy",
"as",
"judged",
"by",
"the",
"Medically",
"Accountable",
"Investigator",
"(",
"MAI",
")",
"and",
"determined",
"by",
"medical",
"history",
",",
"physical",
"examination",
"and",
"medication",
"history",
"\n",
"Subjects",
"have",
"no",
"history",
"of",
"the",
"following",
":",
"ongoing",
"acute",
"or",
"intermittent",
"pain",
",",
"postoperative",
"pain",
",",
"respiratory",
"compromise",
",",
"acute",
"or",
"severe",
"asthma",
",",
"or",
"constipation",
"(",
"less",
"than",
"1",
"bowel",
"movement",
"every",
"2",
"days",
")",
"\n",
"Negative",
"urine",
"drug",
"screening",
"test",
"at",
"the",
"time",
"of",
"screening",
"\n",
"Have",
"normal",
"screening",
"laboratories",
"for",
"white",
"blood",
"cells",
"(",
"WBC",
")",
",",
"hemoglobin",
"(",
"Hgb",
")",
",",
"platelets",
",",
"sodium",
",",
"potassium",
",",
"chloride",
",",
"bicarbonate",
",",
"blood",
"urea",
"nitrogen",
"(",
"BUN",
")",
",",
"creatinine",
",",
"ALT",
"(",
"liver",
"function",
")",
",",
"AST",
"(",
"liver",
"function",
")",
"and",
"bilirubin",
"\n",
"Have",
"normal",
"screening",
"laboratories",
"for",
"urine",
"protein",
"and",
"urine",
"glucose",
"\n",
"Female",
"subjects",
"must",
"be",
"of",
"non",
"-",
"childbearing",
"potential",
"(",
"as",
"defined",
"as",
"surgically",
"sterile",
"[",
"i.e",
".",
"history",
"of",
"hysterectomy",
"or",
"tubal",
"ligation",
"]",
"or",
"postmenopausal",
"for",
"more",
"than",
"1",
"year",
"[",
"no",
"bleeding",
"for",
"12",
"consecutive",
"months",
"]",
",",
"or",
"if",
"of",
"childbearing",
"potential",
"must",
"be",
"non",
"-",
"pregnant",
"at",
"the",
"time",
"of",
"enrollment",
"and",
"on",
"the",
"morning",
"of",
"the",
"first",
"day",
"of",
"each",
"study",
"session",
",",
"and",
"must",
"agree",
"to",
"use",
"hormonal",
"or",
"barrier",
"birth",
"control",
"such",
"as",
"implants",
",",
"injectables",
",",
"combined",
"oral",
"contraceptives",
",",
"some",
"intrauterine",
"devices",
"(",
"IUDs",
")",
",",
"sexual",
"abstinence",
"or",
"a",
"vasectomized",
"parter",
"\n",
"Agrees",
"not",
"to",
"participate",
"in",
"another",
"clinical",
"study",
"/",
"trial",
"during",
"the",
"study",
"period",
"or",
"to",
"participate",
"in",
"an",
"investigational",
"drug",
"study",
"for",
"at",
"least",
"one",
"month",
"after",
"last",
"study",
"session",
"\n",
"Agrees",
"not",
"to",
"donate",
"blood",
"to",
"a",
"blood",
"bank",
"throughout",
"participation",
"in",
"the",
"study",
"and",
"for",
"at",
"least",
"3",
"months",
"after",
"last",
"study",
"day",
"\n",
"Have",
"a",
"normal",
"ECG",
";",
"must",
"not",
"have",
"the",
"following",
"to",
"be",
"acceptable",
":",
"pathologic",
"Q",
"wave",
"abnormalities",
",",
"significant",
"ST",
"-",
"T",
"wave",
"changes",
",",
"left",
"ventricular",
"hypertrophy",
",",
"right",
"bundle",
"branch",
"block",
",",
"left",
"bundle",
"branch",
"block",
".",
"(",
"sinus",
"rhythm",
"is",
"between",
"55",
"-",
"100",
"beats",
"per",
"minute",
")",
"\n",
"Temperature",
"35",
"-",
"37.9",
"°",
"C",
"(",
"95",
"-",
"100.3",
"°",
"F",
")",
"\n",
"Systolic",
"blood",
"pressure",
"90",
"-",
"140",
"mmHg",
"\n",
"Diastolic",
"blood",
"pressure",
"60",
"-",
"90",
"mmHg",
"\n",
"Heart",
"rate",
"55",
"-",
"100",
"beats",
"per",
"minute",
"\n",
"Respiration",
"rate",
"12",
"-",
"18",
"breaths",
"per",
"minute",
"\n"
] |
[
"Scope",
"Observation",
"Condition",
"Value",
"Measurement",
"Qualifier",
"Person",
"Negation"
] |
Tumor óseo de células gigantes grado 3 de Sanerkin is a MORFOLOGIA_NEOPLASIA, Metástasis is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, masa mediastínica is a MORFOLOGIA_NEOPLASIA, Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo is a MORFOLOGIA_NEOPLASIA, Masa medistínica is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, enfermedad a nivel mediastínico is a MORFOLOGIA_NEOPLASIA, infiltración esofágica is a MORFOLOGIA_NEOPLASIA, tumor de células gigantes is a MORFOLOGIA_NEOPLASIA
|
83_task0
|
Sentence: Anamnesis
Mujer de raza blanca, de 33 años de edad, con antecedentes personales relevantes:
» Sin alergias medicamentosas conocidas.
» Sin hábitos tóxicos.
» No presenta cardiopatía ni broncopatía conocidas.
» Tumor óseo de células gigantes grado 3 de Sanerkin de fémur izquierdo tratado mediante exéresis, prótesis y aloinjerto en diciembre de 1999. Metástasis pulmonares bilaterales y ganglionares mediastínicas en octubre de 2000 comprobadas histológicamente. Realizó tratamiento quimioterápico con cisplatino, adriamicina e ifosfamida con progresión de la enfermedad a nivel torácico tras tres ciclos. Posteriormente, Interferón alfa-2a durante un mes, retirado por mala tolerancia. Desde entonces en seguimiento.
Acude a Urgencias en noviembre de 2014 por disnea progresiva, con intolerancia al decúbito, sensación de cansancio, dolor en el costado izquierdo y tos persistente. En estudios de imagen realizados, se objetiva derrame pericárdico severo con signos de taponamiento cardiaco y gran masa extracardiaca con compresión sobre cavidades izquierdas y colapso de las mismas.
Exploración física
Mal estado general, cociente y orientada en las tres esferas, taquipneica en reposo con intolerancia al decúbito saturando al 99% con gafas nasales. Estable hemodinámicamente con tensión arterial 110/70mm Hg. Ingurgitación yugular.
Auscultación cardiopulmonar: corazón rítmico a 120 latidos por minuto (lpm). Soplo diastólico en ápex que cambia con la postura. Murmullo vesicular conservado con hipoventilación generalizada. Abdomen blando y depresible, con hepatomegalia marcada de borde romo. Miembros inferiores sin signos de trombosis venosa profunda ni edemas.
Pruebas complementarias
» Analítica: bioquímica sin alteraciones. Hemograma: Hb 11,7 mg/dL. Resto de series normales.
Coagulación: INR 1,39.
» ECG: taquicardia sinusal a 120 lpm. Bajo voltaje en derivaciones bipolares. Alternancia eléctrica.
» Radiografía simple de tórax PA: cardiomegalia a expensas de cavidades izquierdas. Múltiples implantes tumorales calcificados. Gran masa parahiliar derecha que ejerce efecto masa sobre silueta cardiomediastínica con desplazamiento de las mismas.
» Ecocardiografía transtorácica: aurícula izquierda comprimida por tumoración extracardiaca de gran tamaño. Derrame pericárdico severo con signos ecocardiográficos de taponamiento. Ventrículo izquierdo de dimensiones normales con fracción de eyección conservada.
» TC de tórax y abdomen c/c: afectación metastásica masiva de ambos pulmones. Gran masa mediastínica posterior que se introduce por espacio retrocural y ejerce efecto masa y compromiso de cavidades cardiacas izquierdas. Derrame pericárdico severo, pleural bilateral y peritoneal.
Hepatomegalia de aspecto congestivo.
Diagnóstico
Derrame pericárdico severo con signos de taponamiento cardiaco.
Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo estables.
Masa medistínica en progresión con compresión y colapaso de cavidades cardiacas izquierdas.
Tratamiento
Pericardiocentesis.
Denosumab 120 mg días 1, 8 y 15 subcutáneo por 1 ciclo.
Epirrubicina 50 mg/m2 - ifosfamida 3 g/m2 por 1 ciclo.
Evolución
Se realiza pericardiocentesis urgente con recogida de 450 cc de líquido pericárdico hemático que se envía a citología con resultado negativo para neoplasia. Tras el procedimiento, mejora su situación clínica permaneciendo eupneica. Se mantiene 48 horas obteniéndose 300 cc adicionales y se retira posteriormente.
Por progresión de la enfermedad a nivel mediastínico objetivado mediante TC de tórax y abdomen (no se realiza biopsia por deterioro clínico) inicia el 14 de noviembre denosumab 120 mg días 1, 8 y 15 por vía subcutánea con excelente tolerancia, completando un ciclo.
En diciembre de 2014 por infiltración esofágica comienza con disfagia a sólidos. manteniendo tolerancia a líquidos. Se coloca sonda nasogástrica (SNG) y comienza nutrición enteral programándose realización de gastrostomía de alimentación. Se realizó endoscopia oral con toma de biopsia con resultado histológico: tumor de células gigantes.
En enero de 2015 inicia tratamiento quimioterápico con epirrubicina 50 mg/m2-ifosfamida 3 g/m2 en tres días suspendiéndose el día 3 por disnea y mala tolerancia (sobrecarga de volumen).
Reingresa a los tres días por reagudización de disnea con empeoramiento clínico, desaturando a pesar de VMNI, cianosis periférica y mala situación general por lo que se procede a sedación de la paciente, siendo éxitus finalmente.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: MORFOLOGIA_NEOPLASIA
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Anamnesis
Mujer de raza blanca, de 33 años de edad, con antecedentes personales relevantes:
» Sin alergias medicamentosas conocidas.
» Sin hábitos tóxicos.
» No presenta cardiopatía ni broncopatía conocidas.
» Tumor óseo de células gigantes grado 3 de Sanerkin de fémur izquierdo tratado mediante exéresis, prótesis y aloinjerto en diciembre de 1999. Metástasis pulmonares bilaterales y ganglionares mediastínicas en octubre de 2000 comprobadas histológicamente. Realizó tratamiento quimioterápico con cisplatino, adriamicina e ifosfamida con progresión de la enfermedad a nivel torácico tras tres ciclos. Posteriormente, Interferón alfa-2a durante un mes, retirado por mala tolerancia. Desde entonces en seguimiento.
Acude a Urgencias en noviembre de 2014 por disnea progresiva, con intolerancia al decúbito, sensación de cansancio, dolor en el costado izquierdo y tos persistente. En estudios de imagen realizados, se objetiva derrame pericárdico severo con signos de taponamiento cardiaco y gran masa extracardiaca con compresión sobre cavidades izquierdas y colapso de las mismas.
Exploración física
Mal estado general, cociente y orientada en las tres esferas, taquipneica en reposo con intolerancia al decúbito saturando al 99% con gafas nasales. Estable hemodinámicamente con tensión arterial 110/70mm Hg. Ingurgitación yugular.
Auscultación cardiopulmonar: corazón rítmico a 120 latidos por minuto (lpm). Soplo diastólico en ápex que cambia con la postura. Murmullo vesicular conservado con hipoventilación generalizada. Abdomen blando y depresible, con hepatomegalia marcada de borde romo. Miembros inferiores sin signos de trombosis venosa profunda ni edemas.
Pruebas complementarias
» Analítica: bioquímica sin alteraciones. Hemograma: Hb 11,7 mg/dL. Resto de series normales.
Coagulación: INR 1,39.
» ECG: taquicardia sinusal a 120 lpm. Bajo voltaje en derivaciones bipolares. Alternancia eléctrica.
» Radiografía simple de tórax PA: cardiomegalia a expensas de cavidades izquierdas. Múltiples implantes tumorales calcificados. Gran masa parahiliar derecha que ejerce efecto masa sobre silueta cardiomediastínica con desplazamiento de las mismas.
» Ecocardiografía transtorácica: aurícula izquierda comprimida por tumoración extracardiaca de gran tamaño. Derrame pericárdico severo con signos ecocardiográficos de taponamiento. Ventrículo izquierdo de dimensiones normales con fracción de eyección conservada.
» TC de tórax y abdomen c/c: afectación metastásica masiva de ambos pulmones. Gran masa mediastínica posterior que se introduce por espacio retrocural y ejerce efecto masa y compromiso de cavidades cardiacas izquierdas. Derrame pericárdico severo, pleural bilateral y peritoneal.
Hepatomegalia de aspecto congestivo.
Diagnóstico
Derrame pericárdico severo con signos de taponamiento cardiaco.
Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo estables.
Masa medistínica en progresión con compresión y colapaso de cavidades cardiacas izquierdas.
Tratamiento
Pericardiocentesis.
Denosumab 120 mg días 1, 8 y 15 subcutáneo por 1 ciclo.
Epirrubicina 50 mg/m2 - ifosfamida 3 g/m2 por 1 ciclo.
Evolución
Se realiza pericardiocentesis urgente con recogida de 450 cc de líquido pericárdico hemático que se envía a citología con resultado negativo para neoplasia. Tras el procedimiento, mejora su situación clínica permaneciendo eupneica. Se mantiene 48 horas obteniéndose 300 cc adicionales y se retira posteriormente.
Por progresión de la enfermedad a nivel mediastínico objetivado mediante TC de tórax y abdomen (no se realiza biopsia por deterioro clínico) inicia el 14 de noviembre denosumab 120 mg días 1, 8 y 15 por vía subcutánea con excelente tolerancia, completando un ciclo.
En diciembre de 2014 por infiltración esofágica comienza con disfagia a sólidos. manteniendo tolerancia a líquidos. Se coloca sonda nasogástrica (SNG) y comienza nutrición enteral programándose realización de gastrostomía de alimentación. Se realizó endoscopia oral con toma de biopsia con resultado histológico: tumor de células gigantes.
En enero de 2015 inicia tratamiento quimioterápico con epirrubicina 50 mg/m2-ifosfamida 3 g/m2 en tres días suspendiéndose el día 3 por disnea y mala tolerancia (sobrecarga de volumen).
Reingresa a los tres días por reagudización de disnea con empeoramiento clínico, desaturando a pesar de VMNI, cianosis periférica y mala situación general por lo que se procede a sedación de la paciente, siendo éxitus finalmente.
|
[
"Anamnesis",
"\n",
"Mujer",
"de",
"raza",
"blanca",
",",
"de",
"33",
"años",
"de",
"edad",
",",
"con",
"antecedentes",
"personales",
"relevantes",
":",
"\n",
"»",
"Sin",
"alergias",
"medicamentosas",
"conocidas",
".",
"\n",
"»",
"Sin",
"hábitos",
"tóxicos",
".",
"\n",
"»",
"No",
"presenta",
"cardiopatía",
"ni",
"broncopatía",
"conocidas",
".",
"\n",
"»",
"Tumor",
"óseo",
"de",
"células",
"gigantes",
"grado",
"3",
"de",
"Sanerkin",
"de",
"fémur",
"izquierdo",
"tratado",
"mediante",
"exéresis",
",",
"prótesis",
"y",
"aloinjerto",
"en",
"diciembre",
"de",
"1999",
".",
"Metástasis",
"pulmonares",
"bilaterales",
"y",
"ganglionares",
"mediastínicas",
"en",
"octubre",
"de",
"2000",
"comprobadas",
"histológicamente",
".",
"Realizó",
"tratamiento",
"quimioterápico",
"con",
"cisplatino",
",",
"adriamicina",
"e",
"ifosfamida",
"con",
"progresión",
"de",
"la",
"enfermedad",
"a",
"nivel",
"torácico",
"tras",
"tres",
"ciclos",
".",
"Posteriormente",
",",
"Interferón",
"alfa-2a",
"durante",
"un",
"mes",
",",
"retirado",
"por",
"mala",
"tolerancia",
".",
"Desde",
"entonces",
"en",
"seguimiento",
".",
"\n",
"Acude",
"a",
"Urgencias",
"en",
"noviembre",
"de",
"2014",
"por",
"disnea",
"progresiva",
",",
"con",
"intolerancia",
"al",
"decúbito",
",",
"sensación",
"de",
"cansancio",
",",
"dolor",
"en",
"el",
"costado",
"izquierdo",
"y",
"tos",
"persistente",
".",
"En",
"estudios",
"de",
"imagen",
"realizados",
",",
"se",
"objetiva",
"derrame",
"pericárdico",
"severo",
"con",
"signos",
"de",
"taponamiento",
"cardiaco",
"y",
"gran",
"masa",
"extracardiaca",
"con",
"compresión",
"sobre",
"cavidades",
"izquierdas",
"y",
"colapso",
"de",
"las",
"mismas",
".",
"\n\n",
"Exploración",
"física",
"\n",
"Mal",
"estado",
"general",
",",
"cociente",
"y",
"orientada",
"en",
"las",
"tres",
"esferas",
",",
"taquipneica",
"en",
"reposo",
"con",
"intolerancia",
"al",
"decúbito",
"saturando",
"al",
"99",
"%",
"con",
"gafas",
"nasales",
".",
"Estable",
"hemodinámicamente",
"con",
"tensión",
"arterial",
"110/70",
"mm",
"Hg",
".",
"Ingurgitación",
"yugular",
".",
"\n",
"Auscultación",
"cardiopulmonar",
":",
"corazón",
"rítmico",
"a",
"120",
"latidos",
"por",
"minuto",
"(",
"lpm",
")",
".",
"Soplo",
"diastólico",
"en",
"ápex",
"que",
"cambia",
"con",
"la",
"postura",
".",
"Murmullo",
"vesicular",
"conservado",
"con",
"hipoventilación",
"generalizada",
".",
"Abdomen",
"blando",
"y",
"depresible",
",",
"con",
"hepatomegalia",
"marcada",
"de",
"borde",
"romo",
".",
"Miembros",
"inferiores",
"sin",
"signos",
"de",
"trombosis",
"venosa",
"profunda",
"ni",
"edemas",
".",
"\n\n",
"Pruebas",
"complementarias",
"\n",
"»",
"Analítica",
":",
"bioquímica",
"sin",
"alteraciones",
".",
"Hemograma",
":",
"Hb",
"11,7",
"mg",
"/",
"dL.",
"Resto",
"de",
"series",
"normales",
".",
"\n",
"Coagulación",
":",
"INR",
"1,39",
".",
"\n",
"»",
"ECG",
":",
"taquicardia",
"sinusal",
"a",
"120",
"lpm",
".",
"Bajo",
"voltaje",
"en",
"derivaciones",
"bipolares",
".",
"Alternancia",
"eléctrica",
".",
"\n",
"»",
"Radiografía",
"simple",
"de",
"tórax",
"PA",
":",
"cardiomegalia",
"a",
"expensas",
"de",
"cavidades",
"izquierdas",
".",
"Múltiples",
"implantes",
"tumorales",
"calcificados",
".",
"Gran",
"masa",
"parahiliar",
"derecha",
"que",
"ejerce",
"efecto",
"masa",
"sobre",
"silueta",
"cardiomediastínica",
"con",
"desplazamiento",
"de",
"las",
"mismas",
".",
"\n",
"»",
"Ecocardiografía",
"transtorácica",
":",
"aurícula",
"izquierda",
"comprimida",
"por",
"tumoración",
"extracardiaca",
"de",
"gran",
"tamaño",
".",
"Derrame",
"pericárdico",
"severo",
"con",
"signos",
"ecocardiográficos",
"de",
"taponamiento",
".",
"Ventrículo",
"izquierdo",
"de",
"dimensiones",
"normales",
"con",
"fracción",
"de",
"eyección",
"conservada",
".",
"\n",
"»",
"TC",
"de",
"tórax",
"y",
"abdomen",
"c",
"/",
"c",
":",
"afectación",
"metastásica",
"masiva",
"de",
"ambos",
"pulmones",
".",
"Gran",
"masa",
"mediastínica",
"posterior",
"que",
"se",
"introduce",
"por",
"espacio",
"retrocural",
"y",
"ejerce",
"efecto",
"masa",
"y",
"compromiso",
"de",
"cavidades",
"cardiacas",
"izquierdas",
".",
"Derrame",
"pericárdico",
"severo",
",",
"pleural",
"bilateral",
"y",
"peritoneal",
".",
"\n",
"Hepatomegalia",
"de",
"aspecto",
"congestivo",
".",
"\n\n",
"Diagnóstico",
"\n",
"Derrame",
"pericárdico",
"severo",
"con",
"signos",
"de",
"taponamiento",
"cardiaco",
".",
"\n",
"Metástasis",
"pulmonares",
"y",
"mediastínicas",
"del",
"tumor",
"de",
"células",
"gigantes",
"óseo",
"estables",
".",
"\n",
"Masa",
"medistínica",
"en",
"progresión",
"con",
"compresión",
"y",
"colapaso",
"de",
"cavidades",
"cardiacas",
"izquierdas",
".",
"\n\n",
"Tratamiento",
"\n",
"Pericardiocentesis",
".",
"\n",
"Denosumab",
"120",
"mg",
"días",
"1",
",",
"8",
"y",
"15",
"subcutáneo",
"por",
"1",
"ciclo",
".",
"\n",
"Epirrubicina",
"50",
"mg",
"/",
"m2",
"-",
"ifosfamida",
"3",
"g",
"/",
"m2",
"por",
"1",
"ciclo",
".",
"\n\n",
"Evolución",
"\n",
"Se",
"realiza",
"pericardiocentesis",
"urgente",
"con",
"recogida",
"de",
"450",
"cc",
"de",
"líquido",
"pericárdico",
"hemático",
"que",
"se",
"envía",
"a",
"citología",
"con",
"resultado",
"negativo",
"para",
"neoplasia",
".",
"Tras",
"el",
"procedimiento",
",",
"mejora",
"su",
"situación",
"clínica",
"permaneciendo",
"eupneica",
".",
"Se",
"mantiene",
"48",
"horas",
"obteniéndose",
"300",
"cc",
"adicionales",
"y",
"se",
"retira",
"posteriormente",
".",
"\n\n",
"Por",
"progresión",
"de",
"la",
"enfermedad",
"a",
"nivel",
"mediastínico",
"objetivado",
"mediante",
"TC",
"de",
"tórax",
"y",
"abdomen",
"(",
"no",
"se",
"realiza",
"biopsia",
"por",
"deterioro",
"clínico",
")",
"inicia",
"el",
"14",
"de",
"noviembre",
"denosumab",
"120",
"mg",
"días",
"1",
",",
"8",
"y",
"15",
"por",
"vía",
"subcutánea",
"con",
"excelente",
"tolerancia",
",",
"completando",
"un",
"ciclo",
".",
"\n\n",
"En",
"diciembre",
"de",
"2014",
"por",
"infiltración",
"esofágica",
"comienza",
"con",
"disfagia",
"a",
"sólidos",
".",
"manteniendo",
"tolerancia",
"a",
"líquidos",
".",
"Se",
"coloca",
"sonda",
"nasogástrica",
"(",
"SNG",
")",
"y",
"comienza",
"nutrición",
"enteral",
"programándose",
"realización",
"de",
"gastrostomía",
"de",
"alimentación",
".",
"Se",
"realizó",
"endoscopia",
"oral",
"con",
"toma",
"de",
"biopsia",
"con",
"resultado",
"histológico",
":",
"tumor",
"de",
"células",
"gigantes",
".",
"\n\n",
"En",
"enero",
"de",
"2015",
"inicia",
"tratamiento",
"quimioterápico",
"con",
"epirrubicina",
"50",
"mg",
"/",
"m2-ifosfamida",
"3",
"g",
"/",
"m2",
"en",
"tres",
"días",
"suspendiéndose",
"el",
"día",
"3",
"por",
"disnea",
"y",
"mala",
"tolerancia",
"(",
"sobrecarga",
"de",
"volumen",
")",
".",
"\n\n",
"Reingresa",
"a",
"los",
"tres",
"días",
"por",
"reagudización",
"de",
"disnea",
"con",
"empeoramiento",
"clínico",
",",
"desaturando",
"a",
"pesar",
"de",
"VMNI",
",",
"cianosis",
"periférica",
"y",
"mala",
"situación",
"general",
"por",
"lo",
"que",
"se",
"procede",
"a",
"sedación",
"de",
"la",
"paciente",
",",
"siendo",
"éxitus",
"finalmente",
"."
] |
[
"MORFOLOGIA_NEOPLASIA"
] |
Tumor óseo de células gigantes grado 3 de Sanerkin is a MORFOLOGIA_NEOPLASIA, Metástasis is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, tumoración is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, masa mediastínica is a MORFOLOGIA_NEOPLASIA, Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo is a MORFOLOGIA_NEOPLASIA, Masa medistínica is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, enfermedad a nivel mediastínico is a MORFOLOGIA_NEOPLASIA, infiltración esofágica is a MORFOLOGIA_NEOPLASIA, tumor de células gigantes is a MORFOLOGIA_NEOPLASIA
|
83_task1
|
Sentence: Anamnesis
Mujer de raza blanca, de 33 años de edad, con antecedentes personales relevantes:
» Sin alergias medicamentosas conocidas.
» Sin hábitos tóxicos.
» No presenta cardiopatía ni broncopatía conocidas.
» Tumor óseo de células gigantes grado 3 de Sanerkin de fémur izquierdo tratado mediante exéresis, prótesis y aloinjerto en diciembre de 1999. Metástasis pulmonares bilaterales y ganglionares mediastínicas en octubre de 2000 comprobadas histológicamente. Realizó tratamiento quimioterápico con cisplatino, adriamicina e ifosfamida con progresión de la enfermedad a nivel torácico tras tres ciclos. Posteriormente, Interferón alfa-2a durante un mes, retirado por mala tolerancia. Desde entonces en seguimiento.
Acude a Urgencias en noviembre de 2014 por disnea progresiva, con intolerancia al decúbito, sensación de cansancio, dolor en el costado izquierdo y tos persistente. En estudios de imagen realizados, se objetiva derrame pericárdico severo con signos de taponamiento cardiaco y gran masa extracardiaca con compresión sobre cavidades izquierdas y colapso de las mismas.
Exploración física
Mal estado general, cociente y orientada en las tres esferas, taquipneica en reposo con intolerancia al decúbito saturando al 99% con gafas nasales. Estable hemodinámicamente con tensión arterial 110/70mm Hg. Ingurgitación yugular.
Auscultación cardiopulmonar: corazón rítmico a 120 latidos por minuto (lpm). Soplo diastólico en ápex que cambia con la postura. Murmullo vesicular conservado con hipoventilación generalizada. Abdomen blando y depresible, con hepatomegalia marcada de borde romo. Miembros inferiores sin signos de trombosis venosa profunda ni edemas.
Pruebas complementarias
» Analítica: bioquímica sin alteraciones. Hemograma: Hb 11,7 mg/dL. Resto de series normales.
Coagulación: INR 1,39.
» ECG: taquicardia sinusal a 120 lpm. Bajo voltaje en derivaciones bipolares. Alternancia eléctrica.
» Radiografía simple de tórax PA: cardiomegalia a expensas de cavidades izquierdas. Múltiples implantes tumorales calcificados. Gran masa parahiliar derecha que ejerce efecto masa sobre silueta cardiomediastínica con desplazamiento de las mismas.
» Ecocardiografía transtorácica: aurícula izquierda comprimida por tumoración extracardiaca de gran tamaño. Derrame pericárdico severo con signos ecocardiográficos de taponamiento. Ventrículo izquierdo de dimensiones normales con fracción de eyección conservada.
» TC de tórax y abdomen c/c: afectación metastásica masiva de ambos pulmones. Gran masa mediastínica posterior que se introduce por espacio retrocural y ejerce efecto masa y compromiso de cavidades cardiacas izquierdas. Derrame pericárdico severo, pleural bilateral y peritoneal.
Hepatomegalia de aspecto congestivo.
Diagnóstico
Derrame pericárdico severo con signos de taponamiento cardiaco.
Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo estables.
Masa medistínica en progresión con compresión y colapaso de cavidades cardiacas izquierdas.
Tratamiento
Pericardiocentesis.
Denosumab 120 mg días 1, 8 y 15 subcutáneo por 1 ciclo.
Epirrubicina 50 mg/m2 - ifosfamida 3 g/m2 por 1 ciclo.
Evolución
Se realiza pericardiocentesis urgente con recogida de 450 cc de líquido pericárdico hemático que se envía a citología con resultado negativo para neoplasia. Tras el procedimiento, mejora su situación clínica permaneciendo eupneica. Se mantiene 48 horas obteniéndose 300 cc adicionales y se retira posteriormente.
Por progresión de la enfermedad a nivel mediastínico objetivado mediante TC de tórax y abdomen (no se realiza biopsia por deterioro clínico) inicia el 14 de noviembre denosumab 120 mg días 1, 8 y 15 por vía subcutánea con excelente tolerancia, completando un ciclo.
En diciembre de 2014 por infiltración esofágica comienza con disfagia a sólidos. manteniendo tolerancia a líquidos. Se coloca sonda nasogástrica (SNG) y comienza nutrición enteral programándose realización de gastrostomía de alimentación. Se realizó endoscopia oral con toma de biopsia con resultado histológico: tumor de células gigantes.
En enero de 2015 inicia tratamiento quimioterápico con epirrubicina 50 mg/m2-ifosfamida 3 g/m2 en tres días suspendiéndose el día 3 por disnea y mala tolerancia (sobrecarga de volumen).
Reingresa a los tres días por reagudización de disnea con empeoramiento clínico, desaturando a pesar de VMNI, cianosis periférica y mala situación general por lo que se procede a sedación de la paciente, siendo éxitus finalmente.
Instructions: please typing these entity words according to sentence: Tumor óseo de células gigantes grado 3 de Sanerkin, Metástasis, implantes tumorales, tumoración, metastásica, masa mediastínica, Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo, Masa medistínica, neoplasia, enfermedad a nivel mediastínico, infiltración esofágica, tumor de células gigantes
Options: MORFOLOGIA_NEOPLASIA
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Anamnesis
Mujer de raza blanca, de 33 años de edad, con antecedentes personales relevantes:
» Sin alergias medicamentosas conocidas.
» Sin hábitos tóxicos.
» No presenta cardiopatía ni broncopatía conocidas.
» Tumor óseo de células gigantes grado 3 de Sanerkin de fémur izquierdo tratado mediante exéresis, prótesis y aloinjerto en diciembre de 1999. Metástasis pulmonares bilaterales y ganglionares mediastínicas en octubre de 2000 comprobadas histológicamente. Realizó tratamiento quimioterápico con cisplatino, adriamicina e ifosfamida con progresión de la enfermedad a nivel torácico tras tres ciclos. Posteriormente, Interferón alfa-2a durante un mes, retirado por mala tolerancia. Desde entonces en seguimiento.
Acude a Urgencias en noviembre de 2014 por disnea progresiva, con intolerancia al decúbito, sensación de cansancio, dolor en el costado izquierdo y tos persistente. En estudios de imagen realizados, se objetiva derrame pericárdico severo con signos de taponamiento cardiaco y gran masa extracardiaca con compresión sobre cavidades izquierdas y colapso de las mismas.
Exploración física
Mal estado general, cociente y orientada en las tres esferas, taquipneica en reposo con intolerancia al decúbito saturando al 99% con gafas nasales. Estable hemodinámicamente con tensión arterial 110/70mm Hg. Ingurgitación yugular.
Auscultación cardiopulmonar: corazón rítmico a 120 latidos por minuto (lpm). Soplo diastólico en ápex que cambia con la postura. Murmullo vesicular conservado con hipoventilación generalizada. Abdomen blando y depresible, con hepatomegalia marcada de borde romo. Miembros inferiores sin signos de trombosis venosa profunda ni edemas.
Pruebas complementarias
» Analítica: bioquímica sin alteraciones. Hemograma: Hb 11,7 mg/dL. Resto de series normales.
Coagulación: INR 1,39.
» ECG: taquicardia sinusal a 120 lpm. Bajo voltaje en derivaciones bipolares. Alternancia eléctrica.
» Radiografía simple de tórax PA: cardiomegalia a expensas de cavidades izquierdas. Múltiples implantes tumorales calcificados. Gran masa parahiliar derecha que ejerce efecto masa sobre silueta cardiomediastínica con desplazamiento de las mismas.
» Ecocardiografía transtorácica: aurícula izquierda comprimida por tumoración extracardiaca de gran tamaño. Derrame pericárdico severo con signos ecocardiográficos de taponamiento. Ventrículo izquierdo de dimensiones normales con fracción de eyección conservada.
» TC de tórax y abdomen c/c: afectación metastásica masiva de ambos pulmones. Gran masa mediastínica posterior que se introduce por espacio retrocural y ejerce efecto masa y compromiso de cavidades cardiacas izquierdas. Derrame pericárdico severo, pleural bilateral y peritoneal.
Hepatomegalia de aspecto congestivo.
Diagnóstico
Derrame pericárdico severo con signos de taponamiento cardiaco.
Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo estables.
Masa medistínica en progresión con compresión y colapaso de cavidades cardiacas izquierdas.
Tratamiento
Pericardiocentesis.
Denosumab 120 mg días 1, 8 y 15 subcutáneo por 1 ciclo.
Epirrubicina 50 mg/m2 - ifosfamida 3 g/m2 por 1 ciclo.
Evolución
Se realiza pericardiocentesis urgente con recogida de 450 cc de líquido pericárdico hemático que se envía a citología con resultado negativo para neoplasia. Tras el procedimiento, mejora su situación clínica permaneciendo eupneica. Se mantiene 48 horas obteniéndose 300 cc adicionales y se retira posteriormente.
Por progresión de la enfermedad a nivel mediastínico objetivado mediante TC de tórax y abdomen (no se realiza biopsia por deterioro clínico) inicia el 14 de noviembre denosumab 120 mg días 1, 8 y 15 por vía subcutánea con excelente tolerancia, completando un ciclo.
En diciembre de 2014 por infiltración esofágica comienza con disfagia a sólidos. manteniendo tolerancia a líquidos. Se coloca sonda nasogástrica (SNG) y comienza nutrición enteral programándose realización de gastrostomía de alimentación. Se realizó endoscopia oral con toma de biopsia con resultado histológico: tumor de células gigantes.
En enero de 2015 inicia tratamiento quimioterápico con epirrubicina 50 mg/m2-ifosfamida 3 g/m2 en tres días suspendiéndose el día 3 por disnea y mala tolerancia (sobrecarga de volumen).
Reingresa a los tres días por reagudización de disnea con empeoramiento clínico, desaturando a pesar de VMNI, cianosis periférica y mala situación general por lo que se procede a sedación de la paciente, siendo éxitus finalmente.
|
[
"Anamnesis",
"\n",
"Mujer",
"de",
"raza",
"blanca",
",",
"de",
"33",
"años",
"de",
"edad",
",",
"con",
"antecedentes",
"personales",
"relevantes",
":",
"\n",
"»",
"Sin",
"alergias",
"medicamentosas",
"conocidas",
".",
"\n",
"»",
"Sin",
"hábitos",
"tóxicos",
".",
"\n",
"»",
"No",
"presenta",
"cardiopatía",
"ni",
"broncopatía",
"conocidas",
".",
"\n",
"»",
"Tumor",
"óseo",
"de",
"células",
"gigantes",
"grado",
"3",
"de",
"Sanerkin",
"de",
"fémur",
"izquierdo",
"tratado",
"mediante",
"exéresis",
",",
"prótesis",
"y",
"aloinjerto",
"en",
"diciembre",
"de",
"1999",
".",
"Metástasis",
"pulmonares",
"bilaterales",
"y",
"ganglionares",
"mediastínicas",
"en",
"octubre",
"de",
"2000",
"comprobadas",
"histológicamente",
".",
"Realizó",
"tratamiento",
"quimioterápico",
"con",
"cisplatino",
",",
"adriamicina",
"e",
"ifosfamida",
"con",
"progresión",
"de",
"la",
"enfermedad",
"a",
"nivel",
"torácico",
"tras",
"tres",
"ciclos",
".",
"Posteriormente",
",",
"Interferón",
"alfa-2a",
"durante",
"un",
"mes",
",",
"retirado",
"por",
"mala",
"tolerancia",
".",
"Desde",
"entonces",
"en",
"seguimiento",
".",
"\n",
"Acude",
"a",
"Urgencias",
"en",
"noviembre",
"de",
"2014",
"por",
"disnea",
"progresiva",
",",
"con",
"intolerancia",
"al",
"decúbito",
",",
"sensación",
"de",
"cansancio",
",",
"dolor",
"en",
"el",
"costado",
"izquierdo",
"y",
"tos",
"persistente",
".",
"En",
"estudios",
"de",
"imagen",
"realizados",
",",
"se",
"objetiva",
"derrame",
"pericárdico",
"severo",
"con",
"signos",
"de",
"taponamiento",
"cardiaco",
"y",
"gran",
"masa",
"extracardiaca",
"con",
"compresión",
"sobre",
"cavidades",
"izquierdas",
"y",
"colapso",
"de",
"las",
"mismas",
".",
"\n\n",
"Exploración",
"física",
"\n",
"Mal",
"estado",
"general",
",",
"cociente",
"y",
"orientada",
"en",
"las",
"tres",
"esferas",
",",
"taquipneica",
"en",
"reposo",
"con",
"intolerancia",
"al",
"decúbito",
"saturando",
"al",
"99",
"%",
"con",
"gafas",
"nasales",
".",
"Estable",
"hemodinámicamente",
"con",
"tensión",
"arterial",
"110/70",
"mm",
"Hg",
".",
"Ingurgitación",
"yugular",
".",
"\n",
"Auscultación",
"cardiopulmonar",
":",
"corazón",
"rítmico",
"a",
"120",
"latidos",
"por",
"minuto",
"(",
"lpm",
")",
".",
"Soplo",
"diastólico",
"en",
"ápex",
"que",
"cambia",
"con",
"la",
"postura",
".",
"Murmullo",
"vesicular",
"conservado",
"con",
"hipoventilación",
"generalizada",
".",
"Abdomen",
"blando",
"y",
"depresible",
",",
"con",
"hepatomegalia",
"marcada",
"de",
"borde",
"romo",
".",
"Miembros",
"inferiores",
"sin",
"signos",
"de",
"trombosis",
"venosa",
"profunda",
"ni",
"edemas",
".",
"\n\n",
"Pruebas",
"complementarias",
"\n",
"»",
"Analítica",
":",
"bioquímica",
"sin",
"alteraciones",
".",
"Hemograma",
":",
"Hb",
"11,7",
"mg",
"/",
"dL.",
"Resto",
"de",
"series",
"normales",
".",
"\n",
"Coagulación",
":",
"INR",
"1,39",
".",
"\n",
"»",
"ECG",
":",
"taquicardia",
"sinusal",
"a",
"120",
"lpm",
".",
"Bajo",
"voltaje",
"en",
"derivaciones",
"bipolares",
".",
"Alternancia",
"eléctrica",
".",
"\n",
"»",
"Radiografía",
"simple",
"de",
"tórax",
"PA",
":",
"cardiomegalia",
"a",
"expensas",
"de",
"cavidades",
"izquierdas",
".",
"Múltiples",
"implantes",
"tumorales",
"calcificados",
".",
"Gran",
"masa",
"parahiliar",
"derecha",
"que",
"ejerce",
"efecto",
"masa",
"sobre",
"silueta",
"cardiomediastínica",
"con",
"desplazamiento",
"de",
"las",
"mismas",
".",
"\n",
"»",
"Ecocardiografía",
"transtorácica",
":",
"aurícula",
"izquierda",
"comprimida",
"por",
"tumoración",
"extracardiaca",
"de",
"gran",
"tamaño",
".",
"Derrame",
"pericárdico",
"severo",
"con",
"signos",
"ecocardiográficos",
"de",
"taponamiento",
".",
"Ventrículo",
"izquierdo",
"de",
"dimensiones",
"normales",
"con",
"fracción",
"de",
"eyección",
"conservada",
".",
"\n",
"»",
"TC",
"de",
"tórax",
"y",
"abdomen",
"c",
"/",
"c",
":",
"afectación",
"metastásica",
"masiva",
"de",
"ambos",
"pulmones",
".",
"Gran",
"masa",
"mediastínica",
"posterior",
"que",
"se",
"introduce",
"por",
"espacio",
"retrocural",
"y",
"ejerce",
"efecto",
"masa",
"y",
"compromiso",
"de",
"cavidades",
"cardiacas",
"izquierdas",
".",
"Derrame",
"pericárdico",
"severo",
",",
"pleural",
"bilateral",
"y",
"peritoneal",
".",
"\n",
"Hepatomegalia",
"de",
"aspecto",
"congestivo",
".",
"\n\n",
"Diagnóstico",
"\n",
"Derrame",
"pericárdico",
"severo",
"con",
"signos",
"de",
"taponamiento",
"cardiaco",
".",
"\n",
"Metástasis",
"pulmonares",
"y",
"mediastínicas",
"del",
"tumor",
"de",
"células",
"gigantes",
"óseo",
"estables",
".",
"\n",
"Masa",
"medistínica",
"en",
"progresión",
"con",
"compresión",
"y",
"colapaso",
"de",
"cavidades",
"cardiacas",
"izquierdas",
".",
"\n\n",
"Tratamiento",
"\n",
"Pericardiocentesis",
".",
"\n",
"Denosumab",
"120",
"mg",
"días",
"1",
",",
"8",
"y",
"15",
"subcutáneo",
"por",
"1",
"ciclo",
".",
"\n",
"Epirrubicina",
"50",
"mg",
"/",
"m2",
"-",
"ifosfamida",
"3",
"g",
"/",
"m2",
"por",
"1",
"ciclo",
".",
"\n\n",
"Evolución",
"\n",
"Se",
"realiza",
"pericardiocentesis",
"urgente",
"con",
"recogida",
"de",
"450",
"cc",
"de",
"líquido",
"pericárdico",
"hemático",
"que",
"se",
"envía",
"a",
"citología",
"con",
"resultado",
"negativo",
"para",
"neoplasia",
".",
"Tras",
"el",
"procedimiento",
",",
"mejora",
"su",
"situación",
"clínica",
"permaneciendo",
"eupneica",
".",
"Se",
"mantiene",
"48",
"horas",
"obteniéndose",
"300",
"cc",
"adicionales",
"y",
"se",
"retira",
"posteriormente",
".",
"\n\n",
"Por",
"progresión",
"de",
"la",
"enfermedad",
"a",
"nivel",
"mediastínico",
"objetivado",
"mediante",
"TC",
"de",
"tórax",
"y",
"abdomen",
"(",
"no",
"se",
"realiza",
"biopsia",
"por",
"deterioro",
"clínico",
")",
"inicia",
"el",
"14",
"de",
"noviembre",
"denosumab",
"120",
"mg",
"días",
"1",
",",
"8",
"y",
"15",
"por",
"vía",
"subcutánea",
"con",
"excelente",
"tolerancia",
",",
"completando",
"un",
"ciclo",
".",
"\n\n",
"En",
"diciembre",
"de",
"2014",
"por",
"infiltración",
"esofágica",
"comienza",
"con",
"disfagia",
"a",
"sólidos",
".",
"manteniendo",
"tolerancia",
"a",
"líquidos",
".",
"Se",
"coloca",
"sonda",
"nasogástrica",
"(",
"SNG",
")",
"y",
"comienza",
"nutrición",
"enteral",
"programándose",
"realización",
"de",
"gastrostomía",
"de",
"alimentación",
".",
"Se",
"realizó",
"endoscopia",
"oral",
"con",
"toma",
"de",
"biopsia",
"con",
"resultado",
"histológico",
":",
"tumor",
"de",
"células",
"gigantes",
".",
"\n\n",
"En",
"enero",
"de",
"2015",
"inicia",
"tratamiento",
"quimioterápico",
"con",
"epirrubicina",
"50",
"mg",
"/",
"m2-ifosfamida",
"3",
"g",
"/",
"m2",
"en",
"tres",
"días",
"suspendiéndose",
"el",
"día",
"3",
"por",
"disnea",
"y",
"mala",
"tolerancia",
"(",
"sobrecarga",
"de",
"volumen",
")",
".",
"\n\n",
"Reingresa",
"a",
"los",
"tres",
"días",
"por",
"reagudización",
"de",
"disnea",
"con",
"empeoramiento",
"clínico",
",",
"desaturando",
"a",
"pesar",
"de",
"VMNI",
",",
"cianosis",
"periférica",
"y",
"mala",
"situación",
"general",
"por",
"lo",
"que",
"se",
"procede",
"a",
"sedación",
"de",
"la",
"paciente",
",",
"siendo",
"éxitus",
"finalmente",
"."
] |
[
"MORFOLOGIA_NEOPLASIA"
] |
Tumor óseo de células gigantes grado 3 de Sanerkin, Metástasis, implantes tumorales, tumoración, metastásica, masa mediastínica, Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo, Masa medistínica, neoplasia, enfermedad a nivel mediastínico, infiltración esofágica, tumor de células gigantes
|
83_task2
|
Sentence: Anamnesis
Mujer de raza blanca, de 33 años de edad, con antecedentes personales relevantes:
» Sin alergias medicamentosas conocidas.
» Sin hábitos tóxicos.
» No presenta cardiopatía ni broncopatía conocidas.
» Tumor óseo de células gigantes grado 3 de Sanerkin de fémur izquierdo tratado mediante exéresis, prótesis y aloinjerto en diciembre de 1999. Metástasis pulmonares bilaterales y ganglionares mediastínicas en octubre de 2000 comprobadas histológicamente. Realizó tratamiento quimioterápico con cisplatino, adriamicina e ifosfamida con progresión de la enfermedad a nivel torácico tras tres ciclos. Posteriormente, Interferón alfa-2a durante un mes, retirado por mala tolerancia. Desde entonces en seguimiento.
Acude a Urgencias en noviembre de 2014 por disnea progresiva, con intolerancia al decúbito, sensación de cansancio, dolor en el costado izquierdo y tos persistente. En estudios de imagen realizados, se objetiva derrame pericárdico severo con signos de taponamiento cardiaco y gran masa extracardiaca con compresión sobre cavidades izquierdas y colapso de las mismas.
Exploración física
Mal estado general, cociente y orientada en las tres esferas, taquipneica en reposo con intolerancia al decúbito saturando al 99% con gafas nasales. Estable hemodinámicamente con tensión arterial 110/70mm Hg. Ingurgitación yugular.
Auscultación cardiopulmonar: corazón rítmico a 120 latidos por minuto (lpm). Soplo diastólico en ápex que cambia con la postura. Murmullo vesicular conservado con hipoventilación generalizada. Abdomen blando y depresible, con hepatomegalia marcada de borde romo. Miembros inferiores sin signos de trombosis venosa profunda ni edemas.
Pruebas complementarias
» Analítica: bioquímica sin alteraciones. Hemograma: Hb 11,7 mg/dL. Resto de series normales.
Coagulación: INR 1,39.
» ECG: taquicardia sinusal a 120 lpm. Bajo voltaje en derivaciones bipolares. Alternancia eléctrica.
» Radiografía simple de tórax PA: cardiomegalia a expensas de cavidades izquierdas. Múltiples implantes tumorales calcificados. Gran masa parahiliar derecha que ejerce efecto masa sobre silueta cardiomediastínica con desplazamiento de las mismas.
» Ecocardiografía transtorácica: aurícula izquierda comprimida por tumoración extracardiaca de gran tamaño. Derrame pericárdico severo con signos ecocardiográficos de taponamiento. Ventrículo izquierdo de dimensiones normales con fracción de eyección conservada.
» TC de tórax y abdomen c/c: afectación metastásica masiva de ambos pulmones. Gran masa mediastínica posterior que se introduce por espacio retrocural y ejerce efecto masa y compromiso de cavidades cardiacas izquierdas. Derrame pericárdico severo, pleural bilateral y peritoneal.
Hepatomegalia de aspecto congestivo.
Diagnóstico
Derrame pericárdico severo con signos de taponamiento cardiaco.
Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo estables.
Masa medistínica en progresión con compresión y colapaso de cavidades cardiacas izquierdas.
Tratamiento
Pericardiocentesis.
Denosumab 120 mg días 1, 8 y 15 subcutáneo por 1 ciclo.
Epirrubicina 50 mg/m2 - ifosfamida 3 g/m2 por 1 ciclo.
Evolución
Se realiza pericardiocentesis urgente con recogida de 450 cc de líquido pericárdico hemático que se envía a citología con resultado negativo para neoplasia. Tras el procedimiento, mejora su situación clínica permaneciendo eupneica. Se mantiene 48 horas obteniéndose 300 cc adicionales y se retira posteriormente.
Por progresión de la enfermedad a nivel mediastínico objetivado mediante TC de tórax y abdomen (no se realiza biopsia por deterioro clínico) inicia el 14 de noviembre denosumab 120 mg días 1, 8 y 15 por vía subcutánea con excelente tolerancia, completando un ciclo.
En diciembre de 2014 por infiltración esofágica comienza con disfagia a sólidos. manteniendo tolerancia a líquidos. Se coloca sonda nasogástrica (SNG) y comienza nutrición enteral programándose realización de gastrostomía de alimentación. Se realizó endoscopia oral con toma de biopsia con resultado histológico: tumor de células gigantes.
En enero de 2015 inicia tratamiento quimioterápico con epirrubicina 50 mg/m2-ifosfamida 3 g/m2 en tres días suspendiéndose el día 3 por disnea y mala tolerancia (sobrecarga de volumen).
Reingresa a los tres días por reagudización de disnea con empeoramiento clínico, desaturando a pesar de VMNI, cianosis periférica y mala situación general por lo que se procede a sedación de la paciente, siendo éxitus finalmente.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"I-MORFOLOGIA_NEOPLASIA",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Anamnesis
Mujer de raza blanca, de 33 años de edad, con antecedentes personales relevantes:
» Sin alergias medicamentosas conocidas.
» Sin hábitos tóxicos.
» No presenta cardiopatía ni broncopatía conocidas.
» Tumor óseo de células gigantes grado 3 de Sanerkin de fémur izquierdo tratado mediante exéresis, prótesis y aloinjerto en diciembre de 1999. Metástasis pulmonares bilaterales y ganglionares mediastínicas en octubre de 2000 comprobadas histológicamente. Realizó tratamiento quimioterápico con cisplatino, adriamicina e ifosfamida con progresión de la enfermedad a nivel torácico tras tres ciclos. Posteriormente, Interferón alfa-2a durante un mes, retirado por mala tolerancia. Desde entonces en seguimiento.
Acude a Urgencias en noviembre de 2014 por disnea progresiva, con intolerancia al decúbito, sensación de cansancio, dolor en el costado izquierdo y tos persistente. En estudios de imagen realizados, se objetiva derrame pericárdico severo con signos de taponamiento cardiaco y gran masa extracardiaca con compresión sobre cavidades izquierdas y colapso de las mismas.
Exploración física
Mal estado general, cociente y orientada en las tres esferas, taquipneica en reposo con intolerancia al decúbito saturando al 99% con gafas nasales. Estable hemodinámicamente con tensión arterial 110/70mm Hg. Ingurgitación yugular.
Auscultación cardiopulmonar: corazón rítmico a 120 latidos por minuto (lpm). Soplo diastólico en ápex que cambia con la postura. Murmullo vesicular conservado con hipoventilación generalizada. Abdomen blando y depresible, con hepatomegalia marcada de borde romo. Miembros inferiores sin signos de trombosis venosa profunda ni edemas.
Pruebas complementarias
» Analítica: bioquímica sin alteraciones. Hemograma: Hb 11,7 mg/dL. Resto de series normales.
Coagulación: INR 1,39.
» ECG: taquicardia sinusal a 120 lpm. Bajo voltaje en derivaciones bipolares. Alternancia eléctrica.
» Radiografía simple de tórax PA: cardiomegalia a expensas de cavidades izquierdas. Múltiples implantes tumorales calcificados. Gran masa parahiliar derecha que ejerce efecto masa sobre silueta cardiomediastínica con desplazamiento de las mismas.
» Ecocardiografía transtorácica: aurícula izquierda comprimida por tumoración extracardiaca de gran tamaño. Derrame pericárdico severo con signos ecocardiográficos de taponamiento. Ventrículo izquierdo de dimensiones normales con fracción de eyección conservada.
» TC de tórax y abdomen c/c: afectación metastásica masiva de ambos pulmones. Gran masa mediastínica posterior que se introduce por espacio retrocural y ejerce efecto masa y compromiso de cavidades cardiacas izquierdas. Derrame pericárdico severo, pleural bilateral y peritoneal.
Hepatomegalia de aspecto congestivo.
Diagnóstico
Derrame pericárdico severo con signos de taponamiento cardiaco.
Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo estables.
Masa medistínica en progresión con compresión y colapaso de cavidades cardiacas izquierdas.
Tratamiento
Pericardiocentesis.
Denosumab 120 mg días 1, 8 y 15 subcutáneo por 1 ciclo.
Epirrubicina 50 mg/m2 - ifosfamida 3 g/m2 por 1 ciclo.
Evolución
Se realiza pericardiocentesis urgente con recogida de 450 cc de líquido pericárdico hemático que se envía a citología con resultado negativo para neoplasia. Tras el procedimiento, mejora su situación clínica permaneciendo eupneica. Se mantiene 48 horas obteniéndose 300 cc adicionales y se retira posteriormente.
Por progresión de la enfermedad a nivel mediastínico objetivado mediante TC de tórax y abdomen (no se realiza biopsia por deterioro clínico) inicia el 14 de noviembre denosumab 120 mg días 1, 8 y 15 por vía subcutánea con excelente tolerancia, completando un ciclo.
En diciembre de 2014 por infiltración esofágica comienza con disfagia a sólidos. manteniendo tolerancia a líquidos. Se coloca sonda nasogástrica (SNG) y comienza nutrición enteral programándose realización de gastrostomía de alimentación. Se realizó endoscopia oral con toma de biopsia con resultado histológico: tumor de células gigantes.
En enero de 2015 inicia tratamiento quimioterápico con epirrubicina 50 mg/m2-ifosfamida 3 g/m2 en tres días suspendiéndose el día 3 por disnea y mala tolerancia (sobrecarga de volumen).
Reingresa a los tres días por reagudización de disnea con empeoramiento clínico, desaturando a pesar de VMNI, cianosis periférica y mala situación general por lo que se procede a sedación de la paciente, siendo éxitus finalmente.
|
[
"Anamnesis",
"\n",
"Mujer",
"de",
"raza",
"blanca",
",",
"de",
"33",
"años",
"de",
"edad",
",",
"con",
"antecedentes",
"personales",
"relevantes",
":",
"\n",
"»",
"Sin",
"alergias",
"medicamentosas",
"conocidas",
".",
"\n",
"»",
"Sin",
"hábitos",
"tóxicos",
".",
"\n",
"»",
"No",
"presenta",
"cardiopatía",
"ni",
"broncopatía",
"conocidas",
".",
"\n",
"»",
"Tumor",
"óseo",
"de",
"células",
"gigantes",
"grado",
"3",
"de",
"Sanerkin",
"de",
"fémur",
"izquierdo",
"tratado",
"mediante",
"exéresis",
",",
"prótesis",
"y",
"aloinjerto",
"en",
"diciembre",
"de",
"1999",
".",
"Metástasis",
"pulmonares",
"bilaterales",
"y",
"ganglionares",
"mediastínicas",
"en",
"octubre",
"de",
"2000",
"comprobadas",
"histológicamente",
".",
"Realizó",
"tratamiento",
"quimioterápico",
"con",
"cisplatino",
",",
"adriamicina",
"e",
"ifosfamida",
"con",
"progresión",
"de",
"la",
"enfermedad",
"a",
"nivel",
"torácico",
"tras",
"tres",
"ciclos",
".",
"Posteriormente",
",",
"Interferón",
"alfa-2a",
"durante",
"un",
"mes",
",",
"retirado",
"por",
"mala",
"tolerancia",
".",
"Desde",
"entonces",
"en",
"seguimiento",
".",
"\n",
"Acude",
"a",
"Urgencias",
"en",
"noviembre",
"de",
"2014",
"por",
"disnea",
"progresiva",
",",
"con",
"intolerancia",
"al",
"decúbito",
",",
"sensación",
"de",
"cansancio",
",",
"dolor",
"en",
"el",
"costado",
"izquierdo",
"y",
"tos",
"persistente",
".",
"En",
"estudios",
"de",
"imagen",
"realizados",
",",
"se",
"objetiva",
"derrame",
"pericárdico",
"severo",
"con",
"signos",
"de",
"taponamiento",
"cardiaco",
"y",
"gran",
"masa",
"extracardiaca",
"con",
"compresión",
"sobre",
"cavidades",
"izquierdas",
"y",
"colapso",
"de",
"las",
"mismas",
".",
"\n\n",
"Exploración",
"física",
"\n",
"Mal",
"estado",
"general",
",",
"cociente",
"y",
"orientada",
"en",
"las",
"tres",
"esferas",
",",
"taquipneica",
"en",
"reposo",
"con",
"intolerancia",
"al",
"decúbito",
"saturando",
"al",
"99",
"%",
"con",
"gafas",
"nasales",
".",
"Estable",
"hemodinámicamente",
"con",
"tensión",
"arterial",
"110/70",
"mm",
"Hg",
".",
"Ingurgitación",
"yugular",
".",
"\n",
"Auscultación",
"cardiopulmonar",
":",
"corazón",
"rítmico",
"a",
"120",
"latidos",
"por",
"minuto",
"(",
"lpm",
")",
".",
"Soplo",
"diastólico",
"en",
"ápex",
"que",
"cambia",
"con",
"la",
"postura",
".",
"Murmullo",
"vesicular",
"conservado",
"con",
"hipoventilación",
"generalizada",
".",
"Abdomen",
"blando",
"y",
"depresible",
",",
"con",
"hepatomegalia",
"marcada",
"de",
"borde",
"romo",
".",
"Miembros",
"inferiores",
"sin",
"signos",
"de",
"trombosis",
"venosa",
"profunda",
"ni",
"edemas",
".",
"\n\n",
"Pruebas",
"complementarias",
"\n",
"»",
"Analítica",
":",
"bioquímica",
"sin",
"alteraciones",
".",
"Hemograma",
":",
"Hb",
"11,7",
"mg",
"/",
"dL.",
"Resto",
"de",
"series",
"normales",
".",
"\n",
"Coagulación",
":",
"INR",
"1,39",
".",
"\n",
"»",
"ECG",
":",
"taquicardia",
"sinusal",
"a",
"120",
"lpm",
".",
"Bajo",
"voltaje",
"en",
"derivaciones",
"bipolares",
".",
"Alternancia",
"eléctrica",
".",
"\n",
"»",
"Radiografía",
"simple",
"de",
"tórax",
"PA",
":",
"cardiomegalia",
"a",
"expensas",
"de",
"cavidades",
"izquierdas",
".",
"Múltiples",
"implantes",
"tumorales",
"calcificados",
".",
"Gran",
"masa",
"parahiliar",
"derecha",
"que",
"ejerce",
"efecto",
"masa",
"sobre",
"silueta",
"cardiomediastínica",
"con",
"desplazamiento",
"de",
"las",
"mismas",
".",
"\n",
"»",
"Ecocardiografía",
"transtorácica",
":",
"aurícula",
"izquierda",
"comprimida",
"por",
"tumoración",
"extracardiaca",
"de",
"gran",
"tamaño",
".",
"Derrame",
"pericárdico",
"severo",
"con",
"signos",
"ecocardiográficos",
"de",
"taponamiento",
".",
"Ventrículo",
"izquierdo",
"de",
"dimensiones",
"normales",
"con",
"fracción",
"de",
"eyección",
"conservada",
".",
"\n",
"»",
"TC",
"de",
"tórax",
"y",
"abdomen",
"c",
"/",
"c",
":",
"afectación",
"metastásica",
"masiva",
"de",
"ambos",
"pulmones",
".",
"Gran",
"masa",
"mediastínica",
"posterior",
"que",
"se",
"introduce",
"por",
"espacio",
"retrocural",
"y",
"ejerce",
"efecto",
"masa",
"y",
"compromiso",
"de",
"cavidades",
"cardiacas",
"izquierdas",
".",
"Derrame",
"pericárdico",
"severo",
",",
"pleural",
"bilateral",
"y",
"peritoneal",
".",
"\n",
"Hepatomegalia",
"de",
"aspecto",
"congestivo",
".",
"\n\n",
"Diagnóstico",
"\n",
"Derrame",
"pericárdico",
"severo",
"con",
"signos",
"de",
"taponamiento",
"cardiaco",
".",
"\n",
"Metástasis",
"pulmonares",
"y",
"mediastínicas",
"del",
"tumor",
"de",
"células",
"gigantes",
"óseo",
"estables",
".",
"\n",
"Masa",
"medistínica",
"en",
"progresión",
"con",
"compresión",
"y",
"colapaso",
"de",
"cavidades",
"cardiacas",
"izquierdas",
".",
"\n\n",
"Tratamiento",
"\n",
"Pericardiocentesis",
".",
"\n",
"Denosumab",
"120",
"mg",
"días",
"1",
",",
"8",
"y",
"15",
"subcutáneo",
"por",
"1",
"ciclo",
".",
"\n",
"Epirrubicina",
"50",
"mg",
"/",
"m2",
"-",
"ifosfamida",
"3",
"g",
"/",
"m2",
"por",
"1",
"ciclo",
".",
"\n\n",
"Evolución",
"\n",
"Se",
"realiza",
"pericardiocentesis",
"urgente",
"con",
"recogida",
"de",
"450",
"cc",
"de",
"líquido",
"pericárdico",
"hemático",
"que",
"se",
"envía",
"a",
"citología",
"con",
"resultado",
"negativo",
"para",
"neoplasia",
".",
"Tras",
"el",
"procedimiento",
",",
"mejora",
"su",
"situación",
"clínica",
"permaneciendo",
"eupneica",
".",
"Se",
"mantiene",
"48",
"horas",
"obteniéndose",
"300",
"cc",
"adicionales",
"y",
"se",
"retira",
"posteriormente",
".",
"\n\n",
"Por",
"progresión",
"de",
"la",
"enfermedad",
"a",
"nivel",
"mediastínico",
"objetivado",
"mediante",
"TC",
"de",
"tórax",
"y",
"abdomen",
"(",
"no",
"se",
"realiza",
"biopsia",
"por",
"deterioro",
"clínico",
")",
"inicia",
"el",
"14",
"de",
"noviembre",
"denosumab",
"120",
"mg",
"días",
"1",
",",
"8",
"y",
"15",
"por",
"vía",
"subcutánea",
"con",
"excelente",
"tolerancia",
",",
"completando",
"un",
"ciclo",
".",
"\n\n",
"En",
"diciembre",
"de",
"2014",
"por",
"infiltración",
"esofágica",
"comienza",
"con",
"disfagia",
"a",
"sólidos",
".",
"manteniendo",
"tolerancia",
"a",
"líquidos",
".",
"Se",
"coloca",
"sonda",
"nasogástrica",
"(",
"SNG",
")",
"y",
"comienza",
"nutrición",
"enteral",
"programándose",
"realización",
"de",
"gastrostomía",
"de",
"alimentación",
".",
"Se",
"realizó",
"endoscopia",
"oral",
"con",
"toma",
"de",
"biopsia",
"con",
"resultado",
"histológico",
":",
"tumor",
"de",
"células",
"gigantes",
".",
"\n\n",
"En",
"enero",
"de",
"2015",
"inicia",
"tratamiento",
"quimioterápico",
"con",
"epirrubicina",
"50",
"mg",
"/",
"m2-ifosfamida",
"3",
"g",
"/",
"m2",
"en",
"tres",
"días",
"suspendiéndose",
"el",
"día",
"3",
"por",
"disnea",
"y",
"mala",
"tolerancia",
"(",
"sobrecarga",
"de",
"volumen",
")",
".",
"\n\n",
"Reingresa",
"a",
"los",
"tres",
"días",
"por",
"reagudización",
"de",
"disnea",
"con",
"empeoramiento",
"clínico",
",",
"desaturando",
"a",
"pesar",
"de",
"VMNI",
",",
"cianosis",
"periférica",
"y",
"mala",
"situación",
"general",
"por",
"lo",
"que",
"se",
"procede",
"a",
"sedación",
"de",
"la",
"paciente",
",",
"siendo",
"éxitus",
"finalmente",
"."
] |
[
"MORFOLOGIA_NEOPLASIA"
] |
H37Ra is a Organism, Mouse is a Organism, H37Ra is a Organism, severe combined immuno - deficient ( SCID ) mice is a Organism, H37Ra is a Organism, PhoP is a Protein, H37Ra::phoP is a Organism, H37Ra is a Organism, H37Ra is a Organism, fadE5 is a Protein, rpsL is a Protein, phoP is a Protein, H37Rv is a Organism, mouse is a Organism, phoP is a Protein, H37Ra is a Organism
|
7_task0
|
Sentence: Virulence Studies of H37Ra Complemented Mutants in a Mouse Model
Further assessment of the in vivo growth of different H37Ra knock-in strains was carried out by intravenous infection of severe combined immuno-deficient (SCID) mice. Complementation of H37Ra with the PhoP-expressing cosmid increased the virulence of the H37Ra::phoP recombinant relative to H37Ra, resulting in a 1.0 log and 0.5 log increase in CFU number in lungs and spleens, respectively. In contrast, no effects on the virulence were observed when H37Ra was complemented with fadE5 (Figure 2) or rpsL (unpublished data). However, as already observed in macrophages, integration of phoP did not restore levels of virulence to those of the reference strain H37Rv (Figure 2). This situation is also reflected in the sizes of spleens, which correlate with the CFU data in spleens (Figure S4). Together with the data from the macrophage infection assay, the results from the mouse infection show that the S219L mutation in the phoP gene definitely represents one genetic lesion that contributed to the attenuation of the H37Ra strain.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Organism, Protein
|
[
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O"
] |
Virulence Studies of H37Ra Complemented Mutants in a Mouse Model
Further assessment of the in vivo growth of different H37Ra knock-in strains was carried out by intravenous infection of severe combined immuno-deficient (SCID) mice. Complementation of H37Ra with the PhoP-expressing cosmid increased the virulence of the H37Ra::phoP recombinant relative to H37Ra, resulting in a 1.0 log and 0.5 log increase in CFU number in lungs and spleens, respectively. In contrast, no effects on the virulence were observed when H37Ra was complemented with fadE5 (Figure 2) or rpsL (unpublished data). However, as already observed in macrophages, integration of phoP did not restore levels of virulence to those of the reference strain H37Rv (Figure 2). This situation is also reflected in the sizes of spleens, which correlate with the CFU data in spleens (Figure S4). Together with the data from the macrophage infection assay, the results from the mouse infection show that the S219L mutation in the phoP gene definitely represents one genetic lesion that contributed to the attenuation of the H37Ra strain.
|
[
"Virulence",
"Studies",
"of",
"H37Ra",
"Complemented",
"Mutants",
"in",
"a",
"Mouse",
"Model",
"\n",
"Further",
"assessment",
"of",
"the",
"in",
"vivo",
"growth",
"of",
"different",
"H37Ra",
"knock",
"-",
"in",
"strains",
"was",
"carried",
"out",
"by",
"intravenous",
"infection",
"of",
"severe",
"combined",
"immuno",
"-",
"deficient",
"(",
"SCID",
")",
"mice",
".",
"Complementation",
"of",
"H37Ra",
"with",
"the",
"PhoP",
"-",
"expressing",
"cosmid",
"increased",
"the",
"virulence",
"of",
"the",
"H37Ra::phoP",
"recombinant",
"relative",
"to",
"H37Ra",
",",
"resulting",
"in",
"a",
"1.0",
"log",
"and",
"0.5",
"log",
"increase",
"in",
"CFU",
"number",
"in",
"lungs",
"and",
"spleens",
",",
"respectively",
".",
"In",
"contrast",
",",
"no",
"effects",
"on",
"the",
"virulence",
"were",
"observed",
"when",
"H37Ra",
"was",
"complemented",
"with",
"fadE5",
"(",
"Figure",
"2",
")",
"or",
"rpsL",
"(",
"unpublished",
"data",
")",
".",
"However",
",",
"as",
"already",
"observed",
"in",
"macrophages",
",",
"integration",
"of",
"phoP",
"did",
"not",
"restore",
"levels",
"of",
"virulence",
"to",
"those",
"of",
"the",
"reference",
"strain",
"H37Rv",
"(",
"Figure",
"2",
")",
".",
"This",
"situation",
"is",
"also",
"reflected",
"in",
"the",
"sizes",
"of",
"spleens",
",",
"which",
"correlate",
"with",
"the",
"CFU",
"data",
"in",
"spleens",
"(",
"Figure",
"S4",
")",
".",
"Together",
"with",
"the",
"data",
"from",
"the",
"macrophage",
"infection",
"assay",
",",
"the",
"results",
"from",
"the",
"mouse",
"infection",
"show",
"that",
"the",
"S219L",
"mutation",
"in",
"the",
"phoP",
"gene",
"definitely",
"represents",
"one",
"genetic",
"lesion",
"that",
"contributed",
"to",
"the",
"attenuation",
"of",
"the",
"H37Ra",
"strain",
".",
"\n"
] |
[
"Organism",
"Protein"
] |
H37Ra is a Organism, Mouse is a Organism, H37Ra is a Organism, severe combined immuno - deficient ( SCID ) mice is a Organism, H37Ra is a Organism, PhoP is a Protein, H37Ra::phoP is a Organism, H37Ra is a Organism, H37Ra is a Organism, fadE5 is a Protein, rpsL is a Protein, phoP is a Protein, H37Rv is a Organism, mouse is a Organism, phoP is a Protein, H37Ra is a Organism
|
7_task1
|
Sentence: Virulence Studies of H37Ra Complemented Mutants in a Mouse Model
Further assessment of the in vivo growth of different H37Ra knock-in strains was carried out by intravenous infection of severe combined immuno-deficient (SCID) mice. Complementation of H37Ra with the PhoP-expressing cosmid increased the virulence of the H37Ra::phoP recombinant relative to H37Ra, resulting in a 1.0 log and 0.5 log increase in CFU number in lungs and spleens, respectively. In contrast, no effects on the virulence were observed when H37Ra was complemented with fadE5 (Figure 2) or rpsL (unpublished data). However, as already observed in macrophages, integration of phoP did not restore levels of virulence to those of the reference strain H37Rv (Figure 2). This situation is also reflected in the sizes of spleens, which correlate with the CFU data in spleens (Figure S4). Together with the data from the macrophage infection assay, the results from the mouse infection show that the S219L mutation in the phoP gene definitely represents one genetic lesion that contributed to the attenuation of the H37Ra strain.
Instructions: please typing these entity words according to sentence: H37Ra, Mouse, H37Ra, severe combined immuno - deficient ( SCID ) mice, H37Ra, PhoP, H37Ra::phoP, H37Ra, H37Ra, fadE5, rpsL, phoP, H37Rv, mouse, phoP, H37Ra
Options: Organism, Protein
|
[
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O"
] |
Virulence Studies of H37Ra Complemented Mutants in a Mouse Model
Further assessment of the in vivo growth of different H37Ra knock-in strains was carried out by intravenous infection of severe combined immuno-deficient (SCID) mice. Complementation of H37Ra with the PhoP-expressing cosmid increased the virulence of the H37Ra::phoP recombinant relative to H37Ra, resulting in a 1.0 log and 0.5 log increase in CFU number in lungs and spleens, respectively. In contrast, no effects on the virulence were observed when H37Ra was complemented with fadE5 (Figure 2) or rpsL (unpublished data). However, as already observed in macrophages, integration of phoP did not restore levels of virulence to those of the reference strain H37Rv (Figure 2). This situation is also reflected in the sizes of spleens, which correlate with the CFU data in spleens (Figure S4). Together with the data from the macrophage infection assay, the results from the mouse infection show that the S219L mutation in the phoP gene definitely represents one genetic lesion that contributed to the attenuation of the H37Ra strain.
|
[
"Virulence",
"Studies",
"of",
"H37Ra",
"Complemented",
"Mutants",
"in",
"a",
"Mouse",
"Model",
"\n",
"Further",
"assessment",
"of",
"the",
"in",
"vivo",
"growth",
"of",
"different",
"H37Ra",
"knock",
"-",
"in",
"strains",
"was",
"carried",
"out",
"by",
"intravenous",
"infection",
"of",
"severe",
"combined",
"immuno",
"-",
"deficient",
"(",
"SCID",
")",
"mice",
".",
"Complementation",
"of",
"H37Ra",
"with",
"the",
"PhoP",
"-",
"expressing",
"cosmid",
"increased",
"the",
"virulence",
"of",
"the",
"H37Ra::phoP",
"recombinant",
"relative",
"to",
"H37Ra",
",",
"resulting",
"in",
"a",
"1.0",
"log",
"and",
"0.5",
"log",
"increase",
"in",
"CFU",
"number",
"in",
"lungs",
"and",
"spleens",
",",
"respectively",
".",
"In",
"contrast",
",",
"no",
"effects",
"on",
"the",
"virulence",
"were",
"observed",
"when",
"H37Ra",
"was",
"complemented",
"with",
"fadE5",
"(",
"Figure",
"2",
")",
"or",
"rpsL",
"(",
"unpublished",
"data",
")",
".",
"However",
",",
"as",
"already",
"observed",
"in",
"macrophages",
",",
"integration",
"of",
"phoP",
"did",
"not",
"restore",
"levels",
"of",
"virulence",
"to",
"those",
"of",
"the",
"reference",
"strain",
"H37Rv",
"(",
"Figure",
"2",
")",
".",
"This",
"situation",
"is",
"also",
"reflected",
"in",
"the",
"sizes",
"of",
"spleens",
",",
"which",
"correlate",
"with",
"the",
"CFU",
"data",
"in",
"spleens",
"(",
"Figure",
"S4",
")",
".",
"Together",
"with",
"the",
"data",
"from",
"the",
"macrophage",
"infection",
"assay",
",",
"the",
"results",
"from",
"the",
"mouse",
"infection",
"show",
"that",
"the",
"S219L",
"mutation",
"in",
"the",
"phoP",
"gene",
"definitely",
"represents",
"one",
"genetic",
"lesion",
"that",
"contributed",
"to",
"the",
"attenuation",
"of",
"the",
"H37Ra",
"strain",
".",
"\n"
] |
[
"Organism",
"Protein"
] |
H37Ra, Mouse, H37Ra, severe combined immuno - deficient ( SCID ) mice, H37Ra, PhoP, H37Ra::phoP, H37Ra, H37Ra, fadE5, rpsL, phoP, H37Rv, mouse, phoP, H37Ra
|
7_task2
|
Sentence: Virulence Studies of H37Ra Complemented Mutants in a Mouse Model
Further assessment of the in vivo growth of different H37Ra knock-in strains was carried out by intravenous infection of severe combined immuno-deficient (SCID) mice. Complementation of H37Ra with the PhoP-expressing cosmid increased the virulence of the H37Ra::phoP recombinant relative to H37Ra, resulting in a 1.0 log and 0.5 log increase in CFU number in lungs and spleens, respectively. In contrast, no effects on the virulence were observed when H37Ra was complemented with fadE5 (Figure 2) or rpsL (unpublished data). However, as already observed in macrophages, integration of phoP did not restore levels of virulence to those of the reference strain H37Rv (Figure 2). This situation is also reflected in the sizes of spleens, which correlate with the CFU data in spleens (Figure S4). Together with the data from the macrophage infection assay, the results from the mouse infection show that the S219L mutation in the phoP gene definitely represents one genetic lesion that contributed to the attenuation of the H37Ra strain.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"I-Organism",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Organism",
"O",
"O",
"O"
] |
Virulence Studies of H37Ra Complemented Mutants in a Mouse Model
Further assessment of the in vivo growth of different H37Ra knock-in strains was carried out by intravenous infection of severe combined immuno-deficient (SCID) mice. Complementation of H37Ra with the PhoP-expressing cosmid increased the virulence of the H37Ra::phoP recombinant relative to H37Ra, resulting in a 1.0 log and 0.5 log increase in CFU number in lungs and spleens, respectively. In contrast, no effects on the virulence were observed when H37Ra was complemented with fadE5 (Figure 2) or rpsL (unpublished data). However, as already observed in macrophages, integration of phoP did not restore levels of virulence to those of the reference strain H37Rv (Figure 2). This situation is also reflected in the sizes of spleens, which correlate with the CFU data in spleens (Figure S4). Together with the data from the macrophage infection assay, the results from the mouse infection show that the S219L mutation in the phoP gene definitely represents one genetic lesion that contributed to the attenuation of the H37Ra strain.
|
[
"Virulence",
"Studies",
"of",
"H37Ra",
"Complemented",
"Mutants",
"in",
"a",
"Mouse",
"Model",
"\n",
"Further",
"assessment",
"of",
"the",
"in",
"vivo",
"growth",
"of",
"different",
"H37Ra",
"knock",
"-",
"in",
"strains",
"was",
"carried",
"out",
"by",
"intravenous",
"infection",
"of",
"severe",
"combined",
"immuno",
"-",
"deficient",
"(",
"SCID",
")",
"mice",
".",
"Complementation",
"of",
"H37Ra",
"with",
"the",
"PhoP",
"-",
"expressing",
"cosmid",
"increased",
"the",
"virulence",
"of",
"the",
"H37Ra::phoP",
"recombinant",
"relative",
"to",
"H37Ra",
",",
"resulting",
"in",
"a",
"1.0",
"log",
"and",
"0.5",
"log",
"increase",
"in",
"CFU",
"number",
"in",
"lungs",
"and",
"spleens",
",",
"respectively",
".",
"In",
"contrast",
",",
"no",
"effects",
"on",
"the",
"virulence",
"were",
"observed",
"when",
"H37Ra",
"was",
"complemented",
"with",
"fadE5",
"(",
"Figure",
"2",
")",
"or",
"rpsL",
"(",
"unpublished",
"data",
")",
".",
"However",
",",
"as",
"already",
"observed",
"in",
"macrophages",
",",
"integration",
"of",
"phoP",
"did",
"not",
"restore",
"levels",
"of",
"virulence",
"to",
"those",
"of",
"the",
"reference",
"strain",
"H37Rv",
"(",
"Figure",
"2",
")",
".",
"This",
"situation",
"is",
"also",
"reflected",
"in",
"the",
"sizes",
"of",
"spleens",
",",
"which",
"correlate",
"with",
"the",
"CFU",
"data",
"in",
"spleens",
"(",
"Figure",
"S4",
")",
".",
"Together",
"with",
"the",
"data",
"from",
"the",
"macrophage",
"infection",
"assay",
",",
"the",
"results",
"from",
"the",
"mouse",
"infection",
"show",
"that",
"the",
"S219L",
"mutation",
"in",
"the",
"phoP",
"gene",
"definitely",
"represents",
"one",
"genetic",
"lesion",
"that",
"contributed",
"to",
"the",
"attenuation",
"of",
"the",
"H37Ra",
"strain",
".",
"\n"
] |
[
"Organism",
"Protein"
] |
Airbag is an umlsterm, inflation is an umlsterm, noise is an umlsterm, noise is an umlsterm, sound is an umlsterm, pressure is an umlsterm, injuries is an umlsterm, acoustic trauma is an umlsterm, airbag is an umlsterm, inflation is an umlsterm, man is an umlsterm, hearing loss is an umlsterm, deep - frequency is an umlsterm, acoustic trauma is an umlsterm, airbag is an umlsterm, noise is an umlsterm, attention is an umlsterm
|
HNO.00480765.eng.abstr_task0
|
Sentence: Airbag inflation is associated with a loud noise . This very short noise has a peak amplitude of 170 dB sound pressure level and can make otologic injuries . We report a case of acoustic trauma after airbag inflation . The 24-year-old man has hearing loss both side in the 3000- to 6000-Hz range and in the deep-frequency . The possibility of acoustic trauma from airbag noise are probably much more common and need more attention in the clinic .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O"
] |
Airbag inflation is associated with a loud noise . This very short noise has a peak amplitude of 170 dB sound pressure level and can make otologic injuries . We report a case of acoustic trauma after airbag inflation . The 24-year-old man has hearing loss both side in the 3000- to 6000-Hz range and in the deep-frequency . The possibility of acoustic trauma from airbag noise are probably much more common and need more attention in the clinic .
|
[
"Airbag",
"inflation",
"is",
"associated",
"with",
"a",
"loud",
"noise",
".",
"This",
"very",
"short",
"noise",
"has",
"a",
"peak",
"amplitude",
"of",
"170",
"dB",
"sound",
"pressure",
"level",
"and",
"can",
"make",
"otologic",
"injuries",
".",
"We",
"report",
"a",
"case",
"of",
"acoustic",
"trauma",
"after",
"airbag",
"inflation",
".",
"The",
"24-year",
"-",
"old",
"man",
"has",
"hearing",
"loss",
"both",
"side",
"in",
"the",
"3000-",
"to",
"6000-Hz",
"range",
"and",
"in",
"the",
"deep",
"-",
"frequency",
".",
"The",
"possibility",
"of",
"acoustic",
"trauma",
"from",
"airbag",
"noise",
"are",
"probably",
"much",
"more",
"common",
"and",
"need",
"more",
"attention",
"in",
"the",
"clinic",
"."
] |
[
"umlsterm"
] |
Airbag is an umlsterm, inflation is an umlsterm, noise is an umlsterm, noise is an umlsterm, sound is an umlsterm, pressure is an umlsterm, injuries is an umlsterm, acoustic trauma is an umlsterm, airbag is an umlsterm, inflation is an umlsterm, man is an umlsterm, hearing loss is an umlsterm, deep - frequency is an umlsterm, acoustic trauma is an umlsterm, airbag is an umlsterm, noise is an umlsterm, attention is an umlsterm
|
HNO.00480765.eng.abstr_task1
|
Sentence: Airbag inflation is associated with a loud noise . This very short noise has a peak amplitude of 170 dB sound pressure level and can make otologic injuries . We report a case of acoustic trauma after airbag inflation . The 24-year-old man has hearing loss both side in the 3000- to 6000-Hz range and in the deep-frequency . The possibility of acoustic trauma from airbag noise are probably much more common and need more attention in the clinic .
Instructions: please typing these entity words according to sentence: Airbag, inflation, noise, noise, sound, pressure, injuries, acoustic trauma, airbag, inflation, man, hearing loss, deep - frequency, acoustic trauma, airbag, noise, attention
Options: umlsterm
|
[
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O"
] |
Airbag inflation is associated with a loud noise . This very short noise has a peak amplitude of 170 dB sound pressure level and can make otologic injuries . We report a case of acoustic trauma after airbag inflation . The 24-year-old man has hearing loss both side in the 3000- to 6000-Hz range and in the deep-frequency . The possibility of acoustic trauma from airbag noise are probably much more common and need more attention in the clinic .
|
[
"Airbag",
"inflation",
"is",
"associated",
"with",
"a",
"loud",
"noise",
".",
"This",
"very",
"short",
"noise",
"has",
"a",
"peak",
"amplitude",
"of",
"170",
"dB",
"sound",
"pressure",
"level",
"and",
"can",
"make",
"otologic",
"injuries",
".",
"We",
"report",
"a",
"case",
"of",
"acoustic",
"trauma",
"after",
"airbag",
"inflation",
".",
"The",
"24-year",
"-",
"old",
"man",
"has",
"hearing",
"loss",
"both",
"side",
"in",
"the",
"3000-",
"to",
"6000-Hz",
"range",
"and",
"in",
"the",
"deep",
"-",
"frequency",
".",
"The",
"possibility",
"of",
"acoustic",
"trauma",
"from",
"airbag",
"noise",
"are",
"probably",
"much",
"more",
"common",
"and",
"need",
"more",
"attention",
"in",
"the",
"clinic",
"."
] |
[
"umlsterm"
] |
Airbag, inflation, noise, noise, sound, pressure, injuries, acoustic trauma, airbag, inflation, man, hearing loss, deep - frequency, acoustic trauma, airbag, noise, attention
|
HNO.00480765.eng.abstr_task2
|
Sentence: Airbag inflation is associated with a loud noise . This very short noise has a peak amplitude of 170 dB sound pressure level and can make otologic injuries . We report a case of acoustic trauma after airbag inflation . The 24-year-old man has hearing loss both side in the 3000- to 6000-Hz range and in the deep-frequency . The possibility of acoustic trauma from airbag noise are probably much more common and need more attention in the clinic .
Instructions: please extract entity words from the input sentence
|
[
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O"
] |
Airbag inflation is associated with a loud noise . This very short noise has a peak amplitude of 170 dB sound pressure level and can make otologic injuries . We report a case of acoustic trauma after airbag inflation . The 24-year-old man has hearing loss both side in the 3000- to 6000-Hz range and in the deep-frequency . The possibility of acoustic trauma from airbag noise are probably much more common and need more attention in the clinic .
|
[
"Airbag",
"inflation",
"is",
"associated",
"with",
"a",
"loud",
"noise",
".",
"This",
"very",
"short",
"noise",
"has",
"a",
"peak",
"amplitude",
"of",
"170",
"dB",
"sound",
"pressure",
"level",
"and",
"can",
"make",
"otologic",
"injuries",
".",
"We",
"report",
"a",
"case",
"of",
"acoustic",
"trauma",
"after",
"airbag",
"inflation",
".",
"The",
"24-year",
"-",
"old",
"man",
"has",
"hearing",
"loss",
"both",
"side",
"in",
"the",
"3000-",
"to",
"6000-Hz",
"range",
"and",
"in",
"the",
"deep",
"-",
"frequency",
".",
"The",
"possibility",
"of",
"acoustic",
"trauma",
"from",
"airbag",
"noise",
"are",
"probably",
"much",
"more",
"common",
"and",
"need",
"more",
"attention",
"in",
"the",
"clinic",
"."
] |
[
"umlsterm"
] |
mikroprozessorgesteuerte is an umlsterm, ProTon is an umlsterm, Goldmann - Tonometer is an umlsterm, Augen is an umlsterm, Patienten is an umlsterm, in vitro is an umlsterm, Manometrie is an umlsterm, geraeteinterner is an umlsterm, ProTon - Messwerte is an umlsterm, Standardabweichungen is an umlsterm, Auge is an umlsterm, ProTon - Tonometer is an umlsterm, in vitro is an umlsterm, Instrumenten is an umlsterm, Regressionsgeraden is an umlsterm, ProTon is an umlsterm, Manometerdruck is an umlsterm, ProTon is an umlsterm, Gebrauch is an umlsterm
|
DerOpthalmologe.60930544.ger.abstr_task0
|
Sentence: In einer randomisierten klinischen Kalibrationsstudie wurden 2 neu-artige mikroprozessorgesteuerte Tonometer vom Mackay-Marg-Prinzip ( Tono-Pen , ProTon ; pro Tonometer je 2 Exemplare ) und 2 herkoemmliche Applanationstonometer ( Handapplanationstonometer nach Draeger- , HAT- , Goldmann-Tonometer ) von 2 Untersuchern an 193 Augen von 100 Patienten der Universitaets-Augenklinik sowie in vitro ( Manometrie am Humanbulbus ) angewandt . Die Messergebnisse wurden hinsichtlich ihrer Reproduzierbarkeit , Genauigkeit , Untersucherabhaengigkeit und geraeteinterner messtechnischer Differenzen statistisch ausgewertet . Die Korrelation der Tono-Pen- und ProTon-Messwerte mit denen des HAT ( Messgenauigkeit ) zeigt hohe Standardabweichungen ( SD um +/- 3,1 mmHg ) bei einem Korrelationskoeffizienten r um 0,9 . Die Reproduzierbarkeit von Wiederholungsmessungen eines Tonometers an einem Auge ergibt beim HAT mit r = 0,92 und SD +/- 1,41 mmHg das beste Resultat . Die Applanationstonometermesswerte zeigen gegenueber denjenigen der Mackay-Marg-Tonometer eine statistisch signifikante Untersucherabhaengigkeit . Beim internen Tonometervergleich liegt die Streuung zwischen den Tono-Pen-Geraeten signifikant ueber derjenigen der ProTon-Tonometer . Die Reproduzierbarkeit von Einzelmessungen ist in vitro bei allen 4 Instrumenten hoch . Die Regressionsgeraden von HAT und ProTon sind aehnlich konfiguriert . Das Tono-Pen ueberschaetzt den vorgegebenen Manometerdruck . Bei mangelnder Praezision sind die beiden neuartigen Tonometer Tono-Pen und ProTon in der vorliegenden Ausfuehrung fuer den klinischen Gebrauch ungeeignet .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O"
] |
In einer randomisierten klinischen Kalibrationsstudie wurden 2 neu-artige mikroprozessorgesteuerte Tonometer vom Mackay-Marg-Prinzip ( Tono-Pen , ProTon ; pro Tonometer je 2 Exemplare ) und 2 herkoemmliche Applanationstonometer ( Handapplanationstonometer nach Draeger- , HAT- , Goldmann-Tonometer ) von 2 Untersuchern an 193 Augen von 100 Patienten der Universitaets-Augenklinik sowie in vitro ( Manometrie am Humanbulbus ) angewandt . Die Messergebnisse wurden hinsichtlich ihrer Reproduzierbarkeit , Genauigkeit , Untersucherabhaengigkeit und geraeteinterner messtechnischer Differenzen statistisch ausgewertet . Die Korrelation der Tono-Pen- und ProTon-Messwerte mit denen des HAT ( Messgenauigkeit ) zeigt hohe Standardabweichungen ( SD um +/- 3,1 mmHg ) bei einem Korrelationskoeffizienten r um 0,9 . Die Reproduzierbarkeit von Wiederholungsmessungen eines Tonometers an einem Auge ergibt beim HAT mit r = 0,92 und SD +/- 1,41 mmHg das beste Resultat . Die Applanationstonometermesswerte zeigen gegenueber denjenigen der Mackay-Marg-Tonometer eine statistisch signifikante Untersucherabhaengigkeit . Beim internen Tonometervergleich liegt die Streuung zwischen den Tono-Pen-Geraeten signifikant ueber derjenigen der ProTon-Tonometer . Die Reproduzierbarkeit von Einzelmessungen ist in vitro bei allen 4 Instrumenten hoch . Die Regressionsgeraden von HAT und ProTon sind aehnlich konfiguriert . Das Tono-Pen ueberschaetzt den vorgegebenen Manometerdruck . Bei mangelnder Praezision sind die beiden neuartigen Tonometer Tono-Pen und ProTon in der vorliegenden Ausfuehrung fuer den klinischen Gebrauch ungeeignet .
|
[
"In",
"einer",
"randomisierten",
"klinischen",
"Kalibrationsstudie",
"wurden",
"2",
"neu",
"-",
"artige",
"mikroprozessorgesteuerte",
"Tonometer",
"vom",
"Mackay",
"-",
"Marg",
"-",
"Prinzip",
"(",
"Tono",
"-",
"Pen",
",",
"ProTon",
";",
"pro",
"Tonometer",
"je",
"2",
"Exemplare",
")",
"und",
"2",
"herkoemmliche",
"Applanationstonometer",
"(",
"Handapplanationstonometer",
"nach",
"Draeger-",
",",
"HAT-",
",",
"Goldmann",
"-",
"Tonometer",
")",
"von",
"2",
"Untersuchern",
"an",
"193",
"Augen",
"von",
"100",
"Patienten",
"der",
"Universitaets",
"-",
"Augenklinik",
"sowie",
"in",
"vitro",
"(",
"Manometrie",
"am",
"Humanbulbus",
")",
"angewandt",
".",
"Die",
"Messergebnisse",
"wurden",
"hinsichtlich",
"ihrer",
"Reproduzierbarkeit",
",",
"Genauigkeit",
",",
"Untersucherabhaengigkeit",
"und",
"geraeteinterner",
"messtechnischer",
"Differenzen",
"statistisch",
"ausgewertet",
".",
"Die",
"Korrelation",
"der",
"Tono",
"-",
"Pen-",
"und",
"ProTon",
"-",
"Messwerte",
"mit",
"denen",
"des",
"HAT",
"(",
"Messgenauigkeit",
")",
"zeigt",
"hohe",
"Standardabweichungen",
"(",
"SD",
"um",
"+",
"/-",
"3,1",
"mmHg",
")",
"bei",
"einem",
"Korrelationskoeffizienten",
"r",
"um",
"0,9",
".",
"Die",
"Reproduzierbarkeit",
"von",
"Wiederholungsmessungen",
"eines",
"Tonometers",
"an",
"einem",
"Auge",
"ergibt",
"beim",
"HAT",
"mit",
"r",
"=",
"0,92",
"und",
"SD",
"+",
"/-",
"1,41",
"mmHg",
"das",
"beste",
"Resultat",
".",
"Die",
"Applanationstonometermesswerte",
"zeigen",
"gegenueber",
"denjenigen",
"der",
"Mackay",
"-",
"Marg",
"-",
"Tonometer",
"eine",
"statistisch",
"signifikante",
"Untersucherabhaengigkeit",
".",
"Beim",
"internen",
"Tonometervergleich",
"liegt",
"die",
"Streuung",
"zwischen",
"den",
"Tono",
"-",
"Pen",
"-",
"Geraeten",
"signifikant",
"ueber",
"derjenigen",
"der",
"ProTon",
"-",
"Tonometer",
".",
"Die",
"Reproduzierbarkeit",
"von",
"Einzelmessungen",
"ist",
"in",
"vitro",
"bei",
"allen",
"4",
"Instrumenten",
"hoch",
".",
"Die",
"Regressionsgeraden",
"von",
"HAT",
"und",
"ProTon",
"sind",
"aehnlich",
"konfiguriert",
".",
"Das",
"Tono",
"-",
"Pen",
"ueberschaetzt",
"den",
"vorgegebenen",
"Manometerdruck",
".",
"Bei",
"mangelnder",
"Praezision",
"sind",
"die",
"beiden",
"neuartigen",
"Tonometer",
"Tono",
"-",
"Pen",
"und",
"ProTon",
"in",
"der",
"vorliegenden",
"Ausfuehrung",
"fuer",
"den",
"klinischen",
"Gebrauch",
"ungeeignet",
"."
] |
[
"umlsterm"
] |
mikroprozessorgesteuerte is an umlsterm, ProTon is an umlsterm, Goldmann - Tonometer is an umlsterm, Augen is an umlsterm, Patienten is an umlsterm, in vitro is an umlsterm, Manometrie is an umlsterm, geraeteinterner is an umlsterm, ProTon - Messwerte is an umlsterm, Standardabweichungen is an umlsterm, Auge is an umlsterm, ProTon - Tonometer is an umlsterm, in vitro is an umlsterm, Instrumenten is an umlsterm, Regressionsgeraden is an umlsterm, ProTon is an umlsterm, Manometerdruck is an umlsterm, ProTon is an umlsterm, Gebrauch is an umlsterm
|
DerOpthalmologe.60930544.ger.abstr_task1
|
Sentence: In einer randomisierten klinischen Kalibrationsstudie wurden 2 neu-artige mikroprozessorgesteuerte Tonometer vom Mackay-Marg-Prinzip ( Tono-Pen , ProTon ; pro Tonometer je 2 Exemplare ) und 2 herkoemmliche Applanationstonometer ( Handapplanationstonometer nach Draeger- , HAT- , Goldmann-Tonometer ) von 2 Untersuchern an 193 Augen von 100 Patienten der Universitaets-Augenklinik sowie in vitro ( Manometrie am Humanbulbus ) angewandt . Die Messergebnisse wurden hinsichtlich ihrer Reproduzierbarkeit , Genauigkeit , Untersucherabhaengigkeit und geraeteinterner messtechnischer Differenzen statistisch ausgewertet . Die Korrelation der Tono-Pen- und ProTon-Messwerte mit denen des HAT ( Messgenauigkeit ) zeigt hohe Standardabweichungen ( SD um +/- 3,1 mmHg ) bei einem Korrelationskoeffizienten r um 0,9 . Die Reproduzierbarkeit von Wiederholungsmessungen eines Tonometers an einem Auge ergibt beim HAT mit r = 0,92 und SD +/- 1,41 mmHg das beste Resultat . Die Applanationstonometermesswerte zeigen gegenueber denjenigen der Mackay-Marg-Tonometer eine statistisch signifikante Untersucherabhaengigkeit . Beim internen Tonometervergleich liegt die Streuung zwischen den Tono-Pen-Geraeten signifikant ueber derjenigen der ProTon-Tonometer . Die Reproduzierbarkeit von Einzelmessungen ist in vitro bei allen 4 Instrumenten hoch . Die Regressionsgeraden von HAT und ProTon sind aehnlich konfiguriert . Das Tono-Pen ueberschaetzt den vorgegebenen Manometerdruck . Bei mangelnder Praezision sind die beiden neuartigen Tonometer Tono-Pen und ProTon in der vorliegenden Ausfuehrung fuer den klinischen Gebrauch ungeeignet .
Instructions: please typing these entity words according to sentence: mikroprozessorgesteuerte, ProTon, Goldmann - Tonometer, Augen, Patienten, in vitro, Manometrie, geraeteinterner, ProTon - Messwerte, Standardabweichungen, Auge, ProTon - Tonometer, in vitro, Instrumenten, Regressionsgeraden, ProTon, Manometerdruck, ProTon, Gebrauch
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O"
] |
In einer randomisierten klinischen Kalibrationsstudie wurden 2 neu-artige mikroprozessorgesteuerte Tonometer vom Mackay-Marg-Prinzip ( Tono-Pen , ProTon ; pro Tonometer je 2 Exemplare ) und 2 herkoemmliche Applanationstonometer ( Handapplanationstonometer nach Draeger- , HAT- , Goldmann-Tonometer ) von 2 Untersuchern an 193 Augen von 100 Patienten der Universitaets-Augenklinik sowie in vitro ( Manometrie am Humanbulbus ) angewandt . Die Messergebnisse wurden hinsichtlich ihrer Reproduzierbarkeit , Genauigkeit , Untersucherabhaengigkeit und geraeteinterner messtechnischer Differenzen statistisch ausgewertet . Die Korrelation der Tono-Pen- und ProTon-Messwerte mit denen des HAT ( Messgenauigkeit ) zeigt hohe Standardabweichungen ( SD um +/- 3,1 mmHg ) bei einem Korrelationskoeffizienten r um 0,9 . Die Reproduzierbarkeit von Wiederholungsmessungen eines Tonometers an einem Auge ergibt beim HAT mit r = 0,92 und SD +/- 1,41 mmHg das beste Resultat . Die Applanationstonometermesswerte zeigen gegenueber denjenigen der Mackay-Marg-Tonometer eine statistisch signifikante Untersucherabhaengigkeit . Beim internen Tonometervergleich liegt die Streuung zwischen den Tono-Pen-Geraeten signifikant ueber derjenigen der ProTon-Tonometer . Die Reproduzierbarkeit von Einzelmessungen ist in vitro bei allen 4 Instrumenten hoch . Die Regressionsgeraden von HAT und ProTon sind aehnlich konfiguriert . Das Tono-Pen ueberschaetzt den vorgegebenen Manometerdruck . Bei mangelnder Praezision sind die beiden neuartigen Tonometer Tono-Pen und ProTon in der vorliegenden Ausfuehrung fuer den klinischen Gebrauch ungeeignet .
|
[
"In",
"einer",
"randomisierten",
"klinischen",
"Kalibrationsstudie",
"wurden",
"2",
"neu",
"-",
"artige",
"mikroprozessorgesteuerte",
"Tonometer",
"vom",
"Mackay",
"-",
"Marg",
"-",
"Prinzip",
"(",
"Tono",
"-",
"Pen",
",",
"ProTon",
";",
"pro",
"Tonometer",
"je",
"2",
"Exemplare",
")",
"und",
"2",
"herkoemmliche",
"Applanationstonometer",
"(",
"Handapplanationstonometer",
"nach",
"Draeger-",
",",
"HAT-",
",",
"Goldmann",
"-",
"Tonometer",
")",
"von",
"2",
"Untersuchern",
"an",
"193",
"Augen",
"von",
"100",
"Patienten",
"der",
"Universitaets",
"-",
"Augenklinik",
"sowie",
"in",
"vitro",
"(",
"Manometrie",
"am",
"Humanbulbus",
")",
"angewandt",
".",
"Die",
"Messergebnisse",
"wurden",
"hinsichtlich",
"ihrer",
"Reproduzierbarkeit",
",",
"Genauigkeit",
",",
"Untersucherabhaengigkeit",
"und",
"geraeteinterner",
"messtechnischer",
"Differenzen",
"statistisch",
"ausgewertet",
".",
"Die",
"Korrelation",
"der",
"Tono",
"-",
"Pen-",
"und",
"ProTon",
"-",
"Messwerte",
"mit",
"denen",
"des",
"HAT",
"(",
"Messgenauigkeit",
")",
"zeigt",
"hohe",
"Standardabweichungen",
"(",
"SD",
"um",
"+",
"/-",
"3,1",
"mmHg",
")",
"bei",
"einem",
"Korrelationskoeffizienten",
"r",
"um",
"0,9",
".",
"Die",
"Reproduzierbarkeit",
"von",
"Wiederholungsmessungen",
"eines",
"Tonometers",
"an",
"einem",
"Auge",
"ergibt",
"beim",
"HAT",
"mit",
"r",
"=",
"0,92",
"und",
"SD",
"+",
"/-",
"1,41",
"mmHg",
"das",
"beste",
"Resultat",
".",
"Die",
"Applanationstonometermesswerte",
"zeigen",
"gegenueber",
"denjenigen",
"der",
"Mackay",
"-",
"Marg",
"-",
"Tonometer",
"eine",
"statistisch",
"signifikante",
"Untersucherabhaengigkeit",
".",
"Beim",
"internen",
"Tonometervergleich",
"liegt",
"die",
"Streuung",
"zwischen",
"den",
"Tono",
"-",
"Pen",
"-",
"Geraeten",
"signifikant",
"ueber",
"derjenigen",
"der",
"ProTon",
"-",
"Tonometer",
".",
"Die",
"Reproduzierbarkeit",
"von",
"Einzelmessungen",
"ist",
"in",
"vitro",
"bei",
"allen",
"4",
"Instrumenten",
"hoch",
".",
"Die",
"Regressionsgeraden",
"von",
"HAT",
"und",
"ProTon",
"sind",
"aehnlich",
"konfiguriert",
".",
"Das",
"Tono",
"-",
"Pen",
"ueberschaetzt",
"den",
"vorgegebenen",
"Manometerdruck",
".",
"Bei",
"mangelnder",
"Praezision",
"sind",
"die",
"beiden",
"neuartigen",
"Tonometer",
"Tono",
"-",
"Pen",
"und",
"ProTon",
"in",
"der",
"vorliegenden",
"Ausfuehrung",
"fuer",
"den",
"klinischen",
"Gebrauch",
"ungeeignet",
"."
] |
[
"umlsterm"
] |
mikroprozessorgesteuerte, ProTon, Goldmann - Tonometer, Augen, Patienten, in vitro, Manometrie, geraeteinterner, ProTon - Messwerte, Standardabweichungen, Auge, ProTon - Tonometer, in vitro, Instrumenten, Regressionsgeraden, ProTon, Manometerdruck, ProTon, Gebrauch
|
DerOpthalmologe.60930544.ger.abstr_task2
|
Sentence: In einer randomisierten klinischen Kalibrationsstudie wurden 2 neu-artige mikroprozessorgesteuerte Tonometer vom Mackay-Marg-Prinzip ( Tono-Pen , ProTon ; pro Tonometer je 2 Exemplare ) und 2 herkoemmliche Applanationstonometer ( Handapplanationstonometer nach Draeger- , HAT- , Goldmann-Tonometer ) von 2 Untersuchern an 193 Augen von 100 Patienten der Universitaets-Augenklinik sowie in vitro ( Manometrie am Humanbulbus ) angewandt . Die Messergebnisse wurden hinsichtlich ihrer Reproduzierbarkeit , Genauigkeit , Untersucherabhaengigkeit und geraeteinterner messtechnischer Differenzen statistisch ausgewertet . Die Korrelation der Tono-Pen- und ProTon-Messwerte mit denen des HAT ( Messgenauigkeit ) zeigt hohe Standardabweichungen ( SD um +/- 3,1 mmHg ) bei einem Korrelationskoeffizienten r um 0,9 . Die Reproduzierbarkeit von Wiederholungsmessungen eines Tonometers an einem Auge ergibt beim HAT mit r = 0,92 und SD +/- 1,41 mmHg das beste Resultat . Die Applanationstonometermesswerte zeigen gegenueber denjenigen der Mackay-Marg-Tonometer eine statistisch signifikante Untersucherabhaengigkeit . Beim internen Tonometervergleich liegt die Streuung zwischen den Tono-Pen-Geraeten signifikant ueber derjenigen der ProTon-Tonometer . Die Reproduzierbarkeit von Einzelmessungen ist in vitro bei allen 4 Instrumenten hoch . Die Regressionsgeraden von HAT und ProTon sind aehnlich konfiguriert . Das Tono-Pen ueberschaetzt den vorgegebenen Manometerdruck . Bei mangelnder Praezision sind die beiden neuartigen Tonometer Tono-Pen und ProTon in der vorliegenden Ausfuehrung fuer den klinischen Gebrauch ungeeignet .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O"
] |
In einer randomisierten klinischen Kalibrationsstudie wurden 2 neu-artige mikroprozessorgesteuerte Tonometer vom Mackay-Marg-Prinzip ( Tono-Pen , ProTon ; pro Tonometer je 2 Exemplare ) und 2 herkoemmliche Applanationstonometer ( Handapplanationstonometer nach Draeger- , HAT- , Goldmann-Tonometer ) von 2 Untersuchern an 193 Augen von 100 Patienten der Universitaets-Augenklinik sowie in vitro ( Manometrie am Humanbulbus ) angewandt . Die Messergebnisse wurden hinsichtlich ihrer Reproduzierbarkeit , Genauigkeit , Untersucherabhaengigkeit und geraeteinterner messtechnischer Differenzen statistisch ausgewertet . Die Korrelation der Tono-Pen- und ProTon-Messwerte mit denen des HAT ( Messgenauigkeit ) zeigt hohe Standardabweichungen ( SD um +/- 3,1 mmHg ) bei einem Korrelationskoeffizienten r um 0,9 . Die Reproduzierbarkeit von Wiederholungsmessungen eines Tonometers an einem Auge ergibt beim HAT mit r = 0,92 und SD +/- 1,41 mmHg das beste Resultat . Die Applanationstonometermesswerte zeigen gegenueber denjenigen der Mackay-Marg-Tonometer eine statistisch signifikante Untersucherabhaengigkeit . Beim internen Tonometervergleich liegt die Streuung zwischen den Tono-Pen-Geraeten signifikant ueber derjenigen der ProTon-Tonometer . Die Reproduzierbarkeit von Einzelmessungen ist in vitro bei allen 4 Instrumenten hoch . Die Regressionsgeraden von HAT und ProTon sind aehnlich konfiguriert . Das Tono-Pen ueberschaetzt den vorgegebenen Manometerdruck . Bei mangelnder Praezision sind die beiden neuartigen Tonometer Tono-Pen und ProTon in der vorliegenden Ausfuehrung fuer den klinischen Gebrauch ungeeignet .
|
[
"In",
"einer",
"randomisierten",
"klinischen",
"Kalibrationsstudie",
"wurden",
"2",
"neu",
"-",
"artige",
"mikroprozessorgesteuerte",
"Tonometer",
"vom",
"Mackay",
"-",
"Marg",
"-",
"Prinzip",
"(",
"Tono",
"-",
"Pen",
",",
"ProTon",
";",
"pro",
"Tonometer",
"je",
"2",
"Exemplare",
")",
"und",
"2",
"herkoemmliche",
"Applanationstonometer",
"(",
"Handapplanationstonometer",
"nach",
"Draeger-",
",",
"HAT-",
",",
"Goldmann",
"-",
"Tonometer",
")",
"von",
"2",
"Untersuchern",
"an",
"193",
"Augen",
"von",
"100",
"Patienten",
"der",
"Universitaets",
"-",
"Augenklinik",
"sowie",
"in",
"vitro",
"(",
"Manometrie",
"am",
"Humanbulbus",
")",
"angewandt",
".",
"Die",
"Messergebnisse",
"wurden",
"hinsichtlich",
"ihrer",
"Reproduzierbarkeit",
",",
"Genauigkeit",
",",
"Untersucherabhaengigkeit",
"und",
"geraeteinterner",
"messtechnischer",
"Differenzen",
"statistisch",
"ausgewertet",
".",
"Die",
"Korrelation",
"der",
"Tono",
"-",
"Pen-",
"und",
"ProTon",
"-",
"Messwerte",
"mit",
"denen",
"des",
"HAT",
"(",
"Messgenauigkeit",
")",
"zeigt",
"hohe",
"Standardabweichungen",
"(",
"SD",
"um",
"+",
"/-",
"3,1",
"mmHg",
")",
"bei",
"einem",
"Korrelationskoeffizienten",
"r",
"um",
"0,9",
".",
"Die",
"Reproduzierbarkeit",
"von",
"Wiederholungsmessungen",
"eines",
"Tonometers",
"an",
"einem",
"Auge",
"ergibt",
"beim",
"HAT",
"mit",
"r",
"=",
"0,92",
"und",
"SD",
"+",
"/-",
"1,41",
"mmHg",
"das",
"beste",
"Resultat",
".",
"Die",
"Applanationstonometermesswerte",
"zeigen",
"gegenueber",
"denjenigen",
"der",
"Mackay",
"-",
"Marg",
"-",
"Tonometer",
"eine",
"statistisch",
"signifikante",
"Untersucherabhaengigkeit",
".",
"Beim",
"internen",
"Tonometervergleich",
"liegt",
"die",
"Streuung",
"zwischen",
"den",
"Tono",
"-",
"Pen",
"-",
"Geraeten",
"signifikant",
"ueber",
"derjenigen",
"der",
"ProTon",
"-",
"Tonometer",
".",
"Die",
"Reproduzierbarkeit",
"von",
"Einzelmessungen",
"ist",
"in",
"vitro",
"bei",
"allen",
"4",
"Instrumenten",
"hoch",
".",
"Die",
"Regressionsgeraden",
"von",
"HAT",
"und",
"ProTon",
"sind",
"aehnlich",
"konfiguriert",
".",
"Das",
"Tono",
"-",
"Pen",
"ueberschaetzt",
"den",
"vorgegebenen",
"Manometerdruck",
".",
"Bei",
"mangelnder",
"Praezision",
"sind",
"die",
"beiden",
"neuartigen",
"Tonometer",
"Tono",
"-",
"Pen",
"und",
"ProTon",
"in",
"der",
"vorliegenden",
"Ausfuehrung",
"fuer",
"den",
"klinischen",
"Gebrauch",
"ungeeignet",
"."
] |
[
"umlsterm"
] |
hybrids is a Cell, rat-1 cells is a Cell, embryonic fibroblasts is a Cell, Rat-1 cells is a Cell, EJ bladder carcinoma cells is a Cell, embryonic rat fibroblasts is a Cell, cell hybrids is a Cell, cells is a Cell, hybrid cells is a Cell, hybrid derivatives is a Cell, chromosomes is a Cellular_component, parental hybrids is a Cell, cell hybrids is a Cell, Rat-1 cells is a Cell, Rat-1 cells is a Cell, embryonic rat fibroblasts is a Cell, cells is a Cell, cells is a Cell
|
PMID-3533793_task0
|
Sentence: Suppression and re-expression of transformed phenotype in hybrids of HA-ras-1-transformed rat-1 cells and early-passage rat embryonic fibroblasts.
Rat-1 cells which had been transformed with the activated Ha-ras-1 gene from human EJ bladder carcinoma cells were fused with diploid embryonic rat fibroblasts. Four selected cell hybrids expressed the human transforming gene product p21 at levels of 10 to 30% compared to 100% in the transformed parental cells. The hybrid cells, however, exhibited normal morphology, anchorage requirement for proliferation, and largely extended latency periods of tumorigenicity in newborn rats. Tumorigenic hybrid derivatives contained lower numbers of chromosomes than the tetraploid parental hybrids. DNA of the non-tumorigenic cell hybrids transformed Rat-1 cells to anchorage-independent proliferation as expected for the transforming human Ha-ras gene present in the donor DNA. We conclude that the transforming properties of the activated Ha-ras gene in Rat-1 cells can be suppressed at the post-translational level by the presence of the genome from diploid embryonic rat fibroblasts but additional controls of expression of the transforming gene are likely to exist. Normal cells contain suppressor gene(s) which safeguard these cells against transformation by the product of the transforming Ha-ras-1 oncogene.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Cellular_component, Cell
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"B-Cellular_component",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Suppression and re-expression of transformed phenotype in hybrids of HA-ras-1-transformed rat-1 cells and early-passage rat embryonic fibroblasts.
Rat-1 cells which had been transformed with the activated Ha-ras-1 gene from human EJ bladder carcinoma cells were fused with diploid embryonic rat fibroblasts. Four selected cell hybrids expressed the human transforming gene product p21 at levels of 10 to 30% compared to 100% in the transformed parental cells. The hybrid cells, however, exhibited normal morphology, anchorage requirement for proliferation, and largely extended latency periods of tumorigenicity in newborn rats. Tumorigenic hybrid derivatives contained lower numbers of chromosomes than the tetraploid parental hybrids. DNA of the non-tumorigenic cell hybrids transformed Rat-1 cells to anchorage-independent proliferation as expected for the transforming human Ha-ras gene present in the donor DNA. We conclude that the transforming properties of the activated Ha-ras gene in Rat-1 cells can be suppressed at the post-translational level by the presence of the genome from diploid embryonic rat fibroblasts but additional controls of expression of the transforming gene are likely to exist. Normal cells contain suppressor gene(s) which safeguard these cells against transformation by the product of the transforming Ha-ras-1 oncogene.
|
[
"Suppression",
"and",
"re",
"-",
"expression",
"of",
"transformed",
"phenotype",
"in",
"hybrids",
"of",
"HA",
"-",
"ras-1-transformed",
"rat-1",
"cells",
"and",
"early",
"-",
"passage",
"rat",
"embryonic",
"fibroblasts",
".",
"\n",
"Rat-1",
"cells",
"which",
"had",
"been",
"transformed",
"with",
"the",
"activated",
"Ha",
"-",
"ras-1",
"gene",
"from",
"human",
"EJ",
"bladder",
"carcinoma",
"cells",
"were",
"fused",
"with",
"diploid",
"embryonic",
"rat",
"fibroblasts",
".",
"Four",
"selected",
"cell",
"hybrids",
"expressed",
"the",
"human",
"transforming",
"gene",
"product",
"p21",
"at",
"levels",
"of",
"10",
"to",
"30",
"%",
"compared",
"to",
"100",
"%",
"in",
"the",
"transformed",
"parental",
"cells",
".",
"The",
"hybrid",
"cells",
",",
"however",
",",
"exhibited",
"normal",
"morphology",
",",
"anchorage",
"requirement",
"for",
"proliferation",
",",
"and",
"largely",
"extended",
"latency",
"periods",
"of",
"tumorigenicity",
"in",
"newborn",
"rats",
".",
"Tumorigenic",
"hybrid",
"derivatives",
"contained",
"lower",
"numbers",
"of",
"chromosomes",
"than",
"the",
"tetraploid",
"parental",
"hybrids",
".",
"DNA",
"of",
"the",
"non",
"-",
"tumorigenic",
"cell",
"hybrids",
"transformed",
"Rat-1",
"cells",
"to",
"anchorage",
"-",
"independent",
"proliferation",
"as",
"expected",
"for",
"the",
"transforming",
"human",
"Ha",
"-",
"ras",
"gene",
"present",
"in",
"the",
"donor",
"DNA",
".",
"We",
"conclude",
"that",
"the",
"transforming",
"properties",
"of",
"the",
"activated",
"Ha",
"-",
"ras",
"gene",
"in",
"Rat-1",
"cells",
"can",
"be",
"suppressed",
"at",
"the",
"post",
"-",
"translational",
"level",
"by",
"the",
"presence",
"of",
"the",
"genome",
"from",
"diploid",
"embryonic",
"rat",
"fibroblasts",
"but",
"additional",
"controls",
"of",
"expression",
"of",
"the",
"transforming",
"gene",
"are",
"likely",
"to",
"exist",
".",
"Normal",
"cells",
"contain",
"suppressor",
"gene(s",
")",
"which",
"safeguard",
"these",
"cells",
"against",
"transformation",
"by",
"the",
"product",
"of",
"the",
"transforming",
"Ha",
"-",
"ras-1",
"oncogene",
".",
"\n"
] |
[
"Cell",
"Cellular_component"
] |
hybrids is a Cell, rat-1 cells is a Cell, embryonic fibroblasts is a Cell, Rat-1 cells is a Cell, EJ bladder carcinoma cells is a Cell, embryonic rat fibroblasts is a Cell, cell hybrids is a Cell, cells is a Cell, hybrid cells is a Cell, hybrid derivatives is a Cell, chromosomes is a Cellular_component, parental hybrids is a Cell, cell hybrids is a Cell, Rat-1 cells is a Cell, Rat-1 cells is a Cell, embryonic rat fibroblasts is a Cell, cells is a Cell, cells is a Cell
|
PMID-3533793_task1
|
Sentence: Suppression and re-expression of transformed phenotype in hybrids of HA-ras-1-transformed rat-1 cells and early-passage rat embryonic fibroblasts.
Rat-1 cells which had been transformed with the activated Ha-ras-1 gene from human EJ bladder carcinoma cells were fused with diploid embryonic rat fibroblasts. Four selected cell hybrids expressed the human transforming gene product p21 at levels of 10 to 30% compared to 100% in the transformed parental cells. The hybrid cells, however, exhibited normal morphology, anchorage requirement for proliferation, and largely extended latency periods of tumorigenicity in newborn rats. Tumorigenic hybrid derivatives contained lower numbers of chromosomes than the tetraploid parental hybrids. DNA of the non-tumorigenic cell hybrids transformed Rat-1 cells to anchorage-independent proliferation as expected for the transforming human Ha-ras gene present in the donor DNA. We conclude that the transforming properties of the activated Ha-ras gene in Rat-1 cells can be suppressed at the post-translational level by the presence of the genome from diploid embryonic rat fibroblasts but additional controls of expression of the transforming gene are likely to exist. Normal cells contain suppressor gene(s) which safeguard these cells against transformation by the product of the transforming Ha-ras-1 oncogene.
Instructions: please typing these entity words according to sentence: hybrids, rat-1 cells, embryonic fibroblasts, Rat-1 cells, EJ bladder carcinoma cells, embryonic rat fibroblasts, cell hybrids, cells, hybrid cells, hybrid derivatives, chromosomes, parental hybrids, cell hybrids, Rat-1 cells, Rat-1 cells, embryonic rat fibroblasts, cells, cells
Options: Cellular_component, Cell
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"B-Cellular_component",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Suppression and re-expression of transformed phenotype in hybrids of HA-ras-1-transformed rat-1 cells and early-passage rat embryonic fibroblasts.
Rat-1 cells which had been transformed with the activated Ha-ras-1 gene from human EJ bladder carcinoma cells were fused with diploid embryonic rat fibroblasts. Four selected cell hybrids expressed the human transforming gene product p21 at levels of 10 to 30% compared to 100% in the transformed parental cells. The hybrid cells, however, exhibited normal morphology, anchorage requirement for proliferation, and largely extended latency periods of tumorigenicity in newborn rats. Tumorigenic hybrid derivatives contained lower numbers of chromosomes than the tetraploid parental hybrids. DNA of the non-tumorigenic cell hybrids transformed Rat-1 cells to anchorage-independent proliferation as expected for the transforming human Ha-ras gene present in the donor DNA. We conclude that the transforming properties of the activated Ha-ras gene in Rat-1 cells can be suppressed at the post-translational level by the presence of the genome from diploid embryonic rat fibroblasts but additional controls of expression of the transforming gene are likely to exist. Normal cells contain suppressor gene(s) which safeguard these cells against transformation by the product of the transforming Ha-ras-1 oncogene.
|
[
"Suppression",
"and",
"re",
"-",
"expression",
"of",
"transformed",
"phenotype",
"in",
"hybrids",
"of",
"HA",
"-",
"ras-1-transformed",
"rat-1",
"cells",
"and",
"early",
"-",
"passage",
"rat",
"embryonic",
"fibroblasts",
".",
"\n",
"Rat-1",
"cells",
"which",
"had",
"been",
"transformed",
"with",
"the",
"activated",
"Ha",
"-",
"ras-1",
"gene",
"from",
"human",
"EJ",
"bladder",
"carcinoma",
"cells",
"were",
"fused",
"with",
"diploid",
"embryonic",
"rat",
"fibroblasts",
".",
"Four",
"selected",
"cell",
"hybrids",
"expressed",
"the",
"human",
"transforming",
"gene",
"product",
"p21",
"at",
"levels",
"of",
"10",
"to",
"30",
"%",
"compared",
"to",
"100",
"%",
"in",
"the",
"transformed",
"parental",
"cells",
".",
"The",
"hybrid",
"cells",
",",
"however",
",",
"exhibited",
"normal",
"morphology",
",",
"anchorage",
"requirement",
"for",
"proliferation",
",",
"and",
"largely",
"extended",
"latency",
"periods",
"of",
"tumorigenicity",
"in",
"newborn",
"rats",
".",
"Tumorigenic",
"hybrid",
"derivatives",
"contained",
"lower",
"numbers",
"of",
"chromosomes",
"than",
"the",
"tetraploid",
"parental",
"hybrids",
".",
"DNA",
"of",
"the",
"non",
"-",
"tumorigenic",
"cell",
"hybrids",
"transformed",
"Rat-1",
"cells",
"to",
"anchorage",
"-",
"independent",
"proliferation",
"as",
"expected",
"for",
"the",
"transforming",
"human",
"Ha",
"-",
"ras",
"gene",
"present",
"in",
"the",
"donor",
"DNA",
".",
"We",
"conclude",
"that",
"the",
"transforming",
"properties",
"of",
"the",
"activated",
"Ha",
"-",
"ras",
"gene",
"in",
"Rat-1",
"cells",
"can",
"be",
"suppressed",
"at",
"the",
"post",
"-",
"translational",
"level",
"by",
"the",
"presence",
"of",
"the",
"genome",
"from",
"diploid",
"embryonic",
"rat",
"fibroblasts",
"but",
"additional",
"controls",
"of",
"expression",
"of",
"the",
"transforming",
"gene",
"are",
"likely",
"to",
"exist",
".",
"Normal",
"cells",
"contain",
"suppressor",
"gene(s",
")",
"which",
"safeguard",
"these",
"cells",
"against",
"transformation",
"by",
"the",
"product",
"of",
"the",
"transforming",
"Ha",
"-",
"ras-1",
"oncogene",
".",
"\n"
] |
[
"Cell",
"Cellular_component"
] |
hybrids, rat-1 cells, embryonic fibroblasts, Rat-1 cells, EJ bladder carcinoma cells, embryonic rat fibroblasts, cell hybrids, cells, hybrid cells, hybrid derivatives, chromosomes, parental hybrids, cell hybrids, Rat-1 cells, Rat-1 cells, embryonic rat fibroblasts, cells, cells
|
PMID-3533793_task2
|
Sentence: Suppression and re-expression of transformed phenotype in hybrids of HA-ras-1-transformed rat-1 cells and early-passage rat embryonic fibroblasts.
Rat-1 cells which had been transformed with the activated Ha-ras-1 gene from human EJ bladder carcinoma cells were fused with diploid embryonic rat fibroblasts. Four selected cell hybrids expressed the human transforming gene product p21 at levels of 10 to 30% compared to 100% in the transformed parental cells. The hybrid cells, however, exhibited normal morphology, anchorage requirement for proliferation, and largely extended latency periods of tumorigenicity in newborn rats. Tumorigenic hybrid derivatives contained lower numbers of chromosomes than the tetraploid parental hybrids. DNA of the non-tumorigenic cell hybrids transformed Rat-1 cells to anchorage-independent proliferation as expected for the transforming human Ha-ras gene present in the donor DNA. We conclude that the transforming properties of the activated Ha-ras gene in Rat-1 cells can be suppressed at the post-translational level by the presence of the genome from diploid embryonic rat fibroblasts but additional controls of expression of the transforming gene are likely to exist. Normal cells contain suppressor gene(s) which safeguard these cells against transformation by the product of the transforming Ha-ras-1 oncogene.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"B-Cellular_component",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"I-Cell",
"I-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Cell",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Suppression and re-expression of transformed phenotype in hybrids of HA-ras-1-transformed rat-1 cells and early-passage rat embryonic fibroblasts.
Rat-1 cells which had been transformed with the activated Ha-ras-1 gene from human EJ bladder carcinoma cells were fused with diploid embryonic rat fibroblasts. Four selected cell hybrids expressed the human transforming gene product p21 at levels of 10 to 30% compared to 100% in the transformed parental cells. The hybrid cells, however, exhibited normal morphology, anchorage requirement for proliferation, and largely extended latency periods of tumorigenicity in newborn rats. Tumorigenic hybrid derivatives contained lower numbers of chromosomes than the tetraploid parental hybrids. DNA of the non-tumorigenic cell hybrids transformed Rat-1 cells to anchorage-independent proliferation as expected for the transforming human Ha-ras gene present in the donor DNA. We conclude that the transforming properties of the activated Ha-ras gene in Rat-1 cells can be suppressed at the post-translational level by the presence of the genome from diploid embryonic rat fibroblasts but additional controls of expression of the transforming gene are likely to exist. Normal cells contain suppressor gene(s) which safeguard these cells against transformation by the product of the transforming Ha-ras-1 oncogene.
|
[
"Suppression",
"and",
"re",
"-",
"expression",
"of",
"transformed",
"phenotype",
"in",
"hybrids",
"of",
"HA",
"-",
"ras-1-transformed",
"rat-1",
"cells",
"and",
"early",
"-",
"passage",
"rat",
"embryonic",
"fibroblasts",
".",
"\n",
"Rat-1",
"cells",
"which",
"had",
"been",
"transformed",
"with",
"the",
"activated",
"Ha",
"-",
"ras-1",
"gene",
"from",
"human",
"EJ",
"bladder",
"carcinoma",
"cells",
"were",
"fused",
"with",
"diploid",
"embryonic",
"rat",
"fibroblasts",
".",
"Four",
"selected",
"cell",
"hybrids",
"expressed",
"the",
"human",
"transforming",
"gene",
"product",
"p21",
"at",
"levels",
"of",
"10",
"to",
"30",
"%",
"compared",
"to",
"100",
"%",
"in",
"the",
"transformed",
"parental",
"cells",
".",
"The",
"hybrid",
"cells",
",",
"however",
",",
"exhibited",
"normal",
"morphology",
",",
"anchorage",
"requirement",
"for",
"proliferation",
",",
"and",
"largely",
"extended",
"latency",
"periods",
"of",
"tumorigenicity",
"in",
"newborn",
"rats",
".",
"Tumorigenic",
"hybrid",
"derivatives",
"contained",
"lower",
"numbers",
"of",
"chromosomes",
"than",
"the",
"tetraploid",
"parental",
"hybrids",
".",
"DNA",
"of",
"the",
"non",
"-",
"tumorigenic",
"cell",
"hybrids",
"transformed",
"Rat-1",
"cells",
"to",
"anchorage",
"-",
"independent",
"proliferation",
"as",
"expected",
"for",
"the",
"transforming",
"human",
"Ha",
"-",
"ras",
"gene",
"present",
"in",
"the",
"donor",
"DNA",
".",
"We",
"conclude",
"that",
"the",
"transforming",
"properties",
"of",
"the",
"activated",
"Ha",
"-",
"ras",
"gene",
"in",
"Rat-1",
"cells",
"can",
"be",
"suppressed",
"at",
"the",
"post",
"-",
"translational",
"level",
"by",
"the",
"presence",
"of",
"the",
"genome",
"from",
"diploid",
"embryonic",
"rat",
"fibroblasts",
"but",
"additional",
"controls",
"of",
"expression",
"of",
"the",
"transforming",
"gene",
"are",
"likely",
"to",
"exist",
".",
"Normal",
"cells",
"contain",
"suppressor",
"gene(s",
")",
"which",
"safeguard",
"these",
"cells",
"against",
"transformation",
"by",
"the",
"product",
"of",
"the",
"transforming",
"Ha",
"-",
"ras-1",
"oncogene",
".",
"\n"
] |
[
"Cell",
"Cellular_component"
] |
Patienten is an umlsterm, Kniegelenkverletzung is an umlsterm, vordere Kreuzband is an umlsterm, Verletzung is an umlsterm, Roentgenaufnahme is an umlsterm, Teilruptur is an umlsterm, Ruptur is an umlsterm, Diagnose is an umlsterm, Spezifitaet is an umlsterm, Vorhersagewert is an umlsterm, Roentgenaufnahme is an umlsterm, Kniegelenk is an umlsterm, Diagnose is an umlsterm
|
DerUnfallchirurg.71000280.ger.abstr_task0
|
Sentence: In einer prospektiv angelegten , arthroskopisch kontrollierten Studie wurde bei 58 Patienten mit akuter Kniegelenkverletzung praeoperativ durch manuelle Sonometrie das vordere Kreuzband ( VKB ) auf eine eventuelle Verletzung hin untersucht . Zusaetzlich erfolgte eine klinische Untersuchung ( Lachmann-Test Pivot-shift-Test , nach McIntosh , 90 Grad-Schublade ) , eine gehaltene Roentgenaufnahme sowie eine gehaltene Sonometrie ( Scheuba-Apparat ) . Intraoperativ zeigte sich 9 mal eine Teilruptur und 38 mal eine komplette Ruptur des VKB . Fuer die praeoperativ richtig gestellte Diagnose VKB-Ruptur erzielte die manuelle Sonometrie eine Sensitivitaet ( Sn ) von 85% , eine Spezifitaet ( Sp ) von 91% sowie einen positiven Vorhersagewert ( pV ) von 98% . Klinische Untersuchung , gehaltene Sonometrie sowie die gehaltene Roentgenaufnahme waren im direkten Vergleich insgesamt weniger aussagekraeftig ( Sn 92% - 79% - 53% , Sp 56% - 90% - 86% , pV 89% - 97% - 95% ) . Die manuelle Sonometrie ermoeglicht gerade beim frisch traumatisierten , schmerzhaften Kniegelenk eine rasche und sichere Diagnose , so dass die Weichen fuer das weitere therapeutische Vorgehen fruehzeitig gestellt werden koennen .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
In einer prospektiv angelegten , arthroskopisch kontrollierten Studie wurde bei 58 Patienten mit akuter Kniegelenkverletzung praeoperativ durch manuelle Sonometrie das vordere Kreuzband ( VKB ) auf eine eventuelle Verletzung hin untersucht . Zusaetzlich erfolgte eine klinische Untersuchung ( Lachmann-Test Pivot-shift-Test , nach McIntosh , 90 Grad-Schublade ) , eine gehaltene Roentgenaufnahme sowie eine gehaltene Sonometrie ( Scheuba-Apparat ) . Intraoperativ zeigte sich 9 mal eine Teilruptur und 38 mal eine komplette Ruptur des VKB . Fuer die praeoperativ richtig gestellte Diagnose VKB-Ruptur erzielte die manuelle Sonometrie eine Sensitivitaet ( Sn ) von 85% , eine Spezifitaet ( Sp ) von 91% sowie einen positiven Vorhersagewert ( pV ) von 98% . Klinische Untersuchung , gehaltene Sonometrie sowie die gehaltene Roentgenaufnahme waren im direkten Vergleich insgesamt weniger aussagekraeftig ( Sn 92% - 79% - 53% , Sp 56% - 90% - 86% , pV 89% - 97% - 95% ) . Die manuelle Sonometrie ermoeglicht gerade beim frisch traumatisierten , schmerzhaften Kniegelenk eine rasche und sichere Diagnose , so dass die Weichen fuer das weitere therapeutische Vorgehen fruehzeitig gestellt werden koennen .
|
[
"In",
"einer",
"prospektiv",
"angelegten",
",",
"arthroskopisch",
"kontrollierten",
"Studie",
"wurde",
"bei",
"58",
"Patienten",
"mit",
"akuter",
"Kniegelenkverletzung",
"praeoperativ",
"durch",
"manuelle",
"Sonometrie",
"das",
"vordere",
"Kreuzband",
"(",
"VKB",
")",
"auf",
"eine",
"eventuelle",
"Verletzung",
"hin",
"untersucht",
".",
"Zusaetzlich",
"erfolgte",
"eine",
"klinische",
"Untersuchung",
"(",
"Lachmann",
"-",
"Test",
"Pivot",
"-",
"shift",
"-",
"Test",
",",
"nach",
"McIntosh",
",",
"90",
"Grad",
"-",
"Schublade",
")",
",",
"eine",
"gehaltene",
"Roentgenaufnahme",
"sowie",
"eine",
"gehaltene",
"Sonometrie",
"(",
"Scheuba",
"-",
"Apparat",
")",
".",
"Intraoperativ",
"zeigte",
"sich",
"9",
"mal",
"eine",
"Teilruptur",
"und",
"38",
"mal",
"eine",
"komplette",
"Ruptur",
"des",
"VKB",
".",
"Fuer",
"die",
"praeoperativ",
"richtig",
"gestellte",
"Diagnose",
"VKB",
"-",
"Ruptur",
"erzielte",
"die",
"manuelle",
"Sonometrie",
"eine",
"Sensitivitaet",
"(",
"Sn",
")",
"von",
"85",
"%",
",",
"eine",
"Spezifitaet",
"(",
"Sp",
")",
"von",
"91",
"%",
"sowie",
"einen",
"positiven",
"Vorhersagewert",
"(",
"pV",
")",
"von",
"98",
"%",
".",
"Klinische",
"Untersuchung",
",",
"gehaltene",
"Sonometrie",
"sowie",
"die",
"gehaltene",
"Roentgenaufnahme",
"waren",
"im",
"direkten",
"Vergleich",
"insgesamt",
"weniger",
"aussagekraeftig",
"(",
"Sn",
"92",
"%",
"-",
"79",
"%",
"-",
"53",
"%",
",",
"Sp",
"56",
"%",
"-",
"90",
"%",
"-",
"86",
"%",
",",
"pV",
"89",
"%",
"-",
"97",
"%",
"-",
"95",
"%",
")",
".",
"Die",
"manuelle",
"Sonometrie",
"ermoeglicht",
"gerade",
"beim",
"frisch",
"traumatisierten",
",",
"schmerzhaften",
"Kniegelenk",
"eine",
"rasche",
"und",
"sichere",
"Diagnose",
",",
"so",
"dass",
"die",
"Weichen",
"fuer",
"das",
"weitere",
"therapeutische",
"Vorgehen",
"fruehzeitig",
"gestellt",
"werden",
"koennen",
"."
] |
[
"umlsterm"
] |
Patienten is an umlsterm, Kniegelenkverletzung is an umlsterm, vordere Kreuzband is an umlsterm, Verletzung is an umlsterm, Roentgenaufnahme is an umlsterm, Teilruptur is an umlsterm, Ruptur is an umlsterm, Diagnose is an umlsterm, Spezifitaet is an umlsterm, Vorhersagewert is an umlsterm, Roentgenaufnahme is an umlsterm, Kniegelenk is an umlsterm, Diagnose is an umlsterm
|
DerUnfallchirurg.71000280.ger.abstr_task1
|
Sentence: In einer prospektiv angelegten , arthroskopisch kontrollierten Studie wurde bei 58 Patienten mit akuter Kniegelenkverletzung praeoperativ durch manuelle Sonometrie das vordere Kreuzband ( VKB ) auf eine eventuelle Verletzung hin untersucht . Zusaetzlich erfolgte eine klinische Untersuchung ( Lachmann-Test Pivot-shift-Test , nach McIntosh , 90 Grad-Schublade ) , eine gehaltene Roentgenaufnahme sowie eine gehaltene Sonometrie ( Scheuba-Apparat ) . Intraoperativ zeigte sich 9 mal eine Teilruptur und 38 mal eine komplette Ruptur des VKB . Fuer die praeoperativ richtig gestellte Diagnose VKB-Ruptur erzielte die manuelle Sonometrie eine Sensitivitaet ( Sn ) von 85% , eine Spezifitaet ( Sp ) von 91% sowie einen positiven Vorhersagewert ( pV ) von 98% . Klinische Untersuchung , gehaltene Sonometrie sowie die gehaltene Roentgenaufnahme waren im direkten Vergleich insgesamt weniger aussagekraeftig ( Sn 92% - 79% - 53% , Sp 56% - 90% - 86% , pV 89% - 97% - 95% ) . Die manuelle Sonometrie ermoeglicht gerade beim frisch traumatisierten , schmerzhaften Kniegelenk eine rasche und sichere Diagnose , so dass die Weichen fuer das weitere therapeutische Vorgehen fruehzeitig gestellt werden koennen .
Instructions: please typing these entity words according to sentence: Patienten, Kniegelenkverletzung, vordere Kreuzband, Verletzung, Roentgenaufnahme, Teilruptur, Ruptur, Diagnose, Spezifitaet, Vorhersagewert, Roentgenaufnahme, Kniegelenk, Diagnose
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
In einer prospektiv angelegten , arthroskopisch kontrollierten Studie wurde bei 58 Patienten mit akuter Kniegelenkverletzung praeoperativ durch manuelle Sonometrie das vordere Kreuzband ( VKB ) auf eine eventuelle Verletzung hin untersucht . Zusaetzlich erfolgte eine klinische Untersuchung ( Lachmann-Test Pivot-shift-Test , nach McIntosh , 90 Grad-Schublade ) , eine gehaltene Roentgenaufnahme sowie eine gehaltene Sonometrie ( Scheuba-Apparat ) . Intraoperativ zeigte sich 9 mal eine Teilruptur und 38 mal eine komplette Ruptur des VKB . Fuer die praeoperativ richtig gestellte Diagnose VKB-Ruptur erzielte die manuelle Sonometrie eine Sensitivitaet ( Sn ) von 85% , eine Spezifitaet ( Sp ) von 91% sowie einen positiven Vorhersagewert ( pV ) von 98% . Klinische Untersuchung , gehaltene Sonometrie sowie die gehaltene Roentgenaufnahme waren im direkten Vergleich insgesamt weniger aussagekraeftig ( Sn 92% - 79% - 53% , Sp 56% - 90% - 86% , pV 89% - 97% - 95% ) . Die manuelle Sonometrie ermoeglicht gerade beim frisch traumatisierten , schmerzhaften Kniegelenk eine rasche und sichere Diagnose , so dass die Weichen fuer das weitere therapeutische Vorgehen fruehzeitig gestellt werden koennen .
|
[
"In",
"einer",
"prospektiv",
"angelegten",
",",
"arthroskopisch",
"kontrollierten",
"Studie",
"wurde",
"bei",
"58",
"Patienten",
"mit",
"akuter",
"Kniegelenkverletzung",
"praeoperativ",
"durch",
"manuelle",
"Sonometrie",
"das",
"vordere",
"Kreuzband",
"(",
"VKB",
")",
"auf",
"eine",
"eventuelle",
"Verletzung",
"hin",
"untersucht",
".",
"Zusaetzlich",
"erfolgte",
"eine",
"klinische",
"Untersuchung",
"(",
"Lachmann",
"-",
"Test",
"Pivot",
"-",
"shift",
"-",
"Test",
",",
"nach",
"McIntosh",
",",
"90",
"Grad",
"-",
"Schublade",
")",
",",
"eine",
"gehaltene",
"Roentgenaufnahme",
"sowie",
"eine",
"gehaltene",
"Sonometrie",
"(",
"Scheuba",
"-",
"Apparat",
")",
".",
"Intraoperativ",
"zeigte",
"sich",
"9",
"mal",
"eine",
"Teilruptur",
"und",
"38",
"mal",
"eine",
"komplette",
"Ruptur",
"des",
"VKB",
".",
"Fuer",
"die",
"praeoperativ",
"richtig",
"gestellte",
"Diagnose",
"VKB",
"-",
"Ruptur",
"erzielte",
"die",
"manuelle",
"Sonometrie",
"eine",
"Sensitivitaet",
"(",
"Sn",
")",
"von",
"85",
"%",
",",
"eine",
"Spezifitaet",
"(",
"Sp",
")",
"von",
"91",
"%",
"sowie",
"einen",
"positiven",
"Vorhersagewert",
"(",
"pV",
")",
"von",
"98",
"%",
".",
"Klinische",
"Untersuchung",
",",
"gehaltene",
"Sonometrie",
"sowie",
"die",
"gehaltene",
"Roentgenaufnahme",
"waren",
"im",
"direkten",
"Vergleich",
"insgesamt",
"weniger",
"aussagekraeftig",
"(",
"Sn",
"92",
"%",
"-",
"79",
"%",
"-",
"53",
"%",
",",
"Sp",
"56",
"%",
"-",
"90",
"%",
"-",
"86",
"%",
",",
"pV",
"89",
"%",
"-",
"97",
"%",
"-",
"95",
"%",
")",
".",
"Die",
"manuelle",
"Sonometrie",
"ermoeglicht",
"gerade",
"beim",
"frisch",
"traumatisierten",
",",
"schmerzhaften",
"Kniegelenk",
"eine",
"rasche",
"und",
"sichere",
"Diagnose",
",",
"so",
"dass",
"die",
"Weichen",
"fuer",
"das",
"weitere",
"therapeutische",
"Vorgehen",
"fruehzeitig",
"gestellt",
"werden",
"koennen",
"."
] |
[
"umlsterm"
] |
Patienten, Kniegelenkverletzung, vordere Kreuzband, Verletzung, Roentgenaufnahme, Teilruptur, Ruptur, Diagnose, Spezifitaet, Vorhersagewert, Roentgenaufnahme, Kniegelenk, Diagnose
|
DerUnfallchirurg.71000280.ger.abstr_task2
|
Sentence: In einer prospektiv angelegten , arthroskopisch kontrollierten Studie wurde bei 58 Patienten mit akuter Kniegelenkverletzung praeoperativ durch manuelle Sonometrie das vordere Kreuzband ( VKB ) auf eine eventuelle Verletzung hin untersucht . Zusaetzlich erfolgte eine klinische Untersuchung ( Lachmann-Test Pivot-shift-Test , nach McIntosh , 90 Grad-Schublade ) , eine gehaltene Roentgenaufnahme sowie eine gehaltene Sonometrie ( Scheuba-Apparat ) . Intraoperativ zeigte sich 9 mal eine Teilruptur und 38 mal eine komplette Ruptur des VKB . Fuer die praeoperativ richtig gestellte Diagnose VKB-Ruptur erzielte die manuelle Sonometrie eine Sensitivitaet ( Sn ) von 85% , eine Spezifitaet ( Sp ) von 91% sowie einen positiven Vorhersagewert ( pV ) von 98% . Klinische Untersuchung , gehaltene Sonometrie sowie die gehaltene Roentgenaufnahme waren im direkten Vergleich insgesamt weniger aussagekraeftig ( Sn 92% - 79% - 53% , Sp 56% - 90% - 86% , pV 89% - 97% - 95% ) . Die manuelle Sonometrie ermoeglicht gerade beim frisch traumatisierten , schmerzhaften Kniegelenk eine rasche und sichere Diagnose , so dass die Weichen fuer das weitere therapeutische Vorgehen fruehzeitig gestellt werden koennen .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
In einer prospektiv angelegten , arthroskopisch kontrollierten Studie wurde bei 58 Patienten mit akuter Kniegelenkverletzung praeoperativ durch manuelle Sonometrie das vordere Kreuzband ( VKB ) auf eine eventuelle Verletzung hin untersucht . Zusaetzlich erfolgte eine klinische Untersuchung ( Lachmann-Test Pivot-shift-Test , nach McIntosh , 90 Grad-Schublade ) , eine gehaltene Roentgenaufnahme sowie eine gehaltene Sonometrie ( Scheuba-Apparat ) . Intraoperativ zeigte sich 9 mal eine Teilruptur und 38 mal eine komplette Ruptur des VKB . Fuer die praeoperativ richtig gestellte Diagnose VKB-Ruptur erzielte die manuelle Sonometrie eine Sensitivitaet ( Sn ) von 85% , eine Spezifitaet ( Sp ) von 91% sowie einen positiven Vorhersagewert ( pV ) von 98% . Klinische Untersuchung , gehaltene Sonometrie sowie die gehaltene Roentgenaufnahme waren im direkten Vergleich insgesamt weniger aussagekraeftig ( Sn 92% - 79% - 53% , Sp 56% - 90% - 86% , pV 89% - 97% - 95% ) . Die manuelle Sonometrie ermoeglicht gerade beim frisch traumatisierten , schmerzhaften Kniegelenk eine rasche und sichere Diagnose , so dass die Weichen fuer das weitere therapeutische Vorgehen fruehzeitig gestellt werden koennen .
|
[
"In",
"einer",
"prospektiv",
"angelegten",
",",
"arthroskopisch",
"kontrollierten",
"Studie",
"wurde",
"bei",
"58",
"Patienten",
"mit",
"akuter",
"Kniegelenkverletzung",
"praeoperativ",
"durch",
"manuelle",
"Sonometrie",
"das",
"vordere",
"Kreuzband",
"(",
"VKB",
")",
"auf",
"eine",
"eventuelle",
"Verletzung",
"hin",
"untersucht",
".",
"Zusaetzlich",
"erfolgte",
"eine",
"klinische",
"Untersuchung",
"(",
"Lachmann",
"-",
"Test",
"Pivot",
"-",
"shift",
"-",
"Test",
",",
"nach",
"McIntosh",
",",
"90",
"Grad",
"-",
"Schublade",
")",
",",
"eine",
"gehaltene",
"Roentgenaufnahme",
"sowie",
"eine",
"gehaltene",
"Sonometrie",
"(",
"Scheuba",
"-",
"Apparat",
")",
".",
"Intraoperativ",
"zeigte",
"sich",
"9",
"mal",
"eine",
"Teilruptur",
"und",
"38",
"mal",
"eine",
"komplette",
"Ruptur",
"des",
"VKB",
".",
"Fuer",
"die",
"praeoperativ",
"richtig",
"gestellte",
"Diagnose",
"VKB",
"-",
"Ruptur",
"erzielte",
"die",
"manuelle",
"Sonometrie",
"eine",
"Sensitivitaet",
"(",
"Sn",
")",
"von",
"85",
"%",
",",
"eine",
"Spezifitaet",
"(",
"Sp",
")",
"von",
"91",
"%",
"sowie",
"einen",
"positiven",
"Vorhersagewert",
"(",
"pV",
")",
"von",
"98",
"%",
".",
"Klinische",
"Untersuchung",
",",
"gehaltene",
"Sonometrie",
"sowie",
"die",
"gehaltene",
"Roentgenaufnahme",
"waren",
"im",
"direkten",
"Vergleich",
"insgesamt",
"weniger",
"aussagekraeftig",
"(",
"Sn",
"92",
"%",
"-",
"79",
"%",
"-",
"53",
"%",
",",
"Sp",
"56",
"%",
"-",
"90",
"%",
"-",
"86",
"%",
",",
"pV",
"89",
"%",
"-",
"97",
"%",
"-",
"95",
"%",
")",
".",
"Die",
"manuelle",
"Sonometrie",
"ermoeglicht",
"gerade",
"beim",
"frisch",
"traumatisierten",
",",
"schmerzhaften",
"Kniegelenk",
"eine",
"rasche",
"und",
"sichere",
"Diagnose",
",",
"so",
"dass",
"die",
"Weichen",
"fuer",
"das",
"weitere",
"therapeutische",
"Vorgehen",
"fruehzeitig",
"gestellt",
"werden",
"koennen",
"."
] |
[
"umlsterm"
] |
research is an umlsterm, multiple sclerosis is an umlsterm, lead is an umlsterm, animal experiments is an umlsterm, human is an umlsterm, in vitro is an umlsterm, autoimmune disease is an umlsterm, inhibition is an umlsterm, T cell is an umlsterm, blood brain barrier is an umlsterm, inflammation is an umlsterm, demyelination is an umlsterm, clinical studies is an umlsterm, magnetic resonance imaging is an umlsterm, review is an umlsterm, therapies is an umlsterm
|
DerNervenarzt.70680094.eng.abstr_task0
|
Sentence: Extensive research in the field of multiple sclerosis ( MS ) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis . According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease . Experimental therapeutical strategies are aiming at the inhibition of T cell activation , transmigration through the blood brain barrier and local inflammation and demyelination . Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course . This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Extensive research in the field of multiple sclerosis ( MS ) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis . According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease . Experimental therapeutical strategies are aiming at the inhibition of T cell activation , transmigration through the blood brain barrier and local inflammation and demyelination . Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course . This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept .
|
[
"Extensive",
"research",
"in",
"the",
"field",
"of",
"multiple",
"sclerosis",
"(",
"MS",
")",
"has",
"lead",
"to",
"a",
"preliminary",
"pathogenetic",
"concept",
"without",
"solving",
"the",
"etiopathogenesis",
".",
"According",
"to",
"animal",
"experiments",
"and",
"human",
"in",
"vitro",
"studies",
"MS",
"is",
"a",
"T",
"cell",
"-",
"mediated",
"autoimmune",
"disease",
".",
"Experimental",
"therapeutical",
"strategies",
"are",
"aiming",
"at",
"the",
"inhibition",
"of",
"T",
"cell",
"activation",
",",
"transmigration",
"through",
"the",
"blood",
"brain",
"barrier",
"and",
"local",
"inflammation",
"and",
"demyelination",
".",
"Several",
"substances",
"are",
"already",
"being",
"tested",
"in",
"clinical",
"studies",
"with",
"magnetic",
"resonance",
"imaging",
"as",
"a",
"tool",
"to",
"quantify",
"inflammatory",
"lesions",
"and",
"to",
"shorten",
"the",
"study",
"course",
".",
"This",
"review",
"will",
"give",
"a",
"summary",
"about",
"actual",
"experimental",
"therapies",
"resulting",
"from",
"the",
"current",
"pathogenetic",
"concept",
"."
] |
[
"umlsterm"
] |
research is an umlsterm, multiple sclerosis is an umlsterm, lead is an umlsterm, animal experiments is an umlsterm, human is an umlsterm, in vitro is an umlsterm, autoimmune disease is an umlsterm, inhibition is an umlsterm, T cell is an umlsterm, blood brain barrier is an umlsterm, inflammation is an umlsterm, demyelination is an umlsterm, clinical studies is an umlsterm, magnetic resonance imaging is an umlsterm, review is an umlsterm, therapies is an umlsterm
|
DerNervenarzt.70680094.eng.abstr_task1
|
Sentence: Extensive research in the field of multiple sclerosis ( MS ) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis . According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease . Experimental therapeutical strategies are aiming at the inhibition of T cell activation , transmigration through the blood brain barrier and local inflammation and demyelination . Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course . This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept .
Instructions: please typing these entity words according to sentence: research, multiple sclerosis, lead, animal experiments, human, in vitro, autoimmune disease, inhibition, T cell, blood brain barrier, inflammation, demyelination, clinical studies, magnetic resonance imaging, review, therapies
Options: umlsterm
|
[
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Extensive research in the field of multiple sclerosis ( MS ) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis . According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease . Experimental therapeutical strategies are aiming at the inhibition of T cell activation , transmigration through the blood brain barrier and local inflammation and demyelination . Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course . This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept .
|
[
"Extensive",
"research",
"in",
"the",
"field",
"of",
"multiple",
"sclerosis",
"(",
"MS",
")",
"has",
"lead",
"to",
"a",
"preliminary",
"pathogenetic",
"concept",
"without",
"solving",
"the",
"etiopathogenesis",
".",
"According",
"to",
"animal",
"experiments",
"and",
"human",
"in",
"vitro",
"studies",
"MS",
"is",
"a",
"T",
"cell",
"-",
"mediated",
"autoimmune",
"disease",
".",
"Experimental",
"therapeutical",
"strategies",
"are",
"aiming",
"at",
"the",
"inhibition",
"of",
"T",
"cell",
"activation",
",",
"transmigration",
"through",
"the",
"blood",
"brain",
"barrier",
"and",
"local",
"inflammation",
"and",
"demyelination",
".",
"Several",
"substances",
"are",
"already",
"being",
"tested",
"in",
"clinical",
"studies",
"with",
"magnetic",
"resonance",
"imaging",
"as",
"a",
"tool",
"to",
"quantify",
"inflammatory",
"lesions",
"and",
"to",
"shorten",
"the",
"study",
"course",
".",
"This",
"review",
"will",
"give",
"a",
"summary",
"about",
"actual",
"experimental",
"therapies",
"resulting",
"from",
"the",
"current",
"pathogenetic",
"concept",
"."
] |
[
"umlsterm"
] |
research, multiple sclerosis, lead, animal experiments, human, in vitro, autoimmune disease, inhibition, T cell, blood brain barrier, inflammation, demyelination, clinical studies, magnetic resonance imaging, review, therapies
|
DerNervenarzt.70680094.eng.abstr_task2
|
Sentence: Extensive research in the field of multiple sclerosis ( MS ) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis . According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease . Experimental therapeutical strategies are aiming at the inhibition of T cell activation , transmigration through the blood brain barrier and local inflammation and demyelination . Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course . This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept .
Instructions: please extract entity words from the input sentence
|
[
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Extensive research in the field of multiple sclerosis ( MS ) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis . According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease . Experimental therapeutical strategies are aiming at the inhibition of T cell activation , transmigration through the blood brain barrier and local inflammation and demyelination . Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course . This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept .
|
[
"Extensive",
"research",
"in",
"the",
"field",
"of",
"multiple",
"sclerosis",
"(",
"MS",
")",
"has",
"lead",
"to",
"a",
"preliminary",
"pathogenetic",
"concept",
"without",
"solving",
"the",
"etiopathogenesis",
".",
"According",
"to",
"animal",
"experiments",
"and",
"human",
"in",
"vitro",
"studies",
"MS",
"is",
"a",
"T",
"cell",
"-",
"mediated",
"autoimmune",
"disease",
".",
"Experimental",
"therapeutical",
"strategies",
"are",
"aiming",
"at",
"the",
"inhibition",
"of",
"T",
"cell",
"activation",
",",
"transmigration",
"through",
"the",
"blood",
"brain",
"barrier",
"and",
"local",
"inflammation",
"and",
"demyelination",
".",
"Several",
"substances",
"are",
"already",
"being",
"tested",
"in",
"clinical",
"studies",
"with",
"magnetic",
"resonance",
"imaging",
"as",
"a",
"tool",
"to",
"quantify",
"inflammatory",
"lesions",
"and",
"to",
"shorten",
"the",
"study",
"course",
".",
"This",
"review",
"will",
"give",
"a",
"summary",
"about",
"actual",
"experimental",
"therapies",
"resulting",
"from",
"the",
"current",
"pathogenetic",
"concept",
"."
] |
[
"umlsterm"
] |
p50 is a Protein, p50 is a Protein, p65 is a Protein, Ets-1 is a Protein
|
9094628_task0
|
Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.
The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Protein
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.
The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.
|
[
"Physical",
"interactions",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"play",
"an",
"important",
"role",
"in",
"their",
"cooperative",
"activation",
"of",
"the",
"human",
"immunodeficiency",
"virus",
"enhancer",
"in",
"T",
"cells",
".",
"\n",
"The",
"transcriptional",
"regulatory",
"elements",
"of",
"many",
"inducible",
"T",
"-",
"cell",
"genes",
"contain",
"adjacent",
"or",
"overlapping",
"binding",
"sites",
"for",
"the",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"families",
"of",
"transcription",
"factors",
".",
"Similar",
"arrays",
"of",
"functionally",
"important",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"and",
"Ets",
"binding",
"sites",
"are",
"present",
"in",
"the",
"transcriptional",
"enhancers",
"of",
"human",
"immunodeficiency",
"viruses",
"types",
"1",
"and",
"2",
"(",
"HIV-1",
"and",
"HIV-2",
")",
",",
"suggesting",
"that",
"this",
"pattern",
"of",
"nuclear",
"protein",
"binding",
"sites",
"reflects",
"an",
"evolutionarily",
"conserved",
"mechanism",
"for",
"regulating",
"inducible",
"T",
"-",
"cell",
"gene",
"expression",
"that",
"has",
"been",
"co",
"-",
"opted",
"during",
"HIV",
"evolution",
".",
"Despite",
"these",
"findings",
",",
"the",
"molecular",
"mechanisms",
"by",
"which",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"cooperatively",
"regulate",
"inducible",
"T",
"-",
"cell",
"gene",
"expression",
"remained",
"unknown",
".",
"In",
"the",
"studies",
"described",
"in",
"this",
"report",
",",
"we",
"demonstrated",
"a",
"physical",
"interaction",
"between",
"multiple",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"both",
"in",
"vitro",
"and",
"in",
"activated",
"normal",
"human",
"T",
"cells",
".",
"This",
"interaction",
"is",
"mediated",
"by",
"the",
"Ets",
"domain",
"of",
"Ets",
"proteins",
"and",
"the",
"C",
"-",
"terminal",
"region",
"of",
"the",
"Rel",
"homology",
"domains",
"of",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
".",
"In",
"addition",
",",
"the",
"Ets",
"-",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"interaction",
"requires",
"the",
"presence",
"of",
"DNA",
"binding",
"sites",
"for",
"both",
"proteins",
",",
"as",
"it",
"is",
"abolished",
"by",
"the",
"DNA",
"intercalating",
"agents",
"propidium",
"iodide",
"and",
"ethidium",
"bromide",
"and",
"enhanced",
"by",
"the",
"presence",
"of",
"synthetic",
"oligonucleotides",
"containing",
"binding",
"sites",
"for",
"Ets",
"and",
"NF",
"-",
"kappaB",
"proteins",
".",
"A",
"dominant",
"-",
"negative",
"mutant",
"of",
"NF",
"-",
"kappaB",
"p50",
"that",
"binds",
"DNA",
"but",
"fails",
"to",
"interact",
"with",
"Ets",
"proteins",
"inhibits",
"the",
"synergistic",
"activation",
"of",
"the",
"HIV-1",
"and",
"HIV-2",
"enhancers",
"by",
"NF",
"-",
"kappaB",
"(",
"p50",
"+",
"p65",
")",
"and",
"Ets-1",
",",
"suggesting",
"that",
"physical",
"interaction",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"proteins",
"is",
"required",
"for",
"the",
"transcriptional",
"activity",
"of",
"the",
"HIV-1",
"and",
"HIV-2",
"enhancers",
".",
"Taken",
"together",
",",
"these",
"findings",
"suggest",
"that",
"evolutionarily",
"conserved",
"physical",
"interactions",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"are",
"important",
"in",
"regulating",
"the",
"inducible",
"expression",
"of",
"T",
"-",
"cell",
"genes",
"and",
"viruses",
".",
"These",
"interactions",
"represent",
"a",
"potential",
"target",
"for",
"the",
"development",
"of",
"novel",
"immunosuppressive",
"and",
"antiviral",
"therapies",
"."
] |
[
"Protein"
] |
p50 is a Protein, p50 is a Protein, p65 is a Protein, Ets-1 is a Protein
|
9094628_task1
|
Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.
The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.
Instructions: please typing these entity words according to sentence: p50, p50, p65, Ets-1
Options: Protein
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.
The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.
|
[
"Physical",
"interactions",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"play",
"an",
"important",
"role",
"in",
"their",
"cooperative",
"activation",
"of",
"the",
"human",
"immunodeficiency",
"virus",
"enhancer",
"in",
"T",
"cells",
".",
"\n",
"The",
"transcriptional",
"regulatory",
"elements",
"of",
"many",
"inducible",
"T",
"-",
"cell",
"genes",
"contain",
"adjacent",
"or",
"overlapping",
"binding",
"sites",
"for",
"the",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"families",
"of",
"transcription",
"factors",
".",
"Similar",
"arrays",
"of",
"functionally",
"important",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"and",
"Ets",
"binding",
"sites",
"are",
"present",
"in",
"the",
"transcriptional",
"enhancers",
"of",
"human",
"immunodeficiency",
"viruses",
"types",
"1",
"and",
"2",
"(",
"HIV-1",
"and",
"HIV-2",
")",
",",
"suggesting",
"that",
"this",
"pattern",
"of",
"nuclear",
"protein",
"binding",
"sites",
"reflects",
"an",
"evolutionarily",
"conserved",
"mechanism",
"for",
"regulating",
"inducible",
"T",
"-",
"cell",
"gene",
"expression",
"that",
"has",
"been",
"co",
"-",
"opted",
"during",
"HIV",
"evolution",
".",
"Despite",
"these",
"findings",
",",
"the",
"molecular",
"mechanisms",
"by",
"which",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"cooperatively",
"regulate",
"inducible",
"T",
"-",
"cell",
"gene",
"expression",
"remained",
"unknown",
".",
"In",
"the",
"studies",
"described",
"in",
"this",
"report",
",",
"we",
"demonstrated",
"a",
"physical",
"interaction",
"between",
"multiple",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"both",
"in",
"vitro",
"and",
"in",
"activated",
"normal",
"human",
"T",
"cells",
".",
"This",
"interaction",
"is",
"mediated",
"by",
"the",
"Ets",
"domain",
"of",
"Ets",
"proteins",
"and",
"the",
"C",
"-",
"terminal",
"region",
"of",
"the",
"Rel",
"homology",
"domains",
"of",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
".",
"In",
"addition",
",",
"the",
"Ets",
"-",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"interaction",
"requires",
"the",
"presence",
"of",
"DNA",
"binding",
"sites",
"for",
"both",
"proteins",
",",
"as",
"it",
"is",
"abolished",
"by",
"the",
"DNA",
"intercalating",
"agents",
"propidium",
"iodide",
"and",
"ethidium",
"bromide",
"and",
"enhanced",
"by",
"the",
"presence",
"of",
"synthetic",
"oligonucleotides",
"containing",
"binding",
"sites",
"for",
"Ets",
"and",
"NF",
"-",
"kappaB",
"proteins",
".",
"A",
"dominant",
"-",
"negative",
"mutant",
"of",
"NF",
"-",
"kappaB",
"p50",
"that",
"binds",
"DNA",
"but",
"fails",
"to",
"interact",
"with",
"Ets",
"proteins",
"inhibits",
"the",
"synergistic",
"activation",
"of",
"the",
"HIV-1",
"and",
"HIV-2",
"enhancers",
"by",
"NF",
"-",
"kappaB",
"(",
"p50",
"+",
"p65",
")",
"and",
"Ets-1",
",",
"suggesting",
"that",
"physical",
"interaction",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"proteins",
"is",
"required",
"for",
"the",
"transcriptional",
"activity",
"of",
"the",
"HIV-1",
"and",
"HIV-2",
"enhancers",
".",
"Taken",
"together",
",",
"these",
"findings",
"suggest",
"that",
"evolutionarily",
"conserved",
"physical",
"interactions",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"are",
"important",
"in",
"regulating",
"the",
"inducible",
"expression",
"of",
"T",
"-",
"cell",
"genes",
"and",
"viruses",
".",
"These",
"interactions",
"represent",
"a",
"potential",
"target",
"for",
"the",
"development",
"of",
"novel",
"immunosuppressive",
"and",
"antiviral",
"therapies",
"."
] |
[
"Protein"
] |
p50, p50, p65, Ets-1
|
9094628_task2
|
Sentence: Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.
The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.
The transcriptional regulatory elements of many inducible T-cell genes contain adjacent or overlapping binding sites for the Ets and NF-kappaB/NFAT families of transcription factors. Similar arrays of functionally important NF-kappaB/NFAT and Ets binding sites are present in the transcriptional enhancers of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2), suggesting that this pattern of nuclear protein binding sites reflects an evolutionarily conserved mechanism for regulating inducible T-cell gene expression that has been co-opted during HIV evolution. Despite these findings, the molecular mechanisms by which Ets and NF-kappaB/NFAT proteins cooperatively regulate inducible T-cell gene expression remained unknown. In the studies described in this report, we demonstrated a physical interaction between multiple Ets and NF-kappaB/NFAT proteins both in vitro and in activated normal human T cells. This interaction is mediated by the Ets domain of Ets proteins and the C-terminal region of the Rel homology domains of NF-kappaB/NFAT proteins. In addition, the Ets-NF-kappaB/NFAT interaction requires the presence of DNA binding sites for both proteins, as it is abolished by the DNA intercalating agents propidium iodide and ethidium bromide and enhanced by the presence of synthetic oligonucleotides containing binding sites for Ets and NF-kappaB proteins. A dominant-negative mutant of NF-kappaB p50 that binds DNA but fails to interact with Ets proteins inhibits the synergistic activation of the HIV-1 and HIV-2 enhancers by NF-kappaB (p50 + p65) and Ets-1, suggesting that physical interaction between Ets and NF-kappaB proteins is required for the transcriptional activity of the HIV-1 and HIV-2 enhancers. Taken together, these findings suggest that evolutionarily conserved physical interactions between Ets and NF-kappaB/NFAT proteins are important in regulating the inducible expression of T-cell genes and viruses. These interactions represent a potential target for the development of novel immunosuppressive and antiviral therapies.
|
[
"Physical",
"interactions",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"play",
"an",
"important",
"role",
"in",
"their",
"cooperative",
"activation",
"of",
"the",
"human",
"immunodeficiency",
"virus",
"enhancer",
"in",
"T",
"cells",
".",
"\n",
"The",
"transcriptional",
"regulatory",
"elements",
"of",
"many",
"inducible",
"T",
"-",
"cell",
"genes",
"contain",
"adjacent",
"or",
"overlapping",
"binding",
"sites",
"for",
"the",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"families",
"of",
"transcription",
"factors",
".",
"Similar",
"arrays",
"of",
"functionally",
"important",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"and",
"Ets",
"binding",
"sites",
"are",
"present",
"in",
"the",
"transcriptional",
"enhancers",
"of",
"human",
"immunodeficiency",
"viruses",
"types",
"1",
"and",
"2",
"(",
"HIV-1",
"and",
"HIV-2",
")",
",",
"suggesting",
"that",
"this",
"pattern",
"of",
"nuclear",
"protein",
"binding",
"sites",
"reflects",
"an",
"evolutionarily",
"conserved",
"mechanism",
"for",
"regulating",
"inducible",
"T",
"-",
"cell",
"gene",
"expression",
"that",
"has",
"been",
"co",
"-",
"opted",
"during",
"HIV",
"evolution",
".",
"Despite",
"these",
"findings",
",",
"the",
"molecular",
"mechanisms",
"by",
"which",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"cooperatively",
"regulate",
"inducible",
"T",
"-",
"cell",
"gene",
"expression",
"remained",
"unknown",
".",
"In",
"the",
"studies",
"described",
"in",
"this",
"report",
",",
"we",
"demonstrated",
"a",
"physical",
"interaction",
"between",
"multiple",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"both",
"in",
"vitro",
"and",
"in",
"activated",
"normal",
"human",
"T",
"cells",
".",
"This",
"interaction",
"is",
"mediated",
"by",
"the",
"Ets",
"domain",
"of",
"Ets",
"proteins",
"and",
"the",
"C",
"-",
"terminal",
"region",
"of",
"the",
"Rel",
"homology",
"domains",
"of",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
".",
"In",
"addition",
",",
"the",
"Ets",
"-",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"interaction",
"requires",
"the",
"presence",
"of",
"DNA",
"binding",
"sites",
"for",
"both",
"proteins",
",",
"as",
"it",
"is",
"abolished",
"by",
"the",
"DNA",
"intercalating",
"agents",
"propidium",
"iodide",
"and",
"ethidium",
"bromide",
"and",
"enhanced",
"by",
"the",
"presence",
"of",
"synthetic",
"oligonucleotides",
"containing",
"binding",
"sites",
"for",
"Ets",
"and",
"NF",
"-",
"kappaB",
"proteins",
".",
"A",
"dominant",
"-",
"negative",
"mutant",
"of",
"NF",
"-",
"kappaB",
"p50",
"that",
"binds",
"DNA",
"but",
"fails",
"to",
"interact",
"with",
"Ets",
"proteins",
"inhibits",
"the",
"synergistic",
"activation",
"of",
"the",
"HIV-1",
"and",
"HIV-2",
"enhancers",
"by",
"NF",
"-",
"kappaB",
"(",
"p50",
"+",
"p65",
")",
"and",
"Ets-1",
",",
"suggesting",
"that",
"physical",
"interaction",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"proteins",
"is",
"required",
"for",
"the",
"transcriptional",
"activity",
"of",
"the",
"HIV-1",
"and",
"HIV-2",
"enhancers",
".",
"Taken",
"together",
",",
"these",
"findings",
"suggest",
"that",
"evolutionarily",
"conserved",
"physical",
"interactions",
"between",
"Ets",
"and",
"NF",
"-",
"kappaB",
"/",
"NFAT",
"proteins",
"are",
"important",
"in",
"regulating",
"the",
"inducible",
"expression",
"of",
"T",
"-",
"cell",
"genes",
"and",
"viruses",
".",
"These",
"interactions",
"represent",
"a",
"potential",
"target",
"for",
"the",
"development",
"of",
"novel",
"immunosuppressive",
"and",
"antiviral",
"therapies",
"."
] |
[
"Protein"
] |
Patienten is an umlsterm, Glykogenose is an umlsterm, Immunglobulin- is an umlsterm, Eltern is an umlsterm, Patienten is an umlsterm, Kardiomyopathie is an umlsterm
|
ZfuerKardiologie.90880850.ger.abstr_task0
|
Sentence: Wir berichten ueber einen 17jaehrigen Patienten , der an einer Glykogenose Typ IV ( Morbus Andersen ) und einem Immunglobulin- ( Ig ) -G-II-Subklassenmangel erkrankt war . Anamnestisch bedeutsam ist , dass bei gesunden Eltern des Patienten zwei juengere Brueder im Alter von neun bzw. zehn Jahren an einer dilatativen Kardiomyopathie verstarben .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O"
] |
Wir berichten ueber einen 17jaehrigen Patienten , der an einer Glykogenose Typ IV ( Morbus Andersen ) und einem Immunglobulin- ( Ig ) -G-II-Subklassenmangel erkrankt war . Anamnestisch bedeutsam ist , dass bei gesunden Eltern des Patienten zwei juengere Brueder im Alter von neun bzw. zehn Jahren an einer dilatativen Kardiomyopathie verstarben .
|
[
"Wir",
"berichten",
"ueber",
"einen",
"17jaehrigen",
"Patienten",
",",
"der",
"an",
"einer",
"Glykogenose",
"Typ",
"IV",
"(",
"Morbus",
"Andersen",
")",
"und",
"einem",
"Immunglobulin-",
"(",
"Ig",
")",
"-G",
"-",
"II",
"-",
"Subklassenmangel",
"erkrankt",
"war",
".",
"Anamnestisch",
"bedeutsam",
"ist",
",",
"dass",
"bei",
"gesunden",
"Eltern",
"des",
"Patienten",
"zwei",
"juengere",
"Brueder",
"im",
"Alter",
"von",
"neun",
"bzw",
".",
"zehn",
"Jahren",
"an",
"einer",
"dilatativen",
"Kardiomyopathie",
"verstarben",
"."
] |
[
"umlsterm"
] |
Patienten is an umlsterm, Glykogenose is an umlsterm, Immunglobulin- is an umlsterm, Eltern is an umlsterm, Patienten is an umlsterm, Kardiomyopathie is an umlsterm
|
ZfuerKardiologie.90880850.ger.abstr_task1
|
Sentence: Wir berichten ueber einen 17jaehrigen Patienten , der an einer Glykogenose Typ IV ( Morbus Andersen ) und einem Immunglobulin- ( Ig ) -G-II-Subklassenmangel erkrankt war . Anamnestisch bedeutsam ist , dass bei gesunden Eltern des Patienten zwei juengere Brueder im Alter von neun bzw. zehn Jahren an einer dilatativen Kardiomyopathie verstarben .
Instructions: please typing these entity words according to sentence: Patienten, Glykogenose, Immunglobulin-, Eltern, Patienten, Kardiomyopathie
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O"
] |
Wir berichten ueber einen 17jaehrigen Patienten , der an einer Glykogenose Typ IV ( Morbus Andersen ) und einem Immunglobulin- ( Ig ) -G-II-Subklassenmangel erkrankt war . Anamnestisch bedeutsam ist , dass bei gesunden Eltern des Patienten zwei juengere Brueder im Alter von neun bzw. zehn Jahren an einer dilatativen Kardiomyopathie verstarben .
|
[
"Wir",
"berichten",
"ueber",
"einen",
"17jaehrigen",
"Patienten",
",",
"der",
"an",
"einer",
"Glykogenose",
"Typ",
"IV",
"(",
"Morbus",
"Andersen",
")",
"und",
"einem",
"Immunglobulin-",
"(",
"Ig",
")",
"-G",
"-",
"II",
"-",
"Subklassenmangel",
"erkrankt",
"war",
".",
"Anamnestisch",
"bedeutsam",
"ist",
",",
"dass",
"bei",
"gesunden",
"Eltern",
"des",
"Patienten",
"zwei",
"juengere",
"Brueder",
"im",
"Alter",
"von",
"neun",
"bzw",
".",
"zehn",
"Jahren",
"an",
"einer",
"dilatativen",
"Kardiomyopathie",
"verstarben",
"."
] |
[
"umlsterm"
] |
Patienten, Glykogenose, Immunglobulin-, Eltern, Patienten, Kardiomyopathie
|
ZfuerKardiologie.90880850.ger.abstr_task2
|
Sentence: Wir berichten ueber einen 17jaehrigen Patienten , der an einer Glykogenose Typ IV ( Morbus Andersen ) und einem Immunglobulin- ( Ig ) -G-II-Subklassenmangel erkrankt war . Anamnestisch bedeutsam ist , dass bei gesunden Eltern des Patienten zwei juengere Brueder im Alter von neun bzw. zehn Jahren an einer dilatativen Kardiomyopathie verstarben .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O"
] |
Wir berichten ueber einen 17jaehrigen Patienten , der an einer Glykogenose Typ IV ( Morbus Andersen ) und einem Immunglobulin- ( Ig ) -G-II-Subklassenmangel erkrankt war . Anamnestisch bedeutsam ist , dass bei gesunden Eltern des Patienten zwei juengere Brueder im Alter von neun bzw. zehn Jahren an einer dilatativen Kardiomyopathie verstarben .
|
[
"Wir",
"berichten",
"ueber",
"einen",
"17jaehrigen",
"Patienten",
",",
"der",
"an",
"einer",
"Glykogenose",
"Typ",
"IV",
"(",
"Morbus",
"Andersen",
")",
"und",
"einem",
"Immunglobulin-",
"(",
"Ig",
")",
"-G",
"-",
"II",
"-",
"Subklassenmangel",
"erkrankt",
"war",
".",
"Anamnestisch",
"bedeutsam",
"ist",
",",
"dass",
"bei",
"gesunden",
"Eltern",
"des",
"Patienten",
"zwei",
"juengere",
"Brueder",
"im",
"Alter",
"von",
"neun",
"bzw",
".",
"zehn",
"Jahren",
"an",
"einer",
"dilatativen",
"Kardiomyopathie",
"verstarben",
"."
] |
[
"umlsterm"
] |
white is an umlsterm, woman is an umlsterm, right is an umlsterm, cobra is an umlsterm, Minor is an umlsterm, symptoms is an umlsterm, nausea is an umlsterm, vomiting is an umlsterm, extremity is an umlsterm, skin is an umlsterm, patient is an umlsterm, Antibiotics is an umlsterm, antiinflammatory agents is an umlsterm, therapy is an umlsterm, hydrocolloidal is an umlsterm, wound is an umlsterm, dressings is an umlsterm, therapy is an umlsterm, minor is an umlsterm, Salmonella is an umlsterm, strain is an umlsterm, ulcer is an umlsterm
|
DerHautarzt.40450330.eng.abstr_task0
|
Sentence: We report on a 31-year-old white woman , who was bitten in her right calf by a " spitting cobra " ( Neia nigricollis ) during a safari in Tansania . Minor initial systemic symptoms such as nausea and vomiting were followed by severe oedematous swelling of the extremity after 2 - 3 h and demarcation of a 2.75x2.75 in . area of necrotic skin . The patient returned to her home country , where 8 days after the snake-bite necrosectomy was performed . Antibiotics , antiinflammatory agents and local therapy with hydrocolloidal wound dressings were administered . With this therapy the lesion healed completely with minor scarring within 5 months . A new Salmonella strain was isolated from the ground of the ulcer .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O"
] |
We report on a 31-year-old white woman , who was bitten in her right calf by a " spitting cobra " ( Neia nigricollis ) during a safari in Tansania . Minor initial systemic symptoms such as nausea and vomiting were followed by severe oedematous swelling of the extremity after 2 - 3 h and demarcation of a 2.75x2.75 in . area of necrotic skin . The patient returned to her home country , where 8 days after the snake-bite necrosectomy was performed . Antibiotics , antiinflammatory agents and local therapy with hydrocolloidal wound dressings were administered . With this therapy the lesion healed completely with minor scarring within 5 months . A new Salmonella strain was isolated from the ground of the ulcer .
|
[
"We",
"report",
"on",
"a",
"31-year",
"-",
"old",
"white",
"woman",
",",
"who",
"was",
"bitten",
"in",
"her",
"right",
"calf",
"by",
"a",
"\"",
"spitting",
"cobra",
"\"",
"(",
"Neia",
"nigricollis",
")",
"during",
"a",
"safari",
"in",
"Tansania",
".",
"Minor",
"initial",
"systemic",
"symptoms",
"such",
"as",
"nausea",
"and",
"vomiting",
"were",
"followed",
"by",
"severe",
"oedematous",
"swelling",
"of",
"the",
"extremity",
"after",
"2",
"-",
"3",
"h",
"and",
"demarcation",
"of",
"a",
"2.75x2.75",
"in",
".",
"area",
"of",
"necrotic",
"skin",
".",
"The",
"patient",
"returned",
"to",
"her",
"home",
"country",
",",
"where",
"8",
"days",
"after",
"the",
"snake",
"-",
"bite",
"necrosectomy",
"was",
"performed",
".",
"Antibiotics",
",",
"antiinflammatory",
"agents",
"and",
"local",
"therapy",
"with",
"hydrocolloidal",
"wound",
"dressings",
"were",
"administered",
".",
"With",
"this",
"therapy",
"the",
"lesion",
"healed",
"completely",
"with",
"minor",
"scarring",
"within",
"5",
"months",
".",
"A",
"new",
"Salmonella",
"strain",
"was",
"isolated",
"from",
"the",
"ground",
"of",
"the",
"ulcer",
"."
] |
[
"umlsterm"
] |
white is an umlsterm, woman is an umlsterm, right is an umlsterm, cobra is an umlsterm, Minor is an umlsterm, symptoms is an umlsterm, nausea is an umlsterm, vomiting is an umlsterm, extremity is an umlsterm, skin is an umlsterm, patient is an umlsterm, Antibiotics is an umlsterm, antiinflammatory agents is an umlsterm, therapy is an umlsterm, hydrocolloidal is an umlsterm, wound is an umlsterm, dressings is an umlsterm, therapy is an umlsterm, minor is an umlsterm, Salmonella is an umlsterm, strain is an umlsterm, ulcer is an umlsterm
|
DerHautarzt.40450330.eng.abstr_task1
|
Sentence: We report on a 31-year-old white woman , who was bitten in her right calf by a " spitting cobra " ( Neia nigricollis ) during a safari in Tansania . Minor initial systemic symptoms such as nausea and vomiting were followed by severe oedematous swelling of the extremity after 2 - 3 h and demarcation of a 2.75x2.75 in . area of necrotic skin . The patient returned to her home country , where 8 days after the snake-bite necrosectomy was performed . Antibiotics , antiinflammatory agents and local therapy with hydrocolloidal wound dressings were administered . With this therapy the lesion healed completely with minor scarring within 5 months . A new Salmonella strain was isolated from the ground of the ulcer .
Instructions: please typing these entity words according to sentence: white, woman, right, cobra, Minor, symptoms, nausea, vomiting, extremity, skin, patient, Antibiotics, antiinflammatory agents, therapy, hydrocolloidal, wound, dressings, therapy, minor, Salmonella, strain, ulcer
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O"
] |
We report on a 31-year-old white woman , who was bitten in her right calf by a " spitting cobra " ( Neia nigricollis ) during a safari in Tansania . Minor initial systemic symptoms such as nausea and vomiting were followed by severe oedematous swelling of the extremity after 2 - 3 h and demarcation of a 2.75x2.75 in . area of necrotic skin . The patient returned to her home country , where 8 days after the snake-bite necrosectomy was performed . Antibiotics , antiinflammatory agents and local therapy with hydrocolloidal wound dressings were administered . With this therapy the lesion healed completely with minor scarring within 5 months . A new Salmonella strain was isolated from the ground of the ulcer .
|
[
"We",
"report",
"on",
"a",
"31-year",
"-",
"old",
"white",
"woman",
",",
"who",
"was",
"bitten",
"in",
"her",
"right",
"calf",
"by",
"a",
"\"",
"spitting",
"cobra",
"\"",
"(",
"Neia",
"nigricollis",
")",
"during",
"a",
"safari",
"in",
"Tansania",
".",
"Minor",
"initial",
"systemic",
"symptoms",
"such",
"as",
"nausea",
"and",
"vomiting",
"were",
"followed",
"by",
"severe",
"oedematous",
"swelling",
"of",
"the",
"extremity",
"after",
"2",
"-",
"3",
"h",
"and",
"demarcation",
"of",
"a",
"2.75x2.75",
"in",
".",
"area",
"of",
"necrotic",
"skin",
".",
"The",
"patient",
"returned",
"to",
"her",
"home",
"country",
",",
"where",
"8",
"days",
"after",
"the",
"snake",
"-",
"bite",
"necrosectomy",
"was",
"performed",
".",
"Antibiotics",
",",
"antiinflammatory",
"agents",
"and",
"local",
"therapy",
"with",
"hydrocolloidal",
"wound",
"dressings",
"were",
"administered",
".",
"With",
"this",
"therapy",
"the",
"lesion",
"healed",
"completely",
"with",
"minor",
"scarring",
"within",
"5",
"months",
".",
"A",
"new",
"Salmonella",
"strain",
"was",
"isolated",
"from",
"the",
"ground",
"of",
"the",
"ulcer",
"."
] |
[
"umlsterm"
] |
white, woman, right, cobra, Minor, symptoms, nausea, vomiting, extremity, skin, patient, Antibiotics, antiinflammatory agents, therapy, hydrocolloidal, wound, dressings, therapy, minor, Salmonella, strain, ulcer
|
DerHautarzt.40450330.eng.abstr_task2
|
Sentence: We report on a 31-year-old white woman , who was bitten in her right calf by a " spitting cobra " ( Neia nigricollis ) during a safari in Tansania . Minor initial systemic symptoms such as nausea and vomiting were followed by severe oedematous swelling of the extremity after 2 - 3 h and demarcation of a 2.75x2.75 in . area of necrotic skin . The patient returned to her home country , where 8 days after the snake-bite necrosectomy was performed . Antibiotics , antiinflammatory agents and local therapy with hydrocolloidal wound dressings were administered . With this therapy the lesion healed completely with minor scarring within 5 months . A new Salmonella strain was isolated from the ground of the ulcer .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O"
] |
We report on a 31-year-old white woman , who was bitten in her right calf by a " spitting cobra " ( Neia nigricollis ) during a safari in Tansania . Minor initial systemic symptoms such as nausea and vomiting were followed by severe oedematous swelling of the extremity after 2 - 3 h and demarcation of a 2.75x2.75 in . area of necrotic skin . The patient returned to her home country , where 8 days after the snake-bite necrosectomy was performed . Antibiotics , antiinflammatory agents and local therapy with hydrocolloidal wound dressings were administered . With this therapy the lesion healed completely with minor scarring within 5 months . A new Salmonella strain was isolated from the ground of the ulcer .
|
[
"We",
"report",
"on",
"a",
"31-year",
"-",
"old",
"white",
"woman",
",",
"who",
"was",
"bitten",
"in",
"her",
"right",
"calf",
"by",
"a",
"\"",
"spitting",
"cobra",
"\"",
"(",
"Neia",
"nigricollis",
")",
"during",
"a",
"safari",
"in",
"Tansania",
".",
"Minor",
"initial",
"systemic",
"symptoms",
"such",
"as",
"nausea",
"and",
"vomiting",
"were",
"followed",
"by",
"severe",
"oedematous",
"swelling",
"of",
"the",
"extremity",
"after",
"2",
"-",
"3",
"h",
"and",
"demarcation",
"of",
"a",
"2.75x2.75",
"in",
".",
"area",
"of",
"necrotic",
"skin",
".",
"The",
"patient",
"returned",
"to",
"her",
"home",
"country",
",",
"where",
"8",
"days",
"after",
"the",
"snake",
"-",
"bite",
"necrosectomy",
"was",
"performed",
".",
"Antibiotics",
",",
"antiinflammatory",
"agents",
"and",
"local",
"therapy",
"with",
"hydrocolloidal",
"wound",
"dressings",
"were",
"administered",
".",
"With",
"this",
"therapy",
"the",
"lesion",
"healed",
"completely",
"with",
"minor",
"scarring",
"within",
"5",
"months",
".",
"A",
"new",
"Salmonella",
"strain",
"was",
"isolated",
"from",
"the",
"ground",
"of",
"the",
"ulcer",
"."
] |
[
"umlsterm"
] |
Oesophagusmotilitaetsstoerungen is an umlsterm, gastrooesophagealer Reflux is an umlsterm, systemischen Sklerodermie is an umlsterm, Kindes- is an umlsterm, Patienten is an umlsterm
|
MonatsschriftKinderheilkunde.91470279.ger.abstr_task0
|
Sentence: Fragestellung : Oesophagusmotilitaetsstoerungen und gastrooesophagealer Reflux sind die haeufigsten gastrointestinalen Manifestationen der systemischen Sklerodermie und des Morbus Sharp ( mixed connective tissue disease ) . Ueber den Spontanverlauf dieser internen Organmanifestationen liegen fuer das Kindes- und Jugendalter keine Daten vor . Wir untersuchten diese Fragestellung bei paediatrischen Patienten , die an dieser im Kindesalter seltenen Erkrankung litten , im Rahmen der klinischen Verlaufskontrollen .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Fragestellung : Oesophagusmotilitaetsstoerungen und gastrooesophagealer Reflux sind die haeufigsten gastrointestinalen Manifestationen der systemischen Sklerodermie und des Morbus Sharp ( mixed connective tissue disease ) . Ueber den Spontanverlauf dieser internen Organmanifestationen liegen fuer das Kindes- und Jugendalter keine Daten vor . Wir untersuchten diese Fragestellung bei paediatrischen Patienten , die an dieser im Kindesalter seltenen Erkrankung litten , im Rahmen der klinischen Verlaufskontrollen .
|
[
"Fragestellung",
":",
"Oesophagusmotilitaetsstoerungen",
"und",
"gastrooesophagealer",
"Reflux",
"sind",
"die",
"haeufigsten",
"gastrointestinalen",
"Manifestationen",
"der",
"systemischen",
"Sklerodermie",
"und",
"des",
"Morbus",
"Sharp",
"(",
"mixed",
"connective",
"tissue",
"disease",
")",
".",
"Ueber",
"den",
"Spontanverlauf",
"dieser",
"internen",
"Organmanifestationen",
"liegen",
"fuer",
"das",
"Kindes-",
"und",
"Jugendalter",
"keine",
"Daten",
"vor",
".",
"Wir",
"untersuchten",
"diese",
"Fragestellung",
"bei",
"paediatrischen",
"Patienten",
",",
"die",
"an",
"dieser",
"im",
"Kindesalter",
"seltenen",
"Erkrankung",
"litten",
",",
"im",
"Rahmen",
"der",
"klinischen",
"Verlaufskontrollen",
"."
] |
[
"umlsterm"
] |
Oesophagusmotilitaetsstoerungen is an umlsterm, gastrooesophagealer Reflux is an umlsterm, systemischen Sklerodermie is an umlsterm, Kindes- is an umlsterm, Patienten is an umlsterm
|
MonatsschriftKinderheilkunde.91470279.ger.abstr_task1
|
Sentence: Fragestellung : Oesophagusmotilitaetsstoerungen und gastrooesophagealer Reflux sind die haeufigsten gastrointestinalen Manifestationen der systemischen Sklerodermie und des Morbus Sharp ( mixed connective tissue disease ) . Ueber den Spontanverlauf dieser internen Organmanifestationen liegen fuer das Kindes- und Jugendalter keine Daten vor . Wir untersuchten diese Fragestellung bei paediatrischen Patienten , die an dieser im Kindesalter seltenen Erkrankung litten , im Rahmen der klinischen Verlaufskontrollen .
Instructions: please typing these entity words according to sentence: Oesophagusmotilitaetsstoerungen, gastrooesophagealer Reflux, systemischen Sklerodermie, Kindes-, Patienten
Options: umlsterm
|
[
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Fragestellung : Oesophagusmotilitaetsstoerungen und gastrooesophagealer Reflux sind die haeufigsten gastrointestinalen Manifestationen der systemischen Sklerodermie und des Morbus Sharp ( mixed connective tissue disease ) . Ueber den Spontanverlauf dieser internen Organmanifestationen liegen fuer das Kindes- und Jugendalter keine Daten vor . Wir untersuchten diese Fragestellung bei paediatrischen Patienten , die an dieser im Kindesalter seltenen Erkrankung litten , im Rahmen der klinischen Verlaufskontrollen .
|
[
"Fragestellung",
":",
"Oesophagusmotilitaetsstoerungen",
"und",
"gastrooesophagealer",
"Reflux",
"sind",
"die",
"haeufigsten",
"gastrointestinalen",
"Manifestationen",
"der",
"systemischen",
"Sklerodermie",
"und",
"des",
"Morbus",
"Sharp",
"(",
"mixed",
"connective",
"tissue",
"disease",
")",
".",
"Ueber",
"den",
"Spontanverlauf",
"dieser",
"internen",
"Organmanifestationen",
"liegen",
"fuer",
"das",
"Kindes-",
"und",
"Jugendalter",
"keine",
"Daten",
"vor",
".",
"Wir",
"untersuchten",
"diese",
"Fragestellung",
"bei",
"paediatrischen",
"Patienten",
",",
"die",
"an",
"dieser",
"im",
"Kindesalter",
"seltenen",
"Erkrankung",
"litten",
",",
"im",
"Rahmen",
"der",
"klinischen",
"Verlaufskontrollen",
"."
] |
[
"umlsterm"
] |
Oesophagusmotilitaetsstoerungen, gastrooesophagealer Reflux, systemischen Sklerodermie, Kindes-, Patienten
|
MonatsschriftKinderheilkunde.91470279.ger.abstr_task2
|
Sentence: Fragestellung : Oesophagusmotilitaetsstoerungen und gastrooesophagealer Reflux sind die haeufigsten gastrointestinalen Manifestationen der systemischen Sklerodermie und des Morbus Sharp ( mixed connective tissue disease ) . Ueber den Spontanverlauf dieser internen Organmanifestationen liegen fuer das Kindes- und Jugendalter keine Daten vor . Wir untersuchten diese Fragestellung bei paediatrischen Patienten , die an dieser im Kindesalter seltenen Erkrankung litten , im Rahmen der klinischen Verlaufskontrollen .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Fragestellung : Oesophagusmotilitaetsstoerungen und gastrooesophagealer Reflux sind die haeufigsten gastrointestinalen Manifestationen der systemischen Sklerodermie und des Morbus Sharp ( mixed connective tissue disease ) . Ueber den Spontanverlauf dieser internen Organmanifestationen liegen fuer das Kindes- und Jugendalter keine Daten vor . Wir untersuchten diese Fragestellung bei paediatrischen Patienten , die an dieser im Kindesalter seltenen Erkrankung litten , im Rahmen der klinischen Verlaufskontrollen .
|
[
"Fragestellung",
":",
"Oesophagusmotilitaetsstoerungen",
"und",
"gastrooesophagealer",
"Reflux",
"sind",
"die",
"haeufigsten",
"gastrointestinalen",
"Manifestationen",
"der",
"systemischen",
"Sklerodermie",
"und",
"des",
"Morbus",
"Sharp",
"(",
"mixed",
"connective",
"tissue",
"disease",
")",
".",
"Ueber",
"den",
"Spontanverlauf",
"dieser",
"internen",
"Organmanifestationen",
"liegen",
"fuer",
"das",
"Kindes-",
"und",
"Jugendalter",
"keine",
"Daten",
"vor",
".",
"Wir",
"untersuchten",
"diese",
"Fragestellung",
"bei",
"paediatrischen",
"Patienten",
",",
"die",
"an",
"dieser",
"im",
"Kindesalter",
"seltenen",
"Erkrankung",
"litten",
",",
"im",
"Rahmen",
"der",
"klinischen",
"Verlaufskontrollen",
"."
] |
[
"umlsterm"
] |
Epstein - Barr virus oncoprotein latent membrane protein 1 is a protein_molecule, tumor necrosis factor receptor - associated proteins is a protein_family_or_group, TRADD is a protein_family_or_group, receptor - interacting protein is a protein_molecule, RIP is a protein_molecule, apoptosis is an other_name, RIP is a protein_molecule, NF - kappaB activation is an other_name
|
37899_task0
|
Sentence: The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: other_name, protein_family_or_group, protein_molecule
|
[
"O",
"B-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"O",
"O",
"B-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"B-protein_family_or_group",
"O",
"B-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"O",
"B-protein_molecule",
"O",
"O",
"O",
"O",
"O",
"B-other_name",
"O",
"O",
"B-protein_molecule",
"O",
"B-other_name",
"I-other_name",
"I-other_name",
"I-other_name",
"O"
] |
The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.
|
[
"The",
"Epstein",
"-",
"Barr",
"virus",
"oncoprotein",
"latent",
"membrane",
"protein",
"1",
"engages",
"the",
"tumor",
"necrosis",
"factor",
"receptor",
"-",
"associated",
"proteins",
"TRADD",
"and",
"receptor",
"-",
"interacting",
"protein",
"(",
"RIP",
")",
"but",
"does",
"not",
"induce",
"apoptosis",
"or",
"require",
"RIP",
"for",
"NF",
"-",
"kappaB",
"activation",
"."
] |
[
"protein_molecule",
"(OR cell_line cell_line)",
"protein_family_or_group",
"other_name",
"cell_line",
"(AND other_name other_name)",
"",
"protein_domain_or_region",
"virus",
"amino_acid_monomer",
"protein_complex"
] |
Epstein - Barr virus oncoprotein latent membrane protein 1 is a protein_molecule, tumor necrosis factor receptor - associated proteins is a protein_family_or_group, TRADD is a protein_family_or_group, receptor - interacting protein is a protein_molecule, RIP is a protein_molecule, apoptosis is an other_name, RIP is a protein_molecule, NF - kappaB activation is an other_name
|
37899_task1
|
Sentence: The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.
Instructions: please typing these entity words according to sentence: Epstein - Barr virus oncoprotein latent membrane protein 1, tumor necrosis factor receptor - associated proteins, TRADD, receptor - interacting protein, RIP, apoptosis, RIP, NF - kappaB activation
Options: other_name, protein_family_or_group, protein_molecule
|
[
"O",
"B-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"O",
"O",
"B-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"B-protein_family_or_group",
"O",
"B-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"O",
"B-protein_molecule",
"O",
"O",
"O",
"O",
"O",
"B-other_name",
"O",
"O",
"B-protein_molecule",
"O",
"B-other_name",
"I-other_name",
"I-other_name",
"I-other_name",
"O"
] |
The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.
|
[
"The",
"Epstein",
"-",
"Barr",
"virus",
"oncoprotein",
"latent",
"membrane",
"protein",
"1",
"engages",
"the",
"tumor",
"necrosis",
"factor",
"receptor",
"-",
"associated",
"proteins",
"TRADD",
"and",
"receptor",
"-",
"interacting",
"protein",
"(",
"RIP",
")",
"but",
"does",
"not",
"induce",
"apoptosis",
"or",
"require",
"RIP",
"for",
"NF",
"-",
"kappaB",
"activation",
"."
] |
[
"protein_molecule",
"(OR cell_line cell_line)",
"protein_family_or_group",
"other_name",
"cell_line",
"(AND other_name other_name)",
"",
"protein_domain_or_region",
"virus",
"amino_acid_monomer",
"protein_complex"
] |
Epstein - Barr virus oncoprotein latent membrane protein 1, tumor necrosis factor receptor - associated proteins, TRADD, receptor - interacting protein, RIP, apoptosis, RIP, NF - kappaB activation
|
37899_task2
|
Sentence: The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.
Instructions: please extract entity words from the input sentence
|
[
"O",
"B-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"O",
"O",
"B-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"I-protein_family_or_group",
"B-protein_family_or_group",
"O",
"B-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"I-protein_molecule",
"O",
"B-protein_molecule",
"O",
"O",
"O",
"O",
"O",
"B-other_name",
"O",
"O",
"B-protein_molecule",
"O",
"B-other_name",
"I-other_name",
"I-other_name",
"I-other_name",
"O"
] |
The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.
|
[
"The",
"Epstein",
"-",
"Barr",
"virus",
"oncoprotein",
"latent",
"membrane",
"protein",
"1",
"engages",
"the",
"tumor",
"necrosis",
"factor",
"receptor",
"-",
"associated",
"proteins",
"TRADD",
"and",
"receptor",
"-",
"interacting",
"protein",
"(",
"RIP",
")",
"but",
"does",
"not",
"induce",
"apoptosis",
"or",
"require",
"RIP",
"for",
"NF",
"-",
"kappaB",
"activation",
"."
] |
[
"protein_molecule",
"(OR cell_line cell_line)",
"protein_family_or_group",
"other_name",
"cell_line",
"(AND other_name other_name)",
"",
"protein_domain_or_region",
"virus",
"amino_acid_monomer",
"protein_complex"
] |
Gelenkknorpeldefekte is an umlsterm, Regenerationspotenz is an umlsterm, Knorpelgewebes is an umlsterm, Faserknorpel is an umlsterm, Faserknorpel is an umlsterm, Arthrose is an umlsterm, hyalinen is an umlsterm, Gelenkknorpel is an umlsterm, Regeneratgewebe is an umlsterm, Behandlung is an umlsterm, Knorpelschaeden is an umlsterm, hyalinen is an umlsterm, Gelenkknorpel is an umlsterm, Methode is an umlsterm, Arthrose is an umlsterm
|
DerUnfallchirurg.91020855.ger.abstr_task0
|
Sentence: Gelenkknorpeldefekte gelten als schwer zu therapieren . Die Regenerationspotenz des Knorpelgewebes ist gering und fuehrt zur Bildung von mechanisch minderwertigem Faserknorpel . Die etablierten Behandlungsmethoden koennen zwar die Bildung von Faserknorpel induzieren , die Entstehung einer Arthrose jedoch nicht verhindern . Die autologe Chondrozytentransplantation ( ACT ) stellt gegenwaertig das vielversprechendste klinisch einsetzbare neue Verfahren dar , mit welchen ein dem hyalinen Gelenkknorpel sehr aehnliches Regeneratgewebe im Defektbereich gebildet werden kann . Die jetzt vorliegenden wissenschaftlichen Ergebnisse zeigen ueber einen Nachuntersuchungszeitraum von 2-10 Jahren zu 90 % gute und sehr gute klinische Ergebnisse bei Anwendung an der Femurkondyle und ca. 70 % gute und sehr gute Ergebnisse bei der Behandlung von patellaren Knorpelschaeden . Die Festigkeit dieses Regenerats liegt mit Werten von 2,77 N sehr nahe an Werten fuer gesunden hyalinen Gelenkknorpel ( 3,08 N ) . Bei strenger Indikations-stellung rechtfertigen die vorliegenden mittelfristigen Ergebnisse bereits jetzt einen klinischen Einsatz an speziellen Zentren . Ob diese Methode die Entstehung einer Arthrose verhindern kann , muessen die langfristigen Ergebnisse zeigen .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Gelenkknorpeldefekte gelten als schwer zu therapieren . Die Regenerationspotenz des Knorpelgewebes ist gering und fuehrt zur Bildung von mechanisch minderwertigem Faserknorpel . Die etablierten Behandlungsmethoden koennen zwar die Bildung von Faserknorpel induzieren , die Entstehung einer Arthrose jedoch nicht verhindern . Die autologe Chondrozytentransplantation ( ACT ) stellt gegenwaertig das vielversprechendste klinisch einsetzbare neue Verfahren dar , mit welchen ein dem hyalinen Gelenkknorpel sehr aehnliches Regeneratgewebe im Defektbereich gebildet werden kann . Die jetzt vorliegenden wissenschaftlichen Ergebnisse zeigen ueber einen Nachuntersuchungszeitraum von 2-10 Jahren zu 90 % gute und sehr gute klinische Ergebnisse bei Anwendung an der Femurkondyle und ca. 70 % gute und sehr gute Ergebnisse bei der Behandlung von patellaren Knorpelschaeden . Die Festigkeit dieses Regenerats liegt mit Werten von 2,77 N sehr nahe an Werten fuer gesunden hyalinen Gelenkknorpel ( 3,08 N ) . Bei strenger Indikations-stellung rechtfertigen die vorliegenden mittelfristigen Ergebnisse bereits jetzt einen klinischen Einsatz an speziellen Zentren . Ob diese Methode die Entstehung einer Arthrose verhindern kann , muessen die langfristigen Ergebnisse zeigen .
|
[
"Gelenkknorpeldefekte",
"gelten",
"als",
"schwer",
"zu",
"therapieren",
".",
"Die",
"Regenerationspotenz",
"des",
"Knorpelgewebes",
"ist",
"gering",
"und",
"fuehrt",
"zur",
"Bildung",
"von",
"mechanisch",
"minderwertigem",
"Faserknorpel",
".",
"Die",
"etablierten",
"Behandlungsmethoden",
"koennen",
"zwar",
"die",
"Bildung",
"von",
"Faserknorpel",
"induzieren",
",",
"die",
"Entstehung",
"einer",
"Arthrose",
"jedoch",
"nicht",
"verhindern",
".",
"Die",
"autologe",
"Chondrozytentransplantation",
"(",
"ACT",
")",
"stellt",
"gegenwaertig",
"das",
"vielversprechendste",
"klinisch",
"einsetzbare",
"neue",
"Verfahren",
"dar",
",",
"mit",
"welchen",
"ein",
"dem",
"hyalinen",
"Gelenkknorpel",
"sehr",
"aehnliches",
"Regeneratgewebe",
"im",
"Defektbereich",
"gebildet",
"werden",
"kann",
".",
"Die",
"jetzt",
"vorliegenden",
"wissenschaftlichen",
"Ergebnisse",
"zeigen",
"ueber",
"einen",
"Nachuntersuchungszeitraum",
"von",
"2",
"-",
"10",
"Jahren",
"zu",
"90",
"%",
"gute",
"und",
"sehr",
"gute",
"klinische",
"Ergebnisse",
"bei",
"Anwendung",
"an",
"der",
"Femurkondyle",
"und",
"ca",
".",
"70",
"%",
"gute",
"und",
"sehr",
"gute",
"Ergebnisse",
"bei",
"der",
"Behandlung",
"von",
"patellaren",
"Knorpelschaeden",
".",
"Die",
"Festigkeit",
"dieses",
"Regenerats",
"liegt",
"mit",
"Werten",
"von",
"2,77",
"N",
"sehr",
"nahe",
"an",
"Werten",
"fuer",
"gesunden",
"hyalinen",
"Gelenkknorpel",
"(",
"3,08",
"N",
")",
".",
"Bei",
"strenger",
"Indikations",
"-",
"stellung",
"rechtfertigen",
"die",
"vorliegenden",
"mittelfristigen",
"Ergebnisse",
"bereits",
"jetzt",
"einen",
"klinischen",
"Einsatz",
"an",
"speziellen",
"Zentren",
".",
"Ob",
"diese",
"Methode",
"die",
"Entstehung",
"einer",
"Arthrose",
"verhindern",
"kann",
",",
"muessen",
"die",
"langfristigen",
"Ergebnisse",
"zeigen",
"."
] |
[
"umlsterm"
] |
Gelenkknorpeldefekte is an umlsterm, Regenerationspotenz is an umlsterm, Knorpelgewebes is an umlsterm, Faserknorpel is an umlsterm, Faserknorpel is an umlsterm, Arthrose is an umlsterm, hyalinen is an umlsterm, Gelenkknorpel is an umlsterm, Regeneratgewebe is an umlsterm, Behandlung is an umlsterm, Knorpelschaeden is an umlsterm, hyalinen is an umlsterm, Gelenkknorpel is an umlsterm, Methode is an umlsterm, Arthrose is an umlsterm
|
DerUnfallchirurg.91020855.ger.abstr_task1
|
Sentence: Gelenkknorpeldefekte gelten als schwer zu therapieren . Die Regenerationspotenz des Knorpelgewebes ist gering und fuehrt zur Bildung von mechanisch minderwertigem Faserknorpel . Die etablierten Behandlungsmethoden koennen zwar die Bildung von Faserknorpel induzieren , die Entstehung einer Arthrose jedoch nicht verhindern . Die autologe Chondrozytentransplantation ( ACT ) stellt gegenwaertig das vielversprechendste klinisch einsetzbare neue Verfahren dar , mit welchen ein dem hyalinen Gelenkknorpel sehr aehnliches Regeneratgewebe im Defektbereich gebildet werden kann . Die jetzt vorliegenden wissenschaftlichen Ergebnisse zeigen ueber einen Nachuntersuchungszeitraum von 2-10 Jahren zu 90 % gute und sehr gute klinische Ergebnisse bei Anwendung an der Femurkondyle und ca. 70 % gute und sehr gute Ergebnisse bei der Behandlung von patellaren Knorpelschaeden . Die Festigkeit dieses Regenerats liegt mit Werten von 2,77 N sehr nahe an Werten fuer gesunden hyalinen Gelenkknorpel ( 3,08 N ) . Bei strenger Indikations-stellung rechtfertigen die vorliegenden mittelfristigen Ergebnisse bereits jetzt einen klinischen Einsatz an speziellen Zentren . Ob diese Methode die Entstehung einer Arthrose verhindern kann , muessen die langfristigen Ergebnisse zeigen .
Instructions: please typing these entity words according to sentence: Gelenkknorpeldefekte, Regenerationspotenz, Knorpelgewebes, Faserknorpel, Faserknorpel, Arthrose, hyalinen, Gelenkknorpel, Regeneratgewebe, Behandlung, Knorpelschaeden, hyalinen, Gelenkknorpel, Methode, Arthrose
Options: umlsterm
|
[
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Gelenkknorpeldefekte gelten als schwer zu therapieren . Die Regenerationspotenz des Knorpelgewebes ist gering und fuehrt zur Bildung von mechanisch minderwertigem Faserknorpel . Die etablierten Behandlungsmethoden koennen zwar die Bildung von Faserknorpel induzieren , die Entstehung einer Arthrose jedoch nicht verhindern . Die autologe Chondrozytentransplantation ( ACT ) stellt gegenwaertig das vielversprechendste klinisch einsetzbare neue Verfahren dar , mit welchen ein dem hyalinen Gelenkknorpel sehr aehnliches Regeneratgewebe im Defektbereich gebildet werden kann . Die jetzt vorliegenden wissenschaftlichen Ergebnisse zeigen ueber einen Nachuntersuchungszeitraum von 2-10 Jahren zu 90 % gute und sehr gute klinische Ergebnisse bei Anwendung an der Femurkondyle und ca. 70 % gute und sehr gute Ergebnisse bei der Behandlung von patellaren Knorpelschaeden . Die Festigkeit dieses Regenerats liegt mit Werten von 2,77 N sehr nahe an Werten fuer gesunden hyalinen Gelenkknorpel ( 3,08 N ) . Bei strenger Indikations-stellung rechtfertigen die vorliegenden mittelfristigen Ergebnisse bereits jetzt einen klinischen Einsatz an speziellen Zentren . Ob diese Methode die Entstehung einer Arthrose verhindern kann , muessen die langfristigen Ergebnisse zeigen .
|
[
"Gelenkknorpeldefekte",
"gelten",
"als",
"schwer",
"zu",
"therapieren",
".",
"Die",
"Regenerationspotenz",
"des",
"Knorpelgewebes",
"ist",
"gering",
"und",
"fuehrt",
"zur",
"Bildung",
"von",
"mechanisch",
"minderwertigem",
"Faserknorpel",
".",
"Die",
"etablierten",
"Behandlungsmethoden",
"koennen",
"zwar",
"die",
"Bildung",
"von",
"Faserknorpel",
"induzieren",
",",
"die",
"Entstehung",
"einer",
"Arthrose",
"jedoch",
"nicht",
"verhindern",
".",
"Die",
"autologe",
"Chondrozytentransplantation",
"(",
"ACT",
")",
"stellt",
"gegenwaertig",
"das",
"vielversprechendste",
"klinisch",
"einsetzbare",
"neue",
"Verfahren",
"dar",
",",
"mit",
"welchen",
"ein",
"dem",
"hyalinen",
"Gelenkknorpel",
"sehr",
"aehnliches",
"Regeneratgewebe",
"im",
"Defektbereich",
"gebildet",
"werden",
"kann",
".",
"Die",
"jetzt",
"vorliegenden",
"wissenschaftlichen",
"Ergebnisse",
"zeigen",
"ueber",
"einen",
"Nachuntersuchungszeitraum",
"von",
"2",
"-",
"10",
"Jahren",
"zu",
"90",
"%",
"gute",
"und",
"sehr",
"gute",
"klinische",
"Ergebnisse",
"bei",
"Anwendung",
"an",
"der",
"Femurkondyle",
"und",
"ca",
".",
"70",
"%",
"gute",
"und",
"sehr",
"gute",
"Ergebnisse",
"bei",
"der",
"Behandlung",
"von",
"patellaren",
"Knorpelschaeden",
".",
"Die",
"Festigkeit",
"dieses",
"Regenerats",
"liegt",
"mit",
"Werten",
"von",
"2,77",
"N",
"sehr",
"nahe",
"an",
"Werten",
"fuer",
"gesunden",
"hyalinen",
"Gelenkknorpel",
"(",
"3,08",
"N",
")",
".",
"Bei",
"strenger",
"Indikations",
"-",
"stellung",
"rechtfertigen",
"die",
"vorliegenden",
"mittelfristigen",
"Ergebnisse",
"bereits",
"jetzt",
"einen",
"klinischen",
"Einsatz",
"an",
"speziellen",
"Zentren",
".",
"Ob",
"diese",
"Methode",
"die",
"Entstehung",
"einer",
"Arthrose",
"verhindern",
"kann",
",",
"muessen",
"die",
"langfristigen",
"Ergebnisse",
"zeigen",
"."
] |
[
"umlsterm"
] |
Gelenkknorpeldefekte, Regenerationspotenz, Knorpelgewebes, Faserknorpel, Faserknorpel, Arthrose, hyalinen, Gelenkknorpel, Regeneratgewebe, Behandlung, Knorpelschaeden, hyalinen, Gelenkknorpel, Methode, Arthrose
|
DerUnfallchirurg.91020855.ger.abstr_task2
|
Sentence: Gelenkknorpeldefekte gelten als schwer zu therapieren . Die Regenerationspotenz des Knorpelgewebes ist gering und fuehrt zur Bildung von mechanisch minderwertigem Faserknorpel . Die etablierten Behandlungsmethoden koennen zwar die Bildung von Faserknorpel induzieren , die Entstehung einer Arthrose jedoch nicht verhindern . Die autologe Chondrozytentransplantation ( ACT ) stellt gegenwaertig das vielversprechendste klinisch einsetzbare neue Verfahren dar , mit welchen ein dem hyalinen Gelenkknorpel sehr aehnliches Regeneratgewebe im Defektbereich gebildet werden kann . Die jetzt vorliegenden wissenschaftlichen Ergebnisse zeigen ueber einen Nachuntersuchungszeitraum von 2-10 Jahren zu 90 % gute und sehr gute klinische Ergebnisse bei Anwendung an der Femurkondyle und ca. 70 % gute und sehr gute Ergebnisse bei der Behandlung von patellaren Knorpelschaeden . Die Festigkeit dieses Regenerats liegt mit Werten von 2,77 N sehr nahe an Werten fuer gesunden hyalinen Gelenkknorpel ( 3,08 N ) . Bei strenger Indikations-stellung rechtfertigen die vorliegenden mittelfristigen Ergebnisse bereits jetzt einen klinischen Einsatz an speziellen Zentren . Ob diese Methode die Entstehung einer Arthrose verhindern kann , muessen die langfristigen Ergebnisse zeigen .
Instructions: please extract entity words from the input sentence
|
[
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Gelenkknorpeldefekte gelten als schwer zu therapieren . Die Regenerationspotenz des Knorpelgewebes ist gering und fuehrt zur Bildung von mechanisch minderwertigem Faserknorpel . Die etablierten Behandlungsmethoden koennen zwar die Bildung von Faserknorpel induzieren , die Entstehung einer Arthrose jedoch nicht verhindern . Die autologe Chondrozytentransplantation ( ACT ) stellt gegenwaertig das vielversprechendste klinisch einsetzbare neue Verfahren dar , mit welchen ein dem hyalinen Gelenkknorpel sehr aehnliches Regeneratgewebe im Defektbereich gebildet werden kann . Die jetzt vorliegenden wissenschaftlichen Ergebnisse zeigen ueber einen Nachuntersuchungszeitraum von 2-10 Jahren zu 90 % gute und sehr gute klinische Ergebnisse bei Anwendung an der Femurkondyle und ca. 70 % gute und sehr gute Ergebnisse bei der Behandlung von patellaren Knorpelschaeden . Die Festigkeit dieses Regenerats liegt mit Werten von 2,77 N sehr nahe an Werten fuer gesunden hyalinen Gelenkknorpel ( 3,08 N ) . Bei strenger Indikations-stellung rechtfertigen die vorliegenden mittelfristigen Ergebnisse bereits jetzt einen klinischen Einsatz an speziellen Zentren . Ob diese Methode die Entstehung einer Arthrose verhindern kann , muessen die langfristigen Ergebnisse zeigen .
|
[
"Gelenkknorpeldefekte",
"gelten",
"als",
"schwer",
"zu",
"therapieren",
".",
"Die",
"Regenerationspotenz",
"des",
"Knorpelgewebes",
"ist",
"gering",
"und",
"fuehrt",
"zur",
"Bildung",
"von",
"mechanisch",
"minderwertigem",
"Faserknorpel",
".",
"Die",
"etablierten",
"Behandlungsmethoden",
"koennen",
"zwar",
"die",
"Bildung",
"von",
"Faserknorpel",
"induzieren",
",",
"die",
"Entstehung",
"einer",
"Arthrose",
"jedoch",
"nicht",
"verhindern",
".",
"Die",
"autologe",
"Chondrozytentransplantation",
"(",
"ACT",
")",
"stellt",
"gegenwaertig",
"das",
"vielversprechendste",
"klinisch",
"einsetzbare",
"neue",
"Verfahren",
"dar",
",",
"mit",
"welchen",
"ein",
"dem",
"hyalinen",
"Gelenkknorpel",
"sehr",
"aehnliches",
"Regeneratgewebe",
"im",
"Defektbereich",
"gebildet",
"werden",
"kann",
".",
"Die",
"jetzt",
"vorliegenden",
"wissenschaftlichen",
"Ergebnisse",
"zeigen",
"ueber",
"einen",
"Nachuntersuchungszeitraum",
"von",
"2",
"-",
"10",
"Jahren",
"zu",
"90",
"%",
"gute",
"und",
"sehr",
"gute",
"klinische",
"Ergebnisse",
"bei",
"Anwendung",
"an",
"der",
"Femurkondyle",
"und",
"ca",
".",
"70",
"%",
"gute",
"und",
"sehr",
"gute",
"Ergebnisse",
"bei",
"der",
"Behandlung",
"von",
"patellaren",
"Knorpelschaeden",
".",
"Die",
"Festigkeit",
"dieses",
"Regenerats",
"liegt",
"mit",
"Werten",
"von",
"2,77",
"N",
"sehr",
"nahe",
"an",
"Werten",
"fuer",
"gesunden",
"hyalinen",
"Gelenkknorpel",
"(",
"3,08",
"N",
")",
".",
"Bei",
"strenger",
"Indikations",
"-",
"stellung",
"rechtfertigen",
"die",
"vorliegenden",
"mittelfristigen",
"Ergebnisse",
"bereits",
"jetzt",
"einen",
"klinischen",
"Einsatz",
"an",
"speziellen",
"Zentren",
".",
"Ob",
"diese",
"Methode",
"die",
"Entstehung",
"einer",
"Arthrose",
"verhindern",
"kann",
",",
"muessen",
"die",
"langfristigen",
"Ergebnisse",
"zeigen",
"."
] |
[
"umlsterm"
] |
calmodulin is a Protein, calmodulin is a Protein, calmodulin is a Protein, calmodulin is a Protein, calmodulin is a Protein, serum albumin is a Protein, cytochrome c is a Protein, ribonuclease A is a Protein, triosephosphate isomerase is a Protein, calmodulin is a Protein, calmodulin is a Protein
|
509_task0
|
Sentence: Deamidation of calmodulin at neutral and alkaline pH: quantitative relationships between ammonia loss and the susceptibility of calmodulin to modification by protein carboxyl methyltransferase.
Measurements of ammonia release provide the first direct evidence that calmodulin becomes extensively deamidated during incubations at 37 degrees C, pH 7.4 or pH 11. A stoichiometry of 0.5 mol of NH3 released/mol of calmodulin is observed after 2 h at pH 11 or after 8-9 days at pH 7.4. These treatments also increase the ability of calmodulin to serve as a substrate for the isoaspartate-specific protein carboxyl methyltransferase from bovine brain. The stoichiometries of methylation are highly correlated with the stoichiometries of ammonia release. Deamidation and increased methyl-accepting capacity also occur in parallel for seven other proteins (aldolase, bovine serum albumin, cytochrome c, lysozyme, ovalbumin, ribonuclease A, and triosephosphate isomerase) upon incubation at pH 11. However, in comparison to calmodulin, these other proteins show very little deamidation and increased methylation capacity following incubation at pH 7.4. Deamidation of calmodulin at pH 7.4 is unaffected by the addition of 10(-7) M Ca2+; however, at 4 X 10(-6) M Ca2+, the rate of deamidation is inhibited by approximately 70%. The Ca2+-protection effect is consistent with the suggestion (B. A. Johnson, N. E. Freitag, and D. W. Aswad, (1985) J. Biol. Chem. 260, 10913-10916) that deamidation occurs preferentially at Asn-60 and/or Asn-97, each of which resides in a distinct Ca2+-binding domain.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Protein
|
[
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Deamidation of calmodulin at neutral and alkaline pH: quantitative relationships between ammonia loss and the susceptibility of calmodulin to modification by protein carboxyl methyltransferase.
Measurements of ammonia release provide the first direct evidence that calmodulin becomes extensively deamidated during incubations at 37 degrees C, pH 7.4 or pH 11. A stoichiometry of 0.5 mol of NH3 released/mol of calmodulin is observed after 2 h at pH 11 or after 8-9 days at pH 7.4. These treatments also increase the ability of calmodulin to serve as a substrate for the isoaspartate-specific protein carboxyl methyltransferase from bovine brain. The stoichiometries of methylation are highly correlated with the stoichiometries of ammonia release. Deamidation and increased methyl-accepting capacity also occur in parallel for seven other proteins (aldolase, bovine serum albumin, cytochrome c, lysozyme, ovalbumin, ribonuclease A, and triosephosphate isomerase) upon incubation at pH 11. However, in comparison to calmodulin, these other proteins show very little deamidation and increased methylation capacity following incubation at pH 7.4. Deamidation of calmodulin at pH 7.4 is unaffected by the addition of 10(-7) M Ca2+; however, at 4 X 10(-6) M Ca2+, the rate of deamidation is inhibited by approximately 70%. The Ca2+-protection effect is consistent with the suggestion (B. A. Johnson, N. E. Freitag, and D. W. Aswad, (1985) J. Biol. Chem. 260, 10913-10916) that deamidation occurs preferentially at Asn-60 and/or Asn-97, each of which resides in a distinct Ca2+-binding domain.
|
[
"Deamidation",
"of",
"calmodulin",
"at",
"neutral",
"and",
"alkaline",
"pH",
":",
"quantitative",
"relationships",
"between",
"ammonia",
"loss",
"and",
"the",
"susceptibility",
"of",
"calmodulin",
"to",
"modification",
"by",
"protein",
"carboxyl",
"methyltransferase",
".",
"\n",
"Measurements",
"of",
"ammonia",
"release",
"provide",
"the",
"first",
"direct",
"evidence",
"that",
"calmodulin",
"becomes",
"extensively",
"deamidated",
"during",
"incubations",
"at",
"37",
"degrees",
"C",
",",
"pH",
"7.4",
"or",
"pH",
"11",
".",
"A",
"stoichiometry",
"of",
"0.5",
"mol",
"of",
"NH3",
"released",
"/",
"mol",
"of",
"calmodulin",
"is",
"observed",
"after",
"2",
"h",
"at",
"pH",
"11",
"or",
"after",
"8",
"-",
"9",
"days",
"at",
"pH",
"7.4",
".",
"These",
"treatments",
"also",
"increase",
"the",
"ability",
"of",
"calmodulin",
"to",
"serve",
"as",
"a",
"substrate",
"for",
"the",
"isoaspartate",
"-",
"specific",
"protein",
"carboxyl",
"methyltransferase",
"from",
"bovine",
"brain",
".",
"The",
"stoichiometries",
"of",
"methylation",
"are",
"highly",
"correlated",
"with",
"the",
"stoichiometries",
"of",
"ammonia",
"release",
".",
"Deamidation",
"and",
"increased",
"methyl",
"-",
"accepting",
"capacity",
"also",
"occur",
"in",
"parallel",
"for",
"seven",
"other",
"proteins",
"(",
"aldolase",
",",
"bovine",
"serum",
"albumin",
",",
"cytochrome",
"c",
",",
"lysozyme",
",",
"ovalbumin",
",",
"ribonuclease",
"A",
",",
"and",
"triosephosphate",
"isomerase",
")",
"upon",
"incubation",
"at",
"pH",
"11",
".",
"However",
",",
"in",
"comparison",
"to",
"calmodulin",
",",
"these",
"other",
"proteins",
"show",
"very",
"little",
"deamidation",
"and",
"increased",
"methylation",
"capacity",
"following",
"incubation",
"at",
"pH",
"7.4",
".",
"Deamidation",
"of",
"calmodulin",
"at",
"pH",
"7.4",
"is",
"unaffected",
"by",
"the",
"addition",
"of",
"10(-7",
")",
"M",
"Ca2",
"+",
";",
"however",
",",
"at",
"4",
"X",
"10(-6",
")",
"M",
"Ca2",
"+",
",",
"the",
"rate",
"of",
"deamidation",
"is",
"inhibited",
"by",
"approximately",
"70",
"%",
".",
"The",
"Ca2",
"+",
"-protection",
"effect",
"is",
"consistent",
"with",
"the",
"suggestion",
"(",
"B.",
"A.",
"Johnson",
",",
"N.",
"E.",
"Freitag",
",",
"and",
"D.",
"W.",
"Aswad",
",",
"(",
"1985",
")",
"J.",
"Biol",
".",
"Chem",
".",
"260",
",",
"10913",
"-",
"10916",
")",
"that",
"deamidation",
"occurs",
"preferentially",
"at",
"Asn-60",
"and",
"/",
"or",
"Asn-97",
",",
"each",
"of",
"which",
"resides",
"in",
"a",
"distinct",
"Ca2",
"+",
"-binding",
"domain",
".",
"\n"
] |
[
"Protein"
] |
calmodulin is a Protein, calmodulin is a Protein, calmodulin is a Protein, calmodulin is a Protein, calmodulin is a Protein, serum albumin is a Protein, cytochrome c is a Protein, ribonuclease A is a Protein, triosephosphate isomerase is a Protein, calmodulin is a Protein, calmodulin is a Protein
|
509_task1
|
Sentence: Deamidation of calmodulin at neutral and alkaline pH: quantitative relationships between ammonia loss and the susceptibility of calmodulin to modification by protein carboxyl methyltransferase.
Measurements of ammonia release provide the first direct evidence that calmodulin becomes extensively deamidated during incubations at 37 degrees C, pH 7.4 or pH 11. A stoichiometry of 0.5 mol of NH3 released/mol of calmodulin is observed after 2 h at pH 11 or after 8-9 days at pH 7.4. These treatments also increase the ability of calmodulin to serve as a substrate for the isoaspartate-specific protein carboxyl methyltransferase from bovine brain. The stoichiometries of methylation are highly correlated with the stoichiometries of ammonia release. Deamidation and increased methyl-accepting capacity also occur in parallel for seven other proteins (aldolase, bovine serum albumin, cytochrome c, lysozyme, ovalbumin, ribonuclease A, and triosephosphate isomerase) upon incubation at pH 11. However, in comparison to calmodulin, these other proteins show very little deamidation and increased methylation capacity following incubation at pH 7.4. Deamidation of calmodulin at pH 7.4 is unaffected by the addition of 10(-7) M Ca2+; however, at 4 X 10(-6) M Ca2+, the rate of deamidation is inhibited by approximately 70%. The Ca2+-protection effect is consistent with the suggestion (B. A. Johnson, N. E. Freitag, and D. W. Aswad, (1985) J. Biol. Chem. 260, 10913-10916) that deamidation occurs preferentially at Asn-60 and/or Asn-97, each of which resides in a distinct Ca2+-binding domain.
Instructions: please typing these entity words according to sentence: calmodulin, calmodulin, calmodulin, calmodulin, calmodulin, serum albumin, cytochrome c, ribonuclease A, triosephosphate isomerase, calmodulin, calmodulin
Options: Protein
|
[
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Deamidation of calmodulin at neutral and alkaline pH: quantitative relationships between ammonia loss and the susceptibility of calmodulin to modification by protein carboxyl methyltransferase.
Measurements of ammonia release provide the first direct evidence that calmodulin becomes extensively deamidated during incubations at 37 degrees C, pH 7.4 or pH 11. A stoichiometry of 0.5 mol of NH3 released/mol of calmodulin is observed after 2 h at pH 11 or after 8-9 days at pH 7.4. These treatments also increase the ability of calmodulin to serve as a substrate for the isoaspartate-specific protein carboxyl methyltransferase from bovine brain. The stoichiometries of methylation are highly correlated with the stoichiometries of ammonia release. Deamidation and increased methyl-accepting capacity also occur in parallel for seven other proteins (aldolase, bovine serum albumin, cytochrome c, lysozyme, ovalbumin, ribonuclease A, and triosephosphate isomerase) upon incubation at pH 11. However, in comparison to calmodulin, these other proteins show very little deamidation and increased methylation capacity following incubation at pH 7.4. Deamidation of calmodulin at pH 7.4 is unaffected by the addition of 10(-7) M Ca2+; however, at 4 X 10(-6) M Ca2+, the rate of deamidation is inhibited by approximately 70%. The Ca2+-protection effect is consistent with the suggestion (B. A. Johnson, N. E. Freitag, and D. W. Aswad, (1985) J. Biol. Chem. 260, 10913-10916) that deamidation occurs preferentially at Asn-60 and/or Asn-97, each of which resides in a distinct Ca2+-binding domain.
|
[
"Deamidation",
"of",
"calmodulin",
"at",
"neutral",
"and",
"alkaline",
"pH",
":",
"quantitative",
"relationships",
"between",
"ammonia",
"loss",
"and",
"the",
"susceptibility",
"of",
"calmodulin",
"to",
"modification",
"by",
"protein",
"carboxyl",
"methyltransferase",
".",
"\n",
"Measurements",
"of",
"ammonia",
"release",
"provide",
"the",
"first",
"direct",
"evidence",
"that",
"calmodulin",
"becomes",
"extensively",
"deamidated",
"during",
"incubations",
"at",
"37",
"degrees",
"C",
",",
"pH",
"7.4",
"or",
"pH",
"11",
".",
"A",
"stoichiometry",
"of",
"0.5",
"mol",
"of",
"NH3",
"released",
"/",
"mol",
"of",
"calmodulin",
"is",
"observed",
"after",
"2",
"h",
"at",
"pH",
"11",
"or",
"after",
"8",
"-",
"9",
"days",
"at",
"pH",
"7.4",
".",
"These",
"treatments",
"also",
"increase",
"the",
"ability",
"of",
"calmodulin",
"to",
"serve",
"as",
"a",
"substrate",
"for",
"the",
"isoaspartate",
"-",
"specific",
"protein",
"carboxyl",
"methyltransferase",
"from",
"bovine",
"brain",
".",
"The",
"stoichiometries",
"of",
"methylation",
"are",
"highly",
"correlated",
"with",
"the",
"stoichiometries",
"of",
"ammonia",
"release",
".",
"Deamidation",
"and",
"increased",
"methyl",
"-",
"accepting",
"capacity",
"also",
"occur",
"in",
"parallel",
"for",
"seven",
"other",
"proteins",
"(",
"aldolase",
",",
"bovine",
"serum",
"albumin",
",",
"cytochrome",
"c",
",",
"lysozyme",
",",
"ovalbumin",
",",
"ribonuclease",
"A",
",",
"and",
"triosephosphate",
"isomerase",
")",
"upon",
"incubation",
"at",
"pH",
"11",
".",
"However",
",",
"in",
"comparison",
"to",
"calmodulin",
",",
"these",
"other",
"proteins",
"show",
"very",
"little",
"deamidation",
"and",
"increased",
"methylation",
"capacity",
"following",
"incubation",
"at",
"pH",
"7.4",
".",
"Deamidation",
"of",
"calmodulin",
"at",
"pH",
"7.4",
"is",
"unaffected",
"by",
"the",
"addition",
"of",
"10(-7",
")",
"M",
"Ca2",
"+",
";",
"however",
",",
"at",
"4",
"X",
"10(-6",
")",
"M",
"Ca2",
"+",
",",
"the",
"rate",
"of",
"deamidation",
"is",
"inhibited",
"by",
"approximately",
"70",
"%",
".",
"The",
"Ca2",
"+",
"-protection",
"effect",
"is",
"consistent",
"with",
"the",
"suggestion",
"(",
"B.",
"A.",
"Johnson",
",",
"N.",
"E.",
"Freitag",
",",
"and",
"D.",
"W.",
"Aswad",
",",
"(",
"1985",
")",
"J.",
"Biol",
".",
"Chem",
".",
"260",
",",
"10913",
"-",
"10916",
")",
"that",
"deamidation",
"occurs",
"preferentially",
"at",
"Asn-60",
"and",
"/",
"or",
"Asn-97",
",",
"each",
"of",
"which",
"resides",
"in",
"a",
"distinct",
"Ca2",
"+",
"-binding",
"domain",
".",
"\n"
] |
[
"Protein"
] |
calmodulin, calmodulin, calmodulin, calmodulin, calmodulin, serum albumin, cytochrome c, ribonuclease A, triosephosphate isomerase, calmodulin, calmodulin
|
509_task2
|
Sentence: Deamidation of calmodulin at neutral and alkaline pH: quantitative relationships between ammonia loss and the susceptibility of calmodulin to modification by protein carboxyl methyltransferase.
Measurements of ammonia release provide the first direct evidence that calmodulin becomes extensively deamidated during incubations at 37 degrees C, pH 7.4 or pH 11. A stoichiometry of 0.5 mol of NH3 released/mol of calmodulin is observed after 2 h at pH 11 or after 8-9 days at pH 7.4. These treatments also increase the ability of calmodulin to serve as a substrate for the isoaspartate-specific protein carboxyl methyltransferase from bovine brain. The stoichiometries of methylation are highly correlated with the stoichiometries of ammonia release. Deamidation and increased methyl-accepting capacity also occur in parallel for seven other proteins (aldolase, bovine serum albumin, cytochrome c, lysozyme, ovalbumin, ribonuclease A, and triosephosphate isomerase) upon incubation at pH 11. However, in comparison to calmodulin, these other proteins show very little deamidation and increased methylation capacity following incubation at pH 7.4. Deamidation of calmodulin at pH 7.4 is unaffected by the addition of 10(-7) M Ca2+; however, at 4 X 10(-6) M Ca2+, the rate of deamidation is inhibited by approximately 70%. The Ca2+-protection effect is consistent with the suggestion (B. A. Johnson, N. E. Freitag, and D. W. Aswad, (1985) J. Biol. Chem. 260, 10913-10916) that deamidation occurs preferentially at Asn-60 and/or Asn-97, each of which resides in a distinct Ca2+-binding domain.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"B-Protein",
"I-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Deamidation of calmodulin at neutral and alkaline pH: quantitative relationships between ammonia loss and the susceptibility of calmodulin to modification by protein carboxyl methyltransferase.
Measurements of ammonia release provide the first direct evidence that calmodulin becomes extensively deamidated during incubations at 37 degrees C, pH 7.4 or pH 11. A stoichiometry of 0.5 mol of NH3 released/mol of calmodulin is observed after 2 h at pH 11 or after 8-9 days at pH 7.4. These treatments also increase the ability of calmodulin to serve as a substrate for the isoaspartate-specific protein carboxyl methyltransferase from bovine brain. The stoichiometries of methylation are highly correlated with the stoichiometries of ammonia release. Deamidation and increased methyl-accepting capacity also occur in parallel for seven other proteins (aldolase, bovine serum albumin, cytochrome c, lysozyme, ovalbumin, ribonuclease A, and triosephosphate isomerase) upon incubation at pH 11. However, in comparison to calmodulin, these other proteins show very little deamidation and increased methylation capacity following incubation at pH 7.4. Deamidation of calmodulin at pH 7.4 is unaffected by the addition of 10(-7) M Ca2+; however, at 4 X 10(-6) M Ca2+, the rate of deamidation is inhibited by approximately 70%. The Ca2+-protection effect is consistent with the suggestion (B. A. Johnson, N. E. Freitag, and D. W. Aswad, (1985) J. Biol. Chem. 260, 10913-10916) that deamidation occurs preferentially at Asn-60 and/or Asn-97, each of which resides in a distinct Ca2+-binding domain.
|
[
"Deamidation",
"of",
"calmodulin",
"at",
"neutral",
"and",
"alkaline",
"pH",
":",
"quantitative",
"relationships",
"between",
"ammonia",
"loss",
"and",
"the",
"susceptibility",
"of",
"calmodulin",
"to",
"modification",
"by",
"protein",
"carboxyl",
"methyltransferase",
".",
"\n",
"Measurements",
"of",
"ammonia",
"release",
"provide",
"the",
"first",
"direct",
"evidence",
"that",
"calmodulin",
"becomes",
"extensively",
"deamidated",
"during",
"incubations",
"at",
"37",
"degrees",
"C",
",",
"pH",
"7.4",
"or",
"pH",
"11",
".",
"A",
"stoichiometry",
"of",
"0.5",
"mol",
"of",
"NH3",
"released",
"/",
"mol",
"of",
"calmodulin",
"is",
"observed",
"after",
"2",
"h",
"at",
"pH",
"11",
"or",
"after",
"8",
"-",
"9",
"days",
"at",
"pH",
"7.4",
".",
"These",
"treatments",
"also",
"increase",
"the",
"ability",
"of",
"calmodulin",
"to",
"serve",
"as",
"a",
"substrate",
"for",
"the",
"isoaspartate",
"-",
"specific",
"protein",
"carboxyl",
"methyltransferase",
"from",
"bovine",
"brain",
".",
"The",
"stoichiometries",
"of",
"methylation",
"are",
"highly",
"correlated",
"with",
"the",
"stoichiometries",
"of",
"ammonia",
"release",
".",
"Deamidation",
"and",
"increased",
"methyl",
"-",
"accepting",
"capacity",
"also",
"occur",
"in",
"parallel",
"for",
"seven",
"other",
"proteins",
"(",
"aldolase",
",",
"bovine",
"serum",
"albumin",
",",
"cytochrome",
"c",
",",
"lysozyme",
",",
"ovalbumin",
",",
"ribonuclease",
"A",
",",
"and",
"triosephosphate",
"isomerase",
")",
"upon",
"incubation",
"at",
"pH",
"11",
".",
"However",
",",
"in",
"comparison",
"to",
"calmodulin",
",",
"these",
"other",
"proteins",
"show",
"very",
"little",
"deamidation",
"and",
"increased",
"methylation",
"capacity",
"following",
"incubation",
"at",
"pH",
"7.4",
".",
"Deamidation",
"of",
"calmodulin",
"at",
"pH",
"7.4",
"is",
"unaffected",
"by",
"the",
"addition",
"of",
"10(-7",
")",
"M",
"Ca2",
"+",
";",
"however",
",",
"at",
"4",
"X",
"10(-6",
")",
"M",
"Ca2",
"+",
",",
"the",
"rate",
"of",
"deamidation",
"is",
"inhibited",
"by",
"approximately",
"70",
"%",
".",
"The",
"Ca2",
"+",
"-protection",
"effect",
"is",
"consistent",
"with",
"the",
"suggestion",
"(",
"B.",
"A.",
"Johnson",
",",
"N.",
"E.",
"Freitag",
",",
"and",
"D.",
"W.",
"Aswad",
",",
"(",
"1985",
")",
"J.",
"Biol",
".",
"Chem",
".",
"260",
",",
"10913",
"-",
"10916",
")",
"that",
"deamidation",
"occurs",
"preferentially",
"at",
"Asn-60",
"and",
"/",
"or",
"Asn-97",
",",
"each",
"of",
"which",
"resides",
"in",
"a",
"distinct",
"Ca2",
"+",
"-binding",
"domain",
".",
"\n"
] |
[
"Protein"
] |
children is a Participant_Age, autism spectrum disorders is a Participant_Condition, metals in blood ( zinc ( Zn ) is a Outcome_Physical, copper ( Cu ) is a Outcome_Physical, aluminium ( Al ) is a Outcome_Physical, lead ( Pb ) is a Outcome_Physical, mercury ( Hg ) is a Outcome_Physical, autism spectrum disorder ( ASD ) is a Participant_Condition, neurological is a Participant_Condition, N = 52 is a Participant_Sample-size, average age = 6.2 years is a Participant_Age, N = 22 is a Participant_Sample-size, age = 6.6 years is a Participant_Age, p = 0.595 is a Outcome_Other, Measurement is a Outcome_Other, group membership is a Outcome_Other, blood Cu / Zn ratio is a Outcome_Physical, terms of blood levels of metals is a Outcome_Physical, had significantly is a Outcome_Other, df = 1 , p = 0.010 ) is a Outcome_Other, between the groups was found in terms of uroporphyrin I is a Outcome_Physical, However , the levels of coproporphyrin is a Outcome_Physical, to the controls is a Outcome_Other, higher Cu / Zn ratio is a Outcome_Physical
|
67785_task0
|
Sentence: Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders . The aim of the present study was to determine the levels of metals in blood ( zinc ( Zn ) , copper ( Cu ) , aluminium ( Al ) , lead ( Pb ) and mercury ( Hg ) ) , as well as the specific porphyrin levels in the urine of patients with autism spectrum disorder ( ASD ) compared with patients with other neurological disorders . The study was performed in a group of children with ASD ( N = 52 , average age = 6.2 years ) and a control group of children with other neurological disorders ( N = 22 , average age = 6.6 years ) , matched in terms of intellectual abilities ( Mann-Whitney U = 565.0 , p = 0.595 ) . Measurement of metals in blood was performed by atomic absorption spectrometry , while the HPLC method via a fluorescence detector was used to test urinary porphyrin levels . Results were compared across groups using a multivariate analysis of covariance ( MANCOVA ) . In addition , a generalized linear model was used to establish the impact of group membership on the blood Cu/Zn ratio . In terms of blood levels of metals , no significant difference between the groups was found . However , compared to the control group , ASD group had significantly elevated blood Cu/Zn ratio ( Wald χ ( 2 ) = 6.6 , df = 1 , p = 0.010 ) . Additionally , no significant difference between the groups was found in terms of uroporphyrin I , heptacarboxyporphyrin I , hexacarboxyporphyrin and pentacarboxyporphyrin I . However , the levels of coproporphyrin I and coproporphyrin III were lower in the ASD group compared to the controls . Due to observed higher Cu/Zn ratio , it is suggested to test blood levels of Zn and Cu in all autistic children and give them a Zn supplement if needed .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Age",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"B-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"O",
"B-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"B-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders . The aim of the present study was to determine the levels of metals in blood ( zinc ( Zn ) , copper ( Cu ) , aluminium ( Al ) , lead ( Pb ) and mercury ( Hg ) ) , as well as the specific porphyrin levels in the urine of patients with autism spectrum disorder ( ASD ) compared with patients with other neurological disorders . The study was performed in a group of children with ASD ( N = 52 , average age = 6.2 years ) and a control group of children with other neurological disorders ( N = 22 , average age = 6.6 years ) , matched in terms of intellectual abilities ( Mann-Whitney U = 565.0 , p = 0.595 ) . Measurement of metals in blood was performed by atomic absorption spectrometry , while the HPLC method via a fluorescence detector was used to test urinary porphyrin levels . Results were compared across groups using a multivariate analysis of covariance ( MANCOVA ) . In addition , a generalized linear model was used to establish the impact of group membership on the blood Cu/Zn ratio . In terms of blood levels of metals , no significant difference between the groups was found . However , compared to the control group , ASD group had significantly elevated blood Cu/Zn ratio ( Wald χ ( 2 ) = 6.6 , df = 1 , p = 0.010 ) . Additionally , no significant difference between the groups was found in terms of uroporphyrin I , heptacarboxyporphyrin I , hexacarboxyporphyrin and pentacarboxyporphyrin I . However , the levels of coproporphyrin I and coproporphyrin III were lower in the ASD group compared to the controls . Due to observed higher Cu/Zn ratio , it is suggested to test blood levels of Zn and Cu in all autistic children and give them a Zn supplement if needed .
|
[
"Levels",
"of",
"metals",
"in",
"the",
"blood",
"and",
"specific",
"porphyrins",
"in",
"the",
"urine",
"in",
"children",
"with",
"autism",
"spectrum",
"disorders",
".",
"The",
"aim",
"of",
"the",
"present",
"study",
"was",
"to",
"determine",
"the",
"levels",
"of",
"metals",
"in",
"blood",
"(",
"zinc",
"(",
"Zn",
")",
",",
"copper",
"(",
"Cu",
")",
",",
"aluminium",
"(",
"Al",
")",
",",
"lead",
"(",
"Pb",
")",
"and",
"mercury",
"(",
"Hg",
")",
")",
",",
"as",
"well",
"as",
"the",
"specific",
"porphyrin",
"levels",
"in",
"the",
"urine",
"of",
"patients",
"with",
"autism",
"spectrum",
"disorder",
"(",
"ASD",
")",
"compared",
"with",
"patients",
"with",
"other",
"neurological",
"disorders",
".",
"The",
"study",
"was",
"performed",
"in",
"a",
"group",
"of",
"children",
"with",
"ASD",
"(",
"N",
"=",
"52",
",",
"average",
"age",
"=",
"6.2",
"years",
")",
"and",
"a",
"control",
"group",
"of",
"children",
"with",
"other",
"neurological",
"disorders",
"(",
"N",
"=",
"22",
",",
"average",
"age",
"=",
"6.6",
"years",
")",
",",
"matched",
"in",
"terms",
"of",
"intellectual",
"abilities",
"(",
"Mann",
"-",
"Whitney",
"U",
"=",
"565.0",
",",
"p",
"=",
"0.595",
")",
".",
"Measurement",
"of",
"metals",
"in",
"blood",
"was",
"performed",
"by",
"atomic",
"absorption",
"spectrometry",
",",
"while",
"the",
"HPLC",
"method",
"via",
"a",
"fluorescence",
"detector",
"was",
"used",
"to",
"test",
"urinary",
"porphyrin",
"levels",
".",
"Results",
"were",
"compared",
"across",
"groups",
"using",
"a",
"multivariate",
"analysis",
"of",
"covariance",
"(",
"MANCOVA",
")",
".",
"In",
"addition",
",",
"a",
"generalized",
"linear",
"model",
"was",
"used",
"to",
"establish",
"the",
"impact",
"of",
"group",
"membership",
"on",
"the",
"blood",
"Cu",
"/",
"Zn",
"ratio",
".",
"In",
"terms",
"of",
"blood",
"levels",
"of",
"metals",
",",
"no",
"significant",
"difference",
"between",
"the",
"groups",
"was",
"found",
".",
"However",
",",
"compared",
"to",
"the",
"control",
"group",
",",
"ASD",
"group",
"had",
"significantly",
"elevated",
"blood",
"Cu",
"/",
"Zn",
"ratio",
"(",
"Wald",
"χ",
"(",
"2",
")",
"=",
"6.6",
",",
"df",
"=",
"1",
",",
"p",
"=",
"0.010",
")",
".",
"Additionally",
",",
"no",
"significant",
"difference",
"between",
"the",
"groups",
"was",
"found",
"in",
"terms",
"of",
"uroporphyrin",
"I",
",",
"heptacarboxyporphyrin",
"I",
",",
"hexacarboxyporphyrin",
"and",
"pentacarboxyporphyrin",
"I",
".",
"However",
",",
"the",
"levels",
"of",
"coproporphyrin",
"I",
"and",
"coproporphyrin",
"III",
"were",
"lower",
"in",
"the",
"ASD",
"group",
"compared",
"to",
"the",
"controls",
".",
"Due",
"to",
"observed",
"higher",
"Cu",
"/",
"Zn",
"ratio",
",",
"it",
"is",
"suggested",
"to",
"test",
"blood",
"levels",
"of",
"Zn",
"and",
"Cu",
"in",
"all",
"autistic",
"children",
"and",
"give",
"them",
"a",
"Zn",
"supplement",
"if",
"needed",
"."
] |
[
"Outcome_Physical",
"Participant_Condition",
"Participant_Age",
"Outcome_Other",
"Participant_Sample-size"
] |
children is a Participant_Age, autism spectrum disorders is a Participant_Condition, metals in blood ( zinc ( Zn ) is a Outcome_Physical, copper ( Cu ) is a Outcome_Physical, aluminium ( Al ) is a Outcome_Physical, lead ( Pb ) is a Outcome_Physical, mercury ( Hg ) is a Outcome_Physical, autism spectrum disorder ( ASD ) is a Participant_Condition, neurological is a Participant_Condition, N = 52 is a Participant_Sample-size, average age = 6.2 years is a Participant_Age, N = 22 is a Participant_Sample-size, age = 6.6 years is a Participant_Age, p = 0.595 is a Outcome_Other, Measurement is a Outcome_Other, group membership is a Outcome_Other, blood Cu / Zn ratio is a Outcome_Physical, terms of blood levels of metals is a Outcome_Physical, had significantly is a Outcome_Other, df = 1 , p = 0.010 ) is a Outcome_Other, between the groups was found in terms of uroporphyrin I is a Outcome_Physical, However , the levels of coproporphyrin is a Outcome_Physical, to the controls is a Outcome_Other, higher Cu / Zn ratio is a Outcome_Physical
|
67785_task1
|
Sentence: Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders . The aim of the present study was to determine the levels of metals in blood ( zinc ( Zn ) , copper ( Cu ) , aluminium ( Al ) , lead ( Pb ) and mercury ( Hg ) ) , as well as the specific porphyrin levels in the urine of patients with autism spectrum disorder ( ASD ) compared with patients with other neurological disorders . The study was performed in a group of children with ASD ( N = 52 , average age = 6.2 years ) and a control group of children with other neurological disorders ( N = 22 , average age = 6.6 years ) , matched in terms of intellectual abilities ( Mann-Whitney U = 565.0 , p = 0.595 ) . Measurement of metals in blood was performed by atomic absorption spectrometry , while the HPLC method via a fluorescence detector was used to test urinary porphyrin levels . Results were compared across groups using a multivariate analysis of covariance ( MANCOVA ) . In addition , a generalized linear model was used to establish the impact of group membership on the blood Cu/Zn ratio . In terms of blood levels of metals , no significant difference between the groups was found . However , compared to the control group , ASD group had significantly elevated blood Cu/Zn ratio ( Wald χ ( 2 ) = 6.6 , df = 1 , p = 0.010 ) . Additionally , no significant difference between the groups was found in terms of uroporphyrin I , heptacarboxyporphyrin I , hexacarboxyporphyrin and pentacarboxyporphyrin I . However , the levels of coproporphyrin I and coproporphyrin III were lower in the ASD group compared to the controls . Due to observed higher Cu/Zn ratio , it is suggested to test blood levels of Zn and Cu in all autistic children and give them a Zn supplement if needed .
Instructions: please typing these entity words according to sentence: children, autism spectrum disorders, metals in blood ( zinc ( Zn ), copper ( Cu ), aluminium ( Al ), lead ( Pb ), mercury ( Hg ), autism spectrum disorder ( ASD ), neurological, N = 52, average age = 6.2 years, N = 22, age = 6.6 years, p = 0.595, Measurement, group membership, blood Cu / Zn ratio, terms of blood levels of metals, had significantly, df = 1 , p = 0.010 ), between the groups was found in terms of uroporphyrin I, However , the levels of coproporphyrin, to the controls, higher Cu / Zn ratio
Options: Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Age",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"B-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"O",
"B-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"B-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders . The aim of the present study was to determine the levels of metals in blood ( zinc ( Zn ) , copper ( Cu ) , aluminium ( Al ) , lead ( Pb ) and mercury ( Hg ) ) , as well as the specific porphyrin levels in the urine of patients with autism spectrum disorder ( ASD ) compared with patients with other neurological disorders . The study was performed in a group of children with ASD ( N = 52 , average age = 6.2 years ) and a control group of children with other neurological disorders ( N = 22 , average age = 6.6 years ) , matched in terms of intellectual abilities ( Mann-Whitney U = 565.0 , p = 0.595 ) . Measurement of metals in blood was performed by atomic absorption spectrometry , while the HPLC method via a fluorescence detector was used to test urinary porphyrin levels . Results were compared across groups using a multivariate analysis of covariance ( MANCOVA ) . In addition , a generalized linear model was used to establish the impact of group membership on the blood Cu/Zn ratio . In terms of blood levels of metals , no significant difference between the groups was found . However , compared to the control group , ASD group had significantly elevated blood Cu/Zn ratio ( Wald χ ( 2 ) = 6.6 , df = 1 , p = 0.010 ) . Additionally , no significant difference between the groups was found in terms of uroporphyrin I , heptacarboxyporphyrin I , hexacarboxyporphyrin and pentacarboxyporphyrin I . However , the levels of coproporphyrin I and coproporphyrin III were lower in the ASD group compared to the controls . Due to observed higher Cu/Zn ratio , it is suggested to test blood levels of Zn and Cu in all autistic children and give them a Zn supplement if needed .
|
[
"Levels",
"of",
"metals",
"in",
"the",
"blood",
"and",
"specific",
"porphyrins",
"in",
"the",
"urine",
"in",
"children",
"with",
"autism",
"spectrum",
"disorders",
".",
"The",
"aim",
"of",
"the",
"present",
"study",
"was",
"to",
"determine",
"the",
"levels",
"of",
"metals",
"in",
"blood",
"(",
"zinc",
"(",
"Zn",
")",
",",
"copper",
"(",
"Cu",
")",
",",
"aluminium",
"(",
"Al",
")",
",",
"lead",
"(",
"Pb",
")",
"and",
"mercury",
"(",
"Hg",
")",
")",
",",
"as",
"well",
"as",
"the",
"specific",
"porphyrin",
"levels",
"in",
"the",
"urine",
"of",
"patients",
"with",
"autism",
"spectrum",
"disorder",
"(",
"ASD",
")",
"compared",
"with",
"patients",
"with",
"other",
"neurological",
"disorders",
".",
"The",
"study",
"was",
"performed",
"in",
"a",
"group",
"of",
"children",
"with",
"ASD",
"(",
"N",
"=",
"52",
",",
"average",
"age",
"=",
"6.2",
"years",
")",
"and",
"a",
"control",
"group",
"of",
"children",
"with",
"other",
"neurological",
"disorders",
"(",
"N",
"=",
"22",
",",
"average",
"age",
"=",
"6.6",
"years",
")",
",",
"matched",
"in",
"terms",
"of",
"intellectual",
"abilities",
"(",
"Mann",
"-",
"Whitney",
"U",
"=",
"565.0",
",",
"p",
"=",
"0.595",
")",
".",
"Measurement",
"of",
"metals",
"in",
"blood",
"was",
"performed",
"by",
"atomic",
"absorption",
"spectrometry",
",",
"while",
"the",
"HPLC",
"method",
"via",
"a",
"fluorescence",
"detector",
"was",
"used",
"to",
"test",
"urinary",
"porphyrin",
"levels",
".",
"Results",
"were",
"compared",
"across",
"groups",
"using",
"a",
"multivariate",
"analysis",
"of",
"covariance",
"(",
"MANCOVA",
")",
".",
"In",
"addition",
",",
"a",
"generalized",
"linear",
"model",
"was",
"used",
"to",
"establish",
"the",
"impact",
"of",
"group",
"membership",
"on",
"the",
"blood",
"Cu",
"/",
"Zn",
"ratio",
".",
"In",
"terms",
"of",
"blood",
"levels",
"of",
"metals",
",",
"no",
"significant",
"difference",
"between",
"the",
"groups",
"was",
"found",
".",
"However",
",",
"compared",
"to",
"the",
"control",
"group",
",",
"ASD",
"group",
"had",
"significantly",
"elevated",
"blood",
"Cu",
"/",
"Zn",
"ratio",
"(",
"Wald",
"χ",
"(",
"2",
")",
"=",
"6.6",
",",
"df",
"=",
"1",
",",
"p",
"=",
"0.010",
")",
".",
"Additionally",
",",
"no",
"significant",
"difference",
"between",
"the",
"groups",
"was",
"found",
"in",
"terms",
"of",
"uroporphyrin",
"I",
",",
"heptacarboxyporphyrin",
"I",
",",
"hexacarboxyporphyrin",
"and",
"pentacarboxyporphyrin",
"I",
".",
"However",
",",
"the",
"levels",
"of",
"coproporphyrin",
"I",
"and",
"coproporphyrin",
"III",
"were",
"lower",
"in",
"the",
"ASD",
"group",
"compared",
"to",
"the",
"controls",
".",
"Due",
"to",
"observed",
"higher",
"Cu",
"/",
"Zn",
"ratio",
",",
"it",
"is",
"suggested",
"to",
"test",
"blood",
"levels",
"of",
"Zn",
"and",
"Cu",
"in",
"all",
"autistic",
"children",
"and",
"give",
"them",
"a",
"Zn",
"supplement",
"if",
"needed",
"."
] |
[
"Outcome_Physical",
"Participant_Condition",
"Participant_Age",
"Outcome_Other",
"Participant_Sample-size"
] |
children, autism spectrum disorders, metals in blood ( zinc ( Zn ), copper ( Cu ), aluminium ( Al ), lead ( Pb ), mercury ( Hg ), autism spectrum disorder ( ASD ), neurological, N = 52, average age = 6.2 years, N = 22, age = 6.6 years, p = 0.595, Measurement, group membership, blood Cu / Zn ratio, terms of blood levels of metals, had significantly, df = 1 , p = 0.010 ), between the groups was found in terms of uroporphyrin I, However , the levels of coproporphyrin, to the controls, higher Cu / Zn ratio
|
67785_task2
|
Sentence: Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders . The aim of the present study was to determine the levels of metals in blood ( zinc ( Zn ) , copper ( Cu ) , aluminium ( Al ) , lead ( Pb ) and mercury ( Hg ) ) , as well as the specific porphyrin levels in the urine of patients with autism spectrum disorder ( ASD ) compared with patients with other neurological disorders . The study was performed in a group of children with ASD ( N = 52 , average age = 6.2 years ) and a control group of children with other neurological disorders ( N = 22 , average age = 6.6 years ) , matched in terms of intellectual abilities ( Mann-Whitney U = 565.0 , p = 0.595 ) . Measurement of metals in blood was performed by atomic absorption spectrometry , while the HPLC method via a fluorescence detector was used to test urinary porphyrin levels . Results were compared across groups using a multivariate analysis of covariance ( MANCOVA ) . In addition , a generalized linear model was used to establish the impact of group membership on the blood Cu/Zn ratio . In terms of blood levels of metals , no significant difference between the groups was found . However , compared to the control group , ASD group had significantly elevated blood Cu/Zn ratio ( Wald χ ( 2 ) = 6.6 , df = 1 , p = 0.010 ) . Additionally , no significant difference between the groups was found in terms of uroporphyrin I , heptacarboxyporphyrin I , hexacarboxyporphyrin and pentacarboxyporphyrin I . However , the levels of coproporphyrin I and coproporphyrin III were lower in the ASD group compared to the controls . Due to observed higher Cu/Zn ratio , it is suggested to test blood levels of Zn and Cu in all autistic children and give them a Zn supplement if needed .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Age",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"B-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"O",
"B-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"I-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"B-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Outcome_Other",
"I-Outcome_Other",
"I-Outcome_Other",
"O",
"O",
"O",
"O",
"B-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"I-Outcome_Physical",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Levels of metals in the blood and specific porphyrins in the urine in children with autism spectrum disorders . The aim of the present study was to determine the levels of metals in blood ( zinc ( Zn ) , copper ( Cu ) , aluminium ( Al ) , lead ( Pb ) and mercury ( Hg ) ) , as well as the specific porphyrin levels in the urine of patients with autism spectrum disorder ( ASD ) compared with patients with other neurological disorders . The study was performed in a group of children with ASD ( N = 52 , average age = 6.2 years ) and a control group of children with other neurological disorders ( N = 22 , average age = 6.6 years ) , matched in terms of intellectual abilities ( Mann-Whitney U = 565.0 , p = 0.595 ) . Measurement of metals in blood was performed by atomic absorption spectrometry , while the HPLC method via a fluorescence detector was used to test urinary porphyrin levels . Results were compared across groups using a multivariate analysis of covariance ( MANCOVA ) . In addition , a generalized linear model was used to establish the impact of group membership on the blood Cu/Zn ratio . In terms of blood levels of metals , no significant difference between the groups was found . However , compared to the control group , ASD group had significantly elevated blood Cu/Zn ratio ( Wald χ ( 2 ) = 6.6 , df = 1 , p = 0.010 ) . Additionally , no significant difference between the groups was found in terms of uroporphyrin I , heptacarboxyporphyrin I , hexacarboxyporphyrin and pentacarboxyporphyrin I . However , the levels of coproporphyrin I and coproporphyrin III were lower in the ASD group compared to the controls . Due to observed higher Cu/Zn ratio , it is suggested to test blood levels of Zn and Cu in all autistic children and give them a Zn supplement if needed .
|
[
"Levels",
"of",
"metals",
"in",
"the",
"blood",
"and",
"specific",
"porphyrins",
"in",
"the",
"urine",
"in",
"children",
"with",
"autism",
"spectrum",
"disorders",
".",
"The",
"aim",
"of",
"the",
"present",
"study",
"was",
"to",
"determine",
"the",
"levels",
"of",
"metals",
"in",
"blood",
"(",
"zinc",
"(",
"Zn",
")",
",",
"copper",
"(",
"Cu",
")",
",",
"aluminium",
"(",
"Al",
")",
",",
"lead",
"(",
"Pb",
")",
"and",
"mercury",
"(",
"Hg",
")",
")",
",",
"as",
"well",
"as",
"the",
"specific",
"porphyrin",
"levels",
"in",
"the",
"urine",
"of",
"patients",
"with",
"autism",
"spectrum",
"disorder",
"(",
"ASD",
")",
"compared",
"with",
"patients",
"with",
"other",
"neurological",
"disorders",
".",
"The",
"study",
"was",
"performed",
"in",
"a",
"group",
"of",
"children",
"with",
"ASD",
"(",
"N",
"=",
"52",
",",
"average",
"age",
"=",
"6.2",
"years",
")",
"and",
"a",
"control",
"group",
"of",
"children",
"with",
"other",
"neurological",
"disorders",
"(",
"N",
"=",
"22",
",",
"average",
"age",
"=",
"6.6",
"years",
")",
",",
"matched",
"in",
"terms",
"of",
"intellectual",
"abilities",
"(",
"Mann",
"-",
"Whitney",
"U",
"=",
"565.0",
",",
"p",
"=",
"0.595",
")",
".",
"Measurement",
"of",
"metals",
"in",
"blood",
"was",
"performed",
"by",
"atomic",
"absorption",
"spectrometry",
",",
"while",
"the",
"HPLC",
"method",
"via",
"a",
"fluorescence",
"detector",
"was",
"used",
"to",
"test",
"urinary",
"porphyrin",
"levels",
".",
"Results",
"were",
"compared",
"across",
"groups",
"using",
"a",
"multivariate",
"analysis",
"of",
"covariance",
"(",
"MANCOVA",
")",
".",
"In",
"addition",
",",
"a",
"generalized",
"linear",
"model",
"was",
"used",
"to",
"establish",
"the",
"impact",
"of",
"group",
"membership",
"on",
"the",
"blood",
"Cu",
"/",
"Zn",
"ratio",
".",
"In",
"terms",
"of",
"blood",
"levels",
"of",
"metals",
",",
"no",
"significant",
"difference",
"between",
"the",
"groups",
"was",
"found",
".",
"However",
",",
"compared",
"to",
"the",
"control",
"group",
",",
"ASD",
"group",
"had",
"significantly",
"elevated",
"blood",
"Cu",
"/",
"Zn",
"ratio",
"(",
"Wald",
"χ",
"(",
"2",
")",
"=",
"6.6",
",",
"df",
"=",
"1",
",",
"p",
"=",
"0.010",
")",
".",
"Additionally",
",",
"no",
"significant",
"difference",
"between",
"the",
"groups",
"was",
"found",
"in",
"terms",
"of",
"uroporphyrin",
"I",
",",
"heptacarboxyporphyrin",
"I",
",",
"hexacarboxyporphyrin",
"and",
"pentacarboxyporphyrin",
"I",
".",
"However",
",",
"the",
"levels",
"of",
"coproporphyrin",
"I",
"and",
"coproporphyrin",
"III",
"were",
"lower",
"in",
"the",
"ASD",
"group",
"compared",
"to",
"the",
"controls",
".",
"Due",
"to",
"observed",
"higher",
"Cu",
"/",
"Zn",
"ratio",
",",
"it",
"is",
"suggested",
"to",
"test",
"blood",
"levels",
"of",
"Zn",
"and",
"Cu",
"in",
"all",
"autistic",
"children",
"and",
"give",
"them",
"a",
"Zn",
"supplement",
"if",
"needed",
"."
] |
[
"Outcome_Physical",
"Participant_Condition",
"Participant_Age",
"Outcome_Other",
"Participant_Sample-size"
] |
No Drug Abuse is a Participant_Condition, health motivation -- social skills -- decision - making is a Intervention_Educational, Twenty - one is a Participant_Sample-size, standard care ( control ) , classroom only is a Intervention_Educational, classroom plus semester - long school - as - community component is a Intervention_Educational, 1578 is a Participant_Sample-size, youth is a Participant_Age
|
25149_task0
|
Sentence: Project Towards No Drug Abuse : long-term substance use outcomes evaluation . OBJECTIVES This paper presents up to 5 years post-program outcomes of Project Towards No Drug Abuse ( Project TND ) , a drug abuse prevention program conducted in South California alternative high school system during years 1994-1999 . METHODS The effects of a 9-session health motivation -- social skills -- decision-making curriculum were evaluated . Twenty-one schools recruited were randomly assigned to standard care ( control ) , classroom only , or a classroom plus semester-long school-as-community component . Last 30-day use of cigarettes , alcohol , marijuana , and hard drugs were assessed at three time intervals : short-term ( year 1 ) , middle-term ( years 2 or 3 ) , and long-term ( years 4 or 5 ) . Multilevel random coefficients modeling were employed to estimate the adjusted levels of substance use . RESULTS Among 1578 baseline subjects , follow-up data were available for 68 % ( year 1 ) , 66 % ( years 2 or 3 ) , and 46 % ( years 4 or 5 ) of subjects , respectively . Results revealed significant positive long-term program effects for hard drug use at year 4 or 5 for the two program interventions ( P = 0.02 ) . CONCLUSIONS Project TND reduced hard drug use in the 46 % who were successfully followed . It is the first program to demonstrate long-term self-reported behavioral effects on hard drug use among high-risk youth by using a school-based , limited-session model .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Intervention_Educational, Participant_Age, Participant_Condition, Participant_Sample-size
|
[
"O",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Project Towards No Drug Abuse : long-term substance use outcomes evaluation . OBJECTIVES This paper presents up to 5 years post-program outcomes of Project Towards No Drug Abuse ( Project TND ) , a drug abuse prevention program conducted in South California alternative high school system during years 1994-1999 . METHODS The effects of a 9-session health motivation -- social skills -- decision-making curriculum were evaluated . Twenty-one schools recruited were randomly assigned to standard care ( control ) , classroom only , or a classroom plus semester-long school-as-community component . Last 30-day use of cigarettes , alcohol , marijuana , and hard drugs were assessed at three time intervals : short-term ( year 1 ) , middle-term ( years 2 or 3 ) , and long-term ( years 4 or 5 ) . Multilevel random coefficients modeling were employed to estimate the adjusted levels of substance use . RESULTS Among 1578 baseline subjects , follow-up data were available for 68 % ( year 1 ) , 66 % ( years 2 or 3 ) , and 46 % ( years 4 or 5 ) of subjects , respectively . Results revealed significant positive long-term program effects for hard drug use at year 4 or 5 for the two program interventions ( P = 0.02 ) . CONCLUSIONS Project TND reduced hard drug use in the 46 % who were successfully followed . It is the first program to demonstrate long-term self-reported behavioral effects on hard drug use among high-risk youth by using a school-based , limited-session model .
|
[
"Project",
"Towards",
"No",
"Drug",
"Abuse",
":",
"long",
"-",
"term",
"substance",
"use",
"outcomes",
"evaluation",
".",
"OBJECTIVES",
"This",
"paper",
"presents",
"up",
"to",
"5",
"years",
"post",
"-",
"program",
"outcomes",
"of",
"Project",
"Towards",
"No",
"Drug",
"Abuse",
"(",
"Project",
"TND",
")",
",",
"a",
"drug",
"abuse",
"prevention",
"program",
"conducted",
"in",
"South",
"California",
"alternative",
"high",
"school",
"system",
"during",
"years",
"1994",
"-",
"1999",
".",
"METHODS",
"The",
"effects",
"of",
"a",
"9-session",
"health",
"motivation",
"--",
"social",
"skills",
"--",
"decision",
"-",
"making",
"curriculum",
"were",
"evaluated",
".",
"Twenty",
"-",
"one",
"schools",
"recruited",
"were",
"randomly",
"assigned",
"to",
"standard",
"care",
"(",
"control",
")",
",",
"classroom",
"only",
",",
"or",
"a",
"classroom",
"plus",
"semester",
"-",
"long",
"school",
"-",
"as",
"-",
"community",
"component",
".",
"Last",
"30-day",
"use",
"of",
"cigarettes",
",",
"alcohol",
",",
"marijuana",
",",
"and",
"hard",
"drugs",
"were",
"assessed",
"at",
"three",
"time",
"intervals",
":",
"short",
"-",
"term",
"(",
"year",
"1",
")",
",",
"middle",
"-",
"term",
"(",
"years",
"2",
"or",
"3",
")",
",",
"and",
"long",
"-",
"term",
"(",
"years",
"4",
"or",
"5",
")",
".",
"Multilevel",
"random",
"coefficients",
"modeling",
"were",
"employed",
"to",
"estimate",
"the",
"adjusted",
"levels",
"of",
"substance",
"use",
".",
"RESULTS",
"Among",
"1578",
"baseline",
"subjects",
",",
"follow",
"-",
"up",
"data",
"were",
"available",
"for",
"68",
"%",
"(",
"year",
"1",
")",
",",
"66",
"%",
"(",
"years",
"2",
"or",
"3",
")",
",",
"and",
"46",
"%",
"(",
"years",
"4",
"or",
"5",
")",
"of",
"subjects",
",",
"respectively",
".",
"Results",
"revealed",
"significant",
"positive",
"long",
"-",
"term",
"program",
"effects",
"for",
"hard",
"drug",
"use",
"at",
"year",
"4",
"or",
"5",
"for",
"the",
"two",
"program",
"interventions",
"(",
"P",
"=",
"0.02",
")",
".",
"CONCLUSIONS",
"Project",
"TND",
"reduced",
"hard",
"drug",
"use",
"in",
"the",
"46",
"%",
"who",
"were",
"successfully",
"followed",
".",
"It",
"is",
"the",
"first",
"program",
"to",
"demonstrate",
"long",
"-",
"term",
"self",
"-",
"reported",
"behavioral",
"effects",
"on",
"hard",
"drug",
"use",
"among",
"high",
"-",
"risk",
"youth",
"by",
"using",
"a",
"school",
"-",
"based",
",",
"limited",
"-",
"session",
"model",
"."
] |
[
"Intervention_Educational",
"Participant_Condition",
"Participant_Sample-size",
"Participant_Age"
] |
No Drug Abuse is a Participant_Condition, health motivation -- social skills -- decision - making is a Intervention_Educational, Twenty - one is a Participant_Sample-size, standard care ( control ) , classroom only is a Intervention_Educational, classroom plus semester - long school - as - community component is a Intervention_Educational, 1578 is a Participant_Sample-size, youth is a Participant_Age
|
25149_task1
|
Sentence: Project Towards No Drug Abuse : long-term substance use outcomes evaluation . OBJECTIVES This paper presents up to 5 years post-program outcomes of Project Towards No Drug Abuse ( Project TND ) , a drug abuse prevention program conducted in South California alternative high school system during years 1994-1999 . METHODS The effects of a 9-session health motivation -- social skills -- decision-making curriculum were evaluated . Twenty-one schools recruited were randomly assigned to standard care ( control ) , classroom only , or a classroom plus semester-long school-as-community component . Last 30-day use of cigarettes , alcohol , marijuana , and hard drugs were assessed at three time intervals : short-term ( year 1 ) , middle-term ( years 2 or 3 ) , and long-term ( years 4 or 5 ) . Multilevel random coefficients modeling were employed to estimate the adjusted levels of substance use . RESULTS Among 1578 baseline subjects , follow-up data were available for 68 % ( year 1 ) , 66 % ( years 2 or 3 ) , and 46 % ( years 4 or 5 ) of subjects , respectively . Results revealed significant positive long-term program effects for hard drug use at year 4 or 5 for the two program interventions ( P = 0.02 ) . CONCLUSIONS Project TND reduced hard drug use in the 46 % who were successfully followed . It is the first program to demonstrate long-term self-reported behavioral effects on hard drug use among high-risk youth by using a school-based , limited-session model .
Instructions: please typing these entity words according to sentence: No Drug Abuse, health motivation -- social skills -- decision - making, Twenty - one, standard care ( control ) , classroom only, classroom plus semester - long school - as - community component, 1578, youth
Options: Intervention_Educational, Participant_Age, Participant_Condition, Participant_Sample-size
|
[
"O",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Project Towards No Drug Abuse : long-term substance use outcomes evaluation . OBJECTIVES This paper presents up to 5 years post-program outcomes of Project Towards No Drug Abuse ( Project TND ) , a drug abuse prevention program conducted in South California alternative high school system during years 1994-1999 . METHODS The effects of a 9-session health motivation -- social skills -- decision-making curriculum were evaluated . Twenty-one schools recruited were randomly assigned to standard care ( control ) , classroom only , or a classroom plus semester-long school-as-community component . Last 30-day use of cigarettes , alcohol , marijuana , and hard drugs were assessed at three time intervals : short-term ( year 1 ) , middle-term ( years 2 or 3 ) , and long-term ( years 4 or 5 ) . Multilevel random coefficients modeling were employed to estimate the adjusted levels of substance use . RESULTS Among 1578 baseline subjects , follow-up data were available for 68 % ( year 1 ) , 66 % ( years 2 or 3 ) , and 46 % ( years 4 or 5 ) of subjects , respectively . Results revealed significant positive long-term program effects for hard drug use at year 4 or 5 for the two program interventions ( P = 0.02 ) . CONCLUSIONS Project TND reduced hard drug use in the 46 % who were successfully followed . It is the first program to demonstrate long-term self-reported behavioral effects on hard drug use among high-risk youth by using a school-based , limited-session model .
|
[
"Project",
"Towards",
"No",
"Drug",
"Abuse",
":",
"long",
"-",
"term",
"substance",
"use",
"outcomes",
"evaluation",
".",
"OBJECTIVES",
"This",
"paper",
"presents",
"up",
"to",
"5",
"years",
"post",
"-",
"program",
"outcomes",
"of",
"Project",
"Towards",
"No",
"Drug",
"Abuse",
"(",
"Project",
"TND",
")",
",",
"a",
"drug",
"abuse",
"prevention",
"program",
"conducted",
"in",
"South",
"California",
"alternative",
"high",
"school",
"system",
"during",
"years",
"1994",
"-",
"1999",
".",
"METHODS",
"The",
"effects",
"of",
"a",
"9-session",
"health",
"motivation",
"--",
"social",
"skills",
"--",
"decision",
"-",
"making",
"curriculum",
"were",
"evaluated",
".",
"Twenty",
"-",
"one",
"schools",
"recruited",
"were",
"randomly",
"assigned",
"to",
"standard",
"care",
"(",
"control",
")",
",",
"classroom",
"only",
",",
"or",
"a",
"classroom",
"plus",
"semester",
"-",
"long",
"school",
"-",
"as",
"-",
"community",
"component",
".",
"Last",
"30-day",
"use",
"of",
"cigarettes",
",",
"alcohol",
",",
"marijuana",
",",
"and",
"hard",
"drugs",
"were",
"assessed",
"at",
"three",
"time",
"intervals",
":",
"short",
"-",
"term",
"(",
"year",
"1",
")",
",",
"middle",
"-",
"term",
"(",
"years",
"2",
"or",
"3",
")",
",",
"and",
"long",
"-",
"term",
"(",
"years",
"4",
"or",
"5",
")",
".",
"Multilevel",
"random",
"coefficients",
"modeling",
"were",
"employed",
"to",
"estimate",
"the",
"adjusted",
"levels",
"of",
"substance",
"use",
".",
"RESULTS",
"Among",
"1578",
"baseline",
"subjects",
",",
"follow",
"-",
"up",
"data",
"were",
"available",
"for",
"68",
"%",
"(",
"year",
"1",
")",
",",
"66",
"%",
"(",
"years",
"2",
"or",
"3",
")",
",",
"and",
"46",
"%",
"(",
"years",
"4",
"or",
"5",
")",
"of",
"subjects",
",",
"respectively",
".",
"Results",
"revealed",
"significant",
"positive",
"long",
"-",
"term",
"program",
"effects",
"for",
"hard",
"drug",
"use",
"at",
"year",
"4",
"or",
"5",
"for",
"the",
"two",
"program",
"interventions",
"(",
"P",
"=",
"0.02",
")",
".",
"CONCLUSIONS",
"Project",
"TND",
"reduced",
"hard",
"drug",
"use",
"in",
"the",
"46",
"%",
"who",
"were",
"successfully",
"followed",
".",
"It",
"is",
"the",
"first",
"program",
"to",
"demonstrate",
"long",
"-",
"term",
"self",
"-",
"reported",
"behavioral",
"effects",
"on",
"hard",
"drug",
"use",
"among",
"high",
"-",
"risk",
"youth",
"by",
"using",
"a",
"school",
"-",
"based",
",",
"limited",
"-",
"session",
"model",
"."
] |
[
"Intervention_Educational",
"Participant_Condition",
"Participant_Sample-size",
"Participant_Age"
] |
No Drug Abuse, health motivation -- social skills -- decision - making, Twenty - one, standard care ( control ) , classroom only, classroom plus semester - long school - as - community component, 1578, youth
|
25149_task2
|
Sentence: Project Towards No Drug Abuse : long-term substance use outcomes evaluation . OBJECTIVES This paper presents up to 5 years post-program outcomes of Project Towards No Drug Abuse ( Project TND ) , a drug abuse prevention program conducted in South California alternative high school system during years 1994-1999 . METHODS The effects of a 9-session health motivation -- social skills -- decision-making curriculum were evaluated . Twenty-one schools recruited were randomly assigned to standard care ( control ) , classroom only , or a classroom plus semester-long school-as-community component . Last 30-day use of cigarettes , alcohol , marijuana , and hard drugs were assessed at three time intervals : short-term ( year 1 ) , middle-term ( years 2 or 3 ) , and long-term ( years 4 or 5 ) . Multilevel random coefficients modeling were employed to estimate the adjusted levels of substance use . RESULTS Among 1578 baseline subjects , follow-up data were available for 68 % ( year 1 ) , 66 % ( years 2 or 3 ) , and 46 % ( years 4 or 5 ) of subjects , respectively . Results revealed significant positive long-term program effects for hard drug use at year 4 or 5 for the two program interventions ( P = 0.02 ) . CONCLUSIONS Project TND reduced hard drug use in the 46 % who were successfully followed . It is the first program to demonstrate long-term self-reported behavioral effects on hard drug use among high-risk youth by using a school-based , limited-session model .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"B-Participant_Condition",
"I-Participant_Condition",
"I-Participant_Condition",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"I-Participant_Sample-size",
"I-Participant_Sample-size",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"B-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"I-Intervention_Educational",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Sample-size",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Participant_Age",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Project Towards No Drug Abuse : long-term substance use outcomes evaluation . OBJECTIVES This paper presents up to 5 years post-program outcomes of Project Towards No Drug Abuse ( Project TND ) , a drug abuse prevention program conducted in South California alternative high school system during years 1994-1999 . METHODS The effects of a 9-session health motivation -- social skills -- decision-making curriculum were evaluated . Twenty-one schools recruited were randomly assigned to standard care ( control ) , classroom only , or a classroom plus semester-long school-as-community component . Last 30-day use of cigarettes , alcohol , marijuana , and hard drugs were assessed at three time intervals : short-term ( year 1 ) , middle-term ( years 2 or 3 ) , and long-term ( years 4 or 5 ) . Multilevel random coefficients modeling were employed to estimate the adjusted levels of substance use . RESULTS Among 1578 baseline subjects , follow-up data were available for 68 % ( year 1 ) , 66 % ( years 2 or 3 ) , and 46 % ( years 4 or 5 ) of subjects , respectively . Results revealed significant positive long-term program effects for hard drug use at year 4 or 5 for the two program interventions ( P = 0.02 ) . CONCLUSIONS Project TND reduced hard drug use in the 46 % who were successfully followed . It is the first program to demonstrate long-term self-reported behavioral effects on hard drug use among high-risk youth by using a school-based , limited-session model .
|
[
"Project",
"Towards",
"No",
"Drug",
"Abuse",
":",
"long",
"-",
"term",
"substance",
"use",
"outcomes",
"evaluation",
".",
"OBJECTIVES",
"This",
"paper",
"presents",
"up",
"to",
"5",
"years",
"post",
"-",
"program",
"outcomes",
"of",
"Project",
"Towards",
"No",
"Drug",
"Abuse",
"(",
"Project",
"TND",
")",
",",
"a",
"drug",
"abuse",
"prevention",
"program",
"conducted",
"in",
"South",
"California",
"alternative",
"high",
"school",
"system",
"during",
"years",
"1994",
"-",
"1999",
".",
"METHODS",
"The",
"effects",
"of",
"a",
"9-session",
"health",
"motivation",
"--",
"social",
"skills",
"--",
"decision",
"-",
"making",
"curriculum",
"were",
"evaluated",
".",
"Twenty",
"-",
"one",
"schools",
"recruited",
"were",
"randomly",
"assigned",
"to",
"standard",
"care",
"(",
"control",
")",
",",
"classroom",
"only",
",",
"or",
"a",
"classroom",
"plus",
"semester",
"-",
"long",
"school",
"-",
"as",
"-",
"community",
"component",
".",
"Last",
"30-day",
"use",
"of",
"cigarettes",
",",
"alcohol",
",",
"marijuana",
",",
"and",
"hard",
"drugs",
"were",
"assessed",
"at",
"three",
"time",
"intervals",
":",
"short",
"-",
"term",
"(",
"year",
"1",
")",
",",
"middle",
"-",
"term",
"(",
"years",
"2",
"or",
"3",
")",
",",
"and",
"long",
"-",
"term",
"(",
"years",
"4",
"or",
"5",
")",
".",
"Multilevel",
"random",
"coefficients",
"modeling",
"were",
"employed",
"to",
"estimate",
"the",
"adjusted",
"levels",
"of",
"substance",
"use",
".",
"RESULTS",
"Among",
"1578",
"baseline",
"subjects",
",",
"follow",
"-",
"up",
"data",
"were",
"available",
"for",
"68",
"%",
"(",
"year",
"1",
")",
",",
"66",
"%",
"(",
"years",
"2",
"or",
"3",
")",
",",
"and",
"46",
"%",
"(",
"years",
"4",
"or",
"5",
")",
"of",
"subjects",
",",
"respectively",
".",
"Results",
"revealed",
"significant",
"positive",
"long",
"-",
"term",
"program",
"effects",
"for",
"hard",
"drug",
"use",
"at",
"year",
"4",
"or",
"5",
"for",
"the",
"two",
"program",
"interventions",
"(",
"P",
"=",
"0.02",
")",
".",
"CONCLUSIONS",
"Project",
"TND",
"reduced",
"hard",
"drug",
"use",
"in",
"the",
"46",
"%",
"who",
"were",
"successfully",
"followed",
".",
"It",
"is",
"the",
"first",
"program",
"to",
"demonstrate",
"long",
"-",
"term",
"self",
"-",
"reported",
"behavioral",
"effects",
"on",
"hard",
"drug",
"use",
"among",
"high",
"-",
"risk",
"youth",
"by",
"using",
"a",
"school",
"-",
"based",
",",
"limited",
"-",
"session",
"model",
"."
] |
[
"Intervention_Educational",
"Participant_Condition",
"Participant_Sample-size",
"Participant_Age"
] |
HNPCC is a disease, autosomal dominant is a Concepts_Ideas, 1–5 % is a size, colorectal cancer is a disease, HNPCC is a disease, patients is a cohort-patient, earlier symptoms is a Disorder, more mucinous carcinoma is a Disorder, more synchronous and metachronous colorectal tumors is a Concepts_Ideas, extra - colonic is a body-part, tumors is a disease, better survival is a Concepts_Ideas, HNPCC is a disease, germline mutation is a mutation, defective MMR gene is a Concepts_Ideas, defective MMR gene is a Concepts_Ideas, MSI is a Disorder, tumors is a disease, colorectum is a body-part, HPNCC is a disease, families is a cohort-patient, individuals is a cohort-patient, sporadic is a Concepts_Ideas, colorectal cancer is a disease, HNPCC is a disease, patients is a cohort-patient, HNPCC is a disease, HNPCC is a disease, families is a cohort-patient, MMR is a gene, mutation is a mutation, MSI is a Disorder, CRCs is a disease, HNPCC is a disease, MSI is a Disorder, tumor is a disease, loss of expression of a MMR gene is a Physiology, Chinese is an ethnicity, population is a cohort-patient, colorectal is a body-part, MSI carrier is a Disorder, mismatch repair is a gene, MMR is a gene, germline mutation is a mutation, carriers is a cohort-patient, Chinese is an ethnicity, population is a cohort-patient, colorectal cancer is a disease
|
102_task0
|
Sentence: ** IGNORE LINE **
** IGNORE LINE **
** IGNORE LINE **
Background
HNPCC is an autosomal dominant syndrome, which accounts for about 1–5% of colorectal cancer [1]. HNPCC patients are characterized by earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors and more extra-colonic tumors, but have better survival [1,2]. It is believed that HNPCC is secondary to a germline mutation resulting in a defective MMR gene. A defective MMR gene results in increased DNA replication errors and MSI, which causes the occurrence of tumors in different organs, especially in the colorectum. Identification of HPNCC families is important because the diagnosis, treatment and follow up of these individuals should be different from those with sporadic colorectal cancer [2]. However, the clinical diagnosis of HNPCC patients is very difficult for lack of specific clinical phenotype. Though Amsterdam criteria I and II were established for HNPCC diagnosis[3,4], many HNPCC families still do not meet the criteria.
MSI is an important phenotype of MMR gene mutation. In 1997, the National Cancer Institute (NCI) recommended screening MSI CRCs using the Bethesda guidelines [5]. After compiling evidence from years of global studies and follow up, NCI revised the Bethesda guidelines in 2004, which is called the revised Bethesda standard [6]. NCI recommended screening of HNPCC based on detection of MSI in the tumor and loss of expression of a MMR gene using immunohistochemistry (IHC) staining [6]. However, until now, there has been no research about the applicability of the NCI recommendations to the Chinese population with colorectal cancers. The aim of this study is to detect and study MSI carrier and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: ethnicity, Concepts_Ideas, disease, mutation, cohort-patient, Physiology, body-part, Disorder, size, gene
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"B-size",
"I-size",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"B-Disorder",
"I-Disorder",
"O",
"B-Disorder",
"I-Disorder",
"I-Disorder",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"B-body-part",
"I-body-part",
"I-body-part",
"B-disease",
"O",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-mutation",
"I-mutation",
"O",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-body-part",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Concepts_Ideas",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-gene",
"O",
"B-mutation",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-Disorder",
"O",
"O",
"B-disease",
"O",
"B-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-ethnicity",
"B-cohort-patient",
"O",
"B-body-part",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"I-Disorder",
"O",
"B-gene",
"I-gene",
"O",
"B-gene",
"O",
"O",
"B-mutation",
"I-mutation",
"B-cohort-patient",
"O",
"O",
"B-ethnicity",
"B-cohort-patient",
"O",
"B-disease",
"I-disease",
"O",
"O"
] |
** IGNORE LINE **
** IGNORE LINE **
** IGNORE LINE **
Background
HNPCC is an autosomal dominant syndrome, which accounts for about 1–5% of colorectal cancer [1]. HNPCC patients are characterized by earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors and more extra-colonic tumors, but have better survival [1,2]. It is believed that HNPCC is secondary to a germline mutation resulting in a defective MMR gene. A defective MMR gene results in increased DNA replication errors and MSI, which causes the occurrence of tumors in different organs, especially in the colorectum. Identification of HPNCC families is important because the diagnosis, treatment and follow up of these individuals should be different from those with sporadic colorectal cancer [2]. However, the clinical diagnosis of HNPCC patients is very difficult for lack of specific clinical phenotype. Though Amsterdam criteria I and II were established for HNPCC diagnosis[3,4], many HNPCC families still do not meet the criteria.
MSI is an important phenotype of MMR gene mutation. In 1997, the National Cancer Institute (NCI) recommended screening MSI CRCs using the Bethesda guidelines [5]. After compiling evidence from years of global studies and follow up, NCI revised the Bethesda guidelines in 2004, which is called the revised Bethesda standard [6]. NCI recommended screening of HNPCC based on detection of MSI in the tumor and loss of expression of a MMR gene using immunohistochemistry (IHC) staining [6]. However, until now, there has been no research about the applicability of the NCI recommendations to the Chinese population with colorectal cancers. The aim of this study is to detect and study MSI carrier and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
|
[
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"Background",
"\n\n",
"HNPCC",
"is",
"an",
"autosomal",
"dominant",
"syndrome",
",",
"which",
"accounts",
"for",
"about",
"1–5",
"%",
"of",
"colorectal",
"cancer",
"[",
"1",
"]",
".",
"HNPCC",
"patients",
"are",
"characterized",
"by",
"earlier",
"symptoms",
",",
"more",
"mucinous",
"carcinoma",
",",
"more",
"synchronous",
"and",
"metachronous",
"colorectal",
"tumors",
"and",
"more",
"extra",
"-",
"colonic",
"tumors",
",",
"but",
"have",
"better",
"survival",
"[",
"1,2",
"]",
".",
"It",
"is",
"believed",
"that",
"HNPCC",
"is",
"secondary",
"to",
"a",
"germline",
"mutation",
"resulting",
"in",
"a",
"defective",
"MMR",
"gene",
".",
"A",
"defective",
"MMR",
"gene",
"results",
"in",
"increased",
"DNA",
"replication",
"errors",
"and",
"MSI",
",",
"which",
"causes",
"the",
"occurrence",
"of",
"tumors",
"in",
"different",
"organs",
",",
"especially",
"in",
"the",
"colorectum",
".",
"Identification",
"of",
"HPNCC",
"families",
"is",
"important",
"because",
"the",
"diagnosis",
",",
"treatment",
"and",
"follow",
"up",
"of",
"these",
"individuals",
"should",
"be",
"different",
"from",
"those",
"with",
"sporadic",
"colorectal",
"cancer",
"[",
"2",
"]",
".",
"However",
",",
"the",
"clinical",
"diagnosis",
"of",
"HNPCC",
"patients",
"is",
"very",
"difficult",
"for",
"lack",
"of",
"specific",
"clinical",
"phenotype",
".",
"Though",
"Amsterdam",
"criteria",
"I",
"and",
"II",
"were",
"established",
"for",
"HNPCC",
"diagnosis[3,4",
"]",
",",
"many",
"HNPCC",
"families",
"still",
"do",
"not",
"meet",
"the",
"criteria",
".",
"\n\n",
"MSI",
"is",
"an",
"important",
"phenotype",
"of",
"MMR",
"gene",
"mutation",
".",
"In",
"1997",
",",
"the",
"National",
"Cancer",
"Institute",
"(",
"NCI",
")",
"recommended",
"screening",
"MSI",
"CRCs",
"using",
"the",
"Bethesda",
"guidelines",
"[",
"5",
"]",
".",
"After",
"compiling",
"evidence",
"from",
"years",
"of",
"global",
"studies",
"and",
"follow",
"up",
",",
"NCI",
"revised",
"the",
"Bethesda",
"guidelines",
"in",
"2004",
",",
"which",
"is",
"called",
"the",
"revised",
"Bethesda",
"standard",
"[",
"6",
"]",
".",
"NCI",
"recommended",
"screening",
"of",
"HNPCC",
"based",
"on",
"detection",
"of",
"MSI",
"in",
"the",
"tumor",
"and",
"loss",
"of",
"expression",
"of",
"a",
"MMR",
"gene",
"using",
"immunohistochemistry",
"(",
"IHC",
")",
"staining",
"[",
"6",
"]",
".",
"However",
",",
"until",
"now",
",",
"there",
"has",
"been",
"no",
"research",
"about",
"the",
"applicability",
"of",
"the",
"NCI",
"recommendations",
"to",
"the",
"Chinese",
"population",
"with",
"colorectal",
"cancers",
".",
"The",
"aim",
"of",
"this",
"study",
"is",
"to",
"detect",
"and",
"study",
"MSI",
"carrier",
"and",
"mismatch",
"repair",
"(",
"MMR",
")",
"gene",
"germline",
"mutation",
"carriers",
"among",
"a",
"Chinese",
"population",
"with",
"colorectal",
"cancer",
".",
"\n\n"
] |
[
"Concepts_Ideas",
"Physiology",
"Disorder",
"mutation",
"disease",
"gene",
"body-part",
"cohort-patient",
"ethnicity",
"size"
] |
HNPCC is a disease, autosomal dominant is a Concepts_Ideas, 1–5 % is a size, colorectal cancer is a disease, HNPCC is a disease, patients is a cohort-patient, earlier symptoms is a Disorder, more mucinous carcinoma is a Disorder, more synchronous and metachronous colorectal tumors is a Concepts_Ideas, extra - colonic is a body-part, tumors is a disease, better survival is a Concepts_Ideas, HNPCC is a disease, germline mutation is a mutation, defective MMR gene is a Concepts_Ideas, defective MMR gene is a Concepts_Ideas, MSI is a Disorder, tumors is a disease, colorectum is a body-part, HPNCC is a disease, families is a cohort-patient, individuals is a cohort-patient, sporadic is a Concepts_Ideas, colorectal cancer is a disease, HNPCC is a disease, patients is a cohort-patient, HNPCC is a disease, HNPCC is a disease, families is a cohort-patient, MMR is a gene, mutation is a mutation, MSI is a Disorder, CRCs is a disease, HNPCC is a disease, MSI is a Disorder, tumor is a disease, loss of expression of a MMR gene is a Physiology, Chinese is an ethnicity, population is a cohort-patient, colorectal is a body-part, MSI carrier is a Disorder, mismatch repair is a gene, MMR is a gene, germline mutation is a mutation, carriers is a cohort-patient, Chinese is an ethnicity, population is a cohort-patient, colorectal cancer is a disease
|
102_task1
|
Sentence: ** IGNORE LINE **
** IGNORE LINE **
** IGNORE LINE **
Background
HNPCC is an autosomal dominant syndrome, which accounts for about 1–5% of colorectal cancer [1]. HNPCC patients are characterized by earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors and more extra-colonic tumors, but have better survival [1,2]. It is believed that HNPCC is secondary to a germline mutation resulting in a defective MMR gene. A defective MMR gene results in increased DNA replication errors and MSI, which causes the occurrence of tumors in different organs, especially in the colorectum. Identification of HPNCC families is important because the diagnosis, treatment and follow up of these individuals should be different from those with sporadic colorectal cancer [2]. However, the clinical diagnosis of HNPCC patients is very difficult for lack of specific clinical phenotype. Though Amsterdam criteria I and II were established for HNPCC diagnosis[3,4], many HNPCC families still do not meet the criteria.
MSI is an important phenotype of MMR gene mutation. In 1997, the National Cancer Institute (NCI) recommended screening MSI CRCs using the Bethesda guidelines [5]. After compiling evidence from years of global studies and follow up, NCI revised the Bethesda guidelines in 2004, which is called the revised Bethesda standard [6]. NCI recommended screening of HNPCC based on detection of MSI in the tumor and loss of expression of a MMR gene using immunohistochemistry (IHC) staining [6]. However, until now, there has been no research about the applicability of the NCI recommendations to the Chinese population with colorectal cancers. The aim of this study is to detect and study MSI carrier and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
Instructions: please typing these entity words according to sentence: HNPCC, autosomal dominant, 1–5 %, colorectal cancer, HNPCC, patients, earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors, extra - colonic, tumors, better survival, HNPCC, germline mutation, defective MMR gene, defective MMR gene, MSI, tumors, colorectum, HPNCC, families, individuals, sporadic, colorectal cancer, HNPCC, patients, HNPCC, HNPCC, families, MMR, mutation, MSI, CRCs, HNPCC, MSI, tumor, loss of expression of a MMR gene, Chinese, population, colorectal, MSI carrier, mismatch repair, MMR, germline mutation, carriers, Chinese, population, colorectal cancer
Options: ethnicity, Concepts_Ideas, disease, mutation, cohort-patient, Physiology, body-part, Disorder, size, gene
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"B-size",
"I-size",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"B-Disorder",
"I-Disorder",
"O",
"B-Disorder",
"I-Disorder",
"I-Disorder",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"B-body-part",
"I-body-part",
"I-body-part",
"B-disease",
"O",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-mutation",
"I-mutation",
"O",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-body-part",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Concepts_Ideas",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-gene",
"O",
"B-mutation",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-Disorder",
"O",
"O",
"B-disease",
"O",
"B-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-ethnicity",
"B-cohort-patient",
"O",
"B-body-part",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"I-Disorder",
"O",
"B-gene",
"I-gene",
"O",
"B-gene",
"O",
"O",
"B-mutation",
"I-mutation",
"B-cohort-patient",
"O",
"O",
"B-ethnicity",
"B-cohort-patient",
"O",
"B-disease",
"I-disease",
"O",
"O"
] |
** IGNORE LINE **
** IGNORE LINE **
** IGNORE LINE **
Background
HNPCC is an autosomal dominant syndrome, which accounts for about 1–5% of colorectal cancer [1]. HNPCC patients are characterized by earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors and more extra-colonic tumors, but have better survival [1,2]. It is believed that HNPCC is secondary to a germline mutation resulting in a defective MMR gene. A defective MMR gene results in increased DNA replication errors and MSI, which causes the occurrence of tumors in different organs, especially in the colorectum. Identification of HPNCC families is important because the diagnosis, treatment and follow up of these individuals should be different from those with sporadic colorectal cancer [2]. However, the clinical diagnosis of HNPCC patients is very difficult for lack of specific clinical phenotype. Though Amsterdam criteria I and II were established for HNPCC diagnosis[3,4], many HNPCC families still do not meet the criteria.
MSI is an important phenotype of MMR gene mutation. In 1997, the National Cancer Institute (NCI) recommended screening MSI CRCs using the Bethesda guidelines [5]. After compiling evidence from years of global studies and follow up, NCI revised the Bethesda guidelines in 2004, which is called the revised Bethesda standard [6]. NCI recommended screening of HNPCC based on detection of MSI in the tumor and loss of expression of a MMR gene using immunohistochemistry (IHC) staining [6]. However, until now, there has been no research about the applicability of the NCI recommendations to the Chinese population with colorectal cancers. The aim of this study is to detect and study MSI carrier and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
|
[
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"Background",
"\n\n",
"HNPCC",
"is",
"an",
"autosomal",
"dominant",
"syndrome",
",",
"which",
"accounts",
"for",
"about",
"1–5",
"%",
"of",
"colorectal",
"cancer",
"[",
"1",
"]",
".",
"HNPCC",
"patients",
"are",
"characterized",
"by",
"earlier",
"symptoms",
",",
"more",
"mucinous",
"carcinoma",
",",
"more",
"synchronous",
"and",
"metachronous",
"colorectal",
"tumors",
"and",
"more",
"extra",
"-",
"colonic",
"tumors",
",",
"but",
"have",
"better",
"survival",
"[",
"1,2",
"]",
".",
"It",
"is",
"believed",
"that",
"HNPCC",
"is",
"secondary",
"to",
"a",
"germline",
"mutation",
"resulting",
"in",
"a",
"defective",
"MMR",
"gene",
".",
"A",
"defective",
"MMR",
"gene",
"results",
"in",
"increased",
"DNA",
"replication",
"errors",
"and",
"MSI",
",",
"which",
"causes",
"the",
"occurrence",
"of",
"tumors",
"in",
"different",
"organs",
",",
"especially",
"in",
"the",
"colorectum",
".",
"Identification",
"of",
"HPNCC",
"families",
"is",
"important",
"because",
"the",
"diagnosis",
",",
"treatment",
"and",
"follow",
"up",
"of",
"these",
"individuals",
"should",
"be",
"different",
"from",
"those",
"with",
"sporadic",
"colorectal",
"cancer",
"[",
"2",
"]",
".",
"However",
",",
"the",
"clinical",
"diagnosis",
"of",
"HNPCC",
"patients",
"is",
"very",
"difficult",
"for",
"lack",
"of",
"specific",
"clinical",
"phenotype",
".",
"Though",
"Amsterdam",
"criteria",
"I",
"and",
"II",
"were",
"established",
"for",
"HNPCC",
"diagnosis[3,4",
"]",
",",
"many",
"HNPCC",
"families",
"still",
"do",
"not",
"meet",
"the",
"criteria",
".",
"\n\n",
"MSI",
"is",
"an",
"important",
"phenotype",
"of",
"MMR",
"gene",
"mutation",
".",
"In",
"1997",
",",
"the",
"National",
"Cancer",
"Institute",
"(",
"NCI",
")",
"recommended",
"screening",
"MSI",
"CRCs",
"using",
"the",
"Bethesda",
"guidelines",
"[",
"5",
"]",
".",
"After",
"compiling",
"evidence",
"from",
"years",
"of",
"global",
"studies",
"and",
"follow",
"up",
",",
"NCI",
"revised",
"the",
"Bethesda",
"guidelines",
"in",
"2004",
",",
"which",
"is",
"called",
"the",
"revised",
"Bethesda",
"standard",
"[",
"6",
"]",
".",
"NCI",
"recommended",
"screening",
"of",
"HNPCC",
"based",
"on",
"detection",
"of",
"MSI",
"in",
"the",
"tumor",
"and",
"loss",
"of",
"expression",
"of",
"a",
"MMR",
"gene",
"using",
"immunohistochemistry",
"(",
"IHC",
")",
"staining",
"[",
"6",
"]",
".",
"However",
",",
"until",
"now",
",",
"there",
"has",
"been",
"no",
"research",
"about",
"the",
"applicability",
"of",
"the",
"NCI",
"recommendations",
"to",
"the",
"Chinese",
"population",
"with",
"colorectal",
"cancers",
".",
"The",
"aim",
"of",
"this",
"study",
"is",
"to",
"detect",
"and",
"study",
"MSI",
"carrier",
"and",
"mismatch",
"repair",
"(",
"MMR",
")",
"gene",
"germline",
"mutation",
"carriers",
"among",
"a",
"Chinese",
"population",
"with",
"colorectal",
"cancer",
".",
"\n\n"
] |
[
"Concepts_Ideas",
"Physiology",
"Disorder",
"mutation",
"disease",
"gene",
"body-part",
"cohort-patient",
"ethnicity",
"size"
] |
HNPCC, autosomal dominant, 1–5 %, colorectal cancer, HNPCC, patients, earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors, extra - colonic, tumors, better survival, HNPCC, germline mutation, defective MMR gene, defective MMR gene, MSI, tumors, colorectum, HPNCC, families, individuals, sporadic, colorectal cancer, HNPCC, patients, HNPCC, HNPCC, families, MMR, mutation, MSI, CRCs, HNPCC, MSI, tumor, loss of expression of a MMR gene, Chinese, population, colorectal, MSI carrier, mismatch repair, MMR, germline mutation, carriers, Chinese, population, colorectal cancer
|
102_task2
|
Sentence: ** IGNORE LINE **
** IGNORE LINE **
** IGNORE LINE **
Background
HNPCC is an autosomal dominant syndrome, which accounts for about 1–5% of colorectal cancer [1]. HNPCC patients are characterized by earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors and more extra-colonic tumors, but have better survival [1,2]. It is believed that HNPCC is secondary to a germline mutation resulting in a defective MMR gene. A defective MMR gene results in increased DNA replication errors and MSI, which causes the occurrence of tumors in different organs, especially in the colorectum. Identification of HPNCC families is important because the diagnosis, treatment and follow up of these individuals should be different from those with sporadic colorectal cancer [2]. However, the clinical diagnosis of HNPCC patients is very difficult for lack of specific clinical phenotype. Though Amsterdam criteria I and II were established for HNPCC diagnosis[3,4], many HNPCC families still do not meet the criteria.
MSI is an important phenotype of MMR gene mutation. In 1997, the National Cancer Institute (NCI) recommended screening MSI CRCs using the Bethesda guidelines [5]. After compiling evidence from years of global studies and follow up, NCI revised the Bethesda guidelines in 2004, which is called the revised Bethesda standard [6]. NCI recommended screening of HNPCC based on detection of MSI in the tumor and loss of expression of a MMR gene using immunohistochemistry (IHC) staining [6]. However, until now, there has been no research about the applicability of the NCI recommendations to the Chinese population with colorectal cancers. The aim of this study is to detect and study MSI carrier and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"B-size",
"I-size",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"B-Disorder",
"I-Disorder",
"O",
"B-Disorder",
"I-Disorder",
"I-Disorder",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"B-body-part",
"I-body-part",
"I-body-part",
"B-disease",
"O",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-mutation",
"I-mutation",
"O",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"B-Concepts_Ideas",
"I-Concepts_Ideas",
"I-Concepts_Ideas",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-body-part",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Concepts_Ideas",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-disease",
"B-cohort-patient",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-gene",
"O",
"B-mutation",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-Disorder",
"O",
"O",
"B-disease",
"O",
"B-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"I-Physiology",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-ethnicity",
"B-cohort-patient",
"O",
"B-body-part",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Disorder",
"I-Disorder",
"O",
"B-gene",
"I-gene",
"O",
"B-gene",
"O",
"O",
"B-mutation",
"I-mutation",
"B-cohort-patient",
"O",
"O",
"B-ethnicity",
"B-cohort-patient",
"O",
"B-disease",
"I-disease",
"O",
"O"
] |
** IGNORE LINE **
** IGNORE LINE **
** IGNORE LINE **
Background
HNPCC is an autosomal dominant syndrome, which accounts for about 1–5% of colorectal cancer [1]. HNPCC patients are characterized by earlier symptoms, more mucinous carcinoma, more synchronous and metachronous colorectal tumors and more extra-colonic tumors, but have better survival [1,2]. It is believed that HNPCC is secondary to a germline mutation resulting in a defective MMR gene. A defective MMR gene results in increased DNA replication errors and MSI, which causes the occurrence of tumors in different organs, especially in the colorectum. Identification of HPNCC families is important because the diagnosis, treatment and follow up of these individuals should be different from those with sporadic colorectal cancer [2]. However, the clinical diagnosis of HNPCC patients is very difficult for lack of specific clinical phenotype. Though Amsterdam criteria I and II were established for HNPCC diagnosis[3,4], many HNPCC families still do not meet the criteria.
MSI is an important phenotype of MMR gene mutation. In 1997, the National Cancer Institute (NCI) recommended screening MSI CRCs using the Bethesda guidelines [5]. After compiling evidence from years of global studies and follow up, NCI revised the Bethesda guidelines in 2004, which is called the revised Bethesda standard [6]. NCI recommended screening of HNPCC based on detection of MSI in the tumor and loss of expression of a MMR gene using immunohistochemistry (IHC) staining [6]. However, until now, there has been no research about the applicability of the NCI recommendations to the Chinese population with colorectal cancers. The aim of this study is to detect and study MSI carrier and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
|
[
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"*",
"*",
"IGNORE",
"LINE",
"*",
"*",
"\n",
"Background",
"\n\n",
"HNPCC",
"is",
"an",
"autosomal",
"dominant",
"syndrome",
",",
"which",
"accounts",
"for",
"about",
"1–5",
"%",
"of",
"colorectal",
"cancer",
"[",
"1",
"]",
".",
"HNPCC",
"patients",
"are",
"characterized",
"by",
"earlier",
"symptoms",
",",
"more",
"mucinous",
"carcinoma",
",",
"more",
"synchronous",
"and",
"metachronous",
"colorectal",
"tumors",
"and",
"more",
"extra",
"-",
"colonic",
"tumors",
",",
"but",
"have",
"better",
"survival",
"[",
"1,2",
"]",
".",
"It",
"is",
"believed",
"that",
"HNPCC",
"is",
"secondary",
"to",
"a",
"germline",
"mutation",
"resulting",
"in",
"a",
"defective",
"MMR",
"gene",
".",
"A",
"defective",
"MMR",
"gene",
"results",
"in",
"increased",
"DNA",
"replication",
"errors",
"and",
"MSI",
",",
"which",
"causes",
"the",
"occurrence",
"of",
"tumors",
"in",
"different",
"organs",
",",
"especially",
"in",
"the",
"colorectum",
".",
"Identification",
"of",
"HPNCC",
"families",
"is",
"important",
"because",
"the",
"diagnosis",
",",
"treatment",
"and",
"follow",
"up",
"of",
"these",
"individuals",
"should",
"be",
"different",
"from",
"those",
"with",
"sporadic",
"colorectal",
"cancer",
"[",
"2",
"]",
".",
"However",
",",
"the",
"clinical",
"diagnosis",
"of",
"HNPCC",
"patients",
"is",
"very",
"difficult",
"for",
"lack",
"of",
"specific",
"clinical",
"phenotype",
".",
"Though",
"Amsterdam",
"criteria",
"I",
"and",
"II",
"were",
"established",
"for",
"HNPCC",
"diagnosis[3,4",
"]",
",",
"many",
"HNPCC",
"families",
"still",
"do",
"not",
"meet",
"the",
"criteria",
".",
"\n\n",
"MSI",
"is",
"an",
"important",
"phenotype",
"of",
"MMR",
"gene",
"mutation",
".",
"In",
"1997",
",",
"the",
"National",
"Cancer",
"Institute",
"(",
"NCI",
")",
"recommended",
"screening",
"MSI",
"CRCs",
"using",
"the",
"Bethesda",
"guidelines",
"[",
"5",
"]",
".",
"After",
"compiling",
"evidence",
"from",
"years",
"of",
"global",
"studies",
"and",
"follow",
"up",
",",
"NCI",
"revised",
"the",
"Bethesda",
"guidelines",
"in",
"2004",
",",
"which",
"is",
"called",
"the",
"revised",
"Bethesda",
"standard",
"[",
"6",
"]",
".",
"NCI",
"recommended",
"screening",
"of",
"HNPCC",
"based",
"on",
"detection",
"of",
"MSI",
"in",
"the",
"tumor",
"and",
"loss",
"of",
"expression",
"of",
"a",
"MMR",
"gene",
"using",
"immunohistochemistry",
"(",
"IHC",
")",
"staining",
"[",
"6",
"]",
".",
"However",
",",
"until",
"now",
",",
"there",
"has",
"been",
"no",
"research",
"about",
"the",
"applicability",
"of",
"the",
"NCI",
"recommendations",
"to",
"the",
"Chinese",
"population",
"with",
"colorectal",
"cancers",
".",
"The",
"aim",
"of",
"this",
"study",
"is",
"to",
"detect",
"and",
"study",
"MSI",
"carrier",
"and",
"mismatch",
"repair",
"(",
"MMR",
")",
"gene",
"germline",
"mutation",
"carriers",
"among",
"a",
"Chinese",
"population",
"with",
"colorectal",
"cancer",
".",
"\n\n"
] |
[
"Concepts_Ideas",
"Physiology",
"Disorder",
"mutation",
"disease",
"gene",
"body-part",
"cohort-patient",
"ethnicity",
"size"
] |
OBF-1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, Oct - binding factor 1 is a Protein, OBF-1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, OBF-1 is a Protein, POU domains is a Entity, Oct-1 is a Protein, Oct-2 is a Protein, Oct-4 is a Protein, Oct-6 is a Protein, OBF-1 is a Protein, OBF-1 is a Protein, OBF-1 is a Protein
|
437_task0
|
Sentence: OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins.
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated B cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent in most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Entity, Protein
|
[
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Entity",
"I-Entity",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins.
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated B cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent in most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.
|
[
"OBF-1",
",",
"a",
"novel",
"B",
"cell",
"-",
"specific",
"coactivator",
"that",
"stimulates",
"immunoglobulin",
"promoter",
"activity",
"through",
"association",
"with",
"octamer",
"-",
"binding",
"proteins",
".",
"\n",
"Recent",
"biochemical",
"and",
"genetic",
"studies",
"indicate",
"that",
"in",
"addition",
"to",
"the",
"octamer",
"-",
"binding",
"proteins",
"Oct-1",
"and",
"Oct-2",
",",
"other",
"B",
"cell",
"components",
"are",
"required",
"for",
"lymphoid",
"-",
"restricted",
",",
"octamer",
"site",
"-",
"mediated",
"immunoglobulin",
"gene",
"promoter",
"activity",
".",
"Using",
"a",
"genetic",
"screen",
"in",
"yeast",
",",
"we",
"have",
"isolated",
"B",
"cell",
"-",
"derived",
"cDNAs",
"encoding",
"Oct",
"-",
"binding",
"factor",
"1",
"(",
"OBF-1",
")",
",",
"a",
"novel",
"protein",
"that",
"specifically",
"associates",
"with",
"Oct-1",
"and",
"Oct-2",
".",
"Biochemical",
"studies",
"demonstrate",
"that",
"OBF-1",
"has",
"no",
"intrinsic",
"DNA",
"-",
"binding",
"activity",
"and",
"recognizes",
"the",
"POU",
"domains",
"of",
"Oct-1",
"and",
"Oct-2",
",",
"but",
"not",
"those",
"of",
"Oct-4",
"and",
"Oct-6",
".",
"The",
"OBF-1",
"mRNA",
"is",
"expressed",
"in",
"a",
"highly",
"cell",
"-",
"specific",
"manner",
",",
"being",
"most",
"abundant",
"in",
"B",
"cells",
"and",
"essentially",
"absent",
"in",
"most",
"of",
"the",
"other",
"cells",
"or",
"tissues",
"tested",
".",
"Furthermore",
",",
"expression",
"of",
"OBF-1",
"in",
"HeLa",
"cells",
"selectively",
"stimulates",
"the",
"activity",
"of",
"a",
"natural",
"immunoglobulin",
"promoter",
"in",
"an",
"octamer",
"site",
"-",
"dependent",
"manner",
".",
"Thus",
",",
"OBF-1",
"has",
"all",
"the",
"properties",
"expected",
"for",
"a",
"B",
"cell",
"-",
"specific",
"transcriptional",
"coactivator",
"protein",
"."
] |
[
"Protein",
"Entity"
] |
OBF-1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, Oct - binding factor 1 is a Protein, OBF-1 is a Protein, Oct-1 is a Protein, Oct-2 is a Protein, OBF-1 is a Protein, POU domains is a Entity, Oct-1 is a Protein, Oct-2 is a Protein, Oct-4 is a Protein, Oct-6 is a Protein, OBF-1 is a Protein, OBF-1 is a Protein, OBF-1 is a Protein
|
437_task1
|
Sentence: OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins.
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated B cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent in most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.
Instructions: please typing these entity words according to sentence: OBF-1, Oct-1, Oct-2, Oct - binding factor 1, OBF-1, Oct-1, Oct-2, OBF-1, POU domains, Oct-1, Oct-2, Oct-4, Oct-6, OBF-1, OBF-1, OBF-1
Options: Entity, Protein
|
[
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Entity",
"I-Entity",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins.
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated B cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent in most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.
|
[
"OBF-1",
",",
"a",
"novel",
"B",
"cell",
"-",
"specific",
"coactivator",
"that",
"stimulates",
"immunoglobulin",
"promoter",
"activity",
"through",
"association",
"with",
"octamer",
"-",
"binding",
"proteins",
".",
"\n",
"Recent",
"biochemical",
"and",
"genetic",
"studies",
"indicate",
"that",
"in",
"addition",
"to",
"the",
"octamer",
"-",
"binding",
"proteins",
"Oct-1",
"and",
"Oct-2",
",",
"other",
"B",
"cell",
"components",
"are",
"required",
"for",
"lymphoid",
"-",
"restricted",
",",
"octamer",
"site",
"-",
"mediated",
"immunoglobulin",
"gene",
"promoter",
"activity",
".",
"Using",
"a",
"genetic",
"screen",
"in",
"yeast",
",",
"we",
"have",
"isolated",
"B",
"cell",
"-",
"derived",
"cDNAs",
"encoding",
"Oct",
"-",
"binding",
"factor",
"1",
"(",
"OBF-1",
")",
",",
"a",
"novel",
"protein",
"that",
"specifically",
"associates",
"with",
"Oct-1",
"and",
"Oct-2",
".",
"Biochemical",
"studies",
"demonstrate",
"that",
"OBF-1",
"has",
"no",
"intrinsic",
"DNA",
"-",
"binding",
"activity",
"and",
"recognizes",
"the",
"POU",
"domains",
"of",
"Oct-1",
"and",
"Oct-2",
",",
"but",
"not",
"those",
"of",
"Oct-4",
"and",
"Oct-6",
".",
"The",
"OBF-1",
"mRNA",
"is",
"expressed",
"in",
"a",
"highly",
"cell",
"-",
"specific",
"manner",
",",
"being",
"most",
"abundant",
"in",
"B",
"cells",
"and",
"essentially",
"absent",
"in",
"most",
"of",
"the",
"other",
"cells",
"or",
"tissues",
"tested",
".",
"Furthermore",
",",
"expression",
"of",
"OBF-1",
"in",
"HeLa",
"cells",
"selectively",
"stimulates",
"the",
"activity",
"of",
"a",
"natural",
"immunoglobulin",
"promoter",
"in",
"an",
"octamer",
"site",
"-",
"dependent",
"manner",
".",
"Thus",
",",
"OBF-1",
"has",
"all",
"the",
"properties",
"expected",
"for",
"a",
"B",
"cell",
"-",
"specific",
"transcriptional",
"coactivator",
"protein",
"."
] |
[
"Protein",
"Entity"
] |
OBF-1, Oct-1, Oct-2, Oct - binding factor 1, OBF-1, Oct-1, Oct-2, OBF-1, POU domains, Oct-1, Oct-2, Oct-4, Oct-6, OBF-1, OBF-1, OBF-1
|
437_task2
|
Sentence: OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins.
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated B cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent in most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.
Instructions: please extract entity words from the input sentence
|
[
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"I-Protein",
"I-Protein",
"I-Protein",
"I-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Entity",
"I-Entity",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"B-Protein",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Protein",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"
] |
OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins.
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated B cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent in most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.
|
[
"OBF-1",
",",
"a",
"novel",
"B",
"cell",
"-",
"specific",
"coactivator",
"that",
"stimulates",
"immunoglobulin",
"promoter",
"activity",
"through",
"association",
"with",
"octamer",
"-",
"binding",
"proteins",
".",
"\n",
"Recent",
"biochemical",
"and",
"genetic",
"studies",
"indicate",
"that",
"in",
"addition",
"to",
"the",
"octamer",
"-",
"binding",
"proteins",
"Oct-1",
"and",
"Oct-2",
",",
"other",
"B",
"cell",
"components",
"are",
"required",
"for",
"lymphoid",
"-",
"restricted",
",",
"octamer",
"site",
"-",
"mediated",
"immunoglobulin",
"gene",
"promoter",
"activity",
".",
"Using",
"a",
"genetic",
"screen",
"in",
"yeast",
",",
"we",
"have",
"isolated",
"B",
"cell",
"-",
"derived",
"cDNAs",
"encoding",
"Oct",
"-",
"binding",
"factor",
"1",
"(",
"OBF-1",
")",
",",
"a",
"novel",
"protein",
"that",
"specifically",
"associates",
"with",
"Oct-1",
"and",
"Oct-2",
".",
"Biochemical",
"studies",
"demonstrate",
"that",
"OBF-1",
"has",
"no",
"intrinsic",
"DNA",
"-",
"binding",
"activity",
"and",
"recognizes",
"the",
"POU",
"domains",
"of",
"Oct-1",
"and",
"Oct-2",
",",
"but",
"not",
"those",
"of",
"Oct-4",
"and",
"Oct-6",
".",
"The",
"OBF-1",
"mRNA",
"is",
"expressed",
"in",
"a",
"highly",
"cell",
"-",
"specific",
"manner",
",",
"being",
"most",
"abundant",
"in",
"B",
"cells",
"and",
"essentially",
"absent",
"in",
"most",
"of",
"the",
"other",
"cells",
"or",
"tissues",
"tested",
".",
"Furthermore",
",",
"expression",
"of",
"OBF-1",
"in",
"HeLa",
"cells",
"selectively",
"stimulates",
"the",
"activity",
"of",
"a",
"natural",
"immunoglobulin",
"promoter",
"in",
"an",
"octamer",
"site",
"-",
"dependent",
"manner",
".",
"Thus",
",",
"OBF-1",
"has",
"all",
"the",
"properties",
"expected",
"for",
"a",
"B",
"cell",
"-",
"specific",
"transcriptional",
"coactivator",
"protein",
"."
] |
[
"Protein",
"Entity"
] |
Pankreasverletzungen is an umlsterm, Diagnosestellung is an umlsterm, Verletzungen is an umlsterm, Bauchspeicheldruese is an umlsterm, Ultraschall is an umlsterm, Computertomographie is an umlsterm, Diagnosefindung is an umlsterm, Patienten is an umlsterm, Literatur is an umlsterm, Diagnostik is an umlsterm, Laparotomiezeitpunkt is an umlsterm, Gangbeteiligung is an umlsterm, Behandlungsausmass is an umlsterm, Therapie is an umlsterm, Komplikationen is an umlsterm
|
DerChirurg.70680624.ger.abstr_task0
|
Sentence: Zusammenfassung . Pankreasverletzungen sind im Rahmen des Bauchtraumas mit bis zu 12 % selten , bereiten jedoch oft Schwierigkeiten bei der Diagnosestellung . Bedeutsam ist die hohe Komplikationsrate von 35 % nach Verletzungen der Bauchspeicheldruese . Bildgebende Verfahren wie Ultraschall und Computertomographie erweisen sich nur zu 60-80 % bei der Diagnosefindung als hilfreich . Die klinische Untersuchung ist bei den oftmals polytraumatisierten Patienten eingeschraenkt . Anhand von 10 Fallbeispielen unterschiedlichen Pankreasverletzungsgrades nach Lucas diskutieren wir bezugnehmend auf die aktuelle Literatur den Behandlungsverlauf . Besonders beruecksichtigt wird dabei der Stellenwert der bildgebenden Diagnostik , der Laparotomiezeitpunkt , der Ausschluss einer Gangbeteiligung sowie das Behandlungsausmass und die Therapie der Komplikationen .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O"
] |
Zusammenfassung . Pankreasverletzungen sind im Rahmen des Bauchtraumas mit bis zu 12 % selten , bereiten jedoch oft Schwierigkeiten bei der Diagnosestellung . Bedeutsam ist die hohe Komplikationsrate von 35 % nach Verletzungen der Bauchspeicheldruese . Bildgebende Verfahren wie Ultraschall und Computertomographie erweisen sich nur zu 60-80 % bei der Diagnosefindung als hilfreich . Die klinische Untersuchung ist bei den oftmals polytraumatisierten Patienten eingeschraenkt . Anhand von 10 Fallbeispielen unterschiedlichen Pankreasverletzungsgrades nach Lucas diskutieren wir bezugnehmend auf die aktuelle Literatur den Behandlungsverlauf . Besonders beruecksichtigt wird dabei der Stellenwert der bildgebenden Diagnostik , der Laparotomiezeitpunkt , der Ausschluss einer Gangbeteiligung sowie das Behandlungsausmass und die Therapie der Komplikationen .
|
[
"Zusammenfassung",
".",
"Pankreasverletzungen",
"sind",
"im",
"Rahmen",
"des",
"Bauchtraumas",
"mit",
"bis",
"zu",
"12",
"%",
"selten",
",",
"bereiten",
"jedoch",
"oft",
"Schwierigkeiten",
"bei",
"der",
"Diagnosestellung",
".",
"Bedeutsam",
"ist",
"die",
"hohe",
"Komplikationsrate",
"von",
"35",
"%",
"nach",
"Verletzungen",
"der",
"Bauchspeicheldruese",
".",
"Bildgebende",
"Verfahren",
"wie",
"Ultraschall",
"und",
"Computertomographie",
"erweisen",
"sich",
"nur",
"zu",
"60",
"-",
"80",
"%",
"bei",
"der",
"Diagnosefindung",
"als",
"hilfreich",
".",
"Die",
"klinische",
"Untersuchung",
"ist",
"bei",
"den",
"oftmals",
"polytraumatisierten",
"Patienten",
"eingeschraenkt",
".",
"Anhand",
"von",
"10",
"Fallbeispielen",
"unterschiedlichen",
"Pankreasverletzungsgrades",
"nach",
"Lucas",
"diskutieren",
"wir",
"bezugnehmend",
"auf",
"die",
"aktuelle",
"Literatur",
"den",
"Behandlungsverlauf",
".",
"Besonders",
"beruecksichtigt",
"wird",
"dabei",
"der",
"Stellenwert",
"der",
"bildgebenden",
"Diagnostik",
",",
"der",
"Laparotomiezeitpunkt",
",",
"der",
"Ausschluss",
"einer",
"Gangbeteiligung",
"sowie",
"das",
"Behandlungsausmass",
"und",
"die",
"Therapie",
"der",
"Komplikationen",
"."
] |
[
"umlsterm"
] |
Pankreasverletzungen is an umlsterm, Diagnosestellung is an umlsterm, Verletzungen is an umlsterm, Bauchspeicheldruese is an umlsterm, Ultraschall is an umlsterm, Computertomographie is an umlsterm, Diagnosefindung is an umlsterm, Patienten is an umlsterm, Literatur is an umlsterm, Diagnostik is an umlsterm, Laparotomiezeitpunkt is an umlsterm, Gangbeteiligung is an umlsterm, Behandlungsausmass is an umlsterm, Therapie is an umlsterm, Komplikationen is an umlsterm
|
DerChirurg.70680624.ger.abstr_task1
|
Sentence: Zusammenfassung . Pankreasverletzungen sind im Rahmen des Bauchtraumas mit bis zu 12 % selten , bereiten jedoch oft Schwierigkeiten bei der Diagnosestellung . Bedeutsam ist die hohe Komplikationsrate von 35 % nach Verletzungen der Bauchspeicheldruese . Bildgebende Verfahren wie Ultraschall und Computertomographie erweisen sich nur zu 60-80 % bei der Diagnosefindung als hilfreich . Die klinische Untersuchung ist bei den oftmals polytraumatisierten Patienten eingeschraenkt . Anhand von 10 Fallbeispielen unterschiedlichen Pankreasverletzungsgrades nach Lucas diskutieren wir bezugnehmend auf die aktuelle Literatur den Behandlungsverlauf . Besonders beruecksichtigt wird dabei der Stellenwert der bildgebenden Diagnostik , der Laparotomiezeitpunkt , der Ausschluss einer Gangbeteiligung sowie das Behandlungsausmass und die Therapie der Komplikationen .
Instructions: please typing these entity words according to sentence: Pankreasverletzungen, Diagnosestellung, Verletzungen, Bauchspeicheldruese, Ultraschall, Computertomographie, Diagnosefindung, Patienten, Literatur, Diagnostik, Laparotomiezeitpunkt, Gangbeteiligung, Behandlungsausmass, Therapie, Komplikationen
Options: umlsterm
|
[
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O"
] |
Zusammenfassung . Pankreasverletzungen sind im Rahmen des Bauchtraumas mit bis zu 12 % selten , bereiten jedoch oft Schwierigkeiten bei der Diagnosestellung . Bedeutsam ist die hohe Komplikationsrate von 35 % nach Verletzungen der Bauchspeicheldruese . Bildgebende Verfahren wie Ultraschall und Computertomographie erweisen sich nur zu 60-80 % bei der Diagnosefindung als hilfreich . Die klinische Untersuchung ist bei den oftmals polytraumatisierten Patienten eingeschraenkt . Anhand von 10 Fallbeispielen unterschiedlichen Pankreasverletzungsgrades nach Lucas diskutieren wir bezugnehmend auf die aktuelle Literatur den Behandlungsverlauf . Besonders beruecksichtigt wird dabei der Stellenwert der bildgebenden Diagnostik , der Laparotomiezeitpunkt , der Ausschluss einer Gangbeteiligung sowie das Behandlungsausmass und die Therapie der Komplikationen .
|
[
"Zusammenfassung",
".",
"Pankreasverletzungen",
"sind",
"im",
"Rahmen",
"des",
"Bauchtraumas",
"mit",
"bis",
"zu",
"12",
"%",
"selten",
",",
"bereiten",
"jedoch",
"oft",
"Schwierigkeiten",
"bei",
"der",
"Diagnosestellung",
".",
"Bedeutsam",
"ist",
"die",
"hohe",
"Komplikationsrate",
"von",
"35",
"%",
"nach",
"Verletzungen",
"der",
"Bauchspeicheldruese",
".",
"Bildgebende",
"Verfahren",
"wie",
"Ultraschall",
"und",
"Computertomographie",
"erweisen",
"sich",
"nur",
"zu",
"60",
"-",
"80",
"%",
"bei",
"der",
"Diagnosefindung",
"als",
"hilfreich",
".",
"Die",
"klinische",
"Untersuchung",
"ist",
"bei",
"den",
"oftmals",
"polytraumatisierten",
"Patienten",
"eingeschraenkt",
".",
"Anhand",
"von",
"10",
"Fallbeispielen",
"unterschiedlichen",
"Pankreasverletzungsgrades",
"nach",
"Lucas",
"diskutieren",
"wir",
"bezugnehmend",
"auf",
"die",
"aktuelle",
"Literatur",
"den",
"Behandlungsverlauf",
".",
"Besonders",
"beruecksichtigt",
"wird",
"dabei",
"der",
"Stellenwert",
"der",
"bildgebenden",
"Diagnostik",
",",
"der",
"Laparotomiezeitpunkt",
",",
"der",
"Ausschluss",
"einer",
"Gangbeteiligung",
"sowie",
"das",
"Behandlungsausmass",
"und",
"die",
"Therapie",
"der",
"Komplikationen",
"."
] |
[
"umlsterm"
] |
Pankreasverletzungen, Diagnosestellung, Verletzungen, Bauchspeicheldruese, Ultraschall, Computertomographie, Diagnosefindung, Patienten, Literatur, Diagnostik, Laparotomiezeitpunkt, Gangbeteiligung, Behandlungsausmass, Therapie, Komplikationen
|
DerChirurg.70680624.ger.abstr_task2
|
Sentence: Zusammenfassung . Pankreasverletzungen sind im Rahmen des Bauchtraumas mit bis zu 12 % selten , bereiten jedoch oft Schwierigkeiten bei der Diagnosestellung . Bedeutsam ist die hohe Komplikationsrate von 35 % nach Verletzungen der Bauchspeicheldruese . Bildgebende Verfahren wie Ultraschall und Computertomographie erweisen sich nur zu 60-80 % bei der Diagnosefindung als hilfreich . Die klinische Untersuchung ist bei den oftmals polytraumatisierten Patienten eingeschraenkt . Anhand von 10 Fallbeispielen unterschiedlichen Pankreasverletzungsgrades nach Lucas diskutieren wir bezugnehmend auf die aktuelle Literatur den Behandlungsverlauf . Besonders beruecksichtigt wird dabei der Stellenwert der bildgebenden Diagnostik , der Laparotomiezeitpunkt , der Ausschluss einer Gangbeteiligung sowie das Behandlungsausmass und die Therapie der Komplikationen .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O"
] |
Zusammenfassung . Pankreasverletzungen sind im Rahmen des Bauchtraumas mit bis zu 12 % selten , bereiten jedoch oft Schwierigkeiten bei der Diagnosestellung . Bedeutsam ist die hohe Komplikationsrate von 35 % nach Verletzungen der Bauchspeicheldruese . Bildgebende Verfahren wie Ultraschall und Computertomographie erweisen sich nur zu 60-80 % bei der Diagnosefindung als hilfreich . Die klinische Untersuchung ist bei den oftmals polytraumatisierten Patienten eingeschraenkt . Anhand von 10 Fallbeispielen unterschiedlichen Pankreasverletzungsgrades nach Lucas diskutieren wir bezugnehmend auf die aktuelle Literatur den Behandlungsverlauf . Besonders beruecksichtigt wird dabei der Stellenwert der bildgebenden Diagnostik , der Laparotomiezeitpunkt , der Ausschluss einer Gangbeteiligung sowie das Behandlungsausmass und die Therapie der Komplikationen .
|
[
"Zusammenfassung",
".",
"Pankreasverletzungen",
"sind",
"im",
"Rahmen",
"des",
"Bauchtraumas",
"mit",
"bis",
"zu",
"12",
"%",
"selten",
",",
"bereiten",
"jedoch",
"oft",
"Schwierigkeiten",
"bei",
"der",
"Diagnosestellung",
".",
"Bedeutsam",
"ist",
"die",
"hohe",
"Komplikationsrate",
"von",
"35",
"%",
"nach",
"Verletzungen",
"der",
"Bauchspeicheldruese",
".",
"Bildgebende",
"Verfahren",
"wie",
"Ultraschall",
"und",
"Computertomographie",
"erweisen",
"sich",
"nur",
"zu",
"60",
"-",
"80",
"%",
"bei",
"der",
"Diagnosefindung",
"als",
"hilfreich",
".",
"Die",
"klinische",
"Untersuchung",
"ist",
"bei",
"den",
"oftmals",
"polytraumatisierten",
"Patienten",
"eingeschraenkt",
".",
"Anhand",
"von",
"10",
"Fallbeispielen",
"unterschiedlichen",
"Pankreasverletzungsgrades",
"nach",
"Lucas",
"diskutieren",
"wir",
"bezugnehmend",
"auf",
"die",
"aktuelle",
"Literatur",
"den",
"Behandlungsverlauf",
".",
"Besonders",
"beruecksichtigt",
"wird",
"dabei",
"der",
"Stellenwert",
"der",
"bildgebenden",
"Diagnostik",
",",
"der",
"Laparotomiezeitpunkt",
",",
"der",
"Ausschluss",
"einer",
"Gangbeteiligung",
"sowie",
"das",
"Behandlungsausmass",
"und",
"die",
"Therapie",
"der",
"Komplikationen",
"."
] |
[
"umlsterm"
] |
Patienten is an umlsterm, Tumor- is an umlsterm, Kopf- is an umlsterm, Rueckenschmerzen is an umlsterm, ambulanten Behandlung is an umlsterm, Patienten is an umlsterm, Aerzte is an umlsterm, Patienten is an umlsterm, Schmerzen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Schmerzpatienten is an umlsterm, Patienten is an umlsterm, Therapieresistenz is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Schmerzpatienten is an umlsterm, schmerztherapeutische is an umlsterm, Behandlungseinrichtungen is an umlsterm
|
DerSchmerz.70110101.ger.abstr_task0
|
Sentence: Zur orientierenden Schaetzung der ambulanten Versorgung von Patienten mit Tumor- , Kopf- und Rueckenschmerzen im bayerischen Regierungsbezirk Mittelfranken wurden im Oktober 1995 an alle an der ambulanten Behandlung von Patienten beteiligten Aerzte und nichtaerztlichen Psychotherapeuten dieser Region ( n=2130) Frageboegen gesandt . 264 Kollegen ( 12,4% ) lieferten auswertbare Angaben . Von diesen Kollegen wurden in den letzten 12 Monaten 107 346 Patienten mit chronischen Schmerzen behandelt . Davon wurden 72 255 Patienten ( 67% ) monodisziplinaer und 35 091 Patienten ( 33% ) ambulant-interdisziplinaer behandelt . Der Anteil der Psychotherapeuten und Anaesthesisten an der ambulanten Diagnostik und Therapie von Schmerzpatienten war gering . Bei 22 754 Patienten ( 21% ) wurde aufgrund der Therapieresistenz der Beschwerden unter ambulanten Bedingungen eine multidisziplinaere algesiologische Diagnostik und Therapie unter stationaeren oder teilstationaeren Bedingungen fuer notwendig erachtet . Derartige Einrichtungen bestehen derzeit in Mittelfranken nicht . Die Zahl problematischer Schmerzpatienten ist als Mindestzahl aufzufassen und unterstreicht die Notwendigkeit , wohnortnah adaequate schmerztherapeutische Behandlungseinrichtungen aufzubauen .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O"
] |
Zur orientierenden Schaetzung der ambulanten Versorgung von Patienten mit Tumor- , Kopf- und Rueckenschmerzen im bayerischen Regierungsbezirk Mittelfranken wurden im Oktober 1995 an alle an der ambulanten Behandlung von Patienten beteiligten Aerzte und nichtaerztlichen Psychotherapeuten dieser Region ( n=2130) Frageboegen gesandt . 264 Kollegen ( 12,4% ) lieferten auswertbare Angaben . Von diesen Kollegen wurden in den letzten 12 Monaten 107 346 Patienten mit chronischen Schmerzen behandelt . Davon wurden 72 255 Patienten ( 67% ) monodisziplinaer und 35 091 Patienten ( 33% ) ambulant-interdisziplinaer behandelt . Der Anteil der Psychotherapeuten und Anaesthesisten an der ambulanten Diagnostik und Therapie von Schmerzpatienten war gering . Bei 22 754 Patienten ( 21% ) wurde aufgrund der Therapieresistenz der Beschwerden unter ambulanten Bedingungen eine multidisziplinaere algesiologische Diagnostik und Therapie unter stationaeren oder teilstationaeren Bedingungen fuer notwendig erachtet . Derartige Einrichtungen bestehen derzeit in Mittelfranken nicht . Die Zahl problematischer Schmerzpatienten ist als Mindestzahl aufzufassen und unterstreicht die Notwendigkeit , wohnortnah adaequate schmerztherapeutische Behandlungseinrichtungen aufzubauen .
|
[
"Zur",
"orientierenden",
"Schaetzung",
"der",
"ambulanten",
"Versorgung",
"von",
"Patienten",
"mit",
"Tumor-",
",",
"Kopf-",
"und",
"Rueckenschmerzen",
"im",
"bayerischen",
"Regierungsbezirk",
"Mittelfranken",
"wurden",
"im",
"Oktober",
"1995",
"an",
"alle",
"an",
"der",
"ambulanten",
"Behandlung",
"von",
"Patienten",
"beteiligten",
"Aerzte",
"und",
"nichtaerztlichen",
"Psychotherapeuten",
"dieser",
"Region",
"(",
"n=2130",
")",
"Frageboegen",
"gesandt",
".",
"264",
"Kollegen",
"(",
"12,4",
"%",
")",
"lieferten",
"auswertbare",
"Angaben",
".",
"Von",
"diesen",
"Kollegen",
"wurden",
"in",
"den",
"letzten",
"12",
"Monaten",
"107",
"346",
"Patienten",
"mit",
"chronischen",
"Schmerzen",
"behandelt",
".",
"Davon",
"wurden",
"72",
"255",
"Patienten",
"(",
"67",
"%",
")",
"monodisziplinaer",
"und",
"35",
"091",
"Patienten",
"(",
"33",
"%",
")",
"ambulant",
"-",
"interdisziplinaer",
"behandelt",
".",
"Der",
"Anteil",
"der",
"Psychotherapeuten",
"und",
"Anaesthesisten",
"an",
"der",
"ambulanten",
"Diagnostik",
"und",
"Therapie",
"von",
"Schmerzpatienten",
"war",
"gering",
".",
"Bei",
"22",
"754",
"Patienten",
"(",
"21",
"%",
")",
"wurde",
"aufgrund",
"der",
"Therapieresistenz",
"der",
"Beschwerden",
"unter",
"ambulanten",
"Bedingungen",
"eine",
"multidisziplinaere",
"algesiologische",
"Diagnostik",
"und",
"Therapie",
"unter",
"stationaeren",
"oder",
"teilstationaeren",
"Bedingungen",
"fuer",
"notwendig",
"erachtet",
".",
"Derartige",
"Einrichtungen",
"bestehen",
"derzeit",
"in",
"Mittelfranken",
"nicht",
".",
"Die",
"Zahl",
"problematischer",
"Schmerzpatienten",
"ist",
"als",
"Mindestzahl",
"aufzufassen",
"und",
"unterstreicht",
"die",
"Notwendigkeit",
",",
"wohnortnah",
"adaequate",
"schmerztherapeutische",
"Behandlungseinrichtungen",
"aufzubauen",
"."
] |
[
"umlsterm"
] |
Patienten is an umlsterm, Tumor- is an umlsterm, Kopf- is an umlsterm, Rueckenschmerzen is an umlsterm, ambulanten Behandlung is an umlsterm, Patienten is an umlsterm, Aerzte is an umlsterm, Patienten is an umlsterm, Schmerzen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Schmerzpatienten is an umlsterm, Patienten is an umlsterm, Therapieresistenz is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Schmerzpatienten is an umlsterm, schmerztherapeutische is an umlsterm, Behandlungseinrichtungen is an umlsterm
|
DerSchmerz.70110101.ger.abstr_task1
|
Sentence: Zur orientierenden Schaetzung der ambulanten Versorgung von Patienten mit Tumor- , Kopf- und Rueckenschmerzen im bayerischen Regierungsbezirk Mittelfranken wurden im Oktober 1995 an alle an der ambulanten Behandlung von Patienten beteiligten Aerzte und nichtaerztlichen Psychotherapeuten dieser Region ( n=2130) Frageboegen gesandt . 264 Kollegen ( 12,4% ) lieferten auswertbare Angaben . Von diesen Kollegen wurden in den letzten 12 Monaten 107 346 Patienten mit chronischen Schmerzen behandelt . Davon wurden 72 255 Patienten ( 67% ) monodisziplinaer und 35 091 Patienten ( 33% ) ambulant-interdisziplinaer behandelt . Der Anteil der Psychotherapeuten und Anaesthesisten an der ambulanten Diagnostik und Therapie von Schmerzpatienten war gering . Bei 22 754 Patienten ( 21% ) wurde aufgrund der Therapieresistenz der Beschwerden unter ambulanten Bedingungen eine multidisziplinaere algesiologische Diagnostik und Therapie unter stationaeren oder teilstationaeren Bedingungen fuer notwendig erachtet . Derartige Einrichtungen bestehen derzeit in Mittelfranken nicht . Die Zahl problematischer Schmerzpatienten ist als Mindestzahl aufzufassen und unterstreicht die Notwendigkeit , wohnortnah adaequate schmerztherapeutische Behandlungseinrichtungen aufzubauen .
Instructions: please typing these entity words according to sentence: Patienten, Tumor-, Kopf-, Rueckenschmerzen, ambulanten Behandlung, Patienten, Aerzte, Patienten, Schmerzen, Patienten, Patienten, Diagnostik, Therapie, Schmerzpatienten, Patienten, Therapieresistenz, Diagnostik, Therapie, Schmerzpatienten, schmerztherapeutische, Behandlungseinrichtungen
Options: umlsterm
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O"
] |
Zur orientierenden Schaetzung der ambulanten Versorgung von Patienten mit Tumor- , Kopf- und Rueckenschmerzen im bayerischen Regierungsbezirk Mittelfranken wurden im Oktober 1995 an alle an der ambulanten Behandlung von Patienten beteiligten Aerzte und nichtaerztlichen Psychotherapeuten dieser Region ( n=2130) Frageboegen gesandt . 264 Kollegen ( 12,4% ) lieferten auswertbare Angaben . Von diesen Kollegen wurden in den letzten 12 Monaten 107 346 Patienten mit chronischen Schmerzen behandelt . Davon wurden 72 255 Patienten ( 67% ) monodisziplinaer und 35 091 Patienten ( 33% ) ambulant-interdisziplinaer behandelt . Der Anteil der Psychotherapeuten und Anaesthesisten an der ambulanten Diagnostik und Therapie von Schmerzpatienten war gering . Bei 22 754 Patienten ( 21% ) wurde aufgrund der Therapieresistenz der Beschwerden unter ambulanten Bedingungen eine multidisziplinaere algesiologische Diagnostik und Therapie unter stationaeren oder teilstationaeren Bedingungen fuer notwendig erachtet . Derartige Einrichtungen bestehen derzeit in Mittelfranken nicht . Die Zahl problematischer Schmerzpatienten ist als Mindestzahl aufzufassen und unterstreicht die Notwendigkeit , wohnortnah adaequate schmerztherapeutische Behandlungseinrichtungen aufzubauen .
|
[
"Zur",
"orientierenden",
"Schaetzung",
"der",
"ambulanten",
"Versorgung",
"von",
"Patienten",
"mit",
"Tumor-",
",",
"Kopf-",
"und",
"Rueckenschmerzen",
"im",
"bayerischen",
"Regierungsbezirk",
"Mittelfranken",
"wurden",
"im",
"Oktober",
"1995",
"an",
"alle",
"an",
"der",
"ambulanten",
"Behandlung",
"von",
"Patienten",
"beteiligten",
"Aerzte",
"und",
"nichtaerztlichen",
"Psychotherapeuten",
"dieser",
"Region",
"(",
"n=2130",
")",
"Frageboegen",
"gesandt",
".",
"264",
"Kollegen",
"(",
"12,4",
"%",
")",
"lieferten",
"auswertbare",
"Angaben",
".",
"Von",
"diesen",
"Kollegen",
"wurden",
"in",
"den",
"letzten",
"12",
"Monaten",
"107",
"346",
"Patienten",
"mit",
"chronischen",
"Schmerzen",
"behandelt",
".",
"Davon",
"wurden",
"72",
"255",
"Patienten",
"(",
"67",
"%",
")",
"monodisziplinaer",
"und",
"35",
"091",
"Patienten",
"(",
"33",
"%",
")",
"ambulant",
"-",
"interdisziplinaer",
"behandelt",
".",
"Der",
"Anteil",
"der",
"Psychotherapeuten",
"und",
"Anaesthesisten",
"an",
"der",
"ambulanten",
"Diagnostik",
"und",
"Therapie",
"von",
"Schmerzpatienten",
"war",
"gering",
".",
"Bei",
"22",
"754",
"Patienten",
"(",
"21",
"%",
")",
"wurde",
"aufgrund",
"der",
"Therapieresistenz",
"der",
"Beschwerden",
"unter",
"ambulanten",
"Bedingungen",
"eine",
"multidisziplinaere",
"algesiologische",
"Diagnostik",
"und",
"Therapie",
"unter",
"stationaeren",
"oder",
"teilstationaeren",
"Bedingungen",
"fuer",
"notwendig",
"erachtet",
".",
"Derartige",
"Einrichtungen",
"bestehen",
"derzeit",
"in",
"Mittelfranken",
"nicht",
".",
"Die",
"Zahl",
"problematischer",
"Schmerzpatienten",
"ist",
"als",
"Mindestzahl",
"aufzufassen",
"und",
"unterstreicht",
"die",
"Notwendigkeit",
",",
"wohnortnah",
"adaequate",
"schmerztherapeutische",
"Behandlungseinrichtungen",
"aufzubauen",
"."
] |
[
"umlsterm"
] |
Patienten, Tumor-, Kopf-, Rueckenschmerzen, ambulanten Behandlung, Patienten, Aerzte, Patienten, Schmerzen, Patienten, Patienten, Diagnostik, Therapie, Schmerzpatienten, Patienten, Therapieresistenz, Diagnostik, Therapie, Schmerzpatienten, schmerztherapeutische, Behandlungseinrichtungen
|
DerSchmerz.70110101.ger.abstr_task2
|
Sentence: Zur orientierenden Schaetzung der ambulanten Versorgung von Patienten mit Tumor- , Kopf- und Rueckenschmerzen im bayerischen Regierungsbezirk Mittelfranken wurden im Oktober 1995 an alle an der ambulanten Behandlung von Patienten beteiligten Aerzte und nichtaerztlichen Psychotherapeuten dieser Region ( n=2130) Frageboegen gesandt . 264 Kollegen ( 12,4% ) lieferten auswertbare Angaben . Von diesen Kollegen wurden in den letzten 12 Monaten 107 346 Patienten mit chronischen Schmerzen behandelt . Davon wurden 72 255 Patienten ( 67% ) monodisziplinaer und 35 091 Patienten ( 33% ) ambulant-interdisziplinaer behandelt . Der Anteil der Psychotherapeuten und Anaesthesisten an der ambulanten Diagnostik und Therapie von Schmerzpatienten war gering . Bei 22 754 Patienten ( 21% ) wurde aufgrund der Therapieresistenz der Beschwerden unter ambulanten Bedingungen eine multidisziplinaere algesiologische Diagnostik und Therapie unter stationaeren oder teilstationaeren Bedingungen fuer notwendig erachtet . Derartige Einrichtungen bestehen derzeit in Mittelfranken nicht . Die Zahl problematischer Schmerzpatienten ist als Mindestzahl aufzufassen und unterstreicht die Notwendigkeit , wohnortnah adaequate schmerztherapeutische Behandlungseinrichtungen aufzubauen .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O"
] |
Zur orientierenden Schaetzung der ambulanten Versorgung von Patienten mit Tumor- , Kopf- und Rueckenschmerzen im bayerischen Regierungsbezirk Mittelfranken wurden im Oktober 1995 an alle an der ambulanten Behandlung von Patienten beteiligten Aerzte und nichtaerztlichen Psychotherapeuten dieser Region ( n=2130) Frageboegen gesandt . 264 Kollegen ( 12,4% ) lieferten auswertbare Angaben . Von diesen Kollegen wurden in den letzten 12 Monaten 107 346 Patienten mit chronischen Schmerzen behandelt . Davon wurden 72 255 Patienten ( 67% ) monodisziplinaer und 35 091 Patienten ( 33% ) ambulant-interdisziplinaer behandelt . Der Anteil der Psychotherapeuten und Anaesthesisten an der ambulanten Diagnostik und Therapie von Schmerzpatienten war gering . Bei 22 754 Patienten ( 21% ) wurde aufgrund der Therapieresistenz der Beschwerden unter ambulanten Bedingungen eine multidisziplinaere algesiologische Diagnostik und Therapie unter stationaeren oder teilstationaeren Bedingungen fuer notwendig erachtet . Derartige Einrichtungen bestehen derzeit in Mittelfranken nicht . Die Zahl problematischer Schmerzpatienten ist als Mindestzahl aufzufassen und unterstreicht die Notwendigkeit , wohnortnah adaequate schmerztherapeutische Behandlungseinrichtungen aufzubauen .
|
[
"Zur",
"orientierenden",
"Schaetzung",
"der",
"ambulanten",
"Versorgung",
"von",
"Patienten",
"mit",
"Tumor-",
",",
"Kopf-",
"und",
"Rueckenschmerzen",
"im",
"bayerischen",
"Regierungsbezirk",
"Mittelfranken",
"wurden",
"im",
"Oktober",
"1995",
"an",
"alle",
"an",
"der",
"ambulanten",
"Behandlung",
"von",
"Patienten",
"beteiligten",
"Aerzte",
"und",
"nichtaerztlichen",
"Psychotherapeuten",
"dieser",
"Region",
"(",
"n=2130",
")",
"Frageboegen",
"gesandt",
".",
"264",
"Kollegen",
"(",
"12,4",
"%",
")",
"lieferten",
"auswertbare",
"Angaben",
".",
"Von",
"diesen",
"Kollegen",
"wurden",
"in",
"den",
"letzten",
"12",
"Monaten",
"107",
"346",
"Patienten",
"mit",
"chronischen",
"Schmerzen",
"behandelt",
".",
"Davon",
"wurden",
"72",
"255",
"Patienten",
"(",
"67",
"%",
")",
"monodisziplinaer",
"und",
"35",
"091",
"Patienten",
"(",
"33",
"%",
")",
"ambulant",
"-",
"interdisziplinaer",
"behandelt",
".",
"Der",
"Anteil",
"der",
"Psychotherapeuten",
"und",
"Anaesthesisten",
"an",
"der",
"ambulanten",
"Diagnostik",
"und",
"Therapie",
"von",
"Schmerzpatienten",
"war",
"gering",
".",
"Bei",
"22",
"754",
"Patienten",
"(",
"21",
"%",
")",
"wurde",
"aufgrund",
"der",
"Therapieresistenz",
"der",
"Beschwerden",
"unter",
"ambulanten",
"Bedingungen",
"eine",
"multidisziplinaere",
"algesiologische",
"Diagnostik",
"und",
"Therapie",
"unter",
"stationaeren",
"oder",
"teilstationaeren",
"Bedingungen",
"fuer",
"notwendig",
"erachtet",
".",
"Derartige",
"Einrichtungen",
"bestehen",
"derzeit",
"in",
"Mittelfranken",
"nicht",
".",
"Die",
"Zahl",
"problematischer",
"Schmerzpatienten",
"ist",
"als",
"Mindestzahl",
"aufzufassen",
"und",
"unterstreicht",
"die",
"Notwendigkeit",
",",
"wohnortnah",
"adaequate",
"schmerztherapeutische",
"Behandlungseinrichtungen",
"aufzubauen",
"."
] |
[
"umlsterm"
] |
alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, E - cadherin is a Individual_protein, plakoglobin is a Individual_protein, actin is a Individual_protein
|
661_task0
|
Sentence: The alpha-catenin molecule links E-cadherin/ beta-catenin or E-cadherin/plakoglobin complexes to the actin cytoskeleton.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Individual_protein
|
[
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"O",
"O",
"O",
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"B-Individual_protein",
"O",
"O",
"O",
"B-Individual_protein",
"O",
"O"
] |
The alpha-catenin molecule links E-cadherin/ beta-catenin or E-cadherin/plakoglobin complexes to the actin cytoskeleton.
|
[
"The",
"alpha",
"-",
"catenin",
"molecule",
"links",
"E",
"-",
"cadherin/",
"beta",
"-",
"catenin",
"or",
"E",
"-",
"cadherin",
"/",
"plakoglobin",
"complexes",
"to",
"the",
"actin",
"cytoskeleton",
"."
] |
[
"Individual_protein"
] |
alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, E - cadherin is a Individual_protein, plakoglobin is a Individual_protein, actin is a Individual_protein
|
661_task1
|
Sentence: The alpha-catenin molecule links E-cadherin/ beta-catenin or E-cadherin/plakoglobin complexes to the actin cytoskeleton.
Instructions: please typing these entity words according to sentence: alpha - catenin, beta - catenin, E - cadherin, plakoglobin, actin
Options: Individual_protein
|
[
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"O",
"O",
"O",
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"B-Individual_protein",
"O",
"O",
"O",
"B-Individual_protein",
"O",
"O"
] |
The alpha-catenin molecule links E-cadherin/ beta-catenin or E-cadherin/plakoglobin complexes to the actin cytoskeleton.
|
[
"The",
"alpha",
"-",
"catenin",
"molecule",
"links",
"E",
"-",
"cadherin/",
"beta",
"-",
"catenin",
"or",
"E",
"-",
"cadherin",
"/",
"plakoglobin",
"complexes",
"to",
"the",
"actin",
"cytoskeleton",
"."
] |
[
"Individual_protein"
] |
alpha - catenin, beta - catenin, E - cadherin, plakoglobin, actin
|
661_task2
|
Sentence: The alpha-catenin molecule links E-cadherin/ beta-catenin or E-cadherin/plakoglobin complexes to the actin cytoskeleton.
Instructions: please extract entity words from the input sentence
|
[
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"O",
"O",
"O",
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"B-Individual_protein",
"I-Individual_protein",
"I-Individual_protein",
"O",
"B-Individual_protein",
"O",
"O",
"O",
"B-Individual_protein",
"O",
"O"
] |
The alpha-catenin molecule links E-cadherin/ beta-catenin or E-cadherin/plakoglobin complexes to the actin cytoskeleton.
|
[
"The",
"alpha",
"-",
"catenin",
"molecule",
"links",
"E",
"-",
"cadherin/",
"beta",
"-",
"catenin",
"or",
"E",
"-",
"cadherin",
"/",
"plakoglobin",
"complexes",
"to",
"the",
"actin",
"cytoskeleton",
"."
] |
[
"Individual_protein"
] |
L - noradrenaline is a CHEMICAL, phenylalanine 4-monooxygenase is a GENE-Y, Catecholamines is a CHEMICAL, adrenaline is a CHEMICAL, noradrenaline is a CHEMICAL, dopamine is a CHEMICAL, phenylalanine 4-monooxygenase is a GENE-Y, phenylalanine hydroxylase is a GENE-Y, EC 1.14.16.1 is a GENE-Y, catecholamine is a CHEMICAL, L - noradrenaline is a CHEMICAL, phenylalanine hydroxylase is a GENE-Y, L - noradrenaline is a CHEMICAL, L - noradrenaline is a CHEMICAL, L - phenylalanine is a CHEMICAL, N - ethylmaleimide is a CHEMICAL, L - phenylalanine is a CHEMICAL, L - noradrenaline is a CHEMICAL, L - noradrenaline is a CHEMICAL, L - phenylalanine is a CHEMICAL, catecholamines is a CHEMICAL, phenylalanine hydroxylase is a GENE-Y, tyrosine hydroxylase is a GENE-Y, catecholamine is a CHEMICAL, Fe(III ) is a CHEMICAL
|
23007_task0
|
Sentence: Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase.
Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1). The amines bind to the enzyme by a direct coordination to the high-spin (S = 5/2) Fe(III) at the active site (charge transfer interaction), as seen by resonance Raman and EPR spectroscopy. Experimental evidence is presented that a group with an apparent pKa value of about 5.1 (20 degrees C) is involved in the interaction between the catecholamine and the enzyme. The high-affinity binding of L-noradrenaline to phenylalanine hydroxylase, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline. No binding to the ferrous form of the enzyme was observed. The affinity decreases with decreasing pH, by phosphorylation and by preincubation of the enzyme with the substrate L-phenylalanine, while it increases after alkylation of the enzyme with the activator N-ethylmaleimide. Preincubation of the enzyme with L-phenylalanine also leads to a complete loss of the cooperativity of L-noradrenaline binding (h = 1.0). The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site. The high-affinity of catecholamines to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: GENE-Y, CHEMICAL
|
[
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"O",
"O"
] |
Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase.
Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1). The amines bind to the enzyme by a direct coordination to the high-spin (S = 5/2) Fe(III) at the active site (charge transfer interaction), as seen by resonance Raman and EPR spectroscopy. Experimental evidence is presented that a group with an apparent pKa value of about 5.1 (20 degrees C) is involved in the interaction between the catecholamine and the enzyme. The high-affinity binding of L-noradrenaline to phenylalanine hydroxylase, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline. No binding to the ferrous form of the enzyme was observed. The affinity decreases with decreasing pH, by phosphorylation and by preincubation of the enzyme with the substrate L-phenylalanine, while it increases after alkylation of the enzyme with the activator N-ethylmaleimide. Preincubation of the enzyme with L-phenylalanine also leads to a complete loss of the cooperativity of L-noradrenaline binding (h = 1.0). The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site. The high-affinity of catecholamines to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.
|
[
"Cooperative",
"homotropic",
"interaction",
"of",
"L",
"-",
"noradrenaline",
"with",
"the",
"catalytic",
"site",
"of",
"phenylalanine",
"4-monooxygenase",
".",
"\n",
"Catecholamines",
"(",
"adrenaline",
",",
"noradrenaline",
"and",
"dopamine",
")",
"are",
"potent",
"inhibitors",
"of",
"phenylalanine",
"4-monooxygenase",
"(",
"phenylalanine",
"hydroxylase",
",",
"EC",
"1.14.16.1",
")",
".",
"The",
"amines",
"bind",
"to",
"the",
"enzyme",
"by",
"a",
"direct",
"coordination",
"to",
"the",
"high",
"-",
"spin",
"(",
"S",
"=",
"5/2",
")",
"Fe(III",
")",
"at",
"the",
"active",
"site",
"(",
"charge",
"transfer",
"interaction",
")",
",",
"as",
"seen",
"by",
"resonance",
"Raman",
"and",
"EPR",
"spectroscopy",
".",
"Experimental",
"evidence",
"is",
"presented",
"that",
"a",
"group",
"with",
"an",
"apparent",
"pKa",
"value",
"of",
"about",
"5.1",
"(",
"20",
"degrees",
"C",
")",
"is",
"involved",
"in",
"the",
"interaction",
"between",
"the",
"catecholamine",
"and",
"the",
"enzyme",
".",
"The",
"high",
"-",
"affinity",
"binding",
"of",
"L",
"-",
"noradrenaline",
"to",
"phenylalanine",
"hydroxylase",
",",
"as",
"studied",
"by",
"equilibrium",
"microdialysis",
"(",
"anaerobically",
")",
"and",
"ultrafiltration",
"(",
"aerobically",
")",
",",
"shows",
"positive",
"cooperativity",
"(",
"h",
"=",
"1.9",
")",
";",
"at",
"pH",
"7.2",
"and",
"20",
"degrees",
"C",
"the",
"rat",
"enzyme",
"binds",
"about",
"0.5",
"mol",
"L",
"-",
"noradrenaline",
"/",
"mol",
"subunit",
"with",
"a",
"half",
"-",
"maximal",
"binding",
"(",
"S50",
")",
"at",
"0.25",
"microM",
"L",
"-",
"noradrenaline",
".",
"No",
"binding",
"to",
"the",
"ferrous",
"form",
"of",
"the",
"enzyme",
"was",
"observed",
".",
"The",
"affinity",
"decreases",
"with",
"decreasing",
"pH",
",",
"by",
"phosphorylation",
"and",
"by",
"preincubation",
"of",
"the",
"enzyme",
"with",
"the",
"substrate",
"L",
"-",
"phenylalanine",
",",
"while",
"it",
"increases",
"after",
"alkylation",
"of",
"the",
"enzyme",
"with",
"the",
"activator",
"N",
"-",
"ethylmaleimide",
".",
"Preincubation",
"of",
"the",
"enzyme",
"with",
"L",
"-",
"phenylalanine",
"also",
"leads",
"to",
"a",
"complete",
"loss",
"of",
"the",
"cooperativity",
"of",
"L",
"-",
"noradrenaline",
"binding",
"(",
"h",
"=",
"1.0",
")",
".",
"The",
"many",
"similarities",
"in",
"binding",
"properties",
"of",
"the",
"inhibitor",
"L",
"-",
"noradrenaline",
"and",
"the",
"activator",
"/",
"substrate",
"L",
"-",
"phenylalanine",
"makes",
"it",
"likely",
"that",
"the",
"cooperative",
"interactions",
"of",
"these",
"effectors",
"are",
"due",
"to",
"their",
"binding",
"to",
"the",
"same",
"site",
".",
"The",
"high",
"-",
"affinity",
"of",
"catecholamines",
"to",
"phenylalanine",
"hydroxylase",
"is",
"a",
"valuable",
"probe",
"to",
"study",
"the",
"active",
"site",
"of",
"this",
"enzyme",
"and",
"is",
"also",
"relevant",
"for",
"the",
"homologous",
"enzyme",
"tyrosine",
"hydroxylase",
",",
"which",
"is",
"purified",
"as",
"a",
"stable",
"catecholamine",
"-",
"Fe(III",
")",
"complex",
"."
] |
[
"GENE-Y",
"CHEMICAL"
] |
L - noradrenaline is a CHEMICAL, phenylalanine 4-monooxygenase is a GENE-Y, Catecholamines is a CHEMICAL, adrenaline is a CHEMICAL, noradrenaline is a CHEMICAL, dopamine is a CHEMICAL, phenylalanine 4-monooxygenase is a GENE-Y, phenylalanine hydroxylase is a GENE-Y, EC 1.14.16.1 is a GENE-Y, catecholamine is a CHEMICAL, L - noradrenaline is a CHEMICAL, phenylalanine hydroxylase is a GENE-Y, L - noradrenaline is a CHEMICAL, L - noradrenaline is a CHEMICAL, L - phenylalanine is a CHEMICAL, N - ethylmaleimide is a CHEMICAL, L - phenylalanine is a CHEMICAL, L - noradrenaline is a CHEMICAL, L - noradrenaline is a CHEMICAL, L - phenylalanine is a CHEMICAL, catecholamines is a CHEMICAL, phenylalanine hydroxylase is a GENE-Y, tyrosine hydroxylase is a GENE-Y, catecholamine is a CHEMICAL, Fe(III ) is a CHEMICAL
|
23007_task1
|
Sentence: Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase.
Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1). The amines bind to the enzyme by a direct coordination to the high-spin (S = 5/2) Fe(III) at the active site (charge transfer interaction), as seen by resonance Raman and EPR spectroscopy. Experimental evidence is presented that a group with an apparent pKa value of about 5.1 (20 degrees C) is involved in the interaction between the catecholamine and the enzyme. The high-affinity binding of L-noradrenaline to phenylalanine hydroxylase, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline. No binding to the ferrous form of the enzyme was observed. The affinity decreases with decreasing pH, by phosphorylation and by preincubation of the enzyme with the substrate L-phenylalanine, while it increases after alkylation of the enzyme with the activator N-ethylmaleimide. Preincubation of the enzyme with L-phenylalanine also leads to a complete loss of the cooperativity of L-noradrenaline binding (h = 1.0). The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site. The high-affinity of catecholamines to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.
Instructions: please typing these entity words according to sentence: L - noradrenaline, phenylalanine 4-monooxygenase, Catecholamines, adrenaline, noradrenaline, dopamine, phenylalanine 4-monooxygenase, phenylalanine hydroxylase, EC 1.14.16.1, catecholamine, L - noradrenaline, phenylalanine hydroxylase, L - noradrenaline, L - noradrenaline, L - phenylalanine, N - ethylmaleimide, L - phenylalanine, L - noradrenaline, L - noradrenaline, L - phenylalanine, catecholamines, phenylalanine hydroxylase, tyrosine hydroxylase, catecholamine, Fe(III )
Options: GENE-Y, CHEMICAL
|
[
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"O",
"O"
] |
Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase.
Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1). The amines bind to the enzyme by a direct coordination to the high-spin (S = 5/2) Fe(III) at the active site (charge transfer interaction), as seen by resonance Raman and EPR spectroscopy. Experimental evidence is presented that a group with an apparent pKa value of about 5.1 (20 degrees C) is involved in the interaction between the catecholamine and the enzyme. The high-affinity binding of L-noradrenaline to phenylalanine hydroxylase, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline. No binding to the ferrous form of the enzyme was observed. The affinity decreases with decreasing pH, by phosphorylation and by preincubation of the enzyme with the substrate L-phenylalanine, while it increases after alkylation of the enzyme with the activator N-ethylmaleimide. Preincubation of the enzyme with L-phenylalanine also leads to a complete loss of the cooperativity of L-noradrenaline binding (h = 1.0). The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site. The high-affinity of catecholamines to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.
|
[
"Cooperative",
"homotropic",
"interaction",
"of",
"L",
"-",
"noradrenaline",
"with",
"the",
"catalytic",
"site",
"of",
"phenylalanine",
"4-monooxygenase",
".",
"\n",
"Catecholamines",
"(",
"adrenaline",
",",
"noradrenaline",
"and",
"dopamine",
")",
"are",
"potent",
"inhibitors",
"of",
"phenylalanine",
"4-monooxygenase",
"(",
"phenylalanine",
"hydroxylase",
",",
"EC",
"1.14.16.1",
")",
".",
"The",
"amines",
"bind",
"to",
"the",
"enzyme",
"by",
"a",
"direct",
"coordination",
"to",
"the",
"high",
"-",
"spin",
"(",
"S",
"=",
"5/2",
")",
"Fe(III",
")",
"at",
"the",
"active",
"site",
"(",
"charge",
"transfer",
"interaction",
")",
",",
"as",
"seen",
"by",
"resonance",
"Raman",
"and",
"EPR",
"spectroscopy",
".",
"Experimental",
"evidence",
"is",
"presented",
"that",
"a",
"group",
"with",
"an",
"apparent",
"pKa",
"value",
"of",
"about",
"5.1",
"(",
"20",
"degrees",
"C",
")",
"is",
"involved",
"in",
"the",
"interaction",
"between",
"the",
"catecholamine",
"and",
"the",
"enzyme",
".",
"The",
"high",
"-",
"affinity",
"binding",
"of",
"L",
"-",
"noradrenaline",
"to",
"phenylalanine",
"hydroxylase",
",",
"as",
"studied",
"by",
"equilibrium",
"microdialysis",
"(",
"anaerobically",
")",
"and",
"ultrafiltration",
"(",
"aerobically",
")",
",",
"shows",
"positive",
"cooperativity",
"(",
"h",
"=",
"1.9",
")",
";",
"at",
"pH",
"7.2",
"and",
"20",
"degrees",
"C",
"the",
"rat",
"enzyme",
"binds",
"about",
"0.5",
"mol",
"L",
"-",
"noradrenaline",
"/",
"mol",
"subunit",
"with",
"a",
"half",
"-",
"maximal",
"binding",
"(",
"S50",
")",
"at",
"0.25",
"microM",
"L",
"-",
"noradrenaline",
".",
"No",
"binding",
"to",
"the",
"ferrous",
"form",
"of",
"the",
"enzyme",
"was",
"observed",
".",
"The",
"affinity",
"decreases",
"with",
"decreasing",
"pH",
",",
"by",
"phosphorylation",
"and",
"by",
"preincubation",
"of",
"the",
"enzyme",
"with",
"the",
"substrate",
"L",
"-",
"phenylalanine",
",",
"while",
"it",
"increases",
"after",
"alkylation",
"of",
"the",
"enzyme",
"with",
"the",
"activator",
"N",
"-",
"ethylmaleimide",
".",
"Preincubation",
"of",
"the",
"enzyme",
"with",
"L",
"-",
"phenylalanine",
"also",
"leads",
"to",
"a",
"complete",
"loss",
"of",
"the",
"cooperativity",
"of",
"L",
"-",
"noradrenaline",
"binding",
"(",
"h",
"=",
"1.0",
")",
".",
"The",
"many",
"similarities",
"in",
"binding",
"properties",
"of",
"the",
"inhibitor",
"L",
"-",
"noradrenaline",
"and",
"the",
"activator",
"/",
"substrate",
"L",
"-",
"phenylalanine",
"makes",
"it",
"likely",
"that",
"the",
"cooperative",
"interactions",
"of",
"these",
"effectors",
"are",
"due",
"to",
"their",
"binding",
"to",
"the",
"same",
"site",
".",
"The",
"high",
"-",
"affinity",
"of",
"catecholamines",
"to",
"phenylalanine",
"hydroxylase",
"is",
"a",
"valuable",
"probe",
"to",
"study",
"the",
"active",
"site",
"of",
"this",
"enzyme",
"and",
"is",
"also",
"relevant",
"for",
"the",
"homologous",
"enzyme",
"tyrosine",
"hydroxylase",
",",
"which",
"is",
"purified",
"as",
"a",
"stable",
"catecholamine",
"-",
"Fe(III",
")",
"complex",
"."
] |
[
"GENE-Y",
"CHEMICAL"
] |
L - noradrenaline, phenylalanine 4-monooxygenase, Catecholamines, adrenaline, noradrenaline, dopamine, phenylalanine 4-monooxygenase, phenylalanine hydroxylase, EC 1.14.16.1, catecholamine, L - noradrenaline, phenylalanine hydroxylase, L - noradrenaline, L - noradrenaline, L - phenylalanine, N - ethylmaleimide, L - phenylalanine, L - noradrenaline, L - noradrenaline, L - phenylalanine, catecholamines, phenylalanine hydroxylase, tyrosine hydroxylase, catecholamine, Fe(III )
|
23007_task2
|
Sentence: Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase.
Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1). The amines bind to the enzyme by a direct coordination to the high-spin (S = 5/2) Fe(III) at the active site (charge transfer interaction), as seen by resonance Raman and EPR spectroscopy. Experimental evidence is presented that a group with an apparent pKa value of about 5.1 (20 degrees C) is involved in the interaction between the catecholamine and the enzyme. The high-affinity binding of L-noradrenaline to phenylalanine hydroxylase, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline. No binding to the ferrous form of the enzyme was observed. The affinity decreases with decreasing pH, by phosphorylation and by preincubation of the enzyme with the substrate L-phenylalanine, while it increases after alkylation of the enzyme with the activator N-ethylmaleimide. Preincubation of the enzyme with L-phenylalanine also leads to a complete loss of the cooperativity of L-noradrenaline binding (h = 1.0). The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site. The high-affinity of catecholamines to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"I-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-GENE-Y",
"I-GENE-Y",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"B-CHEMICAL",
"I-CHEMICAL",
"O",
"O"
] |
Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase.
Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1). The amines bind to the enzyme by a direct coordination to the high-spin (S = 5/2) Fe(III) at the active site (charge transfer interaction), as seen by resonance Raman and EPR spectroscopy. Experimental evidence is presented that a group with an apparent pKa value of about 5.1 (20 degrees C) is involved in the interaction between the catecholamine and the enzyme. The high-affinity binding of L-noradrenaline to phenylalanine hydroxylase, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline. No binding to the ferrous form of the enzyme was observed. The affinity decreases with decreasing pH, by phosphorylation and by preincubation of the enzyme with the substrate L-phenylalanine, while it increases after alkylation of the enzyme with the activator N-ethylmaleimide. Preincubation of the enzyme with L-phenylalanine also leads to a complete loss of the cooperativity of L-noradrenaline binding (h = 1.0). The many similarities in binding properties of the inhibitor L-noradrenaline and the activator/substrate L-phenylalanine makes it likely that the cooperative interactions of these effectors are due to their binding to the same site. The high-affinity of catecholamines to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.
|
[
"Cooperative",
"homotropic",
"interaction",
"of",
"L",
"-",
"noradrenaline",
"with",
"the",
"catalytic",
"site",
"of",
"phenylalanine",
"4-monooxygenase",
".",
"\n",
"Catecholamines",
"(",
"adrenaline",
",",
"noradrenaline",
"and",
"dopamine",
")",
"are",
"potent",
"inhibitors",
"of",
"phenylalanine",
"4-monooxygenase",
"(",
"phenylalanine",
"hydroxylase",
",",
"EC",
"1.14.16.1",
")",
".",
"The",
"amines",
"bind",
"to",
"the",
"enzyme",
"by",
"a",
"direct",
"coordination",
"to",
"the",
"high",
"-",
"spin",
"(",
"S",
"=",
"5/2",
")",
"Fe(III",
")",
"at",
"the",
"active",
"site",
"(",
"charge",
"transfer",
"interaction",
")",
",",
"as",
"seen",
"by",
"resonance",
"Raman",
"and",
"EPR",
"spectroscopy",
".",
"Experimental",
"evidence",
"is",
"presented",
"that",
"a",
"group",
"with",
"an",
"apparent",
"pKa",
"value",
"of",
"about",
"5.1",
"(",
"20",
"degrees",
"C",
")",
"is",
"involved",
"in",
"the",
"interaction",
"between",
"the",
"catecholamine",
"and",
"the",
"enzyme",
".",
"The",
"high",
"-",
"affinity",
"binding",
"of",
"L",
"-",
"noradrenaline",
"to",
"phenylalanine",
"hydroxylase",
",",
"as",
"studied",
"by",
"equilibrium",
"microdialysis",
"(",
"anaerobically",
")",
"and",
"ultrafiltration",
"(",
"aerobically",
")",
",",
"shows",
"positive",
"cooperativity",
"(",
"h",
"=",
"1.9",
")",
";",
"at",
"pH",
"7.2",
"and",
"20",
"degrees",
"C",
"the",
"rat",
"enzyme",
"binds",
"about",
"0.5",
"mol",
"L",
"-",
"noradrenaline",
"/",
"mol",
"subunit",
"with",
"a",
"half",
"-",
"maximal",
"binding",
"(",
"S50",
")",
"at",
"0.25",
"microM",
"L",
"-",
"noradrenaline",
".",
"No",
"binding",
"to",
"the",
"ferrous",
"form",
"of",
"the",
"enzyme",
"was",
"observed",
".",
"The",
"affinity",
"decreases",
"with",
"decreasing",
"pH",
",",
"by",
"phosphorylation",
"and",
"by",
"preincubation",
"of",
"the",
"enzyme",
"with",
"the",
"substrate",
"L",
"-",
"phenylalanine",
",",
"while",
"it",
"increases",
"after",
"alkylation",
"of",
"the",
"enzyme",
"with",
"the",
"activator",
"N",
"-",
"ethylmaleimide",
".",
"Preincubation",
"of",
"the",
"enzyme",
"with",
"L",
"-",
"phenylalanine",
"also",
"leads",
"to",
"a",
"complete",
"loss",
"of",
"the",
"cooperativity",
"of",
"L",
"-",
"noradrenaline",
"binding",
"(",
"h",
"=",
"1.0",
")",
".",
"The",
"many",
"similarities",
"in",
"binding",
"properties",
"of",
"the",
"inhibitor",
"L",
"-",
"noradrenaline",
"and",
"the",
"activator",
"/",
"substrate",
"L",
"-",
"phenylalanine",
"makes",
"it",
"likely",
"that",
"the",
"cooperative",
"interactions",
"of",
"these",
"effectors",
"are",
"due",
"to",
"their",
"binding",
"to",
"the",
"same",
"site",
".",
"The",
"high",
"-",
"affinity",
"of",
"catecholamines",
"to",
"phenylalanine",
"hydroxylase",
"is",
"a",
"valuable",
"probe",
"to",
"study",
"the",
"active",
"site",
"of",
"this",
"enzyme",
"and",
"is",
"also",
"relevant",
"for",
"the",
"homologous",
"enzyme",
"tyrosine",
"hydroxylase",
",",
"which",
"is",
"purified",
"as",
"a",
"stable",
"catecholamine",
"-",
"Fe(III",
")",
"complex",
"."
] |
[
"GENE-Y",
"CHEMICAL"
] |
case report is an umlsterm, patient is an umlsterm, gastric cancer is an umlsterm, diagnostic is an umlsterm, non - Hodgkin lymphoma is an umlsterm, adenocarcinoma is an umlsterm, gastric cancer is an umlsterm, EBV is an umlsterm, association is an umlsterm, tumor is an umlsterm, cells is an umlsterm, development is an umlsterm, carcinoma is an umlsterm, lymphoma is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, techniques is an umlsterm, histology is an umlsterm, procedure is an umlsterm, classification is an umlsterm, gastric neoplasms is an umlsterm
|
DerChirurg.90700713.eng.abstr_task0
|
Sentence: Based on the case report of a 51 year-old patient presenting with a lymphoepithelioma like gastric cancer , we discuss the diagnostic challenge to differentiate this entity from gastric non-Hodgkin lymphoma . Since high-level lymphoid stromal reactions are rarely associated with gastric adenocarcinoma , misinterpretation can occur easily . In addition to the lymphoepithelioma like gastric cancer that is often associated with a demonstrable EBV association of the tumor cells , synchronous development of gastric carcinoma and lymphoma must be considered . Establishment of a correct diagnosis requires multiple , deep and multifocally sampled gastric biopsies , and immunohistochemical and molecular techniques to supplement conventional histology . Only through this procedure are correct characterization and classification of these unusual gastric neoplasms possible .
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: umlsterm
|
[
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O"
] |
Based on the case report of a 51 year-old patient presenting with a lymphoepithelioma like gastric cancer , we discuss the diagnostic challenge to differentiate this entity from gastric non-Hodgkin lymphoma . Since high-level lymphoid stromal reactions are rarely associated with gastric adenocarcinoma , misinterpretation can occur easily . In addition to the lymphoepithelioma like gastric cancer that is often associated with a demonstrable EBV association of the tumor cells , synchronous development of gastric carcinoma and lymphoma must be considered . Establishment of a correct diagnosis requires multiple , deep and multifocally sampled gastric biopsies , and immunohistochemical and molecular techniques to supplement conventional histology . Only through this procedure are correct characterization and classification of these unusual gastric neoplasms possible .
|
[
"Based",
"on",
"the",
"case",
"report",
"of",
"a",
"51",
"year",
"-",
"old",
"patient",
"presenting",
"with",
"a",
"lymphoepithelioma",
"like",
"gastric",
"cancer",
",",
"we",
"discuss",
"the",
"diagnostic",
"challenge",
"to",
"differentiate",
"this",
"entity",
"from",
"gastric",
"non",
"-",
"Hodgkin",
"lymphoma",
".",
"Since",
"high",
"-",
"level",
"lymphoid",
"stromal",
"reactions",
"are",
"rarely",
"associated",
"with",
"gastric",
"adenocarcinoma",
",",
"misinterpretation",
"can",
"occur",
"easily",
".",
"In",
"addition",
"to",
"the",
"lymphoepithelioma",
"like",
"gastric",
"cancer",
"that",
"is",
"often",
"associated",
"with",
"a",
"demonstrable",
"EBV",
"association",
"of",
"the",
"tumor",
"cells",
",",
"synchronous",
"development",
"of",
"gastric",
"carcinoma",
"and",
"lymphoma",
"must",
"be",
"considered",
".",
"Establishment",
"of",
"a",
"correct",
"diagnosis",
"requires",
"multiple",
",",
"deep",
"and",
"multifocally",
"sampled",
"gastric",
"biopsies",
",",
"and",
"immunohistochemical",
"and",
"molecular",
"techniques",
"to",
"supplement",
"conventional",
"histology",
".",
"Only",
"through",
"this",
"procedure",
"are",
"correct",
"characterization",
"and",
"classification",
"of",
"these",
"unusual",
"gastric",
"neoplasms",
"possible",
"."
] |
[
"umlsterm"
] |
case report is an umlsterm, patient is an umlsterm, gastric cancer is an umlsterm, diagnostic is an umlsterm, non - Hodgkin lymphoma is an umlsterm, adenocarcinoma is an umlsterm, gastric cancer is an umlsterm, EBV is an umlsterm, association is an umlsterm, tumor is an umlsterm, cells is an umlsterm, development is an umlsterm, carcinoma is an umlsterm, lymphoma is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, techniques is an umlsterm, histology is an umlsterm, procedure is an umlsterm, classification is an umlsterm, gastric neoplasms is an umlsterm
|
DerChirurg.90700713.eng.abstr_task1
|
Sentence: Based on the case report of a 51 year-old patient presenting with a lymphoepithelioma like gastric cancer , we discuss the diagnostic challenge to differentiate this entity from gastric non-Hodgkin lymphoma . Since high-level lymphoid stromal reactions are rarely associated with gastric adenocarcinoma , misinterpretation can occur easily . In addition to the lymphoepithelioma like gastric cancer that is often associated with a demonstrable EBV association of the tumor cells , synchronous development of gastric carcinoma and lymphoma must be considered . Establishment of a correct diagnosis requires multiple , deep and multifocally sampled gastric biopsies , and immunohistochemical and molecular techniques to supplement conventional histology . Only through this procedure are correct characterization and classification of these unusual gastric neoplasms possible .
Instructions: please typing these entity words according to sentence: case report, patient, gastric cancer, diagnostic, non - Hodgkin lymphoma, adenocarcinoma, gastric cancer, EBV, association, tumor, cells, development, carcinoma, lymphoma, diagnosis, biopsies, techniques, histology, procedure, classification, gastric neoplasms
Options: umlsterm
|
[
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O"
] |
Based on the case report of a 51 year-old patient presenting with a lymphoepithelioma like gastric cancer , we discuss the diagnostic challenge to differentiate this entity from gastric non-Hodgkin lymphoma . Since high-level lymphoid stromal reactions are rarely associated with gastric adenocarcinoma , misinterpretation can occur easily . In addition to the lymphoepithelioma like gastric cancer that is often associated with a demonstrable EBV association of the tumor cells , synchronous development of gastric carcinoma and lymphoma must be considered . Establishment of a correct diagnosis requires multiple , deep and multifocally sampled gastric biopsies , and immunohistochemical and molecular techniques to supplement conventional histology . Only through this procedure are correct characterization and classification of these unusual gastric neoplasms possible .
|
[
"Based",
"on",
"the",
"case",
"report",
"of",
"a",
"51",
"year",
"-",
"old",
"patient",
"presenting",
"with",
"a",
"lymphoepithelioma",
"like",
"gastric",
"cancer",
",",
"we",
"discuss",
"the",
"diagnostic",
"challenge",
"to",
"differentiate",
"this",
"entity",
"from",
"gastric",
"non",
"-",
"Hodgkin",
"lymphoma",
".",
"Since",
"high",
"-",
"level",
"lymphoid",
"stromal",
"reactions",
"are",
"rarely",
"associated",
"with",
"gastric",
"adenocarcinoma",
",",
"misinterpretation",
"can",
"occur",
"easily",
".",
"In",
"addition",
"to",
"the",
"lymphoepithelioma",
"like",
"gastric",
"cancer",
"that",
"is",
"often",
"associated",
"with",
"a",
"demonstrable",
"EBV",
"association",
"of",
"the",
"tumor",
"cells",
",",
"synchronous",
"development",
"of",
"gastric",
"carcinoma",
"and",
"lymphoma",
"must",
"be",
"considered",
".",
"Establishment",
"of",
"a",
"correct",
"diagnosis",
"requires",
"multiple",
",",
"deep",
"and",
"multifocally",
"sampled",
"gastric",
"biopsies",
",",
"and",
"immunohistochemical",
"and",
"molecular",
"techniques",
"to",
"supplement",
"conventional",
"histology",
".",
"Only",
"through",
"this",
"procedure",
"are",
"correct",
"characterization",
"and",
"classification",
"of",
"these",
"unusual",
"gastric",
"neoplasms",
"possible",
"."
] |
[
"umlsterm"
] |
case report, patient, gastric cancer, diagnostic, non - Hodgkin lymphoma, adenocarcinoma, gastric cancer, EBV, association, tumor, cells, development, carcinoma, lymphoma, diagnosis, biopsies, techniques, histology, procedure, classification, gastric neoplasms
|
DerChirurg.90700713.eng.abstr_task2
|
Sentence: Based on the case report of a 51 year-old patient presenting with a lymphoepithelioma like gastric cancer , we discuss the diagnostic challenge to differentiate this entity from gastric non-Hodgkin lymphoma . Since high-level lymphoid stromal reactions are rarely associated with gastric adenocarcinoma , misinterpretation can occur easily . In addition to the lymphoepithelioma like gastric cancer that is often associated with a demonstrable EBV association of the tumor cells , synchronous development of gastric carcinoma and lymphoma must be considered . Establishment of a correct diagnosis requires multiple , deep and multifocally sampled gastric biopsies , and immunohistochemical and molecular techniques to supplement conventional histology . Only through this procedure are correct characterization and classification of these unusual gastric neoplasms possible .
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"I-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"O",
"B-umlsterm",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"O",
"B-umlsterm",
"O",
"O",
"O",
"B-umlsterm",
"I-umlsterm",
"O",
"O"
] |
Based on the case report of a 51 year-old patient presenting with a lymphoepithelioma like gastric cancer , we discuss the diagnostic challenge to differentiate this entity from gastric non-Hodgkin lymphoma . Since high-level lymphoid stromal reactions are rarely associated with gastric adenocarcinoma , misinterpretation can occur easily . In addition to the lymphoepithelioma like gastric cancer that is often associated with a demonstrable EBV association of the tumor cells , synchronous development of gastric carcinoma and lymphoma must be considered . Establishment of a correct diagnosis requires multiple , deep and multifocally sampled gastric biopsies , and immunohistochemical and molecular techniques to supplement conventional histology . Only through this procedure are correct characterization and classification of these unusual gastric neoplasms possible .
|
[
"Based",
"on",
"the",
"case",
"report",
"of",
"a",
"51",
"year",
"-",
"old",
"patient",
"presenting",
"with",
"a",
"lymphoepithelioma",
"like",
"gastric",
"cancer",
",",
"we",
"discuss",
"the",
"diagnostic",
"challenge",
"to",
"differentiate",
"this",
"entity",
"from",
"gastric",
"non",
"-",
"Hodgkin",
"lymphoma",
".",
"Since",
"high",
"-",
"level",
"lymphoid",
"stromal",
"reactions",
"are",
"rarely",
"associated",
"with",
"gastric",
"adenocarcinoma",
",",
"misinterpretation",
"can",
"occur",
"easily",
".",
"In",
"addition",
"to",
"the",
"lymphoepithelioma",
"like",
"gastric",
"cancer",
"that",
"is",
"often",
"associated",
"with",
"a",
"demonstrable",
"EBV",
"association",
"of",
"the",
"tumor",
"cells",
",",
"synchronous",
"development",
"of",
"gastric",
"carcinoma",
"and",
"lymphoma",
"must",
"be",
"considered",
".",
"Establishment",
"of",
"a",
"correct",
"diagnosis",
"requires",
"multiple",
",",
"deep",
"and",
"multifocally",
"sampled",
"gastric",
"biopsies",
",",
"and",
"immunohistochemical",
"and",
"molecular",
"techniques",
"to",
"supplement",
"conventional",
"histology",
".",
"Only",
"through",
"this",
"procedure",
"are",
"correct",
"characterization",
"and",
"classification",
"of",
"these",
"unusual",
"gastric",
"neoplasms",
"possible",
"."
] |
[
"umlsterm"
] |
DRB1 is a Gene, DQA1 is a Gene, DQB1 is a Gene, DPB1 is a Gene, TAP1 is a Gene, TAP2 is a Gene, TAP1 is a Gene, TAP2 is a Gene, TAP1 is a Gene, DPB1 is a Gene, DQB1 is a Gene
|
207_task0
|
Sentence: Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Disequilibrium between genetic markers is expected to decline monotonically with recombinational map distance. We present evidence from the HLA class II region that seems to violate this principle. Pairwise disequilibrium values were calculated from six loci ranging in physical separation from 15 kb to 550 kb. The histocompatibility loci DRB1, DQA1, and DQB1, located on the distal end of the class II region, behave as a single evolutionary unit within which extremely high linkage disequilibrium exists. Lower but still significant levels of disequilibrium are present between these loci and DPB1, located at the proximal edge of the HLA complex. The peptide-transporter loci TAP1 and TAP2, located in the intervening region, reveal no disequilibrium with each other and low or negligible disequilibrium with the flanking loci. The action of two genetic process is required to account for this phenomenon: a recombinational hotspot operating between TAP1 and TAP2, to eliminate disequilibrium between these loci, and at the same time selection operating on particular combinations of alleles across the DR-DP region, to create disequilibrium in the favored haplotypes. The forces producing the patterns of disequilibrium observed here have implications for the mapping of train loci and disease genes: markers of TAP1, for example, would give a false impression as to the influence of DPB1 on a trait known to be associated with DQB1.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: Gene
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O"
] |
Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Disequilibrium between genetic markers is expected to decline monotonically with recombinational map distance. We present evidence from the HLA class II region that seems to violate this principle. Pairwise disequilibrium values were calculated from six loci ranging in physical separation from 15 kb to 550 kb. The histocompatibility loci DRB1, DQA1, and DQB1, located on the distal end of the class II region, behave as a single evolutionary unit within which extremely high linkage disequilibrium exists. Lower but still significant levels of disequilibrium are present between these loci and DPB1, located at the proximal edge of the HLA complex. The peptide-transporter loci TAP1 and TAP2, located in the intervening region, reveal no disequilibrium with each other and low or negligible disequilibrium with the flanking loci. The action of two genetic process is required to account for this phenomenon: a recombinational hotspot operating between TAP1 and TAP2, to eliminate disequilibrium between these loci, and at the same time selection operating on particular combinations of alleles across the DR-DP region, to create disequilibrium in the favored haplotypes. The forces producing the patterns of disequilibrium observed here have implications for the mapping of train loci and disease genes: markers of TAP1, for example, would give a false impression as to the influence of DPB1 on a trait known to be associated with DQB1.
|
[
"Discordant",
"patterns",
"of",
"linkage",
"disequilibrium",
"of",
"the",
"peptide",
"-",
"transporter",
"loci",
"within",
"the",
"HLA",
"class",
"II",
"region",
".",
"Disequilibrium",
"between",
"genetic",
"markers",
"is",
"expected",
"to",
"decline",
"monotonically",
"with",
"recombinational",
"map",
"distance",
".",
"We",
"present",
"evidence",
"from",
"the",
"HLA",
"class",
"II",
"region",
"that",
"seems",
"to",
"violate",
"this",
"principle",
".",
"Pairwise",
"disequilibrium",
"values",
"were",
"calculated",
"from",
"six",
"loci",
"ranging",
"in",
"physical",
"separation",
"from",
"15",
"kb",
"to",
"550",
"kb",
".",
"The",
"histocompatibility",
"loci",
"DRB1",
",",
"DQA1",
",",
"and",
"DQB1",
",",
"located",
"on",
"the",
"distal",
"end",
"of",
"the",
"class",
"II",
"region",
",",
"behave",
"as",
"a",
"single",
"evolutionary",
"unit",
"within",
"which",
"extremely",
"high",
"linkage",
"disequilibrium",
"exists",
".",
"Lower",
"but",
"still",
"significant",
"levels",
"of",
"disequilibrium",
"are",
"present",
"between",
"these",
"loci",
"and",
"DPB1",
",",
"located",
"at",
"the",
"proximal",
"edge",
"of",
"the",
"HLA",
"complex",
".",
"The",
"peptide",
"-",
"transporter",
"loci",
"TAP1",
"and",
"TAP2",
",",
"located",
"in",
"the",
"intervening",
"region",
",",
"reveal",
"no",
"disequilibrium",
"with",
"each",
"other",
"and",
"low",
"or",
"negligible",
"disequilibrium",
"with",
"the",
"flanking",
"loci",
".",
"The",
"action",
"of",
"two",
"genetic",
"process",
"is",
"required",
"to",
"account",
"for",
"this",
"phenomenon",
":",
"a",
"recombinational",
"hotspot",
"operating",
"between",
"TAP1",
"and",
"TAP2",
",",
"to",
"eliminate",
"disequilibrium",
"between",
"these",
"loci",
",",
"and",
"at",
"the",
"same",
"time",
"selection",
"operating",
"on",
"particular",
"combinations",
"of",
"alleles",
"across",
"the",
"DR",
"-",
"DP",
"region",
",",
"to",
"create",
"disequilibrium",
"in",
"the",
"favored",
"haplotypes",
".",
"The",
"forces",
"producing",
"the",
"patterns",
"of",
"disequilibrium",
"observed",
"here",
"have",
"implications",
"for",
"the",
"mapping",
"of",
"train",
"loci",
"and",
"disease",
"genes",
":",
"markers",
"of",
"TAP1",
",",
"for",
"example",
",",
"would",
"give",
"a",
"false",
"impression",
"as",
"to",
"the",
"influence",
"of",
"DPB1",
"on",
"a",
"trait",
"known",
"to",
"be",
"associated",
"with",
"DQB1",
".",
"\n"
] |
[
"Gene"
] |
DRB1 is a Gene, DQA1 is a Gene, DQB1 is a Gene, DPB1 is a Gene, TAP1 is a Gene, TAP2 is a Gene, TAP1 is a Gene, TAP2 is a Gene, TAP1 is a Gene, DPB1 is a Gene, DQB1 is a Gene
|
207_task1
|
Sentence: Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Disequilibrium between genetic markers is expected to decline monotonically with recombinational map distance. We present evidence from the HLA class II region that seems to violate this principle. Pairwise disequilibrium values were calculated from six loci ranging in physical separation from 15 kb to 550 kb. The histocompatibility loci DRB1, DQA1, and DQB1, located on the distal end of the class II region, behave as a single evolutionary unit within which extremely high linkage disequilibrium exists. Lower but still significant levels of disequilibrium are present between these loci and DPB1, located at the proximal edge of the HLA complex. The peptide-transporter loci TAP1 and TAP2, located in the intervening region, reveal no disequilibrium with each other and low or negligible disequilibrium with the flanking loci. The action of two genetic process is required to account for this phenomenon: a recombinational hotspot operating between TAP1 and TAP2, to eliminate disequilibrium between these loci, and at the same time selection operating on particular combinations of alleles across the DR-DP region, to create disequilibrium in the favored haplotypes. The forces producing the patterns of disequilibrium observed here have implications for the mapping of train loci and disease genes: markers of TAP1, for example, would give a false impression as to the influence of DPB1 on a trait known to be associated with DQB1.
Instructions: please typing these entity words according to sentence: DRB1, DQA1, DQB1, DPB1, TAP1, TAP2, TAP1, TAP2, TAP1, DPB1, DQB1
Options: Gene
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O"
] |
Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Disequilibrium between genetic markers is expected to decline monotonically with recombinational map distance. We present evidence from the HLA class II region that seems to violate this principle. Pairwise disequilibrium values were calculated from six loci ranging in physical separation from 15 kb to 550 kb. The histocompatibility loci DRB1, DQA1, and DQB1, located on the distal end of the class II region, behave as a single evolutionary unit within which extremely high linkage disequilibrium exists. Lower but still significant levels of disequilibrium are present between these loci and DPB1, located at the proximal edge of the HLA complex. The peptide-transporter loci TAP1 and TAP2, located in the intervening region, reveal no disequilibrium with each other and low or negligible disequilibrium with the flanking loci. The action of two genetic process is required to account for this phenomenon: a recombinational hotspot operating between TAP1 and TAP2, to eliminate disequilibrium between these loci, and at the same time selection operating on particular combinations of alleles across the DR-DP region, to create disequilibrium in the favored haplotypes. The forces producing the patterns of disequilibrium observed here have implications for the mapping of train loci and disease genes: markers of TAP1, for example, would give a false impression as to the influence of DPB1 on a trait known to be associated with DQB1.
|
[
"Discordant",
"patterns",
"of",
"linkage",
"disequilibrium",
"of",
"the",
"peptide",
"-",
"transporter",
"loci",
"within",
"the",
"HLA",
"class",
"II",
"region",
".",
"Disequilibrium",
"between",
"genetic",
"markers",
"is",
"expected",
"to",
"decline",
"monotonically",
"with",
"recombinational",
"map",
"distance",
".",
"We",
"present",
"evidence",
"from",
"the",
"HLA",
"class",
"II",
"region",
"that",
"seems",
"to",
"violate",
"this",
"principle",
".",
"Pairwise",
"disequilibrium",
"values",
"were",
"calculated",
"from",
"six",
"loci",
"ranging",
"in",
"physical",
"separation",
"from",
"15",
"kb",
"to",
"550",
"kb",
".",
"The",
"histocompatibility",
"loci",
"DRB1",
",",
"DQA1",
",",
"and",
"DQB1",
",",
"located",
"on",
"the",
"distal",
"end",
"of",
"the",
"class",
"II",
"region",
",",
"behave",
"as",
"a",
"single",
"evolutionary",
"unit",
"within",
"which",
"extremely",
"high",
"linkage",
"disequilibrium",
"exists",
".",
"Lower",
"but",
"still",
"significant",
"levels",
"of",
"disequilibrium",
"are",
"present",
"between",
"these",
"loci",
"and",
"DPB1",
",",
"located",
"at",
"the",
"proximal",
"edge",
"of",
"the",
"HLA",
"complex",
".",
"The",
"peptide",
"-",
"transporter",
"loci",
"TAP1",
"and",
"TAP2",
",",
"located",
"in",
"the",
"intervening",
"region",
",",
"reveal",
"no",
"disequilibrium",
"with",
"each",
"other",
"and",
"low",
"or",
"negligible",
"disequilibrium",
"with",
"the",
"flanking",
"loci",
".",
"The",
"action",
"of",
"two",
"genetic",
"process",
"is",
"required",
"to",
"account",
"for",
"this",
"phenomenon",
":",
"a",
"recombinational",
"hotspot",
"operating",
"between",
"TAP1",
"and",
"TAP2",
",",
"to",
"eliminate",
"disequilibrium",
"between",
"these",
"loci",
",",
"and",
"at",
"the",
"same",
"time",
"selection",
"operating",
"on",
"particular",
"combinations",
"of",
"alleles",
"across",
"the",
"DR",
"-",
"DP",
"region",
",",
"to",
"create",
"disequilibrium",
"in",
"the",
"favored",
"haplotypes",
".",
"The",
"forces",
"producing",
"the",
"patterns",
"of",
"disequilibrium",
"observed",
"here",
"have",
"implications",
"for",
"the",
"mapping",
"of",
"train",
"loci",
"and",
"disease",
"genes",
":",
"markers",
"of",
"TAP1",
",",
"for",
"example",
",",
"would",
"give",
"a",
"false",
"impression",
"as",
"to",
"the",
"influence",
"of",
"DPB1",
"on",
"a",
"trait",
"known",
"to",
"be",
"associated",
"with",
"DQB1",
".",
"\n"
] |
[
"Gene"
] |
DRB1, DQA1, DQB1, DPB1, TAP1, TAP2, TAP1, TAP2, TAP1, DPB1, DQB1
|
207_task2
|
Sentence: Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Disequilibrium between genetic markers is expected to decline monotonically with recombinational map distance. We present evidence from the HLA class II region that seems to violate this principle. Pairwise disequilibrium values were calculated from six loci ranging in physical separation from 15 kb to 550 kb. The histocompatibility loci DRB1, DQA1, and DQB1, located on the distal end of the class II region, behave as a single evolutionary unit within which extremely high linkage disequilibrium exists. Lower but still significant levels of disequilibrium are present between these loci and DPB1, located at the proximal edge of the HLA complex. The peptide-transporter loci TAP1 and TAP2, located in the intervening region, reveal no disequilibrium with each other and low or negligible disequilibrium with the flanking loci. The action of two genetic process is required to account for this phenomenon: a recombinational hotspot operating between TAP1 and TAP2, to eliminate disequilibrium between these loci, and at the same time selection operating on particular combinations of alleles across the DR-DP region, to create disequilibrium in the favored haplotypes. The forces producing the patterns of disequilibrium observed here have implications for the mapping of train loci and disease genes: markers of TAP1, for example, would give a false impression as to the influence of DPB1 on a trait known to be associated with DQB1.
Instructions: please extract entity words from the input sentence
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Gene",
"O",
"O"
] |
Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Disequilibrium between genetic markers is expected to decline monotonically with recombinational map distance. We present evidence from the HLA class II region that seems to violate this principle. Pairwise disequilibrium values were calculated from six loci ranging in physical separation from 15 kb to 550 kb. The histocompatibility loci DRB1, DQA1, and DQB1, located on the distal end of the class II region, behave as a single evolutionary unit within which extremely high linkage disequilibrium exists. Lower but still significant levels of disequilibrium are present between these loci and DPB1, located at the proximal edge of the HLA complex. The peptide-transporter loci TAP1 and TAP2, located in the intervening region, reveal no disequilibrium with each other and low or negligible disequilibrium with the flanking loci. The action of two genetic process is required to account for this phenomenon: a recombinational hotspot operating between TAP1 and TAP2, to eliminate disequilibrium between these loci, and at the same time selection operating on particular combinations of alleles across the DR-DP region, to create disequilibrium in the favored haplotypes. The forces producing the patterns of disequilibrium observed here have implications for the mapping of train loci and disease genes: markers of TAP1, for example, would give a false impression as to the influence of DPB1 on a trait known to be associated with DQB1.
|
[
"Discordant",
"patterns",
"of",
"linkage",
"disequilibrium",
"of",
"the",
"peptide",
"-",
"transporter",
"loci",
"within",
"the",
"HLA",
"class",
"II",
"region",
".",
"Disequilibrium",
"between",
"genetic",
"markers",
"is",
"expected",
"to",
"decline",
"monotonically",
"with",
"recombinational",
"map",
"distance",
".",
"We",
"present",
"evidence",
"from",
"the",
"HLA",
"class",
"II",
"region",
"that",
"seems",
"to",
"violate",
"this",
"principle",
".",
"Pairwise",
"disequilibrium",
"values",
"were",
"calculated",
"from",
"six",
"loci",
"ranging",
"in",
"physical",
"separation",
"from",
"15",
"kb",
"to",
"550",
"kb",
".",
"The",
"histocompatibility",
"loci",
"DRB1",
",",
"DQA1",
",",
"and",
"DQB1",
",",
"located",
"on",
"the",
"distal",
"end",
"of",
"the",
"class",
"II",
"region",
",",
"behave",
"as",
"a",
"single",
"evolutionary",
"unit",
"within",
"which",
"extremely",
"high",
"linkage",
"disequilibrium",
"exists",
".",
"Lower",
"but",
"still",
"significant",
"levels",
"of",
"disequilibrium",
"are",
"present",
"between",
"these",
"loci",
"and",
"DPB1",
",",
"located",
"at",
"the",
"proximal",
"edge",
"of",
"the",
"HLA",
"complex",
".",
"The",
"peptide",
"-",
"transporter",
"loci",
"TAP1",
"and",
"TAP2",
",",
"located",
"in",
"the",
"intervening",
"region",
",",
"reveal",
"no",
"disequilibrium",
"with",
"each",
"other",
"and",
"low",
"or",
"negligible",
"disequilibrium",
"with",
"the",
"flanking",
"loci",
".",
"The",
"action",
"of",
"two",
"genetic",
"process",
"is",
"required",
"to",
"account",
"for",
"this",
"phenomenon",
":",
"a",
"recombinational",
"hotspot",
"operating",
"between",
"TAP1",
"and",
"TAP2",
",",
"to",
"eliminate",
"disequilibrium",
"between",
"these",
"loci",
",",
"and",
"at",
"the",
"same",
"time",
"selection",
"operating",
"on",
"particular",
"combinations",
"of",
"alleles",
"across",
"the",
"DR",
"-",
"DP",
"region",
",",
"to",
"create",
"disequilibrium",
"in",
"the",
"favored",
"haplotypes",
".",
"The",
"forces",
"producing",
"the",
"patterns",
"of",
"disequilibrium",
"observed",
"here",
"have",
"implications",
"for",
"the",
"mapping",
"of",
"train",
"loci",
"and",
"disease",
"genes",
":",
"markers",
"of",
"TAP1",
",",
"for",
"example",
",",
"would",
"give",
"a",
"false",
"impression",
"as",
"to",
"the",
"influence",
"of",
"DPB1",
"on",
"a",
"trait",
"known",
"to",
"be",
"associated",
"with",
"DQB1",
".",
"\n"
] |
[
"Gene"
] |
triglyceride is a CHEMICAL
|
22532505_task0
|
Sentence: Extracts of Scutellaria baicalensis reduced body weight and blood triglyceride in db/db Mice.
Instructions: please extract entities and their types from the input sentence, all entity types are in options
Options: CHEMICAL
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Extracts of Scutellaria baicalensis reduced body weight and blood triglyceride in db/db Mice.
|
[
"Extracts",
"of",
"Scutellaria",
"baicalensis",
"reduced",
"body",
"weight",
"and",
"blood",
"triglyceride",
"in",
"db",
"/",
"db",
"Mice",
"."
] |
[
"GENE-N",
"CHEMICAL"
] |
triglyceride is a CHEMICAL
|
22532505_task1
|
Sentence: Extracts of Scutellaria baicalensis reduced body weight and blood triglyceride in db/db Mice.
Instructions: please typing these entity words according to sentence: triglyceride
Options: CHEMICAL
|
[
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-CHEMICAL",
"O",
"O",
"O",
"O",
"O",
"O"
] |
Extracts of Scutellaria baicalensis reduced body weight and blood triglyceride in db/db Mice.
|
[
"Extracts",
"of",
"Scutellaria",
"baicalensis",
"reduced",
"body",
"weight",
"and",
"blood",
"triglyceride",
"in",
"db",
"/",
"db",
"Mice",
"."
] |
[
"GENE-N",
"CHEMICAL"
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.